"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Good morning, everyone. We are about to begin Mylan's 2009 Fourth Quarter Earnings Conference Call. [Operator Instructions] For opening remarks and introductions, I would like to turn the conference over to Mr. Dan Crookshank, Mylan's Vice President of Gl",44,"Good morning, everyone. We are about to begin Mylan's 2009 Fourth Quarter Earnings Conference Call. [Operator Instructions] For opening remarks and introductions, I would like to turn the conference over to Mr. Dan Crookshank, Mylan's Vice President of Global Investor Relations. Please go ahead."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Melanie. Good morning, everyone. Joining me for today's call are Mylan's Chairman, Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Operating Officer, Rajiv Malik; Senior Vice President, Co",446,"Thank you, Melanie. Good morning, everyone. Joining me for today's call are Mylan's Chairman, Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Operating Officer, Rajiv Malik; Senior Vice President, Corporate Controller and Principal Financial and Accounting Officer, Dan Rizzo; and Senior Vice President and Treasurer, Brian Byala. As we begin, I'd like to point out that as indicated in this morning's press release, there is a presentation available under live Internet webcast, which President, Heather Bresch, will be referring to as she delivers her prepared remarks this morning. So I highly encourage you to access our webcast at www.mylan.com. to view these slides. In addition, the webcast will be available for replay on our website for up to seven days following the conclusion of today's call.During today's call, including the Q&A, we will be making forward-looking statements including those related to our anticipated business levels, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our quarterly report on Form 10-Q for the quarter ended, September 30, 2009, and in our other Securities and Exchange Commission filings. You can access our Form 10-Q and other SEC filings through the SEC website at www.sec.gov, we encourage you to do so.In addition, during the conference call, we will be presenting and referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP measures. It should be noted that non-GAAP financial measures, such as adjusted revenues, adjusted gross margins, adjusted diluted EPS, should be used only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings release, which is available on our website, as it contains detailed GAAP to non-GAAP reconciliations of our actual 2009 and 2008 fourth quarter and full year results, including the allocation of each reconciling item to specific income statement line items.Before I turn the call over to Robert, let me also remind you that the material in the call with the exception of the participant questions is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission. With that, I'll now turn the call over to Robert."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Dan. Welcome, everyone, and thank you for joining us this morning. Before we get started, I'd like to say hello and once again, recognize all of our employees around the world who continue to dedicate themselves to helping Mylan meet its goal o",1112,"Thank you, Dan. Welcome, everyone, and thank you for joining us this morning. Before we get started, I'd like to say hello and once again, recognize all of our employees around the world who continue to dedicate themselves to helping Mylan meet its goal of becoming the highest quality and most efficient global generics and specialty pharmaceutical company in the industry. Time and time again, our employees deliver results that outpace expectations. On behalf of our Board of Directors and our management team, I would like to thank each and everyone of them. Since I became Mylan's Chief Executive Officer almost eight years ago, we've been committed to a very clear and consistent growth strategy, which is to combine Mylan's existing strong organic capabilities with external opportunities. Today, it is very evident that Mylan has successfully implemented this strategy as demonstrated by the global platform we've created, as well as the strong union we have forged between the vision, that vision, and the impeccable execution today. This ultimately is what's delivering the solid results and anticipated growth that we are here to report to you today.Before we look at 2010 and beyond, I'd like to review a few key accomplishments from 2009. First, I am pleased with the very strong fourth quarter results, capping off yet another extremely successful year, our second full year of operating the new Mylan. As stated many times, we knew that 2009 was going to be a year dependent predominantly on tremendous execution and again, I would like to thank my management team and all of our employees for making that happen.Our fourth quarter adjusted diluted earnings per share came in at $0.33, a 27% increase over the same quarter in 2008. For the year, we delivered an adjusted diluted earnings per share of $1.30, which is a 63% increase over 2008. This surge in our adjusted diluted earnings per share represents the highest annual growth rate among our industry peers by a very significant margin, a statistic that we are proud of and a trend that we fully expect to continue throughout the next several years.In addition to the impeccable execution from our operations, we were able to generate strong operating cash flows throughout the year. Some of the excess cash flows were used to purchase the bulk of the remaining minority interest of Matrix, now a privately held subsidiary, and some was used to deliver on our commitment to continue to delever, by prepaying an approximately $350 million in bank term loans borrowings that were due in 2010 and 2011. We are now in a position where we have only minimal long-term obligations due before 2012. In 2009, we also continue to see the rewards for the hard work and outstanding leadership of Mylan's best-in-class management team. Heather Bresch was promoted to President, and Rajiv Malik succeeded Heather in a position of Chief Operating Officer. These changes as well as many other promotions throughout our company continue to reflect the recognition and strong track record of this management team. We also continue to successfully attract exceptional leaders from outside as well. As you know, today, we announced the employment of John Sheehan as Mylan's new Chief Financial Officer, an appointment that I am very excited about. John's extensive and broad-based technical knowledge, significant multinational manufacturing experience and his ability to lead large complex international finance organizations make him an outstanding addition to Mylan. With that said, I would like to personally thank our very, very strong global corporate finance team for their continued commitment and outstanding performance. This is truly another testament to the strength of Mylan's overall management team.In 2009, we also said farewell to our co-founder, Mike Puskar, who stepped down from the Board of Directors in October. It is my great honor to have succeeded Mike as Chairman of our Board. I was equally as pleased this past year to be able to appoint Rod Piatt as Vice Chairman, and to welcome Mylan's newest Board member, industry veteran Mark Parrish. Mylan was also recognized and rewarded externally in 2009 for its multiple achievements. Our stock price rose 86% during the year. We received positive actions from both independent rating agencies, Moody's and Standard & Poor's, and we were also named to the Fortune 500. Looking to 2010, I am extremely pleased to report that we remain on track to deliver adjusted diluted earnings per share in the range of $1.50 to $1.70. This should translate into an industry-leading earnings per share growth rate over the 2008 and 2010 period. This guidance fully incorporates our continued heavy investment into our business, including our biologics strategy. It also includes any potential negative arbitrage in interest rates as we continue to look at meaningful opportunities in the capital markets to further improve our capital structure as we look to stagger our debt maturities in a more favorable manner.  That said, I fully expect that as we roll forward into 2010, there may be additional opportunities to possibly improve and even further tighten our guidance range. In a few minutes, Heather will provide you with insights into our longer-term strategic growth targets for 2011, '12 and '13. This will include discussions about Mylan's unique position from which we will be able to control our business by continuing to strategically leverage this powerful, one-of-a-kind platform that we have created.  Through continuing our outstanding execution, portfolio expansion, additional commercial diversification, operational efficiency and an even stronger balance sheet, I am extremely confident in our projected annual top-line growth rate of 15%, culminating with revenues in excess of $8.5 billion by 2013, and a bottom line CAGR of 20%. I am also highly confident that we will achieve earnings per share in excess of $2 in 2011. With these achieved growth targets, we also expect to generate approximately $4 billion of cumulative operating cash flows by the end of 2013.Lastly, the most important aspect of our expected growth is that it is predominantly organic, and all the work necessary to achieve these results is either already completed or will be by the end of 2010. This is even more impressive, considering that this anticipated growth does not include any M&A activity or any meaningful contribution from generic biologics or our future launch of Copaxone, which could only provide additional upside after the expiration of the 30-month stay in March of 2012. Let me close by stating that in the eight years I have served as the Chief Executive Officer, I have never been more confident about our industry and about the growth potential for Mylan. With that, I will now turn the call over to our President, Heather Bresch."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert, and good morning, everyone. As you saw from the very strong fourth quarter and full year results we announced earlier today, Mylan continues to perform at levels that exceed even our own high expectations. Throughout the quarter and the",2454,"Thank you, Robert, and good morning, everyone. As you saw from the very strong fourth quarter and full year results we announced earlier today, Mylan continues to perform at levels that exceed even our own high expectations. Throughout the quarter and the year, we continue to submit applications, launch new products, grow our customer base and capture synergies and efficiencies. We maintained our focus and executed relentlessly just as we always have. Our strong '09 performance should demonstrate our ability to hit our 2010 guidance while at the same time, finding additional opportunities to further leverage our powerful operating platform, positioning us to continue delivering outstanding performance in 2011 and beyond. During my prepared remarks today, which will be accompanied by slides on this webcast, I'll review our operational results for the quarter and the year, provide you with an updated perspective on our guidance for 2010 and then give you some color on how we expect to achieve a compound annual EPS growth rate of 20% through 2013. As you can see on Slide 3, Mylan delivered very strong performance in 2009. We generated nearly $5.1 billion in adjusted revenues, about $1.25 billion in adjusted EBITDA and $1.30 in adjusted diluted EPS. 2009 played out much as we expected. During the first half of the year, 180-day exclusivity period we enjoyed on Divalproex in the U.S., was a major contributor to revenue and earnings growth. As promised, we maintained solid revenue and earnings results during the second half of the year through numerous product launches around the world, and accelerated as well as generated additional synergies. These events complemented our global-based business, which contributed to our strong, balanced quarterly results throughout the year. I'd like to echo a comment that Robert makes on every quarterly call, which is that the credit of our success belongs to our employees. So I'd like to take a moment now to thank each and every one of them for routinely going above and beyond to demonstrate that Mylan truly is a world-class generic and specialty pharmaceuticals company, with an operating platform and a work ethic that is second to none. Thanks to their dedication. Our future has never been brighter.Moving on to Slide 4, I'll now walk you through our sales performance by region. Overall, I'd characterize our results as being solid across the board, underscoring the power and consistency of our diversified global operating platform. Also noteworthy is that we maintain the best-in-class customer service levels by simultaneously optimizing our supply chain. This allowed us to respond successfully to opportunities created throughout the year by a variety of market disruptions. Our Generics business in North America continued its strong performance. We generated third-party revenues of $539 million for the quarter as compared to $557 million for the same period in 2008. New products launched in the fourth quarter in the U.S. combined with our strong base business, nearly managed to offset the revenue decrease caused by the loss of exclusivity we enjoyed on Levetiracetam in the last quarter of 2008. For the year, third-party revenues in North America were $2.1 billion, an increase of 14% over the $1.85 billion reported in '08. Contributing to this growth was the 180 days of exclusivity we had on Divalproex, an increase in synergies as well as 5% year-over-year growth in Canada. Our EMEA region hit an all-time record during the fourth quarter. Third-party revenues of $480 million increased $110 million or 30% over the prior year's fourth quarter. Revenues in the current quarter were affected favorably by foreign currency translation, reflecting a weaker U.S. dollar. On a constant currency basis, operational revenue growth was about 19% year-over-year. This operational growth was led by higher volumes and new launches such as Clopidogrel, which we successfully introduced in several markets, including France and Spain. Both of those markets produced record sales as local currency revenues rose about 20% and 30% year-over-year, respectively. Italy also enjoyed record sales during the quarter as local currency revenues increased nearly 60% over the year-ago period, responsible for higher volumes on several key products and a favorable impact of regulatory changes on pricing.For the full year, EMEA performed well. Total revenues increased 1% to $1.65 billion as compared to '08. However, on a constant currency basis, total revenues rose 8%. In general, growth was driven by our base business, new launches and improved cost of goods, which continue to offset pricing pressure. In our Asia Pacific region, for which the fourth quarter is traditionally strongest seasonally, we again delivered solid results. Total revenues were $271 million, up 36% over '08's fourth quarter results of $199 million. Operational revenue growth accounted for 20% of this increase while currency effects contributed the remainder.The operational growth was driven by higher year-over-year local currency revenues in our major business operations in India, Australia and Japan. Our Matrix business had a record quarter due to higher sales of its expanding line of ARV finished dosage form products and third-party APIs for both ARV and other products.In Australia, we achieved high single-digit local currency revenue growth as an approximate 20% increase in product volumes more than offset the impact of price discount. And in Japan, we saw low single-digit local currency revenue year-over-year consistent with the pace at which the generic market there continues to expand. For the full year, total revenues in our APAC region were $882 million, an increase of 10% over '08's results of $802 million. That 10% reflects 16% of operational growth, offset by a negative currency effect of 6% as expected. Matrix led the way with accelerating double-digit growth. And at our Specialty business today, fourth quarter total revenues rose 8% to $87 million. This includes intercompany revenues of $25 million associated with the transfer of Dey's generic products to our Mylan Pharmaceutical subsidiary. As you know, we launched the new version of our EpiPen Auto-Injector in October, and I'm pleased to report that the product is doing very well as expected, and we are receiving positive feedback on its enhanced design features. For the full year, Dey's adjusted third-party revenues were $413 million, a 7% increase over '08 results of $386 million. Excluding revenues associated with the transfer of generic products, revenue growth exceeded 10%, right in line with our original expectation of double-digit growth. Revenues from our Auto-Injector grew almost 10% year-over-year, while performance revenues doubled. In summary, '09 was an outstanding year for Mylan. We produced phenomenal financial results while executing to meet or exceed all of our stated objectives. On Slide 5, looking at our performance for 2008 through 2010, you can see that we truly are reaping what we've sown and delivering industry-leading year-over-year growth. Using the middle of our 2010 guidance as the basis for our calculation, adjusted revenues are rising at a 10% compounded annual rate, EBITDA is coming in at 20% and EPS is growing nicely at 41%. And as I'll discuss, there is still a lot to leverage on our platform, which will allow us to deliver our stated EPS growth target at 20% through 2013.Before moving on to our longer-term outlook, I'll touch briefly on our guidance for 2010, which appears on Slide 6. As Robert mentioned, we are reaffirming our adjusted diluted EPS guidance range for 2010 of $1.50 to $1.70. Most of the elements of that guidance remain intact, the exceptions being revenue and R&D, both of which we've increased as we continue to grow and invest for the future.We anticipate that the second half of 2010 will be stronger than the first half as we capitalize on the full year effect of hundreds of first quarter launches, as well as $120 million of back-end loaded incremental synergies. As you consider our guidance and reflect on our achievements to date, I trust a key takeaway is that you can absolutely, positively depend on us to execute and deliver. As we stated many times, 2010 is the baseline year from which Mylan will continue to grow. We have an extremely powerful platform. We are fanatic about execution, and we know beyond a shadow of a doubt that we are perfectly positioned to leverage our assets over the years to come. In fact, as you'll see, we are just getting started. Looking ahead on Slide 7, we intend to build on our industry-leading year-over-year growth by delivering compound annual growth in revenues of 15% and adjusted EPS of 20% through 2013. We expect this momentum to yield more than $8.5 billion in revenues, while maintaining a relatively stable gross margin and generate more than $2.75 in adjusted diluted EPS. All of this being created organically and while pushing out the launch of Dey's combo products to 2015. Just a further note, there is no reliance on any M&A. Our formula for delivering this performance is not complicated. In fact, it's very simple and straightforward. We will achieve this growth through continued execution of what are by now, very familiar opportunities, as shown on Slide 8. Specifically, we will expand our portfolio, keep realizing additional efficiencies, continue diversifying and further deleverage our balance sheet. By staying focused on leveraging the assets we already have, we will continue to control our growth and our destiny. Moving to the next slide, as you may remember, we stated that while we were vertically integrating, repatriating products and selling our global pipeline, regulatory time frames did not allow any meaningful portfolio expansion from 2008 to 2010.  Looking ahead, however, we stand to reap tremendous benefits of that work as we enjoy once again, the largest pipeline in our history. The approximately 3,000 products submissions we will have made cumulatively by the end of this year, represent a key driver of the $8.5 billion revenue we will generate. In the U.S. alone, we have more than 140 ANDAs pending approval with the FDA, more than 40 of which represent first-to-file opportunity. Further, we believe that approximately 1,000 submissions per year and about 500 launches per year represent sustainable run rate to our company.Turning to Slide 10, we currently have a global supply chain that is second to none, delivering the most efficient high quality product while maintaining superior customer service. From the beginning, we have continued to accelerate and find additional synergies that will deliver a cumulative annual benefit of $350 million by the end of this year. We intend to capture even more efficiencies as we continue to leverage our platform. As of today, 50% of our pipeline is vertically integrated. In addition, you may recall that legacy Merck business in-licensed most of its products, about 75% of them. We've since pushed that figure down to 55%, and by the end of 2013, it will stand at 30%. As you can imagine, the economics associated with these actions are tremendous. When you connect to our pipeline and supply chain to the many attractive markets around the world in which we already operate, you really can begin to see why Mylan is and will be the greatest growth story in the industry.Turning to the next slide. In the largest market in the world, the United States, where we already are a powerhouse, we see more opportunity. We sell one out of every 12 scripts written, branded or generic, with a Mylan product. We enjoy a 12% share of the generics market overall, and we represent the gold standard when it comes to quality and reliability. Additionally, our products command on average, 40% market share. To this, we now add the largest pipeline in our history. Further, we are confident that Dey will continue to deliver double-digit growth, especially as we leverage the market expansion opportunities around EpiPen in the United States and globally, continued growth of Perforomist and additional upside from EMSAM.In Europe, on Slide 12, we're excited about the potential of increased utilization, especially in our growth markets. France, our largest market, is increasing generics utilization, and we have a 31% market share. Bringing our integrated products into this market and capturing increased utilization will prove very beneficial, as it will in our other rapidly growing markets such as Spain, Italy and Portugal.Moving on to the next slide. In Asia-Pacific, it's the same story. We will bring our global competencies to bear as we drive efficiencies while maintaining local commercial expertise. Japan is the world's second largest pharmaceutical market that utilization is low, about 19%. While we rank fourth in market share and are growing from a small base, we believe we will experience accelerated growth as current and upcoming incentives continue to motivate pharmacists to substitute generic products. In Australia, we are maintaining our number one market position and expect utilization rates to continue to increase. We expect Matrix to continue growing an accelerated double-digit clip. An important force behind the growth of Matrix is our ARV portfolio, which now includes 30 products. Today, nearly one out of every three people being treated for HIV/AIDS in the developing world depends on our product. Moreover, we have pledged to do for access what we have already done for affordability for this devastating disease. All of this drives our commitment to continue diversifying our product mix, geographies and financial profile. Finally, as described on Slide 14, we fully intend to build on our past track record of delevering our balance sheet. We continue to demonstrate very strong cash flow and look to generate $4 billion in cumulative operating cash flow through 2013. This gives us the ability to keep investing in our business while continuing to pay down our debt. In addition, we intend to optimize our long-term capital structure, tapping the capital markets opportunistically as appropriate. I think you all realize that we love to think big and unconventionally. But what really separates us is that we deliver and standing still is never an option. No imagination is necessary to see that the stage is set to deliver our anticipated compound annual growth of 20% through 2013. Now, on this final Slide, let's talk about what we're doing today to prepare for tomorrow. Our growth drivers for beyond 2013 includes Copaxone, which we expect will deliver very robust performance. We continue to expand geographically and introduce new therapeutic categories and dosage forms, such as injectables. We also continue to invest today in our biologics platform, which we see as the next big bolus [ph] for the generic industry globally. We also will consider additional M&A opportunities as we look forward to the 2015 launch of Dey's combo product, as well as other complementary product offerings. I am proud of what we've accomplished and truly believe Mylan's best days are yet to come. With that, I'll turn the call over to Dan Rizzo."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I will walk you through our fourth quarter and full year 2009 financial results, our 2010 guidance key assumptions, and then I'll turn it over to our Treasurer, Brian Byala to conclude by provi",1379,"Thank you, Heather, and good morning, everyone. This morning, I will walk you through our fourth quarter and full year 2009 financial results, our 2010 guidance key assumptions, and then I'll turn it over to our Treasurer, Brian Byala to conclude by providing an update on the status of our capital structure and liquidity position. As Dan mentioned earlier, I will at times, be referring to actual and projected financial metrics that have been prepared on an adjusted basis, which again, are non-GAAP financial measures. We present these non-GAAP measures as they are prepared on the same basis used by management and the Board of Directors to evaluate the performance of our business. Now turning back to Slide 3 that details our 2009 financial highlights. As a reminder, the more significant items that are excluded from our non-GAAP adjusted basis results for the 2009 fourth quarter are purchase accounting amortization of $72 million, integration and other expenses of $41 million, net unfavorable litigation settlements of $114 million and imputed interest expense related to our convertible debt of $11 million, and a net tax benefit related to the excluded items and tax benefits from internal reorganizations, together totaling $135 million. Please refer to this morning's earnings release, which is available on our website for a complete reconciliation from our GAAP basis to non-GAAP financial measures for the 2009 and 2008 fourth quarter and full year, as the nature and amount of the adjustments included on the reconciliation can and do change from period to period.On to our 2009 results. As you have heard from Heather, our very strong operational execution across the board enabled us to meet or exceed each element of our 2009 financial guidance, which we last updated in October. Starting with our consolidated top line, total revenues for the quarter were $1.35 billion, an increase of 12% over last year's fourth quarter of $1.2 billion. Revenues in the current quarter were favorably impacted by the effect of foreign currency translation, reflecting a weaker U.S. dollar. Translating currency, current year revenues at prior year exchange rates would have resulted in operational year-over-year revenue growth of approximately 6%, while the change in currency rates also contributed six percentage points of growth.For the full year, adjusted revenues increased 8% to $5.1 billion, which is the upper end of our guidance range. Revenues in the current year were unfavorably impacted by the effect of foreign currency translation, primarily reflecting a stronger U.S. dollar. Compared to last year's full year adjusted revenue of $4.7 billion, operational growth calculated, as I just explained, was 12% and the negative impact of currency was 4%. Looking at our operational profitability measures, adjusted gross margin for the quarter was approximately 44%, resulting in a full year adjusted gross margin of approximately 46.5%, in line with our guidance range. As anticipated, fourth quarter adjusted gross margin was our lowest of the year, reflecting a seasonally light quarter for EpiPen Auto-Injector revenues and price erosion following the loss of exclusivity on Divalproex in the third quarter. We continue to do an excellent job of increasing the efficiency of our R&D spend and leveraging our infrastructure that has allowed us to keep our R&D and SG&A costs in check while increasing the productivity of these expenditures, as you saw in the submission and launches metrics Heather reviewed. Adjusted R&D expense for the quarter was $72 million or 5.3% of revenue, bringing full year adjusted R&D expense to $250 million or about 5% of adjusted revenues. Adjusted SG&A expense was $253 million for the quarter and $990 million for the year or 19.6% of adjusted revenues, just below the middle of our guidance range. Our quarterly adjusted EBITDA was again strong at $312 million in the fourth quarter. This represented our fifth consecutive quarter of generating adjusted EBITDA of $300 million or more. For the year, adjusted EBITDA was $1.25 billion, at the upper end of our guidance range and represented a 21% increase over last year's adjusted EBITDA of $1 billion. Moving now to a couple of our non-operating financial metrics. Interest expense adjusted to exclude imputed interest on our converts was $67 million in the fourth quarter and totaled $276 million for the year, essentially in line with our previous full year projection of approximately $280 million. Our fourth quarter and full year adjusted effective income tax rates came in at 30%, in line with our October projections. In total, these metrics drove strong adjusted net income and adjusted diluted earnings per share. For the fourth quarter, adjusted net income was $143 million, an increase of $23 million or 19% over the $120 million for the same period a year ago.Adjusted diluted EPS was $0.33, an increase of $0.07 or 27% over last year's fourth quarter adjusted diluted EPS of $0.26, and $0.01 stronger than the third quarter this year, demonstrating our ability to maintain our earnings momentum. For the full year, adjusted net income totaled $583 million, which exceeded the upper end of our guidance range. Adjusted diluted EPS totaled $1.30, representing an increase of $0.50 or 63% over last year's $0.80. Contributing to our adjusted diluted EPS during the quarter was the effect of a lower if-converted shares associated with the company's mandatory stock, as a result of the strength of our stock price. Turning to our cash flow metrics. Once again, we produced strong cash flows from operations. For the full year, cash flow from operations were $605 million, which despite including approximately $52 million in net after-tax cash outflows during the fourth quarter related to the DOJ legal settlement, came in near the upper end of our guidance range of $550 million to $625 million. Additionally, after a particularly robust fourth quarter, spending on capital for the full year totaled $170 million, in line with our most recent full year forecast. In summary, we had an exceptionally strong finish to a very successful year on many fronts, building up strong momentum as we enter 2010. Now turning back to Slide 7 that details our 2010 guidance. Heather has already provided you with the update to our guidance for 2010, our baseline year from which Mylan will continue to grow. Before turning it over to Brian, I would like to share the details of some of the assumptions that underlie this guidance, some of which have changed. First, the midpoint of our unchanged 2010 47% to 49% adjusted gross margin guidance range reflects a forecasted expansion of about 160 basis points from 2009, largely as a result of the benefit of our ongoing synergy and operational efficiency programs, and our API and FDF vertical integration efforts that Heather detailed earlier and a continued strong product mix. Continuing this trend, the midpoint of our SG&A as a percent of revenues represents a 60 basis point improvement, as we further leverage our infrastructure and keep our SG&A costs in check while increasing our productivity. With respect to Paragraph IV opportunities, these opportunities, as we said last year, are not a significant element of our 2010 guidance. On the currency front, the FX rates used in our 2010 guidance and our growth targets approximate current market conditions. We continue to forecast 2010 interest expense, net of the imputed interest on our converts, to be in the range of $280 million to $300 million. This range considers the potential for higher short-term interest rates and potentially a higher level of interest expense, should we opportunistically execute a long-term financing transaction during 2010.With regard to income tax, we are now assuming an all-in adjusted effective income tax rate in the range of 28% to 30% over the 2010 to 2013 period, versus 30% in 2009 due to the benefit of additional anticipated tax planning strategies. And finally, two important cash flow metrics. We expect 2010, operating cash flow to be in the range of $725 million to $825 million, almost 30% higher than our strong 2009, based on the midpoint of this range. We project our investment in capital to be around the $250 million run rate for the next several years, as we continue to invest on our global platform. Now let me turn the call over to Brian for an update on our capital structure and liquidity position."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Dan, and good morning, everyone. As we've reported over the last several quarters, we continued to be in great shape from a capital structure liquidity perspective, and our position continues to improve with each passing quarter. Thanks to our",370,"Thank you, Dan, and good morning, everyone. As we've reported over the last several quarters, we continued to be in great shape from a capital structure liquidity perspective, and our position continues to improve with each passing quarter. Thanks to our strong operating cash flow throughout the year, we invested approximately $340 million related to capital and business acquisitions, including purchasing the bulk of the remaining minority shares of Matrix. We prepaid approximately $350 million in long-term debt maturities, and we paid $139 million in preferred dividends.Notwithstanding these cash outflows, that aggregated approximately $830 million, we still closed the year with over $400 million in unrestricted cash and marketable securities. As a result of the previously mentioned debt prepayment, we have no meaningful long-term debt maturities until the third quarter of 2012 and from a covenant perspective, the level of our senior secured debt is approximately 2.7x our last 12-month covenant basis [ph] adjusted EBITDA, which is well below our December 31, 2009 covenant threshold of 4.0x, and also comfortably ahead of our December 31, 2010 threshold of 3.5x.As you already heard from Robert and Heather, we're targeting compound annual earnings growth of 20% for 2013, and expect to generate approximately $4 billion in total operating cash flow in 2010 through 2013. This projected strong cash flow provides us with substantial flexibility to continue to invest in the growth of our business while at the same time, meet the approximate $1 billion in debt payment requirements through 2013, potentially on an accelerated timetable. In addition, we expect we will have opportunities to accelerate repayment of our 2014 debt schedule. And as Dan just mentioned, also look for us to opportunistically go to the capital market to refinance a portion of our term loans, to continue to further optimize the maturity profile of our capital structure. Lastly, let me remind you that our mandatory convertible preferred shares will convert to common stock in November. Not only will this eliminate our $139 million annual dividend commitment, but will also result in the largest market capitalization in the company's history. At recent stock prices, well in excess of $8 billion. I'll now turn the call back over to Dan to start the Q&A."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Brian. Melanie, we're now a ready to open the line for questions.",14,"Thank you, Brian. Melanie, we're now a ready to open the line for questions."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] We will take our first question from Chris Schott of JPMorgan.",13,"[Operator Instructions] We will take our first question from Chris Schott of JPMorgan."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","What do you think of the I guess, roughly $3.5 billion of incremental sales you're anticipating by 2013 being relative to what you did in 2009. How should we think about that being split between your three primary regions right now? And how do you see you",56,"What do you think of the I guess, roughly $3.5 billion of incremental sales you're anticipating by 2013 being relative to what you did in 2009. How should we think about that being split between your three primary regions right now? And how do you see your geographic mix I guess, shifting over that time frame?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Well, I think a couple of things. Certainly, as we talked about in '09 and '10, talking about just the voluminous amount, the one just that we had coming from the pipeline, so we're still on track in '10 to deliver over 500 launches, really coming from al",175,"Well, I think a couple of things. Certainly, as we talked about in '09 and '10, talking about just the voluminous amount, the one just that we had coming from the pipeline, so we're still on track in '10 to deliver over 500 launches, really coming from all regions. So double hundred [ph] in EMEA, we have the 50 to 60 in the United states, we have the 50 to 60 from the Asia-Pac region, so really a nice mix. And we see that mix just continuing. The sustainability of that 500 launches over the longer term as I mentioned, we really believe at the run rate. So I think that it's that, coupled certainly with the statistics that we talked about from the vertical integration, the repatriating of our products that's leading to that efficiencies in our cost of goods. So when you think about the $8.5 million that were projected by the end of 2013 coming from really what's already built and will be built by the end of 2010 in our pipeline."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","But Chris, let me just add, if you did look at pie chart today and how that pie chart would be broken out, clearly, the North America region is the hunter pine guerrilla [ph]. But if you looked at that pie chart in 2013, North America will not be as large",70,"But Chris, let me just add, if you did look at pie chart today and how that pie chart would be broken out, clearly, the North America region is the hunter pine guerrilla [ph]. But if you looked at that pie chart in 2013, North America will not be as large. They're still going to be large but definitely, there's a more diversification, anticipation that we projected through the 2013."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","I know M&A is not included in this guidance you're giving out today. But I guess with Merck and Matrix integration, it's kind of nearing completion as we go through 2010. I guess, at what point do you start looking to pursue additional acquisitions? And w",97,"I know M&A is not included in this guidance you're giving out today. But I guess with Merck and Matrix integration, it's kind of nearing completion as we go through 2010. I guess, at what point do you start looking to pursue additional acquisitions? And when we think about, I guess what are the kind of key markets you'll be targeting and should we think of -- if you were to look at these, these are generally smaller transactions or just how do we think about that piece of the business over the next few years?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Well, I mean I've made a commitment to the shareholders and our stakeholders not to interrupt this massive growth rate that we've anticipated all along. And I've asked those shareholders to stick with us and I will not have any disruption. We see that we'",352,"Well, I mean I've made a commitment to the shareholders and our stakeholders not to interrupt this massive growth rate that we've anticipated all along. And I've asked those shareholders to stick with us and I will not have any disruption. We see that we've delivered, we're going to continue to deliver. I don't really need -- I mean, I think the first thing we should ask ourselves, do I need anything else that's out there? And I've said this many times, I just don't see anything else out there that we would need that would further enhance our strategic and operational capabilities. We have everything you would ever want in this industry on board right now. And when you take a look at the growth for just what we already have, certainly, if I did look at anything in the future, it's not going to be anything that's going to be strategic and certainly not dilutive. I don't want to interrupt the earnings momentum that we have right now. But do I see like both and on -- for example, I think the simplest way to look at the opportunities I'm going to look at, I think when Teva gave their presentation, they said they were going from 22% market share to 35%. If you look at that 22%, you'll see that growth, I think in North America alone, we were at 7.8% or 7.8% there, like it's 7.6% market share in North America. If you take a look at that growth rate, you'll find that there was 10.8% of market share that they included on products that we did not have yet. So if you can just imagine what we are going to focus on, we certainly built this platform of scale. You should just be thinking about those therapeutic categories. That 10.8% share that they have, we don't have it yet, and you should expect us to layer those in as we go along. That's more of the kind of activity I think you should anticipate from me going forward rather than some, a need for some huge acquisition."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Next we'll go to Rich Silver from Barclays Capital.",10,"Next we'll go to Rich Silver from Barclays Capital."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Just on the 2010 guidance, we're finishing 2009 gross margin of 44%, you had 46% in the third quarter and obviously the first half had a higher margin because of generic Depakote. Can you give us some sense of how you get to a 47% to 49% range if there ar",65,"Just on the 2010 guidance, we're finishing 2009 gross margin of 44%, you had 46% in the third quarter and obviously the first half had a higher margin because of generic Depakote. Can you give us some sense of how you get to a 47% to 49% range if there aren't any significant first-to-files, what will be driving the gross margin to that higher level?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","First of all, Dan actually, I thought did a real good job in addressing that. But I'm glad you're giving us an opportunity to go through that again. As you can see, the continued momentum that we have with the cost of goods and our ability in the strong n",245,"First of all, Dan actually, I thought did a real good job in addressing that. But I'm glad you're giving us an opportunity to go through that again. As you can see, the continued momentum that we have with the cost of goods and our ability in the strong number of launches, new launches that we have and the continuation as Heather mentioned, about 2/3, we started out with Merck when we acquired them, 2/3 of their business has been outsourced. We're now done to 55% from the 2/3 that they had. And we see that momentum continuing throughout 2010 and further improving that gross margin as we go along. And also as Heather said Rich, and I would caution all of you in terms of your modeling, we are sliding into '10, just look at slide into '10. As she mentioned, expect the back half of '10 to be better than the first half of '10 simply because of this continued momentum. As we go from fourth quarter '09, slide into '10 and the continued momentum that we had now for the last several quarters, all continue to materialize. And you will see an upswing towards the latter half of next year, both in product launches, the voluminous amount of product launches we expect to get in the second half of the year and the continued improvement that we will have in the cost of goods and the synergies that ought to roll in."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","And one follow-up on share count, can you give us some sense of share count in 2010 and how we should be thinking about that in the out years?",30,"And one follow-up on share count, can you give us some sense of share count in 2010 and how we should be thinking about that in the out years?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Brian, what do we have? That'd [ph] be about 405, if you take a look at the fully diluted?",19,"Brian, what do we have? That'd [ph] be about 405, if you take a look at the fully diluted?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","We've assumed in our guidance in '10 and the out years that the mandatory preferred will convert into about $125 million in November of 2010, and then left at reasonably stable up did a little bit for anticipated stock price...",41,"We've assumed in our guidance in '10 and the out years that the mandatory preferred will convert into about $125 million in November of 2010, and then left at reasonably stable up did a little bit for anticipated stock price..."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","What's the total?",4,"What's the total?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","The base is $306 million plus the $125 million.",9,"The base is $306 million plus the $125 million."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","$306 million plus the $125 million.",6,"$306 million plus the $125 million."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Well 34, 35 as the starting point, okay?",8,"Well 34, 35 as the starting point, okay?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Next we'll go to Randall Stanicky from Goldman Sachs.",10,"Next we'll go to Randall Stanicky from Goldman Sachs."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Just to go back again to the top line guidance clearly, above recent trend and better than peers. Maybe Robert, I'll just ask, can you help us understand maybe growth by region just directionally. And then in the U.S. obviously, you referred to market sha",79,"Just to go back again to the top line guidance clearly, above recent trend and better than peers. Maybe Robert, I'll just ask, can you help us understand maybe growth by region just directionally. And then in the U.S. obviously, you referred to market share opportunities. So maybe can you understand which product categories, I mean obviously, generic or perceptives [ph] stand out but are there other areas that we would expect you guys to be coming in on?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","For surely, you should expect us to come in other areas as I mentioned in the -- and again, focused on that 10.8% market share we do not yet have. And that will be our focus. But Randall, I would tell you that again if you look at the pie chart, we defini",229,"For surely, you should expect us to come in other areas as I mentioned in the -- and again, focused on that 10.8% market share we do not yet have. And that will be our focus. But Randall, I would tell you that again if you look at the pie chart, we definitely see growth in Europe, with increase in generic utilization, definitely. In the sheer number of product applications that we put in , I think Heather mentioned, almost 3,000 submissions certainly by the end of 2010. There's a voluminous amount of that in the EMEA region. And then of course in Asia-Pacific, we're looking at Asia-Pacific albeit small Randall, right now and not material, we do see growth in the Asia-Pacific but I'd say more growth in the European region. And please, I don't want to take away from North America. It doesn't matter that we have what? 75%. I think we heard at the GPhA, now according to IMS' generic utilization. I have to tell you with 10.8% of marketshare that we don't yet have in our portfolio, you can rest assure as we layer those products in, I fully expect to get that similar market share that we enjoy today with some of our competitors. So I do see a lot of opportunity here even in North America. Heather, do you want to add anything?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Yes, and I would just remind you Randall, that we're still seeing accelerated double-digit growth from both Matrix and Dey. So as we have factored in all of these things, it is really -- we are seeing contributions from everywhere. And like I said, we sti",61,"Yes, and I would just remind you Randall, that we're still seeing accelerated double-digit growth from both Matrix and Dey. So as we have factored in all of these things, it is really -- we are seeing contributions from everywhere. And like I said, we still see a lot of upside today, as well as our ARV franchise out of Matrix."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, did you update us on the number of launches in the U.S.? I know you've given us that figure before including the number of high-value for 2010?",28,"Heather, did you update us on the number of launches in the U.S.? I know you've given us that figure before including the number of high-value for 2010?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","We're still on track. I had mentioned about 12 limited competition launches and our overall launches being around 50. So we're still on track to meet that in the United States.",32,"We're still on track. I had mentioned about 12 limited competition launches and our overall launches being around 50. So we're still on track to meet that in the United States."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Next we'll go to John Boris with Citi.",9,"Next we'll go to John Boris with Citi."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","First has to do with the tax planning strategy that you're going to be deploy going forward. Obviously, looking for a 200 basis-point improvement on the tax rate. Can you just take us or help us understand what's going on there to lead do that improvement",61,"First has to do with the tax planning strategy that you're going to be deploy going forward. Obviously, looking for a 200 basis-point improvement on the tax rate. Can you just take us or help us understand what's going on there to lead do that improvement and then how you see that rolling out between the '10 and '13 period?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Going again to specific details that we are a global company and as a global company, we have opportunities in order to more put tax planning in order to optimize our tax structure. When we were simply a U.S. company, there's much more limited planning yo",48,"Going again to specific details that we are a global company and as a global company, we have opportunities in order to more put tax planning in order to optimize our tax structure. When we were simply a U.S. company, there's much more limited planning you can do."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","But just to add on top of that, John, let me just say that, when I tell you that we expect a lot of that growth to come from a lot more in some of the other regions outside of North America, consistently that should tell you a little bit about how we inte",138,"But just to add on top of that, John, let me just say that, when I tell you that we expect a lot of that growth to come from a lot more in some of the other regions outside of North America, consistently that should tell you a little bit about how we intend on improving our tax, our overall marginal tax rate. And that again, is consistent with where we see our top line, where the growth of our top line is coming as well. But there's always a balance there because as we certainly want to do better in North America and as we continue to do better in North America, there's always that trade-off with that tax rate, dependent upon where that volume is coming from. But that's kind of sort of where we are."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","And then just one for Heather, I guess back to the 12 high-value launches for this year. I think you had targeted six in 2009, can you just take us through what those products were, I think there's still a couple remaining that are you anticipating that c",74,"And then just one for Heather, I guess back to the 12 high-value launches for this year. I think you had targeted six in 2009, can you just take us through what those products were, I think there's still a couple remaining that are you anticipating that could be into 2010, and does that take that number from 12 up to maybe 14 or 15 in light of not getting products approved in '09?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","We don't actually hit the six for the second half of '09. And obviously, like I said, still on track for the 12 for '10. I didn't call out every one. I can tell you that we ended up -- we had everything from Lansoprazole, which as you know, continues to b",89,"We don't actually hit the six for the second half of '09. And obviously, like I said, still on track for the 12 for '10. I didn't call out every one. I can tell you that we ended up -- we had everything from Lansoprazole, which as you know, continues to be a nice product for us. Liothyrine, Clindamycin, were the ones that kind of came in the fourth quarter. So we did end up hitting the six and like I said, our numbers still 12 for '10."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Next we'll go to Frank Pinkerton from SunTrust.",9,"Next we'll go to Frank Pinkerton from SunTrust."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Can you just make some a comment between now and 2013? We've seen I guess some changes in the pricing dynamics in different countries, major countries where you have sales around the world. And what are some of the thoughts and assumptions that you're mak",59,"Can you just make some a comment between now and 2013? We've seen I guess some changes in the pricing dynamics in different countries, major countries where you have sales around the world. And what are some of the thoughts and assumptions that you're making for price changes and pricing pressure overall in the generic industry in that guidance?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","I can only tell you that a continuation of price reductions in every single market that the healthcare systems around the world can achieve. And I would say that we're fully expecting that continuation. But what we're doing, we've said this all along our",124,"I can only tell you that a continuation of price reductions in every single market that the healthcare systems around the world can achieve. And I would say that we're fully expecting that continuation. But what we're doing, we've said this all along our lace is to make sure that we drive our cost of goods down and hopefully, quicker than our ability to have to absorb these price reductions. So our strategy has always been about yielding optimum efficiencies. And we think that there's still more of those efficiencies to be had. And so we think that our operational efficiencies with this massive platform that we now are operating is the mitigating balancing act of the continuation of price reduction around the world."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","And then, you made a comment that from strategic standpoint, not a whole lot of assets you're looking at to acquire. But can you make a comment from some of the in-house technologies that Mylan has, things like the Auto-Injector and how do you push that t",75,"And then, you made a comment that from strategic standpoint, not a whole lot of assets you're looking at to acquire. But can you make a comment from some of the in-house technologies that Mylan has, things like the Auto-Injector and how do you push that to other products, things like that patch technology and how you push that to other products? And will that be any part of significant growth in this 2013 strategy?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Absolutely positively, those are incremental growth opportunities for us as we see forward. I mean, the beauty about where we're situated today compared to our concentration say in the last couple of years, I do believe we have that breathing right now, t",76,"Absolutely positively, those are incremental growth opportunities for us as we see forward. I mean, the beauty about where we're situated today compared to our concentration say in the last couple of years, I do believe we have that breathing right now, to really laser focus now on some of the opportunities that you mentioned and to further enhance them, which I do believe will be incremental to what we've already delivered to you hear today."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Our next question will come from Elliot Wilbur from Needham & Company.",11,"Our next question will come from Elliot Wilbur from Needham & Company."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Specifically with respect to price erosion in the U.S. market, is it safe to assume that your expectations embed roughly kind of a mid-single digit erosion rate? And then I know you mentioned Paragraph IV is not being a major component of that growth. But",86,"Specifically with respect to price erosion in the U.S. market, is it safe to assume that your expectations embed roughly kind of a mid-single digit erosion rate? And then I know you mentioned Paragraph IV is not being a major component of that growth. But historically, you've talked about sort of using roughly a 50% probability of success in your internal modeling. I just want to make sure that your numbers do include your entire PIV pipeline and that's roughly the rate of success assumed."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Yes. I mean, I can have Heather address a little bit more detail in terms of the Paragraph IV. But again, let me be clear about -- each region is modeled a little bit differently. In the United States, I would have to tell you with all due respect, a lot",322,"Yes. I mean, I can have Heather address a little bit more detail in terms of the Paragraph IV. But again, let me be clear about -- each region is modeled a little bit differently. In the United States, I would have to tell you with all due respect, a lot of the external dynamics and external environment that we see within the industry is I believe, we are certainly benefiting from. I believe that our customer base has a significant higher appreciation for high-quality, high-volume producers. And so I do see more of that in the United States in terms of single-digit, pricing reduction, which has been consistent in our models offset again by the significant further appreciation for to say a platform like Mylan as a reliable quality supplier. In Europe, we are reliant substantially on a continuation of rightsizing that infrastructure as markets continue to move towards a more, a different kind of a distribution system, whether it's tenders. So we have enough mitigating opportunities over there, mitigating cost opportunities over there that we believe we can keep pace with where we see the European market going. But more importantly Europe, we see a significant increase in generic utilization. And it's through our ability to capture those additional volumes, that's another mitigating factor we see in the European region. In the Asia-Pacific region, as you know in 2008, Australia already went off the cliff completely in terms of changing its whole healthcare system from a more of a brand to generic to more of a commodity type of distribution. We've now settled in 2009 there. We are now rebuilding from a new baseline in Australia. And in Japan, all I can tell you is that even though we're, I would say, not material today, I do see a substantial opportunity in Japan. For increased generic utilization. And Heather, do you want to add anything on the Paragraph IV side?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Just that our assumptions remains the same. As you say that we've said that there is nothing significant in 2010. But we still do the 50% probability weighted and account for an authorized generics.",34,"Just that our assumptions remains the same. As you say that we've said that there is nothing significant in 2010. But we still do the 50% probability weighted and account for an authorized generics."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","We'll take our final question from David Buck of Buckingham Research Group.",13,"We'll take our final question from David Buck of Buckingham Research Group."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","First on the U.S. business, can you talk a little bit about the two factors? One, you touch in a little bit Robert, the supply disruptions in the market, what the impact was in the fourth quarter and what the expectation is for 2010 in terms of pricing. A",102,"First on the U.S. business, can you talk a little bit about the two factors? One, you touch in a little bit Robert, the supply disruptions in the market, what the impact was in the fourth quarter and what the expectation is for 2010 in terms of pricing. And also, what's your view on how the FDA backlog has affected Mylan, if at all and what the expectations as you look into 2010? And then one for Heather, just can you give us some sense of why the back waiting of the synergies, the $125 million, what the drivers are there?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","So maybe I'll start with first on the FDA question. We have seen our timeline definitely been pushed out. I would to still say we're definitely ahead of the market industry. So we're still above the averages that FDA is putting out there as far as their a",81,"So maybe I'll start with first on the FDA question. We have seen our timeline definitely been pushed out. I would to still say we're definitely ahead of the market industry. So we're still above the averages that FDA is putting out there as far as their approval time. But we have seen some delay and we've accounted for that in our modeling assumptions as well. As far as -- I'm sorry, what was the first part of your question."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Just the supply disruptions that you're aware...",8,"Just the supply disruptions that you're aware..."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Yes, the market disruptions, I would say, as you know, we still see everything from the companies, the recall situation, companies still not back in the market. So we have definitely seen some volume uptake. I would tell you that I had said in Q4, it was",131,"Yes, the market disruptions, I would say, as you know, we still see everything from the companies, the recall situation, companies still not back in the market. So we have definitely seen some volume uptake. I would tell you that I had said in Q4, it was not significant. I think that as we see the year go on, as people stay out of the market that it certainly will have a positive, could have a positive upside. We're being very strategic about the opportunities that are in front of us. And I think though as Robert always cautions, we absorbed a lot. So while we take a lot into consideration, as you know, there's a lot of ups and downs that we to look and take all that into consideration."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","In terms of the synergies, Dave, in terms of the back-end rollout, this is really not a new story. Dave, if you watched kind of sort of how the synergies have been rolling in, it's a continuation and a buildup. And I mean, it's happening almost like clock",196,"In terms of the synergies, Dave, in terms of the back-end rollout, this is really not a new story. Dave, if you watched kind of sort of how the synergies have been rolling in, it's a continuation and a buildup. And I mean, it's happening almost like clockwork. And you should expect more of that, more towards the back end and the fact of the matter is, I said a while ago, we didn't see it ending, we might even exceed the $300 million. I think you see that now, and I don't see it stopping. I just don't see the end insight because what we're doing is really managing the business appropriately not trying to upset the balance throughout our regions. But making sure that we're right sized for what the market calls for in any particular time. But the work that's been done in the past, all of the things that Heather has put in place is really rolling out exactly the way we predicted. And that's why I caution [ph] as we go into '10, we're going from '09 slide into '10, and you should see a continuation of the growth in '10."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","And I think '09 story played out just that way.",10,"And I think '09 story played out just that way."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","On Merck Generics, you mentioned the percentage of outsourced products is about 55%. Are you referring to outsourced API or just actually outsourced product?",24,"On Merck Generics, you mentioned the percentage of outsourced products is about 55%. Are you referring to outsourced API or just actually outsourced product?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","This will be finished dosages. One of the benefits we saw, David, that when we acquired Merck was, as strong as that business was, actually David, a lot of that business, 2/3 of that business was done by in-licensing dossiers and reselling them in the mar",108,"This will be finished dosages. One of the benefits we saw, David, that when we acquired Merck was, as strong as that business was, actually David, a lot of that business, 2/3 of that business was done by in-licensing dossiers and reselling them in the markets through other third-party manufacturers. What we brought, the natural complement we brought at Mylan, with Matrix especially, was our ability to bring all that external activity inside, internally and to yield through the integration of those efficiencies that you're now seeing rolling through our numbers exactly as we predicted. And we see more of that to come over the next few years."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Next we'll go to Marc Goodman with UBS.",9,"Next we'll go to Marc Goodman with UBS."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, can you give us a flavor for in France and Australia, what type of price cuts you think you're going to end up going through the governments there?",29,"Heather, can you give us a flavor for in France and Australia, what type of price cuts you think you're going to end up going through the governments there?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","I won't to try to predict what the governments are going to do. Starting with France, things on -- over this past 12 months as we look into now into 2010, I would say that they been in line with our expectations and what we've accounted for. There's nothi",162,"I won't to try to predict what the governments are going to do. Starting with France, things on -- over this past 12 months as we look into now into 2010, I would say that they been in line with our expectations and what we've accounted for. There's nothing that leads me to believe there's something coming into place that we're not accounting for. As you know, they look annually and have a different way of negotiating especially once the products on the repertoire list. So all I can say that in 2010, I don't be see anything that we've not anticipated for in France. As far as Australia goes, they're in the midst of the government contemplating what they're going to do for the next year. So I really don't see 2010 so much as the fact that we'll have to wait and see how that dialogue transcends through the summer and if there would be any adjustments for 2011."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","So in France, are you just kind of assuming maybe 5%-type hit, nothing material?",14,"So in France, are you just kind of assuming maybe 5%-type hit, nothing material?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","I would say without getting into percentage certainly, we are assuming a reduction. But yes, we fully accounted that in our guidance. And in Australia, I just don't see a material change given the significance of what occurred in 2008 and the fact that we",49,"I would say without getting into percentage certainly, we are assuming a reduction. But yes, we fully accounted that in our guidance. And in Australia, I just don't see a material change given the significance of what occurred in 2008 and the fact that we rebased ourselves in '09."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Next we'll go to Greg Gilbert with Bank of America Merrill Lynch.",13,"Next we'll go to Greg Gilbert with Bank of America Merrill Lynch."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","For Heather, any updated comments on your Soladyn and Clonidine applications and whether or not your filer on Toporol XL [ph]. And then for Rob, the uncontinued execution on what's on your plate and maybe some small bolt-ons along the way, what are the ne",70,"For Heather, any updated comments on your Soladyn and Clonidine applications and whether or not your filer on Toporol XL [ph]. And then for Rob, the uncontinued execution on what's on your plate and maybe some small bolt-ons along the way, what are the next big steps in Mylan's evolution that you're thinking about today that may occur a few years our or need to occur a few years out?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Let me answer the last question first because the whole world, the whole world would like to know what's on my mind, Greg. And I'm not ready to tell the whole world yet what's next. Heather?",36,"Let me answer the last question first because the whole world, the whole world would like to know what's on my mind, Greg. And I'm not ready to tell the whole world yet what's next. Heather?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","And as far as Soladyn and Clonidine, I would just say that we still feel very good and confident about our applications. And I can't really say anything more of the timing on that. But still very good about where they are. And as far as you know, we don't",63,"And as far as Soladyn and Clonidine, I would just say that we still feel very good and confident about our applications. And I can't really say anything more of the timing on that. But still very good about where they are. And as far as you know, we don't talk about any of our other applications that aren't in Paragraph IV litigation."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Next we'll go to Ken Cacciatore from Cowen and Company.",11,"Next we'll go to Ken Cacciatore from Cowen and Company."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Robert, you see large pharma constantly talking about going and in fact running to emerging markets and using a bit of a generic strategy. Just wanted to get your thoughts on what they're looking at, if you're looking at similar things. And then going bac",170,"Robert, you see large pharma constantly talking about going and in fact running to emerging markets and using a bit of a generic strategy. Just wanted to get your thoughts on what they're looking at, if you're looking at similar things. And then going back to your -- earlier in the call, you talked about being very focused on deleveraging the balance sheet which I appreciate and certainly, so much changes in a year from where we were a year and a half ago to where we are today. But I'm wondering if that mindset given how well you have performed and the cash flows are coming through, maybe that mindset is locked still back a year and a half ago. And that as you have so many of your competitors looking of the assets available, you said you don't need anything. But it seems that there's a land grab going on. And so maybe, if we're holding on too tight and there are opportunities that you should be pursuing?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","First of all, in terms of the Big Pharma, Ken, I actually welcome and I say this with the largest open arms I could possibly tell. I welcome Big Pharma in the emerging markets because it's just like the brand business. I'll use their language, there's not",345,"First of all, in terms of the Big Pharma, Ken, I actually welcome and I say this with the largest open arms I could possibly tell. I welcome Big Pharma in the emerging markets because it's just like the brand business. I'll use their language, there's nothing more powerful than shared voice. The more voice, the more increase. The more I have their reps out, they're talking about generics, the more increased generic utilization you can expect. I think that Big Pharma coming into the generics sector in these emerging markets is going to accelerate much quicker the increase in generic utilizations. The only thing they have to watch for obviously is how that might bite the remaining portion of the brand aspect of what they have left. So from our perspective, it is beyond welcome. I'll take all the share voice I can get. And in terms of my mindset, this I can give you. And I said this I think in the last conference call. When I tell you, when you go from no debt to $8 billion of debt, 8x debt to EBITDA with a commitment to delever, which we did when we raised the $3 billion and then we went I think around, the 6x debt to EBITDA and made a commitment to go down to 3x debt to EBITDA. And then you know I have that Ken, I hate it. I have to tell you, I am extraordinarily, now that we've matured with the business, now that we've kind of grounded ourselves, now that I see things end up strength of the platform, understand it, lived with it, managed it, I am beyond extremely comfortable with a 3:1 debt to EBITDA ratio. And so, if you look at that as a optimum, 3:1, could I live at 2.5? Yes, of course. But 3:1 debt to EBITDA is I would say that line, that I am most comfortable based on what we built today. And I think it is the optimum capital structure really for our company as I see it."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","One thing that we constanly observe is the U.K. market for everyone seems to always be very difficult and tough. And I don't know if you all agree with that. As a U.S.-centric analyst, we see that market and we see it's tough and awful and nasty. And wond",119,"One thing that we constanly observe is the U.K. market for everyone seems to always be very difficult and tough. And I don't know if you all agree with that. As a U.S.-centric analyst, we see that market and we see it's tough and awful and nasty. And wondering why and I think you're hearing from a lot of the analysts asking the same questions, why that nastiness doesn't spread throughout the European region at some point in time, these governments kind of all start looking at that model. It seems to be the most advantageous in terms of cost. And so I guess that's what I would ask it even more directly, why won't you case spread?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","It's a lot easier said than done, Ken. You can't look at just one aspect of the market, you got to look at the whole distribution, the whole food chain. And you can't just flick a switch and apply some statement over all this countries when there's really",244,"It's a lot easier said than done, Ken. You can't look at just one aspect of the market, you got to look at the whole distribution, the whole food chain. And you can't just flick a switch and apply some statement over all this countries when there's really a lot more involved logistically than just simply the end result of what the U.K. is dealing with. But I think, you have seen a lot of the countries trying to move to more efficient markets, more efficient ways of distributing. I think Germany is a great example. I think, you used to be able to not be able to do business in Germany without a sales rep. Today, the sales reps can be a thing of the past. But just because they're finding other ways to distribute their products. You should not worry about from an investment thesis is that certainly companies like ourselves who began in the United States and have gone global, it's a lot easier for us to make the adjustments because we come from that kind of a market versus some of the companies that are not domestic, trying to make the adjustments. It's a lot more difficult for those companies in Europe to make the adjustments. It's very easy for us to make the adjustment in term of making sure we balance the act between rightsizing the organization for the infrastructure cost versus the distribution system that's in play."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Next we'll go to Ronny Gal from Bernstein.",9,"Next we'll go to Ronny Gal from Bernstein."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Starting at the move from externally manufacturing internally, can you give us an idea about how to measure the impact of this? First, what does that due to your utilization and that your current facilities. And two, versus external manufacturing come rou",54,"Starting at the move from externally manufacturing internally, can you give us an idea about how to measure the impact of this? First, what does that due to your utilization and that your current facilities. And two, versus external manufacturing come roughly as a percentage, what kind of savings to bring those product in?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","First of all, Ronny, you already seen to the impact. The impact is coming right through to our numbers. We couldn't deliver the numbers that we're delivering without the results of what that impact has already been. And I really should have answered your",342,"First of all, Ronny, you already seen to the impact. The impact is coming right through to our numbers. We couldn't deliver the numbers that we're delivering without the results of what that impact has already been. And I really should have answered your first second because when it comes to utilization, Mylan made up it's mark, it's always had a mantra built for the future. We've always built up ahead of ourselves. When we first built -- we first bought Matrix, can tell you from day one, from day one, there was a reason why we bought Matrix, and did not do -- we were the first ones to go to India to be able to do a transaction of that size. But the major reason and not to do a ""commercial business transaction 7,000 miles away"", was to buildout those facilities, the vision came -- our benefit today is from the vision that we had three years ago, quite frankly. This is benefiting from what we saw three years ago in terms of what needs to be done. We've invested substantially in down in India to build out their facilities. I think to give you an example, I think when we bought Matrix, we were at 2,200 employees. Today were up over 5,000 employees. Over double in terms of where we are. I think how many hundreds of millions we put in CapEx out there. About half a billion dollars to build the facility. In this business, Fortune we were fortunate, as you know, lead time is everything. As Heather mentioned, two years ago, she is just us because everything I can do, to deliver the results that we plan to deliver in the future, in terms of which is up to us, it's done. By the end of the first quarter of 2009, I'll be gone. But is now were to rely on the regulatory system. That's why we began to do that in the facilities long before this anticipated volume were not realized and that you now appreciate."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Analysts","Can you give us an about the capacity utilization system today, and where it would be somewhere kind of the year and a half down the road?",27,"Can you give us an about the capacity utilization system today, and where it would be somewhere kind of the year and a half down the road?"
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","It's a rolling forward process, and there's no real production other than that we constantly try to build so that we have excess capacities in noted to take advantage of opportunistic situations that arise in the marketplace as you've seen a couple of the",47,"It's a rolling forward process, and there's no real production other than that we constantly try to build so that we have excess capacities in noted to take advantage of opportunistic situations that arise in the marketplace as you've seen a couple of them in 2009."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","I would like to turn the call back to Mr. Dan Crookshank for any additional closing remarks.",17,"I would like to turn the call back to Mr. Dan Crookshank for any additional closing remarks."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Melanie. On behalf of the Mylan team here, I would like to thank everyone for joining us on the call, and we'll be available to take some calls off-line. Thank you very much for joining us.",38,"Thank you, Melanie. On behalf of the Mylan team here, I would like to thank everyone for joining us on the call, and we'll be available to take some calls off-line. Thank you very much for joining us."
290203,90012098,51644,"Mylan, Inc., 2009 Earnings Call, Feb 25, 2010",2010-02-25,"Earnings Calls","Viatris Inc.","Operator","Ladies and gentlemen, that does conclude today's call. Thank you all for your participation.",14,"Ladies and gentlemen, that does conclude today's call. Thank you all for your participation."
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Good day everyone and welcome to todays Mylans 2010 first quarter earnings conference call. Todays conference is being recorded and now it is my pleasure to turn the conference over to Mr. Dan Crookshank, Mylans Vice President of Global Invest",46,"Good day everyone and welcome to todays Mylans 2010 first quarter earnings conference call. Todays conference is being recorded and now it is my pleasure to turn the conference over to Mr. Dan Crookshank, Mylans Vice President of Global Investor Relations. Please go ahead, sir.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kelsey. Good morning, everyone. Joining me for todays call are Mylans Chairman and Chief Executive Officer, Robert J. Coury, President, Heather Bresch, Executive Vice President and Chief Financial Officer; John Sheehan, Executive Vice Pre",374,"Thank you, Kelsey. Good morning, everyone. Joining me for todays call are Mylans Chairman and Chief Executive Officer, Robert J. Coury, President, Heather Bresch, Executive Vice President and Chief Financial Officer; John Sheehan, Executive Vice President and Chief Operating Officer Rajiv Malik, and Senior Vice President, Corporate Controller and Principal Accounting Officer, Dan Rizzo.
During todays call, including the Q-and-A, we will be making forward-looking statements, including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods.
Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009 and in our other Securities and Exchange Commission filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov and we encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP measures. It should be noted that non-GAAP financial measures such as adjusted revenues, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for or as a superior measure to measures of financial performance prepared in accordance with GAAP.
Please refer to todays earnings press release, which is available on our website as it contains detailed GAAP to non-GAAP reconciliations of our actual 2010 and 2009 first quarter results, including the allocation of each reconciled item to specific income statement line items.
Before I turn the call over to Robert, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylans expressed written permission.
With that Ill now turn the call over to Robert.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thank you, Dan. Welcome everyone and thank you for taken the time to join us today. Id especially like to welcome and thank our employees around the world for another great quarter. The phenomenal execution and continued dedication for Mylans core v",329,"Thank you, Dan. Welcome everyone and thank you for taken the time to join us today. Id especially like to welcome and thank our employees around the world for another great quarter. The phenomenal execution and continued dedication for Mylans core values combined with the exceptional leadership provided by our senior management team that made it possible for us to report yet another strong quarter results.
Im behalf of the Board of Directors and our Executive Management team Id like to thank each and everyone of your contribution. Id also like to take a moment and welcome John Sheehan this morning as all of you know we've announced Johns appointment as Executive Vice President and Chief Financial Officer on our last call and today he joined us for the first earnings report here with Mylan. Welcome John.
Early this morning we reported adjusted diluted and earnings per share $0.36 and reaffirmed our 2010 guidance of the $1.50 to $1.70. These strong results of set the stage for yet another exceptional year at Mylan and they reflect the positive momentum that continues to build from 2009. While this quarter came in slightly better than expected looking forward and as we had guided on our last earnings call, we expect the second quarter results to come in at a comparable level with the majority of our 2010 growth coming in the second half of this year.
Before I turn the call over to our President Heather Bresch, I would like to make another brief comment about the historic healthcare legislation enacted recently in Washington. Even though the reforms did have a financial impact on Mylan, this impact has been fully absorbed in our guidance.
With that said we also anticipate incremental positives due to the passage of this legislation beginning in 2014 when more than 30 million uninsured Americans begin to receive healthcare benefits.
Ill look forward to answer in your questions. Now let me turn the call over to Heather.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert. Good morning everyone. As Robert stated Mylan is off to a great start for the year. We are very please with our first quarter results and remain on track to achieve the 2010 guidance we reported in February and are reiterating today. Du",1139,"Thank you, Robert. Good morning everyone. As Robert stated Mylan is off to a great start for the year. We are very please with our first quarter results and remain on track to achieve the 2010 guidance we reported in February and are reiterating today. During the first quarter we generated total revenues of $1.29 billion compared to last years first quarter adjusted revenues of $1.18 billion an increase of almost 10% and approximately 4% on a constant currency basis.
On the bottom line solid execution in all areas of our business allowed us to generate $0.36 of adjusted diluted EPS and 9% increased over last years first quarter result. Before moving to the performance of our businesses I wanted to tough briefly on our gross margin in R&D expenditures for the quarter. As our results in both areas fell outside of our full year guidance ranges.
Our adjusted gross margin for the quarter was approximately 46% compared to our full year guidance range of 47% to 49%. As I mentioned on our last call we expect to see a larger contribution to gross margins from current year product launches, higher specialty business sales and synergy realization later in the year, mainly in the second half. As such we continue to expect to meet this element of our guidance.
R&D expenditures total $60 million or nearly 5% of revenues. Similar to last year we fully expect R&D expenditures to rise in quarters 2 through 4 such that we also will meet the element of our guidance; more over our R&D output remain strong. We currently have more than 1440 global product submissions pending approval, more than 300 of which were filed during the first quarter, further we still are targeting more than a 1000 submissions in 2010.
Now Id like to walk you thorough the performance of our generic business by region and then our specialty segment. Staring with our generic business in North America, third-party revenues for the first quarter were $560 million unchanged from adjusted third-party revenues reported from North America in the comparable year ago period.
This result is notable in that during last years first quarter, we launched divalproex ER, a product that enjoyed 180 days of exclusivity. Though we launched fewer products than expected during the quarter due to longer than anticipated delays, in FDA approvals our revenues benefited, from new products launched in the U.S. over the last 12 months including lansoprazole and clindamycin-benzoyl peroxide gel.
The new products contributed approximately $55 million in the first quarter revenue. Further as of April 27, we have launched about half of the dozen limited competition product we expect to introduce by year end. 
Our Canadian business also was a contributor with double-digit year-over-year revenue growth for the quarter. As we stated many times the portfolio of countries we manage in Europe is very diverse and dynamic and we continually look for opportunities to maximize its performance.
With that said, in EMEA third-party revenues were $411 million increased $56 million or 16% over the last years first quarter adjusted third-party revenues of $355 million. Revenues were affected favorably by foreign currency translation reflecting a weaker U.S dollar.
On a constant currency basis operational growth in EMEA with 9% year-over-year, that operational result was led not only by continued growth in France, but also in several other countries across the region including Italy, Spain and U.K., and which experience double digit growth. These gains more than offset lower revenues in several markets including the commoditized German market, primarily due to the ongoing implementation of tenders.
In France we had a strong quarter absorbing a well anticipated price cut. In addition our hospital unit delivered strong performance we command market share of 32% in the French generics market overall and 33% in the hospital segment
In Italy our result were affected possibility by some very successful launches in higher product volumes as a result we had captured a disproportionate share the current upside in Italy, further evidence of the opportunity we have to grow in that high potential generics market.
In addition our performance in Spain as an example of our ability to read and react to changing market conditions on a real time basis. As you may know the Spanish government announced during the first quarter then an average price cut of 25% we go into effect in the second quarter.
However we still manage to deliver higher revenues year-over-year as a result of successful product launches. We will continue to adapt our business inline with market changes, so as remain very efficient and competitive in an environment where we expect to see increased generic utilization.
Moving on to Asia-pacific region for the first quarter traditionally our lightest, we delivered very solid result. Total third-party revenues return on $37 million up 27% over 09s first quarter third-party revenues of a $187 million. Operational revenue growth accounted for 11% of this increase while favorable changes in currency rate contributed to the remainder.
In Australia however local currency revenues declined brightly as we continued to experience irrational and unsustainable pricing by competitor. In addition we continued to remain sensitive to any additional government action on healthcare that might affect the generic industry. Nonetheless we will continue to optimize our business in this market so as to remain our leadership position.
In Japan we saw mid single-digit local currency revenue growth year-over-year, which included the impact Biennial Government price reductions are begin to affect our business in March. Also in the region our Matrix business delivered another quarter of year-over-year double-digit growth primarily responsible with higher sales of its expanding line of ARV finished dosage form products.
Finally, our Specialty segment Dey continued to perform well. Total revenues increased 33% year-over-year for the quarter to $101 million, a result that excludes inter company revenues up $17 million associated with the transfer in last years fourth quarter of Deys generic products to our Mylan pharmaceutical division. Including this product Deys revenues rose 20%.
Deys third-party revenues for the quarter were $85 million and increase of more than 30% when excluding from last years first quarter revenues associates with the transfer generic I just mentioned. Including those product Deys third-party revenues rose 7%.
Deys growth came from higher EpiPen auto-injector sales, which resulted from market expansion in a higher price point on the next generation of the product, we began marketing in October. Also contributing todays performance was continued growth Perforomist and incremental sales of EMSAM, which Dey began marketing during last years second quarter.
In summary, I would like to reiterate that we are very pleased with our first quarter performance and remain very confident in our ability to achieve our 2010 guidance metrics, as well as our long-term growth target.
With that I will turn the call over to John.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thanks, Heather and good morning everyone. This morning I would like to walk you through our first quarter 2010 financial results, while at the same time reminding you of our unchanged 2010 financial guidance metrics. Ill conclude by briefly reviewing",1755,"Thanks, Heather and good morning everyone. This morning I would like to walk you through our first quarter 2010 financial results, while at the same time reminding you of our unchanged 2010 financial guidance metrics. Ill conclude by briefly reviewing our capital structure and liquidity position.
Before doing so though Id like to start up by saying that on extremely excited to be here at Mylan and working with each of you as the companys new CFO. I look forward to meeting many of you in the investment community as I get out on the road over the next weeks and months at industry conferences and other up coming investor events.
As most of you maybe aware following 20 years at KPMG, I then spent the last seven years at Delphi Automotive most recently our CFO. As we are very aware the automotive industry experienced nothing sort of the most challenging times ever over the past several years. Although difficult I sound my experiences leading Delphi through a significant re-organization extremely rewarding and valuable as I proactively looked or in my next profession challenge.
As I consider the opportunity to join Mylan, I was very impressed with the growth prospects of the generics and specialty pharmaceutical sector. The soundness of Mylan's growth strategy that was put in motion 2.5 years ago and the significant progress the team has made on executing against that strategy and making that strategic vision become a reality, it was simply an opportunity I could not pass up.
After my first 30 days on the job here at Mylan Ill tell you that I am fully energized and excited to be in a position to meet a completely different set of challenges. Challenges related to long-term growth, I am especially excited to be working with Robert, Heather, Rajiv and the rest of the leadership and employees of Mylan to deliver on the long-term growth target that we recently set for ourselves.
Over the past few months, youve heard Robert comment from the time-to-time about its high level of confidence in the continued solid execution of the companies finance organization well he searched for a new CFO. Well let me tell you during my first 30 days here at Mylan, Ive come to fully understand and appreciate exactly where Robert settlement has been coming from.
My initial observations are that Ive inherited a strong, seasoned and highly capable team of finance professionals across the organization. This well established solid finance infrastructure will no doubt proved to be invaluable in allowing me to focus not just on finance, but also being a strong business leader and value-added partner in the successful operation of our global businesses.
Now, moving on to my review of the first quarter financial result. As Dan mentioned earlier, I'm going to be referring to actual and projected financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. We present these non-GAAP financial measures because they are prepared on the same basis as used by our management and our Board of Directors in evaluating the performance of our business.
This morning's earnings release includes a complete reconciliation from our GAAP to non-GAAP financial measures for our first quarter 2010 and 2009 results. Our earnings release is available on our website and I encourage you to take a look at it, as the nature and amounts of the adjustments included in the reconciliation changes from period-to-period.
In summary, the more significant items that are excluded in coming to our adjusted basis results for the 2010 first quarter, our purchase accounting amortization of $72 million, integration and other expenses of $12 million, imputed interest expense related to our convertible debt of a $11 million and the net tax benefit related to the excluded items of approximately $33 million. (Inaudible) Robert and Heather sentiment on the quarter we are off to a very solid start to the New Year.
Let me start at the top of the income statement. Total revenues for the quarter were $1.29 billion, an increase of nearly 10% over last year's first quarter total adjusted revenues of $1.18 billion. Revenues in the current quarter were favorably impacted by approximately six percentage points related to the affect of foreign currency translation reflecting the weaker US dollar.
Importantly and as Heather made reference too earlier excluding the significant decline in revenues related to divalproex sodium ER, which was expected our year-over-year revenue growth rate would have been much higher. For the full year we do continue to project total revenues in the range of $5.45 to $5.75 billion.
Looking at our operating profitability measures adjusted gross margin for the quarter was approximately 46% compared to our full-year guidance range of 47% to 49%. This margin is lower than the first quarter of 2009 as a result of the loss of exclusivity and divalproex in the second half of 2009. However sequentially it was higher by two percentage points compared to our Q4, 2009 adjusted gross margin.
As Heather mentioned in her remarks we continue to fully expect our operating performance and gross margins to improve as the year progresses, particularly in the second half. Adjusted R&D expenses for the quarter were $60 million or approximately 5% of revenues.
While the spending is consistent with our first quarter of 2009 spending level it is lower than our full-year guidance range of 6% to 7% of revenues. Our projects remain on target and we are planning for higher levels of spending over the remainder of the year. Adjusted SG&A expenses were $245 million for the quarter or 19% of revenues, in the middle of our 18% to 20% full-year guidance range.
Our first quarter adjusted EBITDA was $323 million, if you combine this results with our expectation for generating higher levels of rev earnings later in the year we see ourselves on track to meet our adjusted EBITDA guidance in the range of $1.4 to $1.6 billion for the full year.
Now, let me move to a couple of our non-operating financial metrics. First quarter 2010 interest expense adjusted to exclude imputed interest on our convertible debt with $63 million. As you know a short-term floating interest rates continued to be an historic lows.
We continue to forecast adjusted interest expense for the year to be in the range of $280 to $300 million, which continues to consider the potential for higher short-term interest rates and potentially a higher level of interest expense should we opportunistically execute on the long-term debt refinancing transaction this year. Income taxes; our first quarter adjusted effective income tax rate was 29% inline with our full-year projection for an adjusted effective income tax rate in the range of 28% to 30%.
In summary first quarter adjusted net income was $158 million or $0.36 per share. I believe youre all aware, but let me say it. In calculating our adjusted diluted EPS, the impact of assuming the conversion of our preferred shares into a 125 million common shares was more dilutive than the 35 million quarterly preferred dividends. Therefore, adjusted diluted EPS for the first quarter is calculated based on an average outstanding diluted share count of 437 million shares.
As you all are aware and we were pleased with, the performance of our stock price in the first quarter was strong. Depending on the market value of our common stock going forward, our average outstanding diluted share count could increase over the final three quarters of the year due to further dilution from stock option and other potentially dilutive financial instruments such as warrants related to our convertible debt obligation. Our unchanged full-year adjusted diluted EPS guidance range of $1.50 to $1.70 does consider the potential for a higher average diluted share count.
Turning to our cash flow metrics, our first quarter cash flow from operations was $241 million, this amount includes $99 million income tax refund related to capital losses previously realized on internal reorganizations. Excluding the benefit of these refund cash from operations was $142 million, compared to $126 million in last years first quarter.
We do continue to project full-year operating cash flow in the range of $725 million to $825 million, excluding certain one-off items. First quarter capital spending was $20 million and similar to 2009, but was less than one quarter of our expected annual spend. Based on anticipated projects timing, we do expect spending to increasing Q2 and continued to project capital spending in the range of about $250 million for the full-year.
Now, let me turn to our capital structure and liquidity position. As most of you are aware, this past December, we repaid our 2011 maturities on our bank term loans, which totaled $196 million and as a result, we have no meaningful long-term debt maturities until the first quarter of 2012. 
From a covenant perspective, the level of our senior secured debt is approximately 2.6 times, our last 12 months covenants basis adjusted EBITDA. This is well below our March 31, 2010 covenant threshold of four times and also comfortably ahead of our December 31, 2010 threshold of 3.5 times. At the end of the quarter, we had approximately $550 million of unrestricted cash and marketable securities compared to just over $400 million at December 31. 
Our balance sheet in this morning's earnings release indicates the strong performance of our stock price in the first quarter also had on the effective increasing the value of the cash conversion feature of our cash convertible notes, which increased our long-term debt balance at the end of the first quarter.
This convergence feature is mark-to-market at the end of each period and reflected in that recorded long-term debt balance, there was an equal and offsetting assets that is recorded in the other asset section of our balance sheet related to a financial instrument hedge we have in place in order to offset the value of the bonds conversion features.
Excluding this and unamortized discounts related to both of our convertible note issuances. The balance of our long-term debt was $4.70 billion at March 31, compared to $4.8 billion at December 31, 2009. This difference relates to the impact on our euro denominated debt of the decline in the value of the euro between the two balance sheet dates. In closing, let me once again say, I believe were off to a very solid start to the year.
That concludes my remarks, Ill turn the call back over to Dan and I look forward to the Q-and-A. Dan.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thank you very much, John",5,"Thank you very much, John 
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Kelsey, were now ready to open up the line for questions.",11,"Kelsey, were now ready to open up the line for questions.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","(Operator Instructions) Well go first to Chris Schott with JPMorgan",10,"(Operator Instructions) Well go first to Chris Schott with JPMorgan
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","My first question is, can you just elaborate or just give us your latest thoughts on the current FDA OGD environment, and just as the implications in terms of how many launches youre now targeting for 2010? I just had one quick follow-up after that.",45,"My first question is, can you just elaborate or just give us your latest thoughts on the current FDA OGD environment, and just as the implications in terms of how many launches youre now targeting for 2010? I just had one quick follow-up after that.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Ill give you high level comment and Heather maybe you want to follow-up, but I guess the way I would describe it is, this is what were seeing is not I think something thats acute in any particular company. Its more systemic in this way, even t",209,"Ill give you high level comment and Heather maybe you want to follow-up, but I guess the way I would describe it is, this is what were seeing is not I think something thats acute in any particular company. Its more systemic in this way, even though the OGD is kind of reorganizing itself with some of the some of the announcements that they work.
Some of the backlog and some of the product approvals, we look at what's going on there more from a timing perspective. For example, some of the products to we anticipated to get actually approved in the first quarter has actually been delayed and we anticipate those approvals just to roll forward.
So you would think on one hand that that would be a negative, but really on the other hand, because this is more of a systemic issue with the FDA, the OGD in particular as a whole within the industry, some of the other products that we have in our portfolio that we anticipated competition, we didn't get either. So the two kind of offset on another and what you have is a rolling forward scenario where again this is simply maybe a timing issue and nothing more than that. Heather.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Ill just add to our numbers specifically, we haven't readjusted what we had set for the year, which was I think 45 to 50 approvals in the U.S., and as I mentioned, we already have about six of the limited competition approval that weve revived. So t",85,"Ill just add to our numbers specifically, we haven't readjusted what we had set for the year, which was I think 45 to 50 approvals in the U.S., and as I mentioned, we already have about six of the limited competition approval that weve revived. So to Roberts point, definitely some delays from the timing issue given where we are in the year. So early on we still see them coming in and like I said it havent changed our forecast for the year.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Then just as a follow-up question, can you just elaborate a little bit on the benefit you saw in the quarter based on competitors supply interruptions and just can you give us a little bit of your thoughts on the willingness of your customers to potential",79,"Then just as a follow-up question, can you just elaborate a little bit on the benefit you saw in the quarter based on competitors supply interruptions and just can you give us a little bit of your thoughts on the willingness of your customers to potentially move back to these players, once these supply interruptions are resolved. Some of these share gains youre seeing now, do you believe these are sustainable share gains in some of these markets?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","I would prefer not to try to point to any benefits that Mylan is receiving off of the back or some of the issues that some of the other companies are having. I think at Mylan, were just staying concentrated on delivering a high quality, a high volume o",167,"I would prefer not to try to point to any benefits that Mylan is receiving off of the back or some of the issues that some of the other companies are having. I think at Mylan, were just staying concentrated on delivering a high quality, a high volume of supply in that supply chain and I actually its a mistake to try to give a graph of target, any benefits that were deriving off of on the backs of some others that might be suffered.
I do think that there is a higher appreciation. Ive said this in the past, from the customers. I think were seeing that higher appreciation for a constant, again a high quality supply and I think that, I dont think anything I can tell you theres certainly nothing that has materially stood out, but we do see and have seen over the last several quarters, some appreciation from the customers in terms of their activities, interviews are the players within this sector. 
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Our next question will come from Randall Stanicky with Goldman Sachs.",11,"Our next question will come from Randall Stanicky with Goldman Sachs.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Can you help us understand the gross margin trajectory? How much of that is going to be new product geographic versus cost synergies, as when you go at back half and then Robert, can you just quantify the reform impact from an EPS perspective? Thanks.",45,"Can you help us understand the gross margin trajectory? How much of that is going to be new product geographic versus cost synergies, as when you go at back half and then Robert, can you just quantify the reform impact from an EPS perspective? Thanks.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Sure, let me go first and let me just say that your reform impact, Im not going to classify as material, but if you take a look at the calculation with the higher rebate and what have you, obviously we had some financial impact, but enough where we fel",102,"Sure, let me go first and let me just say that your reform impact, Im not going to classify as material, but if you take a look at the calculation with the higher rebate and what have you, obviously we had some financial impact, but enough where we felt very comfortable again giving the robustness that we see ahead of us, we felt very comfortable that could absorb that impact in terms of the guidance that we give and the targets that we set forth, until we start to see benefits in the 2014 plus range, and Heather on the gross margin? 
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Yes and I think Randell keep in mind, I think theres three important parts to the gross margin improvement there, and certainly we still forecasted current product launches that we expect to happen theres a specialty business as we continue to have",110,"Yes and I think Randell keep in mind, I think theres three important parts to the gross margin improvement there, and certainly we still forecasted current product launches that we expect to happen theres a specialty business as we continue to have performance uptake through the year that certainly as a driver as well then to your points at synergies. So as we look at the repatriation, some of the vertical integration, file transfers that as you know just keep rolling in year-after-year that have been more coming in at the back, its the combination of all three of those that are really driving the second half of the year.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Can you just help us to understand, what Im trying to understand is how much is that linked to product approvals versus synergies, which you probably have a much better line of sight into?",34,"Can you just help us to understand, what Im trying to understand is how much is that linked to product approvals versus synergies, which you probably have a much better line of sight into?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","First of all, let me start off by saying that the first quarter did not come as any surprise to us at all. Quite frankly, if you look at quarter four, to quarter one in 2010, its exactly what weve anticipated. If you recalled, in the last quarter I",218,"First of all, let me start off by saying that the first quarter did not come as any surprise to us at all. Quite frankly, if you look at quarter four, to quarter one in 2010, its exactly what weve anticipated. If you recalled, in the last quarter I looked at the fourth quarter as we entered in the 2010 I said, I want you to look at or slide it into 2010 and then looking at the back end as really the upward trajectory.
So and because we done give quarterly guidance, we give annual guidance, I want to stress that, we dont give quarterly guides, we give annual guidance. I dont believe very responsible to try to look at a quarter and judge with the guidance that we given over the year, because of this trajectory that Ive told you, but to your point and an excellent question, I think that there is actually a strong combination and I dont want to put too much weight on one versus the other.
I will tell you that, we have a voluminous amount of product launches that we see at the later part of the year, but we also rundle to your point that DC continued lower cost of goods savings also coming into that gross margin plan.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","And moving on to Gregg Gilbert with Banc of America/Merrill Lynch.",12,"And moving on to Gregg Gilbert with Banc of America/Merrill Lynch.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","First for John, can you review your debt maturities and how you planned to deal with them, and give us the specific share count youre using for EPS for this years guidance? Then a follow-up for Rob and Heather, from an M&A perspective, at this point",68,"First for John, can you review your debt maturities and how you planned to deal with them, and give us the specific share count youre using for EPS for this years guidance? Then a follow-up for Rob and Heather, from an M&A perspective, at this point, are you more focused on generic opportunities or opportunities to fold some brand assets in today or otherwise support our branded strategy?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Before I turn it over to John, in term of the overall debt maturities as we stated Gregg, we are looking, we basically satisfied any requirements prior to 2012 and really our focuses in 2014, the $3 billion that we have coming due in 2014, and theres b",137,"Before I turn it over to John, in term of the overall debt maturities as we stated Gregg, we are looking, we basically satisfied any requirements prior to 2012 and really our focuses in 2014, the $3 billion that we have coming due in 2014, and theres been our stated intension to basically tap the capital markets in an opportunistic way in order to stager off that maturity from 2014 to something that we believe its a little more responsible and prudent.
As I stated also in the past, the guidance fully anticipates, our ability to tap those markets and any negative arbitrage that we can at least anticipate right now has also, in terms negative arbitrage in the interest rates. I had also been fully incorporated into our guidance, John do you want to add anything.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Nothing.",1,"Nothing.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","So, I think the two parts to your question were in term of existing repayment schedule. As I said my remarks, we really dont have any significant maturity repayments until early 2012 and in 12 were looking at approximately $800 million, $200 mill",105,"So, I think the two parts to your question were in term of existing repayment schedule. As I said my remarks, we really dont have any significant maturity repayments until early 2012 and in 12 were looking at approximately $800 million, $200 million 13 and then as Im sure, youre already aware a significant amount in 2014 over $3 billion. Second half of your question related to the share count that were using and as I said again in my remarks the first quarter amount was 437 million shares and the amount thats baked into our guidance quite honestly as not materially different in that.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","We don't anticipate using that this time our share count lower than that. I think that, correct me if Im wrong, but I think the threshold was $17, a share were we had - really where that crossover occurred. So we don't anticipate for the rest of this y",90,"We don't anticipate using that this time our share count lower than that. I think that, correct me if Im wrong, but I think the threshold was $17, a share were we had - really where that crossover occurred. So we don't anticipate for the rest of this year to be using anything less than the fully diluted share count to taken into consideration, the number of shares that will be added when the mandatory convert comes do in November and then the other part of the question, Heather?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Yes, sure. On the opportunities, obviously as we continue to say we certainly are looking that complimentary products to add to the day portfolio, as well as generic opportunities whether its other therapeutic categories or dosage form such as injectab",55,"Yes, sure. On the opportunities, obviously as we continue to say we certainly are looking that complimentary products to add to the day portfolio, as well as generic opportunities whether its other therapeutic categories or dosage form such as injectable, ophthalmic as weve discussed, things that we would add to those number of the footprint.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Elliot Wilbur with Needham & Company has the next question. Actually, Elliot has removed himself from the queue.So well move to Marc Goodman with UBS.",25,"Elliot Wilbur with Needham & Company has the next question. Actually, Elliot has removed himself from the queue.
So well move to Marc Goodman with UBS.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Two questions, first on France, can you give us a flavor for what the government has done with respect to the price cuts and things like that? Second of all in France, did you mention that was one of the countries that grew double-digits or not, there, be",135,"Two questions, first on France, can you give us a flavor for what the government has done with respect to the price cuts and things like that? Second of all in France, did you mention that was one of the countries that grew double-digits or not, there, because you threw a bunch of countries there, and I wasn't sure whether France was in there?
Then the other question has to do with the gross margin. Kind of just give us a sense of the site transfers that you've had planned from the beginning. How many have you done, or just give us a percentage of the way that youre through the process, and where youll be at the end of the year and then just the FX impact on the gross margin in the quarter?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","So first, I think you asked about Spain, is that correct the price cut that we mentioned in France. Okay the France one is as you know, as is typical in most of the countries the price negotiation though with government and there is typical the one-time l",83,"So first, I think you asked about Spain, is that correct the price cut that we mentioned in France. Okay the France one is as you know, as is typical in most of the countries the price negotiation though with government and there is typical the one-time local price cut that happens, so that France as I stated was anticipated as part of our guidance and so forth and we intended to still maintain our market leadership position. So that was all anticipated.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Was that like 5%?",5,"Was that like 5%?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","We didnt get into an average it doesnt go across the board it depends whether your products on the repertoire list, not on the repertoire list. So there its not just overall, its blended, but it was fully anticipated. As far as",43,"We didnt get into an average it doesnt go across the board it depends whether your products on the repertoire list, not on the repertoire list. So there its not just overall, its blended, but it was fully anticipated. As far as
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","The other question was on gross",6,"The other question was on gross
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Well, before you move into the gross margin, just a double-digit, because you reeled off a bunch of countries that did and I wasnt sure if France was in there?",30,"Well, before you move into the gross margin, just a double-digit, because you reeled off a bunch of countries that did and I wasnt sure if France was in there?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","No, not on double-digits on the growth in the countries was Italy, Spain and the UK.",16,"No, not on double-digits on the growth in the countries was Italy, Spain and the UK.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","In the gross margin question Marc?",6,"In the gross margin question Marc?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Well, there were two. One was the FX impact and then the site transfers?",14,"Well, there were two. One was the FX impact and then the site transfers?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Yes, the site transfers. So, Marc as we had said a while ago all the work not I think it averaged about 165 transfers that we completed actually the first of 09 getting into the all the regulatory queue and obviously thats whats now been rolling",144,"Yes, the site transfers. So, Marc as we had said a while ago all the work not I think it averaged about 165 transfers that we completed actually the first of 09 getting into the all the regulatory queue and obviously thats whats now been rolling in the end of 09 and well continue to roll and intend, but I cant tell you ever broken out the percentage of have those fallen an expect our guidance, obviously absorbed them, certainly leading to that second half trajectory that weve talked about, the majority of those being in and obviously through the end of 2010, all of those now will been absorbed in.. So, certainly the majority of those are in the last half of this year, will then be completed for all like I said the 165 transfers that weve talked about through the synergies.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","John on the FX on the gross margin.",8,"John on the FX on the gross margin.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Go ahead, Dan. I will let Dan respond.",8,"Go ahead, Dan. I will let Dan respond.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","The FX impact on gross margin dollars is roughly comparable to the impact you are seeing on the revenue side, but more importantly at a percentage gross margin percentage, which is a slight negative impact on gross margin percentage, but not significant,",57,"The FX impact on gross margin dollars is roughly comparable to the impact you are seeing on the revenue side, but more importantly at a percentage gross margin percentage, which is a slight negative impact on gross margin percentage, but not significant, because its affecting sales and cost of sales in almost be go in opposite directions?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","And moving on to John Boris with Citi.",8,"And moving on to John Boris with Citi.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","First question just has to do with the Japanese market and the price cuts by annual price cuts that they take there. What was the wholesaler behavior like in the quarter? Did they not buy product and can you just give any comment on what generic volumes a",60,"First question just has to do with the Japanese market and the price cuts by annual price cuts that they take there. What was the wholesaler behavior like in the quarter? Did they not buy product and can you just give any comment on what generic volumes are actually doing in the Japanese market and then I have one follow-up?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","So just to the two parts of that, the Biennial obviously again this is something well anticipated and known throughout the market there in the players, so the patterns of the inventory. We didnt see any extraordinary phenomenon on any front with the Ja",78,"So just to the two parts of that, the Biennial obviously again this is something well anticipated and known throughout the market there in the players, so the patterns of the inventory. We didnt see any extraordinary phenomenon on any front with the Japanese price cut. As far as the volume go, they are still holding around that 19% to 20% generic utilization rate, we havent seen any significant move one way or the other on that front.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Then just back to a question that was asked earlier on healthcare reform. Can you just provide some commentary on what percent of your revenue in the U.S. is exposed to Medicaid and to the 340-B provision?",37,"Then just back to a question that was asked earlier on healthcare reform. Can you just provide some commentary on what percent of your revenue in the U.S. is exposed to Medicaid and to the 340-B provision?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Its even more minimal since Medicare Part-D, because dual eligible were taken out and moved into Medicare Part-D. So I believe that Medicaid population is now right under 10%.",30,"Its even more minimal since Medicare Part-D, because dual eligible were taken out and moved into Medicare Part-D. So I believe that Medicaid population is now right under 10%.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","We will now have Ann Trimble with Barclays Capital.",9,"We will now have Ann Trimble with Barclays Capital.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Its Ann Trimble for Rich Silver. Could you discuss the reason behind the sequential decline in EMEA revenues?",19,"Its Ann Trimble for Rich Silver. Could you discuss the reason behind the sequential decline in EMEA revenues?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","If you look, obviously theres some seasonality in the product and just buying pattern as youre going into holiday months and so forth coming into the first quarter. So theres nothing extraordinary, we certainly had year-over-year growth when we l",61,"If you look, obviously theres some seasonality in the product and just buying pattern as youre going into holiday months and so forth coming into the first quarter. So theres nothing extraordinary, we certainly had year-over-year growth when we look at quarter-over-quarter in the EMEA. So, sequentially again theres nothing out of the ordinary if you look Q4 year-over-year as well.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Then as a quick follow-up, could you elaborate on your comments on the Spain price cuts and timing of the expected impact?",23,"Then as a quick follow-up, could you elaborate on your comments on the Spain price cuts and timing of the expected impact?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","I am sorry. Can repeat it please.",7,"I am sorry. Can repeat it please.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Could you elaborate on your comments on the Spain price cuts and timing of the expected impact?",17,"Could you elaborate on your comments on the Spain price cuts and timing of the expected impact?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","As I said, it was 25% and we are obviously, as I mentioned have been able to not only now anticipate and absorbed that as well as weve had on quite of you successful product launches and increase volume uptake, which has been able to have the offset 25",51,"As I said, it was 25% and we are obviously, as I mentioned have been able to not only now anticipate and absorbed that as well as weve had on quite of you successful product launches and increase volume uptake, which has been able to have the offset 25% price cuts.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Well now hear from Ronny Gal with Bernstein.",9,"Well now hear from Ronny Gal with Bernstein.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","First, about the refinancing of the debt, I guess what would be the impact of this during the year, and roughly in the year, did you assume it to happen? Just to understand the impact if this refinance will not take place this year?",44,"First, about the refinancing of the debt, I guess what would be the impact of this during the year, and roughly in the year, did you assume it to happen? Just to understand the impact if this refinance will not take place this year?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Ronny, as we mentioned we have been confidently looking that, what we considered to be opportunistic moment for Mylan to tap the markets and when we think that we reached that point, we will certainly make the announcement and then so to that point, we ca",179,"Ronny, as we mentioned we have been confidently looking that, what we considered to be opportunistic moment for Mylan to tap the markets and when we think that we reached that point, we will certainly make the announcement and then so to that point, we cant really predict exactly what the impact would be in terms to any arbitraries in terms of the interest rate, all in interest rates that we pay now versus any impact on the interest rate that we may pay.
Once we tap the markets and understand what were going to end up within terms of the overall yield, but let me just say that we can easily at least and what we already have done is pay attention to the broader markets to some of the deals that have gone off, look at some of the rates that theyve ended up with, look at what our are all-in rate is, and I think fairly and practically predict that there will be some negative arbitraries and we fully have incorporated that into our 2010 guidance.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Yes, I understand, but I was just wondering what youve modeled, if you can break that down for us, once the news hits, we can actually assess it for ourselves?",30,"Yes, I understand, but I was just wondering what youve modeled, if you can break that down for us, once the news hits, we can actually assess it for ourselves?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Understood, and I was going to add here to Robert that, we thought about two separate factors, one being the refinancing that Robert was referring to, and then combined to fact that there is certainly risk for interest rates increasing and we didnt spe",92,"Understood, and I was going to add here to Robert that, we thought about two separate factors, one being the refinancing that Robert was referring to, and then combined to fact that there is certainly risk for interest rates increasing and we didnt specifically think about a particular time when we would be doing that refinancing transaction nor can we predict exactly when interest rates are going to rise, so we took those two factors into consideration in thinking about that 280 to 300 as an appropriate number for full-year interest expense.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Well hear from David Buck with Buckingham Research.",9,"Well hear from David Buck with Buckingham Research.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Yes, hi its Jim Dawson for David Buck. You got into this a little bit, but can you talk about the expectation for the European business forward and any pricing changes which we aware of?",35,"Yes, hi its Jim Dawson for David Buck. You got into this a little bit, but can you talk about the expectation for the European business forward and any pricing changes which we aware of?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","What we have forecasted obviously growth overall for EMEA. And other than the pricing that I spoke about this morning (inaudible) and the ones that weve anticipated I right now dont know anything else thats coming to the year.",39,"What we have forecasted obviously growth overall for EMEA. And other than the pricing that I spoke about this morning (inaudible) and the ones that weve anticipated I right now dont know anything else thats coming to the year.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","But as we mentioned many, many times, overall and longer term we do expect there to be a continuation of price cuts within that region and weve fully have incorporated that into not only our guidance, but evening our targets, but the opportunity for us",307,"But as we mentioned many, many times, overall and longer term we do expect there to be a continuation of price cuts within that region and weve fully have incorporated that into not only our guidance, but evening our targets, but the opportunity for us is to balance that with the increase in volumes that we anticipate strictly as a result of the lower cost of the pharmaceutical products as a whole, especially the generics through increased generic utilization, but most importantly in addition, I have to tell you again we do not view some of the markets over in Europe is being the most efficient markets when it comes to the pull though effect of generics and generic utilization as a whole.
So we look at that as an opportunity and as the markets continue and these countries continue to decide to reduce its prices, it basically comes directly up against the actual infra structure in the current models that are in place. So you can fully expect as we continue to monitor each country, as they make -- each of them make their decision about what type of pharmaceutical model they want to have for their country, whether or not they want to support a higher infrastructure cost or whether or not they want a different type of pull through effect.
We on the other hand as management will manage each one of those countries and right size the infrastructure according to what the government wants in terms of that particular region, so we are not concerned at all but overall, we are certainly not concerned in our ability to deliver what we have feel appropriate targets that we set ourselves, but overall I think you should all anticipate a continuation of price cuts going forward as we look out in the whole EMEA section.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Okay and just had one more on got in difficult just a little bit as well early on the call, but regarding the supply disruptions you mentioned in your release. Can you talk about you have benefited -- and can you quantified that from increased sales and/o",84,"Okay and just had one more on got in difficult just a little bit as well early on the call, but regarding the supply disruptions you mentioned in your release. Can you talk about you have benefited -- and can you quantified that from increased sales and/or increased gross margins and in the first quarter and also talk about what you are seeing in the current quarter being the second quarter and how much of that is a factor in accelerating second half growth?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","As I mentioned before, Jim, I dont even think its even appropriate. First of all I dont see, I can tell you write off the bad there is nothing material that I can even pint to say somehow were getting some hick up benefit from on the backs of",260,"As I mentioned before, Jim, I dont even think its even appropriate. First of all I dont see, I can tell you write off the bad there is nothing material that I can even pint to say somehow were getting some hick up benefit from on the backs of another company selling. I think that you Mylan continues to keep its head down and to continue to march forward in our quest to deliver very very high quality volumes and I think that value of our consistent content supply chain is becoming more and more appreciated by customers.
I would not and I think its again inappropriate to point that were somehow better fitting, I dont see anything material that I can even point to right now, but I just think its a longer term trend that will basically bleeds its way in. If we are going to benefit from some of the disruptions that others have had, I see it more of a bleed-in rather than this roller coaster, high, low quarter-over-quarter. I just think its not when Im seeing and certainly not the way we are driving our business. I think that the increases that we are seeing are increases that have come in over period of time and we just dont see that ending, we see that more and more the way we see ourselves working with our customer base and the appreciation that they are showing us in return, we just see that continuing over a longer haul not anything over a short period of time.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Im moving on to Michael Tong with Wells Fargo",10,"Im moving on to Michael Tong with Wells Fargo
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Just maybe a little bit more big-picture question. Weve talked a lot about the Generics business, but Im just wondering whats your thought process behind your Specialty business, going forward, in terms of growing that business and whats your",48,"Just maybe a little bit more big-picture question. Weve talked a lot about the Generics business, but Im just wondering whats your thought process behind your Specialty business, going forward, in terms of growing that business and whats your thoughts about how you go about growing it?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Well, Im pretty excited about what we actually already have in terms of the growth prospects of the assets that were currently managing; obviously I have very distinct strategic plans to growing the business, but those plans and the robustness of my vi",191,"Well, Im pretty excited about what we actually already have in terms of the growth prospects of the assets that were currently managing; obviously I have very distinct strategic plans to growing the business, but those plans and the robustness of my vision and thinking of what I see that business could ultimately be. Its certainly being offset to mediate it -- certainly been offset and mitigating by the financial discipline that has been set forth here at Mylan.
I would love to have a lot of things, I love to do a lot of things, but as I promised in the past, Im not going to do anything thats going to jeopardize the earning growth that we set for, that we have outlined and I will tell you with that said, I still see business development opportunities where we are aggressively looking and continue to look where we can look at whether it's a product or product portfolio or anything that we think that would be complimentary, that would be add-ons to that business, but again not at the behest of jeopardizing the earnings growth that we set forth earlier.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","And if I can have one follow-up for John, did I hear you correctly about the interest expense outlook for the year? Does it include or exclude the accretion or the imputed interest from your converts?",37,"And if I can have one follow-up for John, did I hear you correctly about the interest expense outlook for the year? Does it include or exclude the accretion or the imputed interest from your converts?
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","It excludes, the number, the 280 to 300 excludes.",9,"It excludes, the number, the 280 to 300 excludes.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","One final question that will come from Ken Cacciatore with Cowen & Company.",12,"One final question that will come from Ken Cacciatore with Cowen & Company.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Quick question back on France. Some of our industry contacts indicate that Mylan was the most aggressive in terms of pricing in that marketplace. So just trying to understand beyond kind of what is being set from the government perspective, if you could g",86,"Quick question back on France. Some of our industry contacts indicate that Mylan was the most aggressive in terms of pricing in that marketplace. So just trying to understand beyond kind of what is being set from the government perspective, if you could give a little commentary if that is true. If it is true, you are the market leader, I'm trying to understand contextually what may be going on competitively there that has you kind of acting as the most aggressive in the pricing dynamics.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thank you, Ken, for the question. That way I would characterize it and quite complimentary to the leadership of Didier and France as well as Didiers leadership in every other country, Id like to actually, hoping the question was that Mylan was the m",176,"Thank you, Ken, for the question. That way I would characterize it and quite complimentary to the leadership of Didier and France as well as Didiers leadership in every other country, Id like to actually, hoping the question was that Mylan was the most aggressive in managing its business. As Mylan is the most aggressive in managing its business in every single market as you know the dynamics of the generic marketplace are changing at rapid speed and so if that's what youre hearing on the outside then Kudos to Didier for containing to manage as aggressively as he should be doing.
Not being the most aggressive necessarily in the market, but a constant balance between pricing levels versus volumes versus market share versus there are many, many, many variables that a leader must take into consideration as dynamic at the generic industry is. And Im extremely pleased with the results that he put up in the first quarter, so again thank you for the question and its a high compliment to Didier and his team.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Mr. Crookshank, I will turn it back to you for closing or additional remarks.",14,"Mr. Crookshank, I will turn it back to you for closing or additional remarks.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Great, we all will be available as the day goes on for follow-up conversation as you like. And that said, thank you once again for joining the Mylan team for the conference call.",33,"Great, we all will be available as the day goes on for follow-up conversation as you like. And that said, thank you once again for joining the Mylan team for the conference call.
"
290203,104551358,58483,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Thank you. Again, ladies and gentlemen that concludes our conference for today. We thank you all for your participation.",19,"Thank you. Again, ladies and gentlemen that concludes our conference for today. We thank you all for your participation.


"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Well, good day, everyone, and welcome to todays Mylan's 2010 First Quarter Earnings Conference Call. [Operator Instructions] And now it is my pleasure to turn the conference over to Mr. Dan Crookshank, Mylans Vice President of Global Investor Relati",43,"Well, good day, everyone, and welcome to todays Mylan's 2010 First Quarter Earnings Conference Call. [Operator Instructions] And now it is my pleasure to turn the conference over to Mr. Dan Crookshank, Mylans Vice President of Global Investor Relations. Please go ahead, sir."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kelsey. Good morning, everyone. Joining me for todays call are Mylans Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; Executive Vice Pre",374,"Thank you, Kelsey. Good morning, everyone. Joining me for todays call are Mylans Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; Executive Vice President and Chief Operating Officer, Rajiv Malik; and Senior Vice President, Corporate Controller and Principal Accounting Officer, Dan Rizzo. 
During todays call, including the Q&A, we will be making forward-looking statements, including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our annual report on Form 10-K for the year ended December 31, 2009, and in our other Securities and Exchange Commission filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov. And we encourage you to do so. 
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP measures. It should be noted that non-GAAP financial measures such as adjusted revenues, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Please refer to todays earnings press release, which is available on our website, as it contains detailed GAAP to non-GAAP reconciliations of our actual 2010 and 2009 first quarter results, including the allocation of each reconciled item to specific income statement line items. 
Before I turn the call over to Robert, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylans expressed written permission. 
With that, I'll now turn the call over to Robert."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thank you, Dan. Welcome, everyone, and thank you for taking the time to join us today. I'd especially like to welcome and thank our employees around the world for another great quarter. The phenomenal execution and continued dedication to Mylan's core val",330,"Thank you, Dan. Welcome, everyone, and thank you for taking the time to join us today. I'd especially like to welcome and thank our employees around the world for another great quarter. The phenomenal execution and continued dedication to Mylan's core values combined with the exceptional leadership provided by our senior management team have made it possible for us to report yet another strong quarter results. On behalf of the Board of Directors and our executive management team, I would like to thank each and everyone of you for your contribution. I'd also like to take a moment to welcome John Sheehan this morning. As all of you know, we have announced John's appointment as Executive Vice President and Chief Financial Officer on our last call. And today, he joins us for the first earnings report here with Mylan. Welcome, John.
Early this morning, we reported adjusted diluted earnings per share of $0.36 and reaffirmed our 2010 guidance of $1.50 to $1.70. These strong results set the stage for yet another exceptional year at Mylan and they reflect the positive momentum that continues to build from 2009. While this quarter came in slightly better than expected, looking forward and as we had guided on our last earnings call, we expect the second quarter results to come in at a comparable level with the majority of our 2010 growth coming in the second half of this year.
Before I turn the call over to our President, Heather Bresch, I would like to make another brief comment about the historic healthcare legislation enacted recently in Washington. Even though the reforms did have a financial impact on Mylan, this impact had been fully absorbed in our guidance. With that said, we also anticipate incremental positives due to the passage of this legislation beginning in 2014, when more than 30 million uninsured Americans begin to receive healthcare benefits. 
I look forward to answering your questions. Now let me turn the call over to Heather."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert, and good morning, everyone. As Robert stated, Mylan is off to a great start for the year. We're very pleased with our first quarter results and remain on track to achieve the 2010 guidance we reported in February and are reiterating tod",1132,"Thank you, Robert, and good morning, everyone. As Robert stated, Mylan is off to a great start for the year. We're very pleased with our first quarter results and remain on track to achieve the 2010 guidance we reported in February and are reiterating today. During the first quarter, we generated total revenues of $1.29 billion compared to last year's first quarter adjusted revenues of $1.18 billion, an increase of almost 10% and approximately 4% on a constant currency basis. On the bottom line, solid execution on all areas of our business allowed us to generate $0.36 of adjusted diluted EPS, a 9% increase over last year's first quarter result.
Before moving to the performance of our businesses, I wanted to touch briefly on our gross margin and R&D expenditures for the quarter, as our results in both areas fell outside of our full year guidance ranges. Our adjusted gross margin for the quarter was approximately 46% compared to our full year guidance range of 47% to 49%. As I mentioned on our last call, we expect to see a larger contribution to gross margins from current year product launches, higher Specialty business sales and synergy realization later in the year, mainly in the second half. As such, we continue to expect to meet this element of our guidance.
R&D expenditures totaled $60 million or nearly 5% of revenues. Similar to last year, we fully expect R&D expenditures to rise in quarters two through four, such that we also will meet this element of our guidance. Moreover, our R&D output remain strong. We currently have more than 1,440 global product submissions pending approval, more than 300 of which were filed during the first quarter. Further, we still are targeting more than 1,000 submissions in 2010. Now I'd like to walk you through the performance of our Generics business by region and then our Specialty segment. 
Starting with our Generics business in North America. Third-party revenues for the first quarter were $560 million, unchanged from adjusted third-party revenues reported for North America in the comparable year-ago period. This result is notable. And that during last year's first quarter, we launched Divalproex ER, a product that enjoyed 180 days of exclusivity. Though we launched fewer products than expected during the quarter due to longer-than-anticipated delays in FDA approvals, our revenues benefited from new products launched in the U.S. over the last 12 months, including Lansoprazole and Clindamycin/Benzoyl Peroxide Gel. The new products contributed approximately $55 million in the first quarter revenue. Further as of April 27, we have launched about half of the dozen limited competition product we expect to introduce by year end. Our Canadian business also was a contributor with double-digit year-over-year revenue growth for the quarter. 
As we stated many times, the portfolio of countries we manage in Europe is very diverse and dynamic and we continually look for opportunities to maximize its performance. With that said, in EMEA third-party revenues were $411 million, increased $56 million or 16% over the last year's first quarter adjusted third-party revenues of $355 million. Revenues were affected favorably by foreign currency translation reflecting a weaker U.S. dollar. On a constant currency basis, operational growth in EMEA was 9% year-over-year. That operational result was led not only by continued growth in France but also in several other countries across the region, including Italy, Spain and the U.K. and which experienced double-digit growth. These gains more than offset lower revenues in several markets including the commoditized German market, primarily due to the ongoing implementation of tenders.
In France, we had a strong quarter absorbing a well-anticipated price cuts. In addition, our hospital units delivered strong performance. We command market share of 32% in the French generics market overall and 33% in the Hospital segment. 
In Italy, our results were affected positively by some very successful launches on higher product volumes. As a result, we have captured a disproportionate share of the current upside in Italy, further evidence of the opportunity we have to grow in that high potential generics market. 
In addition, our performance in Spain is an example of our ability to read and react to changing market conditions on a real-time basis. As you may know, the Spanish government announced during the first quarter that an average price cut of 25% will go into effect in the second quarter. However, we still managed to deliver higher revenues year-over-year as a result of successful product launches. We will continue to adapt our business in line with market changes so as to remain very efficient and competitive in an environment where we expect to see increased generic utilization.
Moving onto Asia Pacific region. For the first quarter, traditionally our lightest, we delivered very solid result. Total third-party revenues were $237 million, up 27% over '09's first quarter third-party revenues of $187 million. Operational revenue growth accounted for 11% of this increase while favorable changes in currency rates contributed to the remainder. 
In Australia, however, local currency revenues declined slightly as we continue to experience irrational and unsustainable pricing by competitors. In addition, we continue to remain sensitive to any additional government action on healthcare that might affect the generics industry. Nonetheless, we will continue to optimize our business in this market so as to remain our leadership position. 
In Japan, we saw a mid-single-digit local currency revenue growth year-over-year, which included the impact of biennial government price reductions that began to affect our business in March. Also in the region, our Matrix business delivered another quarter of year-over-year double-digit growth, primarily responsible with higher sales of its expanding line of ARV finished dosage form products.
Finally, our Specialty segment, Dey, continue to perform well. Total revenues increased 33% year-over-year for the quarter to $101 million, a result that excludes intercompany revenues of $17 million associated with the transfer in last year's fourth quarter of Dey's generic products to our Mylan Pharmaceuticals division. Including this product, Dey's revenues rose 20%. Dey's third-party revenues for the quarter were $85 million, an increase of more than 30% when excluding from last year's first quarter revenues associated with the transfer generics I just mentioned. Including those products, Dey's third-party revenues rose 7%. Dey's growth came from higher EpiPen Auto-Injector sales, which resulted from market expansion and a higher price point on the next generation of the product we begin marketing in October. Also contributing to Dey's performance was continued growth of Perforomist and incremental sales of EMSAM, which Dey began marketing during last year's second quarter. 
In summary, I'd like to reiterate that we're very pleased with our first quarter performance and remain very confident in our ability to achieve our 2010 guidance metrics as well as our long-term growth target. 
With that I'll turn the call over to John."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thanks, Heather, and good morning, everyone. This morning, I'd like to walk you through our first quarter 2010 financial results while at the same time reminding you of our unchanged 2010 financial guidance metrics. I'll conclude by briefly reviewing our",1757,"Thanks, Heather, and good morning, everyone. This morning, I'd like to walk you through our first quarter 2010 financial results while at the same time reminding you of our unchanged 2010 financial guidance metrics. I'll conclude by briefly reviewing our capital structure and liquidity position. Before doing so though, I'd like to start out by saying that I'm extremely excited to be here at Mylan and working with each of you as the company's new CFO. I look forward to meeting many of you in the investment community as I get out on the road over the next weeks and months at industry conferences and other upcoming investor events. 
As most of you may be aware, following 20 years at KPMG, I then spent the last seven years at Delphi Automotive, most recently as CFO. As we're all very aware, the automotive industry experienced nothing short of the most challenging times ever over the past several years. Although difficult, I found my experiences leading Delphi through a significant reorganization extremely rewarding and valuable as I proactively looked for my next professional challenge. As I considered the opportunity to join Mylan, I was very impressed with the growth prospects of the generics and specialty pharmaceuticals sector. The soundness of Mylan's growth strategy that was put in motion two and a half years ago and the significant progress the team has made on executing against that strategy and making that strategic vision become a reality. It was simply of an opportunity I could not pass up. 
After my first 30 days on the job here at Mylan, I'll tell you that I am fully energized and excited to be in a position to meet a completely different set of challenges. Challenges related to long-term growth. I'm especially excited to be working with Robert, Heather, Rajiv and the rest of the leadership and employees at Mylan to deliver on the long-term growth targets that we recently set for ourselves. 
Over the past few months, you've heard Robert comment from time to time about his high level of confidence in the continued solid execution of the company's finance organization while he searched for a new CFO. Well, let me tell you, during my first 30 days here at Mylan, I've come to fully understand and appreciate exactly where Robert's sentiment has been coming from. My initial observations are that I've inherited a strong, seasoned and highly capable team of finance professionals across the organization. These well-established solid finance infrastructure will no doubt prove to be invaluable in allowing me to focus not just on finance, but also being a strong business leader and value-added partner in the successful operation of our global businesses.
Now moving on to my review of the first quarter financial results. As Dan mentioned earlier, I'm going to be referring to actual and projected financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. We present these non-GAAP financial measures because they're prepared on the same basis as used by our management and our Board of Directors in evaluating the performance of our business. This morning's earnings release includes a complete reconciliation from our GAAP to non-GAAP financial measures for our first quarter 2010 and 2009 results. Our earnings release is available on our website and I encourage you to take a look at it as the nature and amount of the adjustments included in the reconciliation changes from period-to-period.
In summary, the more significant items that are excluded in coming to our adjusted basis results for the 2010 first quarter are purchase accounting amortization of $72 million, integration and other expenses of $12 million, imputed interest expense related to our convertible debt of $11 million and a net tax benefit related to the excluded items of approximately $33 million. Echoing Robert and Heather's sentiment on the quarter, we're off to a very solid start to the new year.
Let me start at the top of the income statement. Total revenues for the quarter were $1.29 billion, an increase of nearly 10% over last year's first quarter, total adjusted revenues of $1.18 billion. Revenues in the current quarter were favorably impacted by approximately six percentage points related to the effect of foreign currency translation, reflecting the weaker U.S. dollar. Importantly, and as Heather made reference to earlier, excluding the significant decline in revenues related to Divalproex Sodium ER, which was expected, our year-over-year revenue growth rate would have been much higher. For the full year, we do continue to project total revenues in the range of $5.45 billion to $5.75 billion.
Looking at our operating profitability measures, adjusted gross margin for the quarter was approximately 46% compared to our full year guidance range of 47% to 49%. This margin is lower than the first quarter of 2009 as a result of the loss of exclusivity in Divalproex in the second half of 2009. However, sequentially, it was higher by two percentage points compared to our Q4 2009 adjusted gross margin. As Heather mentioned in her remarks, we continue to fully expect our operating performance and gross margins to improve as the year progresses, particularly in the second half. 
Adjusted R&D expense for the quarter was $60 million or approximately 5% of revenues. While this spending is consistent with our first quarter 2009 spending level, it is lower than our full year guidance range of 6% to 7% of revenues. Our projects remain on target and we are planning for higher levels of spending over the remainder of the year. 
Adjusted SG&A expenses were $245 million for the quarter or 19% of revenues, in the middle of our 18% to 20% full year guidance range. 
Our first quarter adjusted EBITDA was $323 million. If you combine this result with our expectation for generating higher levels of rev earnings later in the year, we see ourselves on track to meet our adjusted EBITDA guidance in the range of $1.4 billion to $1.6 billion for the full year.
Now let me move to a couple of our non-operating financial metrics. First quarter 2010 interest expense adjusted to exclude imputed interest on our convertible debt was $63 million. As you know, short-term floating interest rates continue to be at historic lows. We continue to forecast adjusted interest expense for the year to be in the range of $280 million to $300 million, which continues to consider the potential for higher short-term interest rates and potentially, a higher level of interest expense should we opportunistically execute on a long-term debt refinancing transaction this year. 
Income taxes. Our first quarter adjusted effective income tax rate was 29%, in line with our full year projection for an adjusted effective income tax rate in the range of 28% to 30%.
In summary, first quarter adjusted net income was $158 million or $0.36 per share. I believe you're all aware, but let me say it. In calculating our adjusted diluted EPS, the impact of assuming the conversion of our preferred shares into 125 million common shares was more dilutive than the 35 million quarterly preferred dividend. Therefore, adjusted diluted EPS for the first quarter is calculated based on an average outstanding diluted share count of 437 million shares. As you're all aware and we were pleased with, the performance of our stock price in the first quarter was strong. Depending on the market value of our common stock going forward, our average outstanding diluted share count could increase over the final three quarters of the year due to further dilution from stock options and other potentially dilutive financial instruments, such as warrants related to our convertible debt obligations. Our unchanged full year adjusted diluted EPS guidance range of $1.50 to $1.70 does consider the potential for a higher average diluted share count.
Turning to our cash flow metrics. Our first quarter cash flow from operations was $241 million. This amount includes a $99 million income tax refund related to capital losses previously realized on internal reorganizations. Excluding the benefit of this refund, cash from operations was $142 million, compared to $126 million in last year's first quarter. We do continue to project full year operating cash flow in the range of $725 million to $825 million, excluding certain one-off items. 
First quarter capital spending was $20 million and similar to 2009, but was less than one quarter of our expected annual spend. Based on anticipated projects timing, we do expect spending to increase in Q2 and continue to project capital spending in the range of about $250 million for the full year.
Now let me turn to our capital structure and liquidity position. As most of you are aware, this past December, we repaid our 2011 maturities on our bank term loans, which totaled $196 million. And as a result, we have no meaningful long-term debt maturities until the first quarter of 2012. From a covenant perspective, the level of our senior secured debt is approximately 2.6x our last 12-month covenant basis adjusted EBITDA. This is well below our March 31, 2010, covenant threshold of 4x and also comfortably ahead of our December 31, 2010, threshold of 3.5x. At the end of the quarter, we had approximately $550 million of unrestricted cash and marketable securities compared to just over $400 million at December 31. 
Our balance sheet in this morning's earnings release indicates the strong performance of our stock price in the first quarter, also had on the effective increasing the value of the cash conversion feature of our cash convertible notes, which increased our long-term debt balance at the end of the first quarter. This conversion feature is mark-to-market at the end of each period and reflected in the recorded long-term debt balance. There is an equal and offsetting asset that is recorded in the Other Assets section of our balance sheet related to a financial instrument hedge we have in place in order to offset the value of the bond's conversion feature. Excluding this and unamortized discounts related to both of our convertible note issuances, the balance of our long-term debt was $4.7 billion at March 31 compared to $4.8 billion at December 31, 2009. This difference relates to the impact on our euro-denominated debt of the decline in the value of the euro between the two balance sheet dates.
In closing, let me once again say, I believe we're off to a very solid start to the year. That concludes my remarks. I'll turn the call back over to Dan and I'll look forward to the Q&A. Dan?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Thanks very much, John. Kelsey, we're now ready to open up the line for questions.",15,"Thanks very much, John. Kelsey, we're now ready to open up the line for questions."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] We'll go first with Chris Schott with JPMorgan.",10,"[Operator Instructions] We'll go first with Chris Schott with JPMorgan."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","My first question is can you just elaborate or just give us your latest thoughts on the current FDA/OGD environment? And just the implications in terms of how many launches you're now targeting for 2010? I just have one quick follow-up after that.",44,"My first question is can you just elaborate or just give us your latest thoughts on the current FDA/OGD environment? And just the implications in terms of how many launches you're now targeting for 2010? I just have one quick follow-up after that."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","I'll give you a high-level comment, and Heather, maybe you want to follow up. But I guess the way I would describe it is this is what we're seeing. It's not something that I would say that's acute to any particular company. It's more systemic in this way.",210,"I'll give you a high-level comment, and Heather, maybe you want to follow up. But I guess the way I would describe it is this is what we're seeing. It's not something that I would say that's acute to any particular company. It's more systemic in this way. Even though the OGD is kind of reorganizing itself with some of the announcements that there were, and some of the backlog and some of the product approvals, we look at what's going on. They're more from a timing perspective. For example, some of the products that we anticipate that get actually approved in the first quarter has actually been delayed, and we anticipate those approvals just to roll forward. So you would think on one hand that, that would be a negative. But really, on the other hand, because this is more of a systemic issue with the FDA and the OGD in particular, as a whole within the industry, some of the other products that we have in our portfolio that we anticipated competition, we didn't get either. So the two kind of offset one another and what you have is a rolling-forward scenario, where, again, this is simply merely a timing issue and nothing more than that. Heather?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","And I'll just add to our numbers specifically. We haven't readjusted what we had set for the year, which was I think 45 to 50 approvals in the U.S. And as I mentioned, we already have about six of the limited competition approvals that we've received so f",86,"And I'll just add to our numbers specifically. We haven't readjusted what we had set for the year, which was I think 45 to 50 approvals in the U.S. And as I mentioned, we already have about six of the limited competition approvals that we've received so far. So Robert's point, definitely some delays from a timing issue given where we are in the year so early on. We still see them coming in and like I said, haven't changed our forecast for the year."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Just as a follow-up question. Can you just elaborate a little bit on the benefit you saw in the quarter based on competitors' supply interruptions? And just can you give us a little bit of your thoughts on the willingness of your customers to potentially",79,"Just as a follow-up question. Can you just elaborate a little bit on the benefit you saw in the quarter based on competitors' supply interruptions? And just can you give us a little bit of your thoughts on the willingness of your customers to potentially move back to these players once these supply interruptions are resolved? Is this somebody's share gains you're seeing now? Do you believe that these are sustainable share gains in some of these markets?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","I would prefer not to try to point to any benefits that Mylan is receiving off of the backs or off of some of the issues that some of the other companies are having. I think at Mylan, we're just staying concentrated on delivering a high quality, a high vo",157,"I would prefer not to try to point to any benefits that Mylan is receiving off of the backs or off of some of the issues that some of the other companies are having. I think at Mylan, we're just staying concentrated on delivering a high quality, a high volume of supply in that supply chain. I actually think it's a mistake to try to telegraph or target any benefits that we're deriving on the backs of some others that might be suffering. I do think that there is a higher appreciation, I've said this in the past, from the customers. I think we're seeing that higher appreciation for a constant, again, high-quality supply. I can tell you this, there's certainly nothing that has materially stood out, but we do see and have seen over the last several quarters some appreciation from the customers in terms of their activities and their views of players within the sector."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","And our next question will come from Randall Stanicky with Goldman Sachs.",12,"And our next question will come from Randall Stanicky with Goldman Sachs."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Can you help us understand the gross margin trajectory. How much of that is going to renew product geographic versus cost synergies is going to go to back half? And then Robert, can you just quantify the reform impact from an EPS perspective thing?",44,"Can you help us understand the gross margin trajectory. How much of that is going to renew product geographic versus cost synergies is going to go to back half? And then Robert, can you just quantify the reform impact from an EPS perspective thing?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Sure. Let me go first and let me just say that the reform impact, I'm not going to classify it as material but if you take a look at the calculation of the higher rebates and what have you. Obviously, we had some financial impact, but enough where we felt",104,"Sure. Let me go first and let me just say that the reform impact, I'm not going to classify it as material but if you take a look at the calculation of the higher rebates and what have you. Obviously, we had some financial impact, but enough where we felt very comfortable again given the robustness that we see ahead of us. We felt very comfortable that we could absorb that impact in terms of the guidance that we've given and the targets that we set forth until we start to see benefits in the 2014 plus range. And Heather, on the gross margin?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","And I think, Randall, keep in mind, I think there's three important parts to the gross margin improvement. There is certainly the still-forecasted current product launches that we expect to happen. There is our Specialty business as you know as we continu",115,"And I think, Randall, keep in mind, I think there's three important parts to the gross margin improvement. There is certainly the still-forecasted current product launches that we expect to happen. There is our Specialty business as you know as we continue to have Perforomist's uptake through the year. That, certainly, is a driver as well as the end to your point at synergies. So as we look at the repatriation, some of the vertical integration, site transfers that as you know, just keep rolling in on year-after-year that have been more coming in at the back. It's a combination of all three of those that are really driving that second half of the year."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Can you just help us still understand? And what I'm trying to understand is how much of that is linked to product approvals versus synergies , which you probably have well, much better line of sight into?",37,"Can you just help us still understand? And what I'm trying to understand is how much of that is linked to product approvals versus synergies , which you probably have well, much better line of sight into?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","First of all, let me start off by saying that the first quarter did not come as any surprise to us at all. Quite frankly, if you look at quarter four to quarter one in 2010, it's exactly what we've anticipated. If you recall in the last quarter, I looked",218,"First of all, let me start off by saying that the first quarter did not come as any surprise to us at all. Quite frankly, if you look at quarter four to quarter one in 2010, it's exactly what we've anticipated. If you recall in the last quarter, I looked at the fourth quarter as we entered into 2010, I said I want you to look at us delighted into 2010 and then looking at the back end, as really, the upward trajectory. And because we don't give quarterly guidance, we give annual guidance. I want to stress that. We don't give quarterly guidance. We give annual guidance. It would be, I don't believe that we're responsible to try to look at a quarter and judge with the guidance that we've given over the year because of this trajectory that I've told you. But to your point, in an excellent question, I think that there's actually a strong combination, and I don't want to put too much weight on one versus the other. I will tell you that we have a voluminous amount of product launches that we see at the latter part of the year. But we also, Randall, to your point, do see continued lower cost of goods savings also coming into that gross margin play."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","And moving on to Greg Gilbert with BofA Merrill Lynch.",10,"And moving on to Greg Gilbert with BofA Merrill Lynch."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","First, for John. Can you review your debt maturities and how you plan to deal with them and give us the specific share count you're using for EPS for this year's guidance? And then a follow for Rob and Heather. From an M&A perspective, at this point, are",68,"First, for John. Can you review your debt maturities and how you plan to deal with them and give us the specific share count you're using for EPS for this year's guidance? And then a follow for Rob and Heather. From an M&A perspective, at this point, are you more focused on generic opportunities or opportunities to fold brand assets in today or otherwise support a branded strategy?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Before I turn it over to John, in terms of the overall debt maturities as we stated, Greg, we are looking. We basically satisfied any requirements prior to 2012 and really, our focus is the 2014. The $3 billion that we have coming due in 2014. And it's be",140,"Before I turn it over to John, in terms of the overall debt maturities as we stated, Greg, we are looking. We basically satisfied any requirements prior to 2012 and really, our focus is the 2014. The $3 billion that we have coming due in 2014. And it's been our stated intention to basically tap the capital markets in an opportunistic way in order to stagger out that maturity from 2014 to something that we believe is a little bit more responsible and prudent. And as I stated also in the past, the guidance fully anticipates our ability to tap those markets and any negative arbitrage that we can at least anticipate right now has also, in terms of negative arbitrage in the interest rates, has also been fully incorporated into our guidance. John, do you want to add anything?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","So I think the two parts to your question were in terms of existing repayment schedule. As I've said in my remarks, we really don't have any significant maturity repayments until early 2012. And in '12, we're looking at approximately $800 million. $200 mi",109,"So I think the two parts to your question were in terms of existing repayment schedule. As I've said in my remarks, we really don't have any significant maturity repayments until early 2012. And in '12, we're looking at approximately $800 million. $200 million in '13 and then, as I'm sure you're already aware, a significant amount in 2014 over $3 billion. The second half of your question related to the share count that we're using and as I've said again in my remarks, the first quarter amount was 437 million shares and the amount that's baked in to our guidance, quite honestly, is not materially different than that."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","We don't anticipate using at this time a share count lower than that. I think that, and correct me if I'm wrong, but I think the threshold was $17 a share where we had -- really with where crossover occurred. So we don't anticipate for the rest of this ye",91,"We don't anticipate using at this time a share count lower than that. I think that, and correct me if I'm wrong, but I think the threshold was $17 a share where we had -- really with where crossover occurred. So we don't anticipate for the rest of this year to be using anything less than the fully diluted share count to take into consideration the number of shares that will be added when the mandatory convert comes due in November. And then the other part of the question, Heather?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Yes, sure. On the opportunities, obviously, as we continue to state we certainly are looking at complementary products to add to the Dey portfolio as well as generic opportunities whether it's other therapeutic categories or dosage forms such as injectabl",55,"Yes, sure. On the opportunities, obviously, as we continue to state we certainly are looking at complementary products to add to the Dey portfolio as well as generic opportunities whether it's other therapeutic categories or dosage forms such as injectables, ophthalmic, as we've discussed, things that we would add to those number of the footprint."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","We'll move to Marc Goodman with UBS.",8,"We'll move to Marc Goodman with UBS."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","First, on France. Can you give us a flavor for what the government has done with respect to the price cuts and things like that? And second of all, in France, did you mention that, that was one of the countries that grew double digits or not there? Becaus",134,"First, on France. Can you give us a flavor for what the government has done with respect to the price cuts and things like that? And second of all, in France, did you mention that, that was one of the countries that grew double digits or not there? Because you threw a bunch of countries and I wasn't that France was in there? And then the other question has to do with the gross margin. Heather, just give us a sense of the site transfers that you've had planned from the beginning? How many have you done or just give us a percentage of the way that you're through the process and where you'll be at the end of the year? And then just the FX impact on the gross margin in the quarter."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","So first I think you asked about Spain. Is that correct, the price cuts that we mentioned in Spain?",19,"So first I think you asked about Spain. Is that correct, the price cuts that we mentioned in Spain?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","France.",1,"France."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Okay. The France one as you know, as is typical than most of the countries. The price negotiations are with the government. And there's typically the one-time local price cuts that happened. So the France, as I've stated was anticipated as part of our gui",63,"Okay. The France one as you know, as is typical than most of the countries. The price negotiations are with the government. And there's typically the one-time local price cuts that happened. So the France, as I've stated was anticipated as part of our guidance and so forth. And we intended to still maintain our market leadership position. So that was all anticipated."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Was that like 5%?",5,"Was that like 5%?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","We didn't get in to an average. It doesn't go across the board. It depends whether your product's on the repertoire list. It's not on repertoire list, so there is not just -- overall it's blended. But it was fully anticipated. As far as -- other question?",48,"We didn't get in to an average. It doesn't go across the board. It depends whether your product's on the repertoire list. It's not on repertoire list, so there is not just -- overall it's blended. But it was fully anticipated. As far as -- other question?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","The other question was on gross margins.",7,"The other question was on gross margins."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Before you move to the gross margins, just with double digits, because you reeled off a bunch of countries, but then I wasn't sure if France was in there.",29,"Before you move to the gross margins, just with double digits, because you reeled off a bunch of countries, but then I wasn't sure if France was in there."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","No, not on double digits. The growth on the countries was Italy, Spain and the U.K.",16,"No, not on double digits. The growth on the countries was Italy, Spain and the U.K."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","And the gross margin question, Mark?",6,"And the gross margin question, Mark?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Well, there were two. One was the FX impact and then the site transfers.",14,"Well, there were two. One was the FX impact and then the site transfers."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Yes, the site transfers. So, Mark, as we had said a while ago, all the work about, I think it averaged about 160 site transfers that we completed, actually the first quarter of '09 getting into the older regulatory keys. And obviously, that's what's now b",150,"Yes, the site transfers. So, Mark, as we had said a while ago, all the work about, I think it averaged about 160 site transfers that we completed, actually the first quarter of '09 getting into the older regulatory keys. And obviously, that's what's now been rolling in the end of '09 and will continue to roll in '10. What I can't tell you -- we haven't broken out the percentage of how those have fallen in except our guidance obviously absorb them, certainly leading to that second half trajectory that we've talked about. The majority of those being in and obviously, through the end of 2010. All of those now will have been absorbed in. So certainly, the majority of those are in the last half of this year will then be completed for all, like I said, the 160 site transfers that we've talked about through the synergies."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Then John, on the FX and the gross margin?",9,"Then John, on the FX and the gross margin?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","I'll let Dan respond.",5,"I'll let Dan respond."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","The FX impact on gross margin dollars is roughly comparable with the impact you're seeing on the revenue side, but more importantly on a percentage, gross margin percentage. There's a slight negative impact on gross margin percentage, but not significant",55,"The FX impact on gross margin dollars is roughly comparable with the impact you're seeing on the revenue side, but more importantly on a percentage, gross margin percentage. There's a slight negative impact on gross margin percentage, but not significant because it's affecting sales and cost of sales in almost equal and opposite directions."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","And moving on to John Boris with Citi.",8,"And moving on to John Boris with Citi."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","First question just has to do with the Japanese market and the price cuts, biannual price cuts that they take there. What was the wholesaler behavior like in the quarter today, not by product? And can you just give any comment on what generic volumes are",57,"First question just has to do with the Japanese market and the price cuts, biannual price cuts that they take there. What was the wholesaler behavior like in the quarter today, not by product? And can you just give any comment on what generic volumes are actually doing in the Japanese market? Then I have one follow-up."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","So just to the two parts of that. The biannual, obviously again, this is something well anticipated and known throughout the market there and the players. So the patterns of the inventory, we didn't see any extraordinary phenomenon on any front with the J",77,"So just to the two parts of that. The biannual, obviously again, this is something well anticipated and known throughout the market there and the players. So the patterns of the inventory, we didn't see any extraordinary phenomenon on any front with the Japanese price cut. As far as the volumes go, they're still holding around that 19% to 20% generic utilization rate. We haven't seen any significant move one way or the other on that front."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","And then just back to question that was asked earlier on health care reform. Can you just provide some commentary on what percent of your revenue in the U.S. is exposed to Medicaid and to the 340B provision?",38,"And then just back to question that was asked earlier on health care reform. Can you just provide some commentary on what percent of your revenue in the U.S. is exposed to Medicaid and to the 340B provision?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","It's even more minimal since Medicare Part D. Because dual eligibles were taken out and moved into Medicare Part D. So I believe the Medicaid population is now right under 10%.",32,"It's even more minimal since Medicare Part D. Because dual eligibles were taken out and moved into Medicare Part D. So I believe the Medicaid population is now right under 10%."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","We will now hear from Ann Trimble with Barclays Capital.",10,"We will now hear from Ann Trimble with Barclays Capital."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","It's Ann Trimble for Rick Silver. Could you discuss the reason behind the sequential decline in EMEA revenues?",19,"It's Ann Trimble for Rick Silver. Could you discuss the reason behind the sequential decline in EMEA revenues?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","As you look, obviously there's a lot of some seasonality in the products and just buying patterns as you're going into holiday month and so forth coming in to the first quarter. So there's nothing extraordinary. We certainly had year-over-year growth when",66,"As you look, obviously there's a lot of some seasonality in the products and just buying patterns as you're going into holiday month and so forth coming in to the first quarter. So there's nothing extraordinary. We certainly had year-over-year growth when you look at quarter-over-quarter in EMEA. So sequentially, again there is nothing out of the ordinary if you look at Q4 year-over-year as well."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","And then as a quick follow-up, could you elaborate on your comments on the Spain price cuts and timing of the expected impact?",24,"And then as a quick follow-up, could you elaborate on your comments on the Spain price cuts and timing of the expected impact?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","As I've said, it was 25%, and we're obviously, as I mentioned, have been able to not only now anticipate and take that and absorb that, but as well as we've had quite a few successful product launches and increased volume uptake, which has been able to ha",55,"As I've said, it was 25%, and we're obviously, as I mentioned, have been able to not only now anticipate and take that and absorb that, but as well as we've had quite a few successful product launches and increased volume uptake, which has been able to have us offset the 25% price cut."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","We'll now hear from Ronny Gal with Bernstein.",9,"We'll now hear from Ronny Gal with Bernstein."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","First, about the refinancing of the debt. Roughly, I guess what would be the impact of this during the year? And roughly when in the year did you assume it will happen? Just to understand the impact if this refinance will not take place here.",45,"First, about the refinancing of the debt. Roughly, I guess what would be the impact of this during the year? And roughly when in the year did you assume it will happen? Just to understand the impact if this refinance will not take place here."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Ronny, as we mentioned, we have been constantly looking at what we consider to be the opportunistic moment for Mylan to tap to the B markets. And when we think that we've reached that point, we will certainly make the announcement. So to that point, we ca",182,"Ronny, as we mentioned, we have been constantly looking at what we consider to be the opportunistic moment for Mylan to tap to the B markets. And when we think that we've reached that point, we will certainly make the announcement. So to that point, we can't really predict exactly what the impact would be in terms, if any, to any arbitrage in terms of the interest rate, the all-in interest rate that we pay now versus any impact on the interest rate that we may pay. Once we tap the markets and understand what we're going to end up with in terms of the overall yield. But let me just say that we can easily, at least, and what we already have done is pay attention to the broader markets, to some of the deals that have gone off, look at some of the rates that they've ended up with, look at what our all-in rate is and I think, fairly and practically predict that there will be some negative arbitrage and we fully have incorporated that into our 2010 guidance."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","I was just wondering what you've modeled. If you can break that down for us so we can -- once the news hits, we can actually assess it for ourselves.",31,"I was just wondering what you've modeled. If you can break that down for us so we can -- once the news hits, we can actually assess it for ourselves."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","I was going to add here to Robert that we thought about two separate factors. One being the refinancing that Robert was referring to. And then combined to the fact that there is certainly risks for interest rates increasing,, and we didn't specifically th",94,"I was going to add here to Robert that we thought about two separate factors. One being the refinancing that Robert was referring to. And then combined to the fact that there is certainly risks for interest rates increasing,, and we didn't specifically think about a particular time when we would be doing the refinancing transaction nor can we predict exactly when interest rates are going to rise, but we took those two factors into consideration in thinking about the $280 million to $300 million as an appropriate number for full year interest expense."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","We'll hear from David Buck with Buckingham Research Group.",10,"We'll hear from David Buck with Buckingham Research Group."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","It's Jim Dawson for David Buck. You got into this a little bit, but can you talk about the expectation for the European business forward and any pricing changes we should be aware of?",35,"It's Jim Dawson for David Buck. You got into this a little bit, but can you talk about the expectation for the European business forward and any pricing changes we should be aware of?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","I mean look, we have forecasted obviously growth overall for EMEA and other than the pricing that I spoke about this morning, Spain, France and the ones that we've anticipated, I right now, don't know of anything else that's coming through the year.",43,"I mean look, we have forecasted obviously growth overall for EMEA and other than the pricing that I spoke about this morning, Spain, France and the ones that we've anticipated, I right now, don't know of anything else that's coming through the year."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","But as we've mentioned many, many times, overall and longer term, we do expect there to be a continuation of price cuts within that region. And we fully have incorporated that into, not only our guidance, but even in our targets. But those things, the opp",306,"But as we've mentioned many, many times, overall and longer term, we do expect there to be a continuation of price cuts within that region. And we fully have incorporated that into, not only our guidance, but even in our targets. But those things, the opportunity for us is to balance that with the increase in volumes that we anticipate strictly as a result of the lower cost of the pharmaceutical products as a whole, especially the increased generics through increased generic utilization. But most importantly, in addition, I have to tell you again, we do not view some of the markets over in Europe as being the most efficient markets when it comes to the pull-through effect of generics and generic utilization as a whole. So we look at that as an opportunity and as the markets continue and these countries continue to decide to reduce its prices, it basically comes directly up against the actual infrastructure in the current models that are in place. So you can fully expect, as we continue to monitor each country as each of them make their decision about what type of pharmaceutical model they want to have for their country, whether or not they want to support a higher infrastructure costs or whether or not they want a different type of pull-through effect. We on the other hand, as management, will manage each one of those countries and rightsize the infrastructure according to what the government wants in terms of that particular region. So we are not concerned at all, but overall, we are certainly not concerned in our ability to deliver what we feel are appropriate targets that we set for ourselves. But overall, I think you should all anticipate a continuation of price cuts going forward, as we look out in the whole EMEA section."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","You got in this a little bit as well or earlier in call, but regarding the supply disruptions you mentioned in your release. Can you talk about if you have benefited from -- and can you quantify that from increased sales and/or increased gross margins in",78,"You got in this a little bit as well or earlier in call, but regarding the supply disruptions you mentioned in your release. Can you talk about if you have benefited from -- and can you quantify that from increased sales and/or increased gross margins in the first quarter? And also talk about what you're seeing in the current quarter being the second quarter, and how much of that is a factor in accelerating the second half growth?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","As I mentioned before, Jim, I don't even think it's even appropriate. First of all, I don't see -- I can tell you right off the bat, there's nothing material that I can even point to, to say somehow we're getting some hiccup benefit on the backs of anothe",259,"As I mentioned before, Jim, I don't even think it's even appropriate. First of all, I don't see -- I can tell you right off the bat, there's nothing material that I can even point to, to say somehow we're getting some hiccup benefit on the backs of another company failing. I think that Mylan continues to keep its head down and to continue to march forward in our quest to deliver very, very high quality volumes. And I think that the value of our consistent, constant supply chain is becoming more and more appreciated by customers. I would not and I think it's, again, inappropriate to point that we're somehow benefiting. I don't see anything material that I can even point to right now, but I just think it's a longer-term trend that will basically bleed its way in if we are going to benefit from some of the disruptions that others have had. I see it more of a bleed-in rather than this roller coaster, high, low quarter-over-quarter. I just think it's not what I'm seeing and it's certainly not the way we are driving our business. I think that the increases that we are seeing are increases that have come in over a period of time, and we just don't see that ending. We see that more and more the way we see ourselves working with our customer base, and the appreciation that they are showing us in return, we just see that continuing over a longer haul, not anything over a short period of time."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","And moving on to Michael Tong with Wells Fargo.",9,"And moving on to Michael Tong with Wells Fargo."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Just maybe a little bit more big-picture question. We've talked a lot about the Generics business, but I'm just wondering what your thought process behind your Specialty business going forward is in terms of growing that business? And what your thoughts a",49,"Just maybe a little bit more big-picture question. We've talked a lot about the Generics business, but I'm just wondering what your thought process behind your Specialty business going forward is in terms of growing that business? And what your thoughts about how you go about growing it?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Well, I mean I'm pretty excited about what we actually already have in terms of the growth prospects of the assets that we're currently managing. Obviously, I have very distinct strategic plans to growing the business, but those plans and the robustness o",187,"Well, I mean I'm pretty excited about what we actually already have in terms of the growth prospects of the assets that we're currently managing. Obviously, I have very distinct strategic plans to growing the business, but those plans and the robustness of my vision and thinking of what I see that business could ultimately be, it certainly being offset and mitigating by the financial discipline that has been set forth here at Mylan. I would love to have a lot of things. I love to do a lot of things, but as I promised in the past, I'm not going to do anything that's going to jeopardize the earnings growth that we've set forth, that we've outlined. And I will tell you that with that said, I still see business development opportunities where we are aggressively looking and continue to look where we can look at whether it's a product or a product portfolio or anything that we think that would be complementary that would be add-ons to that business, but again, not at the behest of jeopardizing the earnings growth that we set forth earlier."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","And if I can have one follow-up for John. Did I hear you correctly about the interest expense outlook for the year? Does it include or exclude the accretion or the imputed interest from your converts?",37,"And if I can have one follow-up for John. Did I hear you correctly about the interest expense outlook for the year? Does it include or exclude the accretion or the imputed interest from your converts?"
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","It excludes. The number of the 280 to 300 excludes.",10,"It excludes. The number of the 280 to 300 excludes."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Again, we have time for one final question that will come from Ken Cacciatore with Cowen and Company.",18,"Again, we have time for one final question that will come from Ken Cacciatore with Cowen and Company."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Analysts","Quick question back on France. Some of our industry contacts indicate that Mylan was the most aggressive in terms of pricing in that marketplace. And so just trying to understand beyond kind of what's being set from the government perspective, if you coul",84,"Quick question back on France. Some of our industry contacts indicate that Mylan was the most aggressive in terms of pricing in that marketplace. And so just trying to understand beyond kind of what's being set from the government perspective, if you could give a little commentary if that's true. Or if it's true you are the market leader. I'm trying to understand, contextually, what maybe going on competitively there that has you kind of acting as the most aggressive in the pricing dynamics."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","The way I would characterize it and quite complementary to the leadership of Didier and France as well as Didier's leadership in every other country, I'd like to actually, hoping the question was that Mylan was the most aggressive in managing its business",171,"The way I would characterize it and quite complementary to the leadership of Didier and France as well as Didier's leadership in every other country, I'd like to actually, hoping the question was that Mylan was the most aggressive in managing its business, as Mylan is the most aggressive in managing its business in every single market. As you know, the dynamics of the generic marketplace are changing at rapid speed. And so, if that's what you're hearing on the outside then kudos to Didier for continuing to manage as aggressively as he should be doing, not being the most aggressive necessarily in the market, but a constant balance between pricing levels versus volumes versus market share versus there are many, many, many variables that a leader must take into consideration as dynamic as the generic industry is. And I'm extremely pleased with the results that he put up in the first quarter. So again, thank you for the question and that's a high compliment to Didier and his team."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Mr. Crookshank, I'll turn it back to you for closing or additional remarks.",13,"Mr. Crookshank, I'll turn it back to you for closing or additional remarks."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Executives","Well, we'll be available as the day goes on for follow-up conversations as you like. And that's it. Thank you, once again for joining the Mylan team for the conference call.",31,"Well, we'll be available as the day goes on for follow-up conversations as you like. And that's it. Thank you, once again for joining the Mylan team for the conference call."
290203,104551358,59223,"Mylan, Inc., Q1 2010 Earnings Call, Apr-29-2010",2010-04-29,"Earnings Calls","Viatris Inc.","Operator","Thank you. Again, ladies and gentlemen, that concludes our conference for today. We thank you all for your participation.",19,"Thank you. Again, ladies and gentlemen, that concludes our conference for today. We thank you all for your participation."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","Good day, and welcome to the Mylan's Second Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King. Please go ahead, ma'am.",34,"Good day, and welcome to the Mylan's Second Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King. Please go ahead, ma'am."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Thank you, Nancy. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; Senior Vice President",374,"Thank you, Nancy. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; Senior Vice President, Corporate Controller and Chief Accounting Officer, Dan Rizzo; and Brian Byala, Senior Vice President and Treasurer.
During today's call, including the Q&A, we will be making forward-looking statements, including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods.
Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our annual report on Form 10-K for the year ended December 31, 2009, and in our other Securities and Exchange Commission filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP measures.
It should be noted that non-GAAP financial measures such as adjusted revenues, adjusted gross margins and adjusted diluted EPS should be used only as a supplement to, not as a substitute for or as a superior measure to measures of financial performance prepared in accordance with GAAP.
Please refer to today's earnings press release, which is available on our website as a contains detailed GAAP to non-GAAP reconciliations of our actual 2010 and 2009 second quarter results, including the allocation of each reconciled item to a specific income statement line item.
Before I turn the call over to Robert, let me also remind you that the material in this call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'll now turn the call over to Robert."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris. Good afternoon, everyone, and thank you for joining us on today's call. Once again, I would like to start by sincerely thanking each and every one of our employees around the world for yet another great quarter. It is truly your continued",347,"Thank you, Kris. Good afternoon, everyone, and thank you for joining us on today's call. Once again, I would like to start by sincerely thanking each and every one of our employees around the world for yet another great quarter. It is truly your continued outstanding hard work and dedication to Mylan that makes it possible for us to again deliver such strong results. 
We were able to deliver adjusted diluted earnings per share of $0.37 despite many challenges, including the delay of certain product approvals, global pricing pressures and the impact of negative currency trends. This quarter's strong results only continue to demonstrate the underlying strength of our overall business.
Considering these results and several significant recent announcements, we are now able to narrow our 2010 adjusted diluted earnings per share range to $1.55 to $1.65. Also, even though we haven't provided formal earnings guidance for 2011, we remain confident in our forecast to achieve adjusted diluted earnings per share of $2 by the end of 2011. 
Before I turn the call over to our President, Heather Bresch, I would like to review at a high level a couple of our significant corporate achievements since our last earnings call.
First, in May, we successfully raised $1.25 billion in long-term notes, and with most of the proceeds we prepaid $1 billion of secured term loan borrowings. 
Second, I was also extremely pleased to be able to fulfill yet another one of our stated objectives by our recent announcement of our intention to acquire Bioniche Pharma, a high-growth global injectable pharmaceutical company. As we reported at the time of the announcement, this business is expected to be immediately accretive in year one, not accounting for any synergies. 
In addition, we expect Bioniche Pharma's growth rate to be well above our stated long-term growth rates. The addition of Bioniche Pharma will only add further assurance in our ability to meet our stated objectives.
With that said, I'd like to forward -- I look forward to answering your questions, but I'd now like to turn the call over to Heather."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert, and good afternoon, everyone. As Robert said, we're very pleased with our exceptional second quarter performance and remain confident in our ability to deliver 2010 results in line with the updated guidance we are announcing today. In",2228,"Thank you, Robert, and good afternoon, everyone. As Robert said, we're very pleased with our exceptional second quarter performance and remain confident in our ability to deliver 2010 results in line with the updated guidance we are announcing today. 
In addition, we're excited about the growth we see coming in '11, which we believe will result in earnings of $2 per share, as well as our long-term growth targets. During my prepared remarks, I'll provide you with more color around our performance during the past quarter and on what we expect as drivers to achieve the second half of '10, plus '11 and beyond. 
First, though, I'd like to take this opportunity to thank our employees. Their outstanding work ethic and commitment to excellence have once again made it possible for Mylan to deliver very strong results. I'd like to start by touching briefly upon a few of the elements of our 2010 guidance.
First, in addition to narrowing our range for adjusted EPS, which Robert mentioned, we are tightening and revising our range for adjusted revenues. We now expect to generate revenues between $5.4 billion and $5.6 billion. 
Next, our adjusted gross margin for the quarter was approximately 45% compared to our full year guidance range of 47% to 49%. We've mentioned in the past that product mix is an important driver of gross margin, and approval delays in the U.S. played a role in this quarter's performance. Therefore, we remain confident in our ability to meet this element of our guidance due to recent approvals we've received on higher-margin limited-competition products, higher specialty business sales, our planned Bioniche Pharma acquisition and continued synergy realization in the second half of the year. 
Finally, as it relates to R&D. We are revising this element of our guidance to 5% to 6% from 6% to 7%. Our adjusted expenditure for the quarter totaled $66 million or approximately 5% of revenues. At this level of investment, our R&D activities are hitting on all cylinders, and our output remains very strong. We currently have 1,480 global product submissions pending approval, and we are on track to achieve our target of 1,000 global submissions annually in 2010 through 2013. In addition, because of Bioniche Pharma's robust pipeline, we do not see a need for any meaningful external R&D activity during the remainder of the year. 
I'd like to turn now to the topic of pricing, which has received much attention lately. Our company has a very long history of delivering profitable growth in the U.S., which is by far one of the world's most competitive pharmaceutical markets. As such, we're very experienced at anticipating and responding to price and reimbursement cuts and managing fluctuations in volume. Now that we have a diversified global platform, we are able to effectively manage these same dynamics on even a larger scale and have more levers available to manage, drive and grow our business.
As we've stated before, we anticipated greater pricing pressure, especially in Europe, than in previous years and took these dynamics into consideration going into 2010. Though these pressures were slightly greater than what we anticipated, we have been able to absorb them.
Being able to manage such dynamics creates tremendous opportunities for Mylan. In fact, we believe we are positioned to leverage our vertically and horizontally integrated capabilities, economies of scale, and reliable and responsive supply chain across our global operations. All the hard work done over the last three years under the campaign of synergies have transformed us into a highly competitive organization. 
This tremendous advantage is the realization of the vision we set out to achieve when we brought together legacy Mylan, the former Merck business and Matrix Laboratories nearly three years ago. During those first three years, we focused on executing the integration of the businesses and on capturing significant synergies. Our strong results throughout that period demonstrate our phenomenal success in that regard. Now that same result has succeeded, paving the way for our strong top and bottom line growth in 2011 and beyond. 
Now I would like to walk you through the performance of our commercial operation.
During the second quarter, we generated total revenues of $1.37 billion compared to last year's second quarter total adjusted result of $1.27 billion. That's an increase of approximately 8%. Revenues grew in both our Generics and Specialty segments. On the bottom line, solid execution across our business allowed us to generate $0.37 of adjusted diluted EPS, a 16% increase over last year's second quarter result. This result is in line with our guidance. 
Within our Generics segment, our North America operations delivered third-party revenues for the second quarter of $589 million, up 12% from last year's second quarter results of $526 million. The increase was driven by sales of new products and increased volumes on our base business. This performance is a true testament to the strength of critical mass in controlling your supply chain so as to seize on market opportunities. 
Our higher revenues also absorbed the loss of exclusivity on Divalproex, which we enjoyed during last year's second quarter.
Complimenting this very strong performance was the record number of product approvals we received during the quarter from the FDA, with a year-to-date total of 33. We have also launched, to date, eight of the dozen limited-competition products we expect to introduce by the year end. These achievements demonstrate the strength of our pipeline and are among the many reasons we're so confident about our future.
I'd also like to add that we remain on track to achieve our full year target of 50 to 60 launches in the U.S. 
Currently in the U.S., we have 131 ANDAs pending FDA approval, representing about $92 billion in annual brand sales, and 41 of these pending ANDAs are potential first-to-file opportunities representing more than $21 billion in annual brand sales. 
In Canada, we saw local currency third-party sales grow about 19% versus the year-ago quarter, led by products launched in the last 18 months. Pricing pressures in Ontario, Qubec and other provinces due to recent or pending legislation have been offset by a required reduction in payments to pharmacies, particularly in Ontario, resulting in a net impact that we expect will be relatively neutral to our business. 
In EMEA [Europe, the Middle East and Africa], where France drives our performance, third-party revenues of $379 million fell about 4% last year's second quarter third-party revenues of $393 million. However, on a constant-currency basis, operational growth in EMEA was nearly 3% year-over-year. The increase was driven by new product launches in several markets, totaling approximately $31 million, as well as increased volumes in certain countries. We remain committed to optimizing our business to align the new market dynamics in this region. 
In France, our sales dipped slightly versus a year-ago quarter as competitive pressure resulted in lowering price, which offset the favorable contribution from new products and increased sales of existing products. However, our market leadership position remains very strong.
In Spain, we saw a double-digit increase in sales as new product launches more than offset the negative effect on pricing in the portfolio. We also experienced single-digit growth in a variety of countries such as the UK. 
In Italy, second quarter local currency sales almost doubled versus the year-ago quarter due to new product launches and increased market penetration, which resulted in increased volume, as well as regulatory changes that have affected pricing positively. 
Moving onto Asia-Pacific region. We delivered solid second quarter results. Total third-party revenues were $265 million, up nearly 23% over last year's second quarter result of $216 million. On a constant-currency basis, sales increased about 12%. 
In Australia, local currency revenues declined slightly. We are continuing to optimize our business to align to new market dynamics while maintaining our leadership position. 
In Japan, local currency sales rose approximately 7% due to new product launches and continued market expansion. We remain optimistic about longer-term growth opportunities presented by this market and our ability to capture our share of that growth. 
Also in the region, our Matrix business delivered another very strong quarter of year-over-year growth. Primarily responsible were sales of ARV finished dosage forms to third-parties, which more than doubled versus the second quarter of '09, and sales of API to third parties. 
Finally, Dey Pharma, our Specialty segment, continued to perform well during the second quarter. Third-party revenues rose 14% over the same period last year after adjusting last year's third-party sales for the transfer of Dey's generics product to our Mylan Pharms [Mylan Pharmaceuticals] division. The primary driver of that growth was domestic sales of our EpiPen Auto-Injector. 
Moving on, I'd like to express how excited we are about our planned acquisition of Bioniche Pharma.
Bioniche Pharma will further our stated objective of identifying bolt-on acquisitions to fill gaps in our U.S. product portfolio and therapeutic categories. It also will give us the critical mass needed to immediately enter the North American injectables market. As Robert mentioned, we expect the business to be accretive in year one without accounting for any synergies. 
For those of you unfamiliar with the company, Bioniche Pharma is a leading U.S.-focused specialty injectable company based in Galway, Ireland. The company focuses on the development, production and sale of high-quality injectable products, many of which are difficult to develop or produce or that experience limited competition. The products are used in hospital settings and span several therapeutic categories including analgesics, orthopedics, oncology and urology. 
Bioniche currently markets about 30 products, and its pipeline includes 15 ANDAs pending approval with the FDA. The company also has more than 25 additional products in various stages of development. Net revenues totaled approximately $130 million for the 12 months ended May 31, 2010, and approximately $43.5 million for the last three months ended May 31, 2010.
Though the transaction remains subject to regulatory approval and other customary closing conditions, we expect the deal to close in September. 
We're excited about this transaction for two reasons. First, we expect Bioniche Pharma's top line growth rate to be well above our stated growth target, which only further bolsters our confidence in them. And because Bioniche Pharma is a higher gross margin business, we expect it to have a positive impact on Mylan's overall gross margin.
Further, while we are not providing synergy numbers, as there is little overlap with our existing operation, we do see opportunities to capture synergies both commercial and technical. We anticipate that once we close, integration activities will be swift and seamless. 
Secondly, we consider this transaction to be strategic in that Bioniche Pharma will become one of the pillars of Mylan Institutional, our newly formed institutional business, which will serve hospitals and long-term care facilities in North America with a differentiated and tailored pharmaceutical product offering.
We expect that offering will initially include that of UDL, the largest unit dose provider to hospitals in the U.S., and Bioniche Pharma's high quality injectables. Moreover, because of the nature of the institutional marketplace, the new Mylan Institutional will fill an important prerequisite to the viability of the commercialization of Mylan's own generic biologics platform in the near future, as well as commercialization of specialized products such as Copaxone. 
As you can see, we have a lot to be excited about in the second half of 2010, from receiving new product approvals to driving continued increases in volumes around the world and achieving annual synergies of $350 million, if not more. 
Looking ahead to 2011. We are as bullish as ever about our prospects and believe our momentum going into the year will be very strong. Specifically, we look forward in 2011 to the additional revenues that will result from the approximately 500 products we expect to launch globally. Among them will be oral contraceptives, which we expect to begin launching in the U.S. around mid-year; the monetization of first-to-file opportunities, such as our previously announced settlements related to Voriconazole, Letrozole, and Venlafaxine; and our recently announced settlement on Minocycline, which John will elaborate on shortly. 
In addition, we will see the expiration of 30-month stays on a number of additional first-to-file opportunities, and we expect to launch in excess of a dozen limited-competition products.
Finally, let me remind you that our legacy Merck Generics business inlicensed about 70% of its product when we purchased it back in '07. By year-end, we'll be at about 55% and expect to keep pushing that figure lower throughout '11 in achieving internalization of 70% by 2013, resulting a positive financial impact. 
At this time, beyond 2011 and through '13, we continue to see strong growth in our overall business and expect to accelerate our top line growth by executing on the key drivers of portfolio expansion, continued realization of operational efficiencies, continued diversification and balance sheet deleveraging. 
In summary, I'd like to remind everyone that we have stated many times that 2010 is the baseline year from which Mylan will continue to grow. We have an extremely powerful platform, a proven ability to execute and an unshakable belief that we are perfectly positioned to leverage our assets over the years to come. The results we announce today only reinforce our confidence that we will deliver performance in 2010 and beyond that is in line with our updated guidance and with our long-term targets.
With that, I'll turn over to John."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Thanks, Heather. This afternoon, I will walk you through our second quarter 2010 financial results and discuss our 2010 financial guidance, the range of which we have narrowed. I will conclude by briefly reviewing our capital structure and liquidity posit",2637,"Thanks, Heather. This afternoon, I will walk you through our second quarter 2010 financial results and discuss our 2010 financial guidance, the range of which we have narrowed. I will conclude by briefly reviewing our capital structure and liquidity position. 
Before I begin, I would like to comment briefly on what I've seen at Mylan during, this, my first full quarter as CFO.
One of the aspects of joining Mylan that I found most intriguing was that of the growth prospects of the Generics and Specialty Pharmaceuticals sector, and in particular, how well poised Mylan is to take advantage of such opportunities. This has been quickly confirmed for me with our recent approvals and subsequent launches of Valacyclovir and the Clonidine patch, and most recently, our approval and launch of Minocycline and subsequent legal settlement, which I will discuss in more detail later. 
Additionally, this growth continues to increase our ability to leverage our global production capabilities and robust R&D pipeline. When I was making my decision to join Mylan, one of the key points that both Robert and Heather continued to stress with me was the soundness of Mylan's growth strategy, and perhaps most important, the company's ability to execute against these strategies and make their vision become a reality. This, too, has been clearly demonstrated to me in my short time here with our recently announced planned acquisition of Bioniche Pharma, which immediately makes Mylan a player in the North American injectables market, yet another successful accomplishment of a stated objective.
Whether it be product approvals, such as those we have recently seen, or acquisitions such as Bioniche, it is developments and actions such as these that demonstrate that Mylan executes on what says it's going to do and continues to make me confident in Mylan's long-term growth targets. 
Now moving on to my review of our second quarter financial results. As Kris mentioned, I'm going to be referring to actual and projected financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. We present these non-GAAP financial measures because they're prepared on the same basis as used by our management and Board of Directors to evaluate the performance of our business. This afternoon's earnings release includes a complete reconciliation from our GAAP to non-GAAP financial measures for our second quarter 2010 and 2009 results. Earnings release is available on our website and I encourage you to take a look at it. 
In summary, the more significant items that are excluded in arriving at our adjusted basis results for the 2010 second quarter are: purchase accounting amortization of $71 million; integration and other expenses of $18 million; incremental interest expense, which is primarily the imputed interest expense related to our convertible debt, of $14 million; charges related to the net settlement of litigation, totaling $12 million; costs associated with our recent issuance of the new senior unsecured notes, which I will discuss later, totaling $15 million, which was mainly related to the write-off of debt issuance costs and certain costs associated with the termination of interest rate swaps; and finally, the net tax benefit related to the excluded items, of approximately $53 million. 
I strongly agree with Robert and Heather's comments on the quarter and first six months, both of which were very solid operationally and financially. Let me start at the top of the income statement.
Total revenues for the quarter were $1.37 billion, an increase of 8% over last year's second quarter total adjusted revenue of $1.27 billion. The effect of foreign currency translation did not have a significant impact on our second quarter results as compared to the same prior-year period, as the effect of a weaker euro was offset by the strengthening of the currencies of our other subsidiaries, mainly the rupee, the yen and the Australian dollar.
To reiterate what Heather mentioned earlier, new product launches and favorable volume on our existing base business more than compensated for the decline in sales due to the loss of exclusivity on Divalproex ER in the prior year. 
Absent the drop in sales as a result of Divalproex, our increase in sales in both the current quarter and current year-to-date period would have been significantly higher. For the full year, we continue to project total revenues in the range of $5.4 billion to $5.6 billion.
Looking at our operating profitability measures, adjusted gross margin for the quarter was approximately 45% compared to 47% in the prior year and two points below our full year guidance range of 47% to 49%. Our Q2 gross margin was dampened by close to 1% as a result of an atypical level of inventory charges. 
The year-over-year decrease in margin is primarily the result of the loss of exclusivity on Divalproex in the second half of 2009. For the reasons Heather mentioned in her remarks, we continue to fully expect our operating performance and gross margin to improve during the second half of 2010, and we expect full year margin will be within our guidance range, though nearer to the low end. 
Adjusted R&D expense for the quarter was $66 million or approximately 5% of revenues. This spending is slightly above that of our first quarter 2010 spending level, but is in line with our revised full year guidance range of 5% to 6% of revenues as Heather previously discussed. Importantly, our R&D projects remain on target, and we are planning for higher levels of spending over the remainder of the year. 
Adjusted SG&A expense was $251 million for the quarter or 18% of revenues, within our full year guidance range of 18% to 20%. Our second quarter adjusted EBITDA was $335 million. If you combine this result with our expectation for generating higher levels of earnings later in the year, we see ourselves on track to meet our adjusted EBITDA guidance, which we have revised to a range of $1.45 billion to $1.55 billion for the full year. 
Now let me move to couple of non-operating financial metrics. Second quarter 2010 adjusted interest expense was $65 million. We continue to forecast adjusted interest expense for the year to be in the range of $280 million to $300 million, which continues to consider the potential for higher short-term interest rates and a higher level of interest expense as a result of our Q2 issuance of new senior unsecured notes. 
Income taxes. Our second quarter adjusted effective income tax rate was 29%. Today's narrowed guidance range incorporates a full year projected adjusted effective income tax rate range of 28% to 29%.
In summary, second quarter adjusted net income was $163 million or $0.37 per share, which was slightly negatively impacted by changes in foreign currency exchange rates versus those existing at the time when we provided earnings guidance earlier in the year. 
In calculating our adjusted diluted EPS, the impact of assuming the conversion of our preferred shares into 125 million common shares was more dilutive than the $35 million quarterly preferred dividend. Therefore, adjusted diluted EPS for the second quarter is calculated based on an average outstanding diluted share count of 440 million shares. 
Touching briefly on the year-to-date results. The more significant items that are excluded in arriving at our adjusted basis results for the 2010 year-to-date period are: purchase accounting amortization of $143 million; integration and other expenses of $31 million; incremental interest expense, which is primarily the imputed interest expense related to our convertible debt, of $24 million; charges related to the net settlement of litigation totaling $13 million; costs associated with our recent issuance of new unsecured notes totaling $15 million; and finally, the net tax benefit related to the excluded items of approximately $86 million. 
For the six months ended June 30, 2010, total revenues were $2.66 billion, an increase of 9% over adjusted revenues of $2.45 billion in the same prior-year period. Foreign currency translations did impact our year-to-date result with a favorable effect of approximately 3% due mainly to the strengthening of the Canadian dollar, the rupee, the yen and the Australian dollar versus the U.S. dollar. The euro did not have a significant effect. 
Adjusted gross margin for the six months was approximately 45%, with the impact of Divalproex also having an unfavorable effect on our year-to-date margin when compared to the prior year. Adjusted R&D expense was $126 million, and adjusted SG&A was $496 million for the current six-month period. Our adjusted EBITDA for the first half of 2010 was $658 million. Adjusted income was $322 million, and adjusted diluted EPS was $0.73 per share. 
As in the quarter, adjusted diluted EPS was calculated assuming the conversion of our preferred shares into 125 million shares of common stock. The number of shares assumed in the conversion of our preferred stock is dependent upon our stock price. We expect our share price to continue to remain at a level at which 125 million shares will be the assumed conversion amount. Additionally, depending on the market value of our common stock going forward, our average outstanding diluted share count could increase further due to the additional dilution from stock options and other potentially dilutive financial instruments, such as our convertible debt obligations and the related warrant. 
We have considered the potential for a higher average diluted share count in our full year adjusted diluted EPS guidance range, which, as Robert indicated, we have narrowed to $1.55 to $1.65 per share, with adjusted EPS in the fourth quarter expected to exceed that of the third quarter. 
In our earnings release this afternoon, we provided a comparison of exchange rates that were used in preparing our initial guidance to those that were used in preparing our revised guidance. Prospectively, we will continue to update you on the FX rates we are using whenever we revise our guidance. This is intended to ease your understanding of our forecast.
As you'll see, certain currencies, in particular the euro, have weakened since our original guidance was prepared. It is important to note, however, that most of our non-U.S. operations have their revenues and their cost structures based in their local currencies. 
For our euro-based entities, their euro-denominated cash flows are offset against euro-denominated debt. As such, while changes in the euro, either positive or negative, will impact our reported U.S. dollar results, there is little impact from a truly economic standpoint. 
Turning to our cash flow metrics. Our second quarter cash flow from operations was $118 million compared to $210 million in last year's second quarter. The decrease is primarily the result of the timing of collection of receivables, for which a substantial amount was received in early July; the timing of income tax payments; and the payment of approximately $22 million related to the termination of certain interest rate swaps associated with the financing completed this quarter. We do continue to project full year operating cash flow in the range of $725 million to $825 million excluding certain one-off items. 
Second quarter capital spending of $33 million was more than 2009 but well below our expected annual spend. However, based on anticipated project timing, we do expect spending to increase significantly in the second half of 2010 and continue to project capital spending in the range of about $250 million for the full year. 
Let me now turn to our capital structure and liquidity position. In May, we completed a private placement of $550 million of senior unsecured notes due in 2017 and bearing interest at 7 5/8% and $700 million of senior unsecured notes due in 2020 and bearing interest at 7 7/8%.
$1 billion of the net proceeds were used to pay down existing indebtedness under our credit facility. This bond issuance was in accordance with our objective of extending the maturity profile of our outstanding indebtedness. We continue to have no meaningful long-term debt maturities until the $600 million due under our convertible notes in the first quarter of 2012, which we currently intend to repay with available cash at that time. 
In addition, it is important to keep in mind that the last $35 million quarterly dividend payment related to our outstanding preferred stock is scheduled to be paid on November 15, 2010.
Also, as mentioned previously, we incurred charges of approximately $15 million associated with the issuance of these senior notes. Approximately half of this charge was to write off capitalized debt issuance costs associated with the amounts that were repaid, with the other half related to the termination of interest rate swaps also associated with the debt that was repaid. The swaps terminated restored us to what we believe to be an appropriate ratio of fixed to floating rate debt. 
Concerning leverage, as Robert has stated many times, it is our commitment to achieving a long-term leverage ratio of less -- of 3:1 or less. We are firmly committed to balancing growth in our business through the continued use of prudent and responsible financing. As such, Mylan remains committed to deleveraging over time to meet this long-term capital structure goal.
From a covenant perspective, the level of our senior secured debt is approximately 1.9x our last 12-month covenant basis adjusted EBITDA. This is well below our June 30, 2010, covenant threshold of 4x times and also comfortably ahead of our December 31, 2010 threshold of 3.5x. 
At the end of the current -- of the quarter, we had approximately $833 million of unrestricted cash and marketable securities compared to just over $400 million at December 31. We expect to use some of this cash, along with available borrowings, to finance the acquisition of Bioniche.
Bioniche is an exciting opportunity for Mylan and one that we believe will be accretive to Mylan's earnings in the first year, even before considering any synergies. It is important to note, however, that we do not believe that the impact from this acquisition will be significant to our 2010 results.
In addition to a revenue growth rate that is in excess of Mylan's growth rate, the Bioniche acquisition will be especially complementary, as A, its margins are in excess of our consolidated margins, and B, their relatively lower effective tax rate as a result of being domiciled in Ireland.
While we expect the contribution from the sale of Bioniche's products to benefit our overall gross margin, we do not foresee a significant change in our overall consolidated corporate tax rate. 
One last item that I would like to briefly address is our recently announced approval, launch and settlement with respect to Minocycline ER.
Our Matrix subsidiary received final approval of its ANDA on July 20, 2010, and we began shipping immediately. On July 22, 2010, we reached a settlement with Medicis, the innovator, to resolve outstanding patent litigation. Under the terms of the agreement, we agreed to cease additional distribution of the product until November 11, 2011, or earlier under certain circumstances. 
With respect to the product already shipped, we have been released by Medicis of any potential liability associated therewith. However, because of uncertainties that could affect pricing and market conditions, accounting rules require that we defer revenue recognition. As we've done in similar situations in the past, most recently related to Amlodipine, we will defer the revenue from our initial shipments of the product until such time as the product is sold by our customers.
To reiterate: as these shipments were made in July, this is a third quarter item. We expect this revenue to be recognized throughout the second half of the year and into 2011. 
In closing, let me say once again: I am pleased with our very solid first half of the year, and I'm extremely excited about our prospects for the remainder of 2010 and beyond.
That concludes my remarks, and I'll turn the call back over to Kris to start the Q&A."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Operator, you can begin the question-and-answer.",6,"Operator, you can begin the question-and-answer."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] We'll go first to Elliot Wilbur of Needham & Company.",12,"[Operator Instructions] We'll go first to Elliot Wilbur of Needham & Company."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","With respect to gross margin performance year-to-date and then full year guidance. Just kind of backing into what would sort of have to happen in the second half of the year. It looks like you'd have to do close to around 49% even at the low-end of revenu",121,"With respect to gross margin performance year-to-date and then full year guidance. Just kind of backing into what would sort of have to happen in the second half of the year. It looks like you'd have to do close to around 49% even at the low-end of revenue guidance in order to sort of achieve, I guess, just the low end of your current forecast. And I understand that's a very complex calculation, but it just seems from our vantage point that, that's going to be a very difficult number to achieve outside of some contribution from a large exclusivity type product. I'm just maybe wondering if you could walk us through what kind of the incremental levers there maybe."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","I'm not sure there's much more to walk through. I think you've done a very eloquent job of kind of outlining the -- both bookends. And certainly, it's not uncommon. Mylan in the past had gross margins much larger than the 49%. And even though we don't hav",112,"I'm not sure there's much more to walk through. I think you've done a very eloquent job of kind of outlining the -- both bookends. And certainly, it's not uncommon. Mylan in the past had gross margins much larger than the 49%. And even though we don't have Paragraph IVs in 2010, as Heather mentioned many, many times, there are a significant number products that we see that are very high gross margin product, and we fully expect to launch those products. We already begun that, already beginning in the third quarter and expect to see a lot more as we continue to roll out for the rest of the year."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","I want to make sure that I understand the messaging with respect to 2011, because I think previously, the company seemed quite confident that full year earnings per share would be in excess of $2. And then, the commentary in the press release today seems",105,"I want to make sure that I understand the messaging with respect to 2011, because I think previously, the company seemed quite confident that full year earnings per share would be in excess of $2. And then, the commentary in the press release today seems to be suggestive that you'll be earning $2 by the end of 2011. I'm just -- I'm wondering, are we talking about an annualized EPS run rate of $2 by the end of 2011 now? Or are you still confident that, at least at this juncture without official guidance in place, that you can still earn that $2 per share?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","The answer is simply, yes. As you know, we haven't given official range of guidance for 2011. But as I stated in my prepared remarks, and especially, getting closer to 2011 with additional visibility, the answer is absolutely yes.",39,"The answer is simply, yes. As you know, we haven't given official range of guidance for 2011. But as I stated in my prepared remarks, and especially, getting closer to 2011 with additional visibility, the answer is absolutely yes."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the next question from Gregg Gilbert from Bank of America Merrill Lynch.",16,"And we'll take the next question from Gregg Gilbert from Bank of America Merrill Lynch."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Can you talk about which of the product or which types of products were delayed? Robert, you alluded to some of that, and Heather too, in the prepared remarks.",29,"Can you talk about which of the product or which types of products were delayed? Robert, you alluded to some of that, and Heather too, in the prepared remarks."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Sure. Well, as we were just discussing, the Clonidine, our Clonidine patch as well as Minocycline were obviously two important approvals, recent approvals for us. And certainly building to the previous question on gross margin, those -- that type of produ",62,"Sure. Well, as we were just discussing, the Clonidine, our Clonidine patch as well as Minocycline were obviously two important approvals, recent approvals for us. And certainly building to the previous question on gross margin, those -- that type of product, those limited competition launch is obviously important for us. And those are -- that's the type of approvals we're speaking of."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","You were talking about delays that were rectified.",8,"You were talking about delays that were rectified."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Heather, do you expect AMP implementation to affect your business in the U.S. in any material way? And lastly, what's your latest thinking on patent settlement legislation? Whether it will happen and whether it would address settlements you've already sig",47,"Heather, do you expect AMP implementation to affect your business in the U.S. in any material way? And lastly, what's your latest thinking on patent settlement legislation? Whether it will happen and whether it would address settlements you've already signed? I know that's seems to change weekly."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Sure. As far as the patent settlement legislation's concerned, I don't know how closely you watched the war supplemental bill and domestic spending that they were trying to push through. I [indiscernible] (00:55:32) that since it did not get attached, I -",105,"Sure. As far as the patent settlement legislation's concerned, I don't know how closely you watched the war supplemental bill and domestic spending that they were trying to push through. I [indiscernible] (00:55:32) that since it did not get attached, I -- my bet is it's extremely unlikely they'll patent settlements reattached this year. And as you know, we've been very vocal out there about even looking at patent settlements without an authorized generic fix is just handicapping the generic industry. And we have continued to certainly push that agenda on the Hill as well. And your first -- is it first industry [ph] (00:55:57)..."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","AMP.",1,"AMP."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","AMP. No, not material -- remember that, I think, that there's still -- it's going to be interesting. This is supposed to, I think, be published for the first time in October as far as the weighted average AMP. And we certainly are watching that closely, a",105,"AMP. No, not material -- remember that, I think, that there's still -- it's going to be interesting. This is supposed to, I think, be published for the first time in October as far as the weighted average AMP. And we certainly are watching that closely, and I'm sure there's a lot of concern out there. Obviously, we thought that was the best of all worlds as far as how the legislation originally came out, and what ultimately we were able to end up getting it to, that weighted average being published. But at this time, we don't see any material effect to our business."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll move on to next question from Marc Goodman from UBS.",13,"And we'll move on to next question from Marc Goodman from UBS."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","There was a comment that inventory charges that were atypical hit the gross margin. Could you just elaborate on those? Second of all, can you give us a flavor of how your German business did in the quarter and year-to-date, things like that? And then thir",90,"There was a comment that inventory charges that were atypical hit the gross margin. Could you just elaborate on those? Second of all, can you give us a flavor of how your German business did in the quarter and year-to-date, things like that? And then third, on France. You mentioned there was some pricing pressure. Can you just give us a flavor? Is that something that just started happening in the quarter? Or has that been going on all year? I don't remember if you called that out last quarter."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","So I'll take the first one on the gross margin. And without going specifically into the products or the locations within our Generics segment, there were some inventory amounts that were written off. And as the gross margin in this quarter was at 45%, I f",90,"So I'll take the first one on the gross margin. And without going specifically into the products or the locations within our Generics segment, there were some inventory amounts that were written off. And as the gross margin in this quarter was at 45%, I felt it helpful to understand that those atypical charges -- without those atypical charges, we would have been nearly a full percentage point higher in the gross margin. But it helped to understand how we were getting to the second half of the year."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","But just to be clear before we move on. You're not -- you absorbed that into your numbers. So you're still going to do 47%-plus gross margin, absorbing that?",29,"But just to be clear before we move on. You're not -- you absorbed that into your numbers. So you're still going to do 47%-plus gross margin, absorbing that?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Absolutely. All I was trying to do was to help you understand how the margin will not be burdened by that in the second half of the year.",28,"Absolutely. All I was trying to do was to help you understand how the margin will not be burdened by that in the second half of the year."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","And as far as Germany goes. Our Germany business this quarter was right in line with our expectation. So we -- it's still a very good driver for us. And, frankly...",31,"And as far as Germany goes. Our Germany business this quarter was right in line with our expectation. So we -- it's still a very good driver for us. And, frankly..."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Does that mean, was there growth there? Or I mean, is that business growing this year versus last year? Is it declining? Like where are you just relative to what's happening with all the tenders and the pricing?",38,"Does that mean, was there growth there? Or I mean, is that business growing this year versus last year? Is it declining? Like where are you just relative to what's happening with all the tenders and the pricing?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, look, I mean, like I said, it was right in line with what we expected Germany to do. It certainly, year-over-year, it has seen some decline in pressure just because, to your point, the tender market. But it was right in line with what we expected Ge",164,"Well, look, I mean, like I said, it was right in line with what we expected Germany to do. It certainly, year-over-year, it has seen some decline in pressure just because, to your point, the tender market. But it was right in line with what we expected Germany to do. And we've been -- as we've stated before, things were well-positioned with our competitive product of how we're competing that tender market. France, as far as France. No, it's nothing new. It was nothing new this quarter. What we did just want to point out is, as we've been saying, that competitive pressure, we've seen that. We anticipated the majority of that. And as I've said, we will continue to adjust our business and, given our experience here in the U.S. in what I've stated to be the most highly competitive in the world, believe that, that's the kind of experience we're being able to bear over there in Europe. Nothing new about France."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. Again, Marc, there's nothing new there. We've been projecting and been living with what we've anticipated as a downward trend in pricing, only to be offset by those metrics that we've been all along telling you, our ability to rightsize and our abili",54,"Yes. Again, Marc, there's nothing new there. We've been projecting and been living with what we've anticipated as a downward trend in pricing, only to be offset by those metrics that we've been all along telling you, our ability to rightsize and our ability to yield additional efficiencies, especially in our cost of goods."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Let me just ask one other thing, which is kind of just an extension of what the prior question was from the start. It just gets back with the $2 thing in 2011. I just want to make sure I understand this. So previously, you were $2-plus, now you're $2. You",117,"Let me just ask one other thing, which is kind of just an extension of what the prior question was from the start. It just gets back with the $2 thing in 2011. I just want to make sure I understand this. So previously, you were $2-plus, now you're $2. You've got Bioniche that helps you sometime in accretive. So I guess I'm just trying to understand what changed, relative? Is this -- this is basically the new European pricing. I mean everybody's concerned, everybody's been assuming that numbers are coming down. They're not really coming down that much for you. And I'm just trying to understand what's going on behind the scenes, excluding this Bioniche acquisition?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, Marc -- well, actually, I mean, I really appreciate this last question, only because if you have -- I want to make sure everyone is clear. You're exactly right in your description. I mean, please remember, and I probably should have pointed this out",247,"Well, Marc -- well, actually, I mean, I really appreciate this last question, only because if you have -- I want to make sure everyone is clear. You're exactly right in your description. I mean, please remember, and I probably should have pointed this out, not only have we not changed, not only does the underlying business continue to be strong, not only do I feel we have not brought down the numbers. But remember in that $2, when I -- again, remember, I forecasted that. And remembering that $2, that was with a different FX. I'm totally absorbing, as I update the $2 for 2011, the negative movement in the FX. And believe me, it's much more substantial in 2011 than it is for the rest of 2010. So yes, I appreciate, yes, this last question. And I hope we made that clear. And Bioniche, let me just address Bioniche real quick in terms of that. Remember, all along I've been telegraphing exactly what we were going to do in terms of our platform, identifying voids and layering in those voids. Bioniche is just simply doing just what we said that we were going to do. So it's been fully anticipated, as we roll out, that we -- not just on the Injectable portfolio, but other particular niche areas that we are going to layer in to our platform that will only continue to allow us to continue to achieve the objectives that we set forth."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","We'll move onto the next question from Randall Stanicky from Goldman Sachs.",13,"We'll move onto the next question from Randall Stanicky from Goldman Sachs."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Just so we're all clear. 3% constant currency growth in EMEA this quarter, 9% prior. How do we think about the sort of normalized growth for the back half going forward here on a constant-currency basis?",37,"Just so we're all clear. 3% constant currency growth in EMEA this quarter, 9% prior. How do we think about the sort of normalized growth for the back half going forward here on a constant-currency basis?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","So look, I think as we've said all along, when you look at Mylan, as Robert stressed, our overall business and that contribution. Certainly, again, some seasonality as far as when you look at the Europe and just the historical trends and our earnings ther",76,"So look, I think as we've said all along, when you look at Mylan, as Robert stressed, our overall business and that contribution. Certainly, again, some seasonality as far as when you look at the Europe and just the historical trends and our earnings there. And I think as John pointed out, the fourth quarter being overweighted on the third quarter. So I think that, that's kind of how you should think about Europe as well."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","So the first half being sort of -- the second half being sort of similar to the first half in terms of constant currency growth?",25,"So the first half being sort of -- the second half being sort of similar to the first half in terms of constant currency growth?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, and I -- well, I was more stressing that the fourth quarter being heavier than the third quarter.",19,"Well, and I -- well, I was more stressing that the fourth quarter being heavier than the third quarter."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes, I mean, that should be make clear. We continue to see that trend, as we told you, the latter half of the year. And we continue to see that, I'm not going to call it a hockey stick, but certainly a slope in the upward direction where the third quarter",70,"Yes, I mean, that should be make clear. We continue to see that trend, as we told you, the latter half of the year. And we continue to see that, I'm not going to call it a hockey stick, but certainly a slope in the upward direction where the third quarter will certainly be better than the second quarter, but the fourth quarter is certainly better than the third quarter."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Well, and just -- Robert, that's a good point. I mean, quarter you gave us a little bit of directional color. Given that there it's a pretty sharp back half EPS ramp, just thinking about the overall earnings for the company, how do we think about 3Q versu",49,"Well, and just -- Robert, that's a good point. I mean, quarter you gave us a little bit of directional color. Given that there it's a pretty sharp back half EPS ramp, just thinking about the overall earnings for the company, how do we think about 3Q versus 4Q?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","I would tell you if you take our mid-point, which hasn't changed, I would tell you that absolutely weight it more, much more to the fourth quarter than you should the third quarter, but the third quarter obviously being better than the second quarter. Tha",52,"I would tell you if you take our mid-point, which hasn't changed, I would tell you that absolutely weight it more, much more to the fourth quarter than you should the third quarter, but the third quarter obviously being better than the second quarter. That's how I would think about it."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","We'll take the next question from Chris Schott from JPMorgan.",11,"We'll take the next question from Chris Schott from JPMorgan."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Can you update us with regards to your site transfers and some of the realized cost savings from those moves? Is -- how much have we pushed through as we've got this far into 2010? And what should we think about in terms of incremental dollar savings as w",54,"Can you update us with regards to your site transfers and some of the realized cost savings from those moves? Is -- how much have we pushed through as we've got this far into 2010? And what should we think about in terms of incremental dollar savings as we look towards the second half?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","So I think a couple important metrics. We are on track, if not even exceeding a bit. And I think probably the first metric around that is just our synergies. If you remember, we're originally at $300 million, and the beginning of this year, we upped that",174,"So I think a couple important metrics. We are on track, if not even exceeding a bit. And I think probably the first metric around that is just our synergies. If you remember, we're originally at $300 million, and the beginning of this year, we upped that to $350 million. And I've stated, certainly we're on track to meet if not exceed that $350 million. And the majority of that increment over '09 was all driven to the site transfers and vertical integration. As far as -- so as you think about how that's contributing. I've said that we'll be at, by the end of this year, at about 55% having those products repatriated back to -- back internally to our supply-chain, and by the end of 2013, 70%. So certainly, we see a significant financial impact positively for the second half of '10. But also, we're going to -- that's going to continue, obviously, as we continue to bring these products in until we get to, like I said, the 70% in '13."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Second question was just coming back to France. Can you just elaborate what you're anticipating in terms of further price actions as you get later this year? I know we've had moves in several other European countries. But are you expecting that we'll see",71,"Second question was just coming back to France. Can you just elaborate what you're anticipating in terms of further price actions as you get later this year? I know we've had moves in several other European countries. But are you expecting that we'll see anything from France in the terms of -- there that's out of the ordinary relative to what we've maybe seen the last year or two or so?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","No, nothing as far as we know. We don't really see anything else in France this year.",17,"No, nothing as far as we know. We don't really see anything else in France this year."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Following the acquisition in the injectable market this quarter. Can you just elaborate a little bit in terms of what your top priorities are at this point from a business development standpoint? And what's your liquidity to pursue deals that might be in",52,"Following the acquisition in the injectable market this quarter. Can you just elaborate a little bit in terms of what your top priorities are at this point from a business development standpoint? And what's your liquidity to pursue deals that might be in the size of a Bioniche given the deleveraging priorities?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. I think what you should anticipate is exactly, again, what I've been saying. This one has been done. The other portfolio voids that I see I don't believe is anywhere near the size of, say, the injectable opportunity that we've just executed on. I've",158,"Yes. I think what you should anticipate is exactly, again, what I've been saying. This one has been done. The other portfolio voids that I see I don't believe is anywhere near the size of, say, the injectable opportunity that we've just executed on. I've also guided you -- there's -- I am looking and would like to look in Japan. That was another area, I think, that if I can find a right opportunity, it doesn't need to be large, but enough to give us further impetus to execute on our stated long-term objectives over there. So that's another area. But other than that, I don't really see anything else. And as you mentioned, we are extremely committed to the 3:1 debt-to-EBITDA ratio or below. And our cash position is, is such -- we're at a very, very strong cash position to execute on the strategies that I've just outlined to you and still maintain our objective."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the next question from Rich Silver from Barclays Capital.",13,"And we'll take the next question from Rich Silver from Barclays Capital."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Just coming back to the third quarter and the fourth quarter. Maybe I missed this, but can you help us a little bit in terms of what gives us that big bump up? How much of that is seasonality versus new launches versus synergies? Just some sense of why th",56,"Just coming back to the third quarter and the fourth quarter. Maybe I missed this, but can you help us a little bit in terms of what gives us that big bump up? How much of that is seasonality versus new launches versus synergies? Just some sense of why the big jump in the fourth quarter?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, I think he really hit on all the buckets. I mean, if you think about it, we do definitely have some seasonality, we definitely -- as we continue to yield the efficiencies, that's really where the continued growth slope is, as more and more of those",109,"Well, I think he really hit on all the buckets. I mean, if you think about it, we do definitely have some seasonality, we definitely -- as we continue to yield the efficiencies, that's really where the continued growth slope is, as more and more of those efficiencies and synergies and repatriating the external reliance to internal capabilities continues to grow each and every quarter. And that's why the fourth quarter will certainly be heavier there. Plus our anticipated product launches and product approvals, we think, again, are more back-weighted than they are front-weighted in the third quarter. Heather, do you want to add anything on top of that?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","No, not -- and I would say, even just, even these recent approvals -- so, Rich, as you can appreciate, as we get longer into the life-cycle of those products, a better -- more contribution as well.",37,"No, not -- and I would say, even just, even these recent approvals -- so, Rich, as you can appreciate, as we get longer into the life-cycle of those products, a better -- more contribution as well."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","And then just to carry that into 2011. Heather, in your prepared remarks, you spoke obviously about the 500 products globally, the OCs and then first-to-files, as well as limited competition products. Just want to make sure I understand that historically,",125,"And then just to carry that into 2011. Heather, in your prepared remarks, you spoke obviously about the 500 products globally, the OCs and then first-to-files, as well as limited competition products. Just want to make sure I understand that historically, it seemed like more of the growth would be coming from x U.S. In fact, rationale for doing the Merck Generics deals was less dependence on first-to-files and such in the U.S. Is that still the case for 2011, that we shouldn't expect the U.S. to be the primary driver, but rather x U.S.? And then the last question is just on FX. The rates that you disclosed in the press release today, are those the rates that we should be looking for 2011?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","The answer is, yes. And what we're going to for you for now on, now that we set a baseline, rather than have you guess what rates we're using at anytime, anytime we change guidance on a going-forward basis, you're going to know exactly the rates that we'r",370,"The answer is, yes. And what we're going to for you for now on, now that we set a baseline, rather than have you guess what rates we're using at anytime, anytime we change guidance on a going-forward basis, you're going to know exactly the rates that we're using in our guidance. And so the answer is yes to that. In terms of x U.S., U.S. reliance, Paragraph IVs or not, let me just explain. 2011 to me is a completely different year. To me, 2011, as I've stated all along, remember I said that 2010 is simply what we call the baseline year that represents what these three conglomerates coming together really means to grow from. 2011 completely -- it really is the first year of, the first full year of recognizing what these three assets are potentially capable of doing. If you recall, the growth, the -- our CAGR up to this point was predominantly weighted on our ability to yield the efficiencies out of these three assets. Not only is that going to continue in '11 and beyond, but now you're going to see top line growth, a robust growth in top line by the sheer number products that we're going to launch. And if you also recall, we had hardly any Paragraph IV opportunities in the last three years, especially in 2010, in our numbers and our projections, where -- because we've been building our pipeline, incubating those opportunities. You've already seen some of the settlements that are going to come through. And, yes, and we cannot forget and we should not ignore that the United States is the largest pharmaceutical company in the world by dollars. And that in the United States, I've often said, you do a little bit, you get a lot. And in the rest of the world, you do a lot, and you get a little bit. So yes, I think that these are very meaningful. But we're not going to shy away from the opportunities that we have in the United States to continue to grow our overall platform, on top of the additional opportunities that we see in market expansions throughout the world. You want to add anything, Heather?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","I mean, the only thing I'd add, Rich, is I was just trying to give some color because those -- we've spoke in the past, and people keep saying what are the drivers and give as much clarity as we can. Certainly, to Rob's point, why I wanted to point out la",113,"I mean, the only thing I'd add, Rich, is I was just trying to give some color because those -- we've spoke in the past, and people keep saying what are the drivers and give as much clarity as we can. Certainly, to Rob's point, why I wanted to point out launching 500 products around the globe. Those are very important in all other regions as well. But being able -- things that -- people are much more tangible, which are the first-to-file opportunities, the settlements we've already announced, as well as showing that we see an excess of a dozen of those limited-type competition products being launched in the U.S. next year."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And taking the next question, we'll go to David Buck from Buckingham Research Group.",14,"And taking the next question, we'll go to David Buck from Buckingham Research Group."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","First on Asia-Pacific. Can you -- it looked like it had a pretty strong quarter for the second quarter. Can talk about whether you're expecting to see that grow sequentially, and maybe what accounted for that? And then on Minocycline. Can you -- based on",93,"First on Asia-Pacific. Can you -- it looked like it had a pretty strong quarter for the second quarter. Can talk about whether you're expecting to see that grow sequentially, and maybe what accounted for that? And then on Minocycline. Can you -- based on the comments, John, it sounded like you may have launched as much as six months or so of demand. Is that accurate? And if not, can you help me out there? And then just a quick reminder on when you'd expect Venlafaxine to come down next year."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Let me -- John, why don't you get rid of the two ones, and then let me tell them about the -- just a little bit on the comment on the region.",32,"Let me -- John, why don't you get rid of the two ones, and then let me tell them about the -- just a little bit on the comment on the region."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. So on the Minocycline. My comment was is that we would be recognizing revenue expected over the remainder of 2010 and into 2011. So I think that that's more -- speaks for itself.",34,"Yes. So on the Minocycline. My comment was is that we would be recognizing revenue expected over the remainder of 2010 and into 2011. So I think that that's more -- speaks for itself."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","We haven't specifically stated what type of quantities were out there. And, Heather, what's the other products he's mentioned?",20,"We haven't specifically stated what type of quantities were out there. And, Heather, what's the other products he's mentioned?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. So we don't have a -- we haven't announced any launch timing around that.",15,"Yes. So we don't have a -- we haven't announced any launch timing around that."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","In terms of the region. David, let me just let you view it like this as we continue to roll forward. And Matrix in that region just continues to hit on all cylinders plus, plus, plus, very strong. I'm extremely pleased with what's going on now in Australi",163,"In terms of the region. David, let me just let you view it like this as we continue to roll forward. And Matrix in that region just continues to hit on all cylinders plus, plus, plus, very strong. I'm extremely pleased with what's going on now in Australia. I think they've turned the corner in terms of that base. And I think their -- I'm very, very comfortable. Our new leader there, Martin Cross, I think's got a firm handle in that particular country. And so I'm very -- I feel very good about that. In Japan, I would tell you that 2010 is a restructuring year for me. There is a lot of work to do in Japan. That I can tell you. So I'm really looking for the work that we're doing from now to the end of 2010 to really look at 2011 and beyond for the kind of growth that we anticipate in the longer-term for the Japanese market."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","And just to sort of clarify. For the second half of the year, would you expect growth in Asia-Pacific?",19,"And just to sort of clarify. For the second half of the year, would you expect growth in Asia-Pacific?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes, we've continued to say that, especially as Rob pointed out, that Matrix, accelerated double-digit growth.",16,"Yes, we've continued to say that, especially as Rob pointed out, that Matrix, accelerated double-digit growth."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll move on to the next question from John Boris from Citi [Citigroup].",15,"And we'll move on to the next question from John Boris from Citi [Citigroup]."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Just on price in particular. Are you anticipating any additional price cuts in Australia? Obviously, they had a round that was pretty significant before. Are you anticipating anything in the back half of this year or into 2011? And then on your 2011 guida",71,"Just on price in particular. Are you anticipating any additional price cuts in Australia? Obviously, they had a round that was pretty significant before. Are you anticipating anything in the back half of this year or into 2011? And then on your 2011 guidance, can you just help us understand what your price assumption is? Is it for pricing to erode at comparable levels, higher levels or lower levels than currently?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. I mean, in terms of pricing. I wish we had the crystal ball, but you can only anticipate that we're doing the responsible thing by measuring current environment, current activity along with past trends. And really looking at each country on an indivi",198,"Yes. I mean, in terms of pricing. I wish we had the crystal ball, but you can only anticipate that we're doing the responsible thing by measuring current environment, current activity along with past trends. And really looking at each country on an individual basis and trying to evaluate not just each country, but how it rolls up as a whole. As you know, we have a certain natural erosion in the U.S. business and then with each country, the models is really the same, it really doesn't change. No, I don't think that the governments are going to allow us to increase prices or give us anything back. So I think it would be wise in your models to figure that there is some natural erosion. And then in terms of Australia, in particularly, I think you're going to -- I think we just -- I think we headed off, just here recently, some legislation that would've allowed additional price cutting there. But I mean, in Australia in particularly, I think you're going to hear a lot of noise in Australia. And certainly, we don't think it's going to stop, and we're not anticipating it to stop."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes, and I guess just a little more to that on the Australia front. Obviously, because of the changing government now, the dynamics, I would say there's a chance that, that legislation that was stopped, it -- that was rolling into 2011, so if anything the",70,"Yes, and I guess just a little more to that on the Australia front. Obviously, because of the changing government now, the dynamics, I would say there's a chance that, that legislation that was stopped, it -- that was rolling into 2011, so if anything there, that could be pushed out further if it takes them longer. But certainly don't see anything else in '10 as far as that goes."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","So just help me understand. In 2011, is your price erosion rate comparable to the '10 level? Or is it greater than the 2010 level?",25,"So just help me understand. In 2011, is your price erosion rate comparable to the '10 level? Or is it greater than the 2010 level?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","As I said, John, each country is done differently, and then we roll it up. And we don't, we -- I would say for Australia, I would say given the heavy, heavy hit that we've taken, say over the last 18 months, there in Australia, I don't anticipate, lets ju",82,"As I said, John, each country is done differently, and then we roll it up. And we don't, we -- I would say for Australia, I would say given the heavy, heavy hit that we've taken, say over the last 18 months, there in Australia, I don't anticipate, lets just say, as aggressive of a hit that we had to take in Australia, because it was pretty hefty. I do not anticipate as aggressive of a hit, if that's helpful to you."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","And then on Catapres Transdermal. My understanding is it's a pretty difficult product to manufacture. Can you just provide some commentary on launch quantities and whether you have adequate supply to meet the demand within that marketplace?",37,"And then on Catapres Transdermal. My understanding is it's a pretty difficult product to manufacture. Can you just provide some commentary on launch quantities and whether you have adequate supply to meet the demand within that marketplace?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","All I can answer to that is, first of all, absolutely yes. And let me remind you, even on the Fentanyl, when we launched Fentanyl. One thing I can tell you is that oftentimes, the FDA does call us every now and then against drug shortage and ask us if we",77,"All I can answer to that is, first of all, absolutely yes. And let me remind you, even on the Fentanyl, when we launched Fentanyl. One thing I can tell you is that oftentimes, the FDA does call us every now and then against drug shortage and ask us if we those capabilities. And each and every time, when it comes to those patches, Mylan is a premier producer of its patches because of our patch technology."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","And the only thing I'd add to that, just to -- in further support of that. Our Clonidine patch is a very eloquent patch compared to the other out on the market. And there has already been some shortages in the marketplace prior to us getting approval. So",82,"And the only thing I'd add to that, just to -- in further support of that. Our Clonidine patch is a very eloquent patch compared to the other out on the market. And there has already been some shortages in the marketplace prior to us getting approval. So to your point is, we certainly see it as a limted-competition launch, and we see it is as a very important product to us over the -- over '10 and '11 as well."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the next question from Shibani Malhotra from RBC Capital.",13,"And we'll take the next question from Shibani Malhotra from RBC Capital."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","A couple of, more accounting related. Firstly, would you be able to give us a breakdown of your Matrix sales in terms of which regions the sales came from? How we should be accounting for that? And then the second question is on the Fentanyl. I mean, we'v",74,"A couple of, more accounting related. Firstly, would you be able to give us a breakdown of your Matrix sales in terms of which regions the sales came from? How we should be accounting for that? And then the second question is on the Fentanyl. I mean, we've seen new competition in the market or perhaps increased competition, and just wondering if you are seeing any impact on pricing or share related to that."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, the answer is, on Fentanyl, we're not seeing what you're seeing at all. In terms of Matrix, no, we don't breakdown.",22,"Well, the answer is, on Fentanyl, we're not seeing what you're seeing at all. In terms of Matrix, no, we don't breakdown."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Right. What I would say to you, Shibani is that we have integrated Matrix into our global platform, and that's why it's no longer a separate segment. And so you should be thinking about our Generics segment and with Matrix...",40,"Right. What I would say to you, Shibani is that we have integrated Matrix into our global platform, and that's why it's no longer a separate segment. And so you should be thinking about our Generics segment and with Matrix..."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","So we've never really broken it down in terms of certain things. So, yes.",15,"So we've never really broken it down in terms of certain things. So, yes."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, first, I -- I mean, I don't want to send a signal over to Japan that we're coming on a rampage from an acquisition point of view, because the culture over there, that's one of the things that they fear, is international external companies coming in",308,"Well, first, I -- I mean, I don't want to send a signal over to Japan that we're coming on a rampage from an acquisition point of view, because the culture over there, that's one of the things that they fear, is international external companies coming in and buying them up. I think that I feel very, very strongly that generating additional activity in Japan on top of what we have, I think I feel very strongly about that being a part of our -- of the business plan and how I see us executing on grabbing our disproportionate share of the real strong growth opportunities that we see in Japan in the longer term. So I'm using 2010 to basically restructure what we already have, thinking about, rolling forward, what else I would like to have to marry up and bolt-on to what I already got in order to execute, again, in gaining our -- and garner our disproportionate share of what we think the growth opportunities are over there. That could mean as much as investing partly in a Japanese company, or if it's small enough, an outright acquisition over there, or even a joint venture of some sort over there, where there's some joint development opportunities there. So I think there's a lot of options. I don't want -- I'm glad you asked the question for clarification because I don't want you to think there's only one way that I intend on doing something in Japan. But when the -- the last question that was post to us was how we think about capital and allocating capital. I just wanted to kind of put the parameters around sort of the levels that I'm looking for. And I think at those kind of levels, I can accomplish everything that we need to get done in Japan."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the next question from Ronny Gal from Sanford Bernstein.",13,"And we'll take the next question from Ronny Gal from Sanford Bernstein."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","First, just a quick clarification. That legislation in Australia that was just about to be ratified that included an implementation of an AMP in October 1. Your point is that, that essentially has been deferred indefinitely. Is that correct?",39,"First, just a quick clarification. That legislation in Australia that was just about to be ratified that included an implementation of an AMP in October 1. Your point is that, that essentially has been deferred indefinitely. Is that correct?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, yes. They just -- it did not -- it was not able to get passed through their legislature because of the change at the top. So this -- it will have to go back, and the -- like Rob said, we don't have a crystal ball. But I think conventional wisdom rig",90,"Well, yes. They just -- it did not -- it was not able to get passed through their legislature because of the change at the top. So this -- it will have to go back, and the -- like Rob said, we don't have a crystal ball. But I think conventional wisdom right now is, that was -- that would have gone in and affected early in '11. So to the extent that legislation, however long it takes or doesn't, certainly that timeframe will probably get pushed out a bit."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","But we're feeling pretty good about it, Ron.",9,"But we're feeling pretty good about it, Ron."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Robert, two questions. Now that you got a hospital-integrated force, it sounds like something that could integrate pretty well into biosimilar initiative. When do you think you'll be able to start the first clinical on a biosimilar based on where you guys",100,"Robert, two questions. Now that you got a hospital-integrated force, it sounds like something that could integrate pretty well into biosimilar initiative. When do you think you'll be able to start the first clinical on a biosimilar based on where you guys are in that group? And second, in kind of related issue. How do you -- what's your take about the Lovenox approval by the FDA? What does it tell you about the willingness to approve complex molecules? And if, to the extent that you're willing to disclose it, do you also have an Enox product somewhere in development?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Okay, well there's a lot there. Let me start by saying in terms of our biosimilar strategy. Literally, we are right on track. I am extremely pleased with what I'm seeing so far in the development, the joint development between Mylan and Biocon. I'm loving",729,"Okay, well there's a lot there. Let me start by saying in terms of our biosimilar strategy. Literally, we are right on track. I am extremely pleased with what I'm seeing so far in the development, the joint development between Mylan and Biocon. I'm loving the early results of some of the work that's being done. And so I think that that's coming along just fine and yes, the Bioniche is exactly what we were looking for in terms of that entering in, being able from a commercial point of view, being able to enter into the biosimilar market, including here in the United States. So we are very pleased. And as you mentioned, it does line up quite well to our strategy. As far as the -- my commentary in terms of just the whole issue around the FDA in terms of their most recent actions. First, I have to tell you, I believe that certain people are really trying to speak too much for the FDA and on behalf of the FDA. I think we should leave it up to the FDA to continue to speak. Certainly they have. Teva continues to try to create the fact that somehow -- that the science is not there. Well, it's there. And the FDA has and continues to demonstrate that they will look and respect good science. And they have confirmed that in their answer to the citizens petition of Teva. If you read the citizens petition, I think the FDA's actions were almost exactly what they told Teva in their answer to the citizens petition. And people should have taken note of that. No, this Lovenox is not a surprise. And lastly, in terms of Teva's position about generic Copaxone, I find it extremely difficult to believe that they could actually say so aggressively and openly, especially after the FDA's actions. I do believe, Ronny, I think you were the one that might have put out a note. I agree absolutely, if it was you, I do believe it was you. You talked about there being almost a change at the FDA in terms of it stepping itself up to be more open and demonstrating its commitment to Congress and the legislatures that it'll be more open-minded into a biosimilar strategy and an ability to approve these complex compounds. And lastly, when you take a look at our application, even our application with the FDA. That should've been a red flag. Because as you all know, and quite surprisingly, the FDA has accepted our application several months in advance of how long it took to accept the application of Momenta's and Sandoz' Copaxone application. That should've told people something right there. I've tried to explain that these are very, very strong indications in terms of my confidence level about how I feel about the particular program or how I think the FDA is thinking about things. I think the FDA is doing a fantastic job in that front. And the most important point, I think, from a Mylan perspective, that you should know, is that there are several analysts that are still somehow -- I don't know where they get their information but I think were under the impression that our formulation is a Natco formulation. That is just wrong. We certainly have -- Teva certainly knows now that it's not a Natco formulation. It's a Mylan formulation. It's a formulation to bring Copaxone to a highly regulated market like the United States. And certainly, Mylan knows how to file an application and the requirements. So I want you to combine the fact that how quickly our petition was accepted by the FDA compared to Momenta's and Sandoz'. That should've been, again, a signal and a red flag. I want you to look at Mylan's track record of -- its regulatory track record and our relationship for very, very complex compounds, and the fact that when it comes to science, we know how the FDA respects science. It's exactly what they looked at when they examined our application. And no, we don't have a Natco formulation. We have a Mylan formulation. And that needs to be clearly understood and corrected for all those analysts who I think been under a wrong impression. Again, certainly Teva knows, because in our litigation we had to turn over that to them."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And moving next to Michael Tong from Wells Fargo.",9,"And moving next to Michael Tong from Wells Fargo."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Robert, just sort of one follow-up a little bit on 2011. Sorry to beat this dead horse. But I heard your commentary about FX being more of an issue in 2011, as it impacts the bottom line, than 2010. And just trying to reconcile the local cost offsetting c",117,"Robert, just sort of one follow-up a little bit on 2011. Sorry to beat this dead horse. But I heard your commentary about FX being more of an issue in 2011, as it impacts the bottom line, than 2010. And just trying to reconcile the local cost offsetting currency impact statement that you had for 2010. So what's the disconnect there? Is there something that we need to think about more for 2011 in terms of FX? And than secondly, on  Bioniche, maybe a longer-term question. What assets does Bioniche bring to you to get you ready for biosimilars? And what additional assets do you think you need in order to be competitive in that market longer-term?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, let me go back. I'll go backwards. If you -- it is our feeling here, it's our vision here, that in order to market biosimilar products here in the United States, having a large hospital presence, we think, is going to be critical. Okay? So they brin",283,"Well, let me go back. I'll go backwards. If you -- it is our feeling here, it's our vision here, that in order to market biosimilar products here in the United States, having a large hospital presence, we think, is going to be critical. Okay? So they bring that to us instantly. And no, I don't believe I really need any more at this time in terms of assets. Bioniche has resolved almost every metric that we outline. One, I said I will not do a transaction unless it was financially accretive. They are. Two, they fill a strategic void in a therapeutic category that we were not in before. And three, they do it in a very large way. We have instant critical mass to be meaningful as we work, over the next few years, to build upon that as we get ready to layer in our biosimilars, as legislation and the FDA continues to set forth its revelatory path. In terms of the FX. You've missed absolutely nothing except something very small, which could be very large in your thinking. And that is, there's only six months left in 2010. There's a whole year left in 2011. And, if you couple the fact that we see continued growth in 2011, you don't only have a whole year left, but you have larger numbers. So if you take a look at the fact that I'm using today's current rates compared to when I originally gave that projection, that forecast of $2 in 2011, and adjust the prior rates to today's rates and then roll it forward, I think that if you do the math, you'll see exactly what I meant by that."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the final question from Ken Cacciatore from Cowen and Company.",14,"And we'll take the final question from Ken Cacciatore from Cowen and Company."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Robert, just some clarification on your discussion about Natco and it being a Mylan formulation. Is this not the formulation that Natco is marketing in India? And if not, what part of the relationship do they then have with you?",40,"Robert, just some clarification on your discussion about Natco and it being a Mylan formulation. Is this not the formulation that Natco is marketing in India? And if not, what part of the relationship do they then have with you?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Okay. The answer is no, it's not the formulation that they are marketing in India. And yes, they have a voluminous amount of integral relationships with us on a number of fronts, in terms of being able to be effective, to distribute this product around th",51,"Okay. The answer is no, it's not the formulation that they are marketing in India. And yes, they have a voluminous amount of integral relationships with us on a number of fronts, in terms of being able to be effective, to distribute this product around the world. As well as manufacturing."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","The international markets -- and I'm going to go at this probably a little bit differently, but I think folks are asking it the same way. When asking or discussing or trying to get from you what we should think about growth, you answered a couple question",201,"The international markets -- and I'm going to go at this probably a little bit differently, but I think folks are asking it the same way. When asking or discussing or trying to get from you what we should think about growth, you answered a couple questions by throwing in there efficiencies and rationalizing. So clearly kind of below the line, which is -- I understand. But you just did another 3% kind of year-over-year organic growth, constant currency, if I understand you correctly. So why would investors, or why should investors think that the international -- your European business specifically grow more than 5% a year? Is there somehow -- you talk about the product flow, and I guess you're assuming it's going to inflect. I guess we're a couple of years now past on the integration. What is it in terms of top line that gives you confidence that this is not just a 5% growth company? Or is that the right way to model it, and we should continue to understand that you're going to generate great efficiencies beyond -- I mean, below the line? Or is that just the wrong way to look at the top line?"
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","No, I actually think that you've asked and almost basically answered the question. I think that if you look at the growth from 2007 to 2010 when we acquired this, I told you that, that CGAR would predominantly become -- that growth would predominantly com",188,"No, I actually think that you've asked and almost basically answered the question. I think that if you look at the growth from 2007 to 2010 when we acquired this, I told you that, that CGAR would predominantly become -- that growth would predominantly come from the efficiencies from the bottom line. I told you that within this timeframe, by the end of 2010, we are loading up. So again, you've answer the question. It's 2011 and beyond that you're going to see an explosion of the number of a products that we intend to launch. So yes, I think that you can expect in 2011 top line growth mainly, predominately coming from the number of voluminous amount of products that we intend to launch. Everything we've been incubating at the end of '07, '08, '09, '10 is now going to -- that's how long it takes to get these products approved. Everything we put in our pipeline will begin to be launched in a voluminous way 2011 and beyond. And yes, we do intend to continue to get bottom line improvement as well, as we roll on."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And that concludes today's question-and-answer session. I'd like to turn the conference back over to our speakers for any closing remarks.",22,"And that concludes today's question-and-answer session. I'd like to turn the conference back over to our speakers for any closing remarks."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","No, just thank you all, and thank you all for your confidence and support. And again, thank you to our employees around the world. Thank you.",26,"No, just thank you all, and thank you all for your confidence and support. And again, thank you to our employees around the world. Thank you."
290203,109299417,70193,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","That concludes today's presentation. Thank you for your participation.",10,"That concludes today's presentation. Thank you for your participation."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","Good day, and welcome to the Mylan's Second Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King. Please go ahead, ma'am.",34,"Good day, and welcome to the Mylan's Second Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King. Please go ahead, ma'am."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Thank you, Nancy. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; Senior Vice President",374,"Thank you, Nancy. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; Senior Vice President, Corporate Controller and Chief Accounting Officer, Dan Rizzo; and Brian Byala, Senior Vice President and Treasurer.
During today's call, including the Q&A, we will be making forward-looking statements, including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods.
Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our annual report on Form 10-K for the year ended December 31, 2009, and in our other Securities and Exchange Commission filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP measures.
It should be noted that non-GAAP financial measures such as adjusted revenues, adjusted gross margins and adjusted diluted EPS should be used only as a supplement to, not as a substitute for or as a superior measure to measures of financial performance prepared in accordance with GAAP.
Please refer to today's earnings press release, which is available on our website as a contains detailed GAAP to non-GAAP reconciliations of our actual 2010 and 2009 second quarter results, including the allocation of each reconciled item to a specific income statement line item.
Before I turn the call over to Robert, let me also remind you that the material in this call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'll now turn the call over to Robert."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris. Good afternoon, everyone, and thank you for joining us on today's call. Once again, I would like to start by sincerely thanking each and every one of our employees around the world for yet another great quarter. It is truly your continued",347,"Thank you, Kris. Good afternoon, everyone, and thank you for joining us on today's call. Once again, I would like to start by sincerely thanking each and every one of our employees around the world for yet another great quarter. It is truly your continued outstanding hard work and dedication to Mylan that makes it possible for us to again deliver such strong results. 
We were able to deliver adjusted diluted earnings per share of $0.37 despite many challenges, including the delay of certain product approvals, global pricing pressures and the impact of negative currency trends. This quarter's strong results only continue to demonstrate the underlying strength of our overall business.
Considering these results and several significant recent announcements, we are now able to narrow our 2010 adjusted diluted earnings per share range to $1.55 to $1.65. Also, even though we haven't provided formal earnings guidance for 2011, we remain confident in our forecast to achieve adjusted diluted earnings per share of $2 by the end of 2011. 
Before I turn the call over to our President, Heather Bresch, I would like to review at a high level a couple of our significant corporate achievements since our last earnings call.
First, in May, we successfully raised $1.25 billion in long-term notes, and with most of the proceeds we prepaid $1 billion of secured term loan borrowings. 
Second, I was also extremely pleased to be able to fulfill yet another one of our stated objectives by our recent announcement of our intention to acquire Bioniche Pharma, a high-growth global injectable pharmaceutical company. As we reported at the time of the announcement, this business is expected to be immediately accretive in year one, not accounting for any synergies. 
In addition, we expect Bioniche Pharma's growth rate to be well above our stated long-term growth rates. The addition of Bioniche Pharma will only add further assurance in our ability to meet our stated objectives.
With that said, I'd like to forward -- I look forward to answering your questions, but I'd now like to turn the call over to Heather."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert, and good afternoon, everyone. As Robert said, we're very pleased with our exceptional second quarter performance and remain confident in our ability to deliver 2010 results in line with the updated guidance we are announcing today. In",2230,"Thank you, Robert, and good afternoon, everyone. As Robert said, we're very pleased with our exceptional second quarter performance and remain confident in our ability to deliver 2010 results in line with the updated guidance we are announcing today. 
In addition, we're excited about the growth we see coming in '11, which we believe will result in earnings of $2 per share, as well as our long-term growth targets. During my prepared remarks, I'll provide you with more color around our performance during the past quarter and on what we expect as drivers to achieve the second half of '10, plus '11 and beyond. 
First, though, I'd like to take this opportunity to thank our employees. Their outstanding work ethic and commitment to excellence have once again made it possible for Mylan to deliver very strong results. I'd like to start by touching briefly upon a few of the elements of our 2010 guidance.
First, in addition to narrowing our range for adjusted EPS, which Robert mentioned, we are tightening and revising our range for adjusted revenues. We now expect to generate revenues between $5.4 billion and $5.6 billion. 
Next, our adjusted gross margin for the quarter was approximately 45% compared to our full year guidance range of 47% to 49%. We've mentioned in the past that product mix is an important driver of gross margin, and approval delays in the U.S. played a role in this quarter's performance. Therefore, we remain confident in our ability to meet this element of our guidance due to recent approvals we've received on higher-margin limited-competition products, higher specialty business sales, our planned Bioniche Pharma acquisition and continued synergy realization in the second half of the year. 
Finally, as it relates to R&D. We are revising this element of our guidance to 5% to 6% from 6% to 7%. Our adjusted expenditure for the quarter totaled $66 million or approximately 5% of revenues. At this level of investment, our R&D activities are hitting on all cylinders, and our output remains very strong. We currently have 1,480 global product submissions pending approval, and we are on track to achieve our target of 1,000 global submissions annually in 2010 through 2013. In addition, because of Bioniche Pharma's robust pipeline, we do not see a need for any meaningful external R&D activity during the remainder of the year. 
I'd like to turn now to the topic of pricing, which has received much attention lately. Our company has a very long history of delivering profitable growth in the U.S., which is by far one of the world's most competitive pharmaceutical markets. As such, we're very experienced at anticipating and responding to price and reimbursement cuts and managing fluctuations in volume. Now that we have a diversified global platform, we are able to effectively manage these same dynamics on even a larger scale and have more levers available to manage, drive and grow our business.
As we've stated before, we anticipated greater pricing pressure, especially in Europe, than in previous years and took these dynamics into consideration going into 2010. Though these pressures were slightly greater than what we anticipated, we have been able to absorb them.
Being able to manage such dynamics creates tremendous opportunities for Mylan. In fact, we believe we are positioned to leverage our vertically and horizontally integrated capabilities, economies of scale, and reliable and responsive supply chain across our global operations. All the hard work done over the last three years under the campaign of synergies have transformed us into a highly competitive organization. 
This tremendous advantage is the realization of the vision we set out to achieve when we brought together legacy Mylan, the former Merck business and Matrix Laboratories nearly three years ago. During those first three years, we focused on executing the integration of the businesses and on capturing significant synergies. Our strong results throughout that period demonstrate our phenomenal success in that regard. Now that same result has succeeded, paving the way for our strong top and bottom line growth in 2011 and beyond. 
Now I would like to walk you through the performance of our commercial operation.
During the second quarter, we generated total revenues of $1.37 billion compared to last year's second quarter total adjusted result of $1.27 billion. That's an increase of approximately 8%. Revenues grew in both our Generics and Specialty segments. On the bottom line, solid execution across our business allowed us to generate $0.37 of adjusted diluted EPS, a 16% increase over last year's second quarter result. This result is in line with our guidance. 
Within our Generics segment, our North America operations delivered third-party revenues for the second quarter of $589 million, up 12% from last year's second quarter results of $526 million. The increase was driven by sales of new products and increased volumes on our base business. This performance is a true testament to the strength of critical mass in controlling your supply chain so as to seize on market opportunities. 
Our higher revenues also absorbed the loss of exclusivity on Divalproex, which we enjoyed during last year's second quarter.
Complimenting this very strong performance was the record number of product approvals we received during the quarter from the FDA, with a year-to-date total of 33. We have also launched, to date, eight of the dozen limited-competition products we expect to introduce by the year end. These achievements demonstrate the strength of our pipeline and are among the many reasons we're so confident about our future.
I'd also like to add that we remain on track to achieve our full year target of 50 to 60 launches in the U.S. 
Currently in the U.S., we have 131 ANDAs pending FDA approval, representing about $92 billion in annual brand sales, and 41 of these pending ANDAs are potential first-to-file opportunities representing more than $21 billion in annual brand sales. 
In Canada, we saw local currency third-party sales grow about 19% versus the year-ago quarter, led by products launched in the last 18 months. Pricing pressures in Ontario, Qubec and other provinces due to recent or pending legislation have been offset by a required reduction in payments to pharmacies, particularly in Ontario, resulting in a net impact that we expect will be relatively neutral to our business. 
In EMEA [Europe, the Middle East and Africa], where France drives our performance, third-party revenues of $379 million fell about 4% last year's second quarter third-party revenues of $393 million. However, on a constant-currency basis, operational growth in EMEA was nearly 3% year-over-year. The increase was driven by new product launches in several markets, totaling approximately $31 million, as well as increased volumes in certain countries. We remain committed to optimizing our business to align the new market dynamics in this region. 
In France, our sales dipped slightly versus a year-ago quarter as competitive pressure resulted in lowering price, which offset the favorable contribution from new products and increased sales of existing products. However, our market leadership position remains very strong.
In Spain, we saw a double-digit increase in sales as new product launches more than offset the negative effect on pricing in the portfolio. We also experienced single-digit growth in a variety of countries such as the UK. 
In Italy, second quarter local currency sales almost doubled versus the year-ago quarter due to new product launches and increased market penetration, which resulted in increased volume, as well as regulatory changes that have affected pricing positively. 
Moving onto Asia-Pacific region. We delivered solid second quarter results. Total third-party revenues were $265 million, up nearly 23% over last year's second quarter result of $216 million. On a constant-currency basis, sales increased about 12%. 
In Australia, local currency revenues declined slightly. We are continuing to optimize our business to align to new market dynamics while maintaining our leadership position. 
In Japan, local currency sales rose approximately 7% due to new product launches and continued market expansion. We remain optimistic about longer-term growth opportunities presented by this market and our ability to capture our share of that growth. 
Also in the region, our Matrix business delivered another very strong quarter of year-over-year growth. Primarily responsible were sales of ARV finished dosage forms to third-parties, which more than doubled versus the second quarter of '09, and sales of API to third parties. 
Finally, Dey Pharma, our Specialty segment, continued to perform well during the second quarter. Third-party revenues rose 14% over the same period last year after adjusting last year's third-party sales for the transfer of Dey's generics product to our Mylan Pharms [Mylan Pharmaceuticals] division. The primary driver of that growth was domestic sales of our EpiPen Auto-Injector. 
Moving on, I'd like to express how excited we are about our planned acquisition of Bioniche Pharma.
Bioniche Pharma will further our stated objective of identifying bolt-on acquisitions to fill gaps in our U.S. product portfolio and therapeutic categories. It also will give us the critical mass needed to immediately enter the North American injectables market. As Robert mentioned, we expect the business to be accretive in year one without accounting for any synergies. 
For those of you unfamiliar with the company, Bioniche Pharma is a leading U.S.-focused specialty injectable company based in Galway, Ireland. The company focuses on the development, production and sale of high-quality injectable products, many of which are difficult to develop or produce or that experience limited competition. The products are used in hospital settings and span several therapeutic categories including analgesics, orthopedics, oncology and urology. 
Bioniche currently markets about 30 products, and its pipeline includes 15 ANDAs pending approval with the FDA. The company also has more than 25 additional products in various stages of development. Net revenues totaled approximately $130 million for the 12 months ended May 31, 2010, and approximately $43.5 million for the last three months ended May 31, 2010.
Though the transaction remains subject to regulatory approval and other customary closing conditions, we expect the deal to close in September. 
We're excited about this transaction for two reasons. First, we expect Bioniche Pharma's top line growth rate to be well above our stated growth target, which only further bolsters our confidence in them. And because Bioniche Pharma is a higher gross margin business, we expect it to have a positive impact on Mylan's overall gross margin.
Further, while we are not providing synergy numbers, as there is little overlap with our existing operation, we do see opportunities to capture synergies both commercial and technical. We anticipate that once we close, integration activities will be swift and seamless. 
Secondly, we consider this transaction to be strategic in that Bioniche Pharma will become one of the pillars of Mylan Institutional, our newly formed institutional business, which will serve hospitals and long-term care facilities in North America with a differentiated and tailored pharmaceutical product offering.
We expect that offering will initially include that of UDL, the largest unit dose provider to hospitals in the U.S., and Bioniche Pharma's high quality injectables. Moreover, because of the nature of the institutional marketplace, the new Mylan Institutional will fill an important prerequisite to the viability of the commercialization of Mylan's own generic biologics platform in the near future, as well as commercialization of specialized products such as Copaxone. 
As you can see, we have a lot to be excited about in the second half of 2010, from receiving new product approvals to driving continued increases in volumes around the world and achieving annual synergies of $350 million, if not more. 
Looking ahead to 2011. We are as bullish as ever about our prospects and believe our momentum going into the year will be very strong. Specifically, we look forward in 2011 to the additional revenues that will result from the approximately 500 products we expect to launch globally. Among them will be oral contraceptives, which we expect to begin launching in the U.S. around midyear; the monetization of first-to-file opportunities, such as our previously announced settlements related to voriconazole, letrozole, and venlafaxine; and our recently announced settlement on minocycline, which John will elaborate on shortly. 
In addition, we will see the expiration of 30-month stays on a number of additional first-to-file opportunities, and we expect to launch in excess of a dozen limited-competition products.
Finally, let me remind you that our legacy Merck Generics business inlicensed about 70% of its products when we purchased it back in '07. By year end, we'll be at about 55% and expect to keep pushing that figure lower throughout '11 and achieving internalization of 70% by 2013, resulting in a positive financial impact. 
At this time, beyond 2011 and through '13, we continue to see strong growth in our overall business and expect to accelerate our top line growth by executing on the key drivers of portfolio expansion, continued realization of operational efficiencies, continued diversification and balance sheet deleveraging. 
In summary, I'd like to remind everyone that we have stated many times that 2010 is the baseline year from which Mylan will continue to grow. We have an extremely powerful platform, a proven ability to execute and an unshakable belief that we are perfectly positioned to leverage our assets over the years to come. The results we announce today only reinforce our confidence that we will deliver performance in 2010 and beyond that is in line with our updated guidance and with our long-term targets.
With that, I'll turn over to John."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Thanks, Heather. This afternoon, I will walk you through our second quarter 2010 financial results and discuss our 2010 financial guidance, the range of which we have narrowed. I will conclude by briefly reviewing our capital structure and liquidity posit",2637,"Thanks, Heather. This afternoon, I will walk you through our second quarter 2010 financial results and discuss our 2010 financial guidance, the range of which we have narrowed. I will conclude by briefly reviewing our capital structure and liquidity position. 
Before I begin, I would like to comment briefly on what I've seen at Mylan during, this, my first full quarter as CFO. One of the aspects of joining Mylan that I found most intriguing was that of the growth prospects of the Generics and Specialty Pharmaceuticals sector, and in particular, how well poised Mylan is to take advantage of such opportunities. This has been quickly confirmed for me with our recent approvals and subsequent launches of valacyclovir and the clonidine patch, and most recently, our approval and launch of minocycline and subsequent legal settlement, which I will discuss in more detail later. 
Additionally, this growth continues to increase our ability to leverage our global production capabilities and robust R&D pipeline. When I was making my decision to join Mylan, one of the key points that both Robert and Heather continued to stress with me was the soundness of Mylan's growth strategy, and perhaps most important, the company's ability to execute against these strategies and make their vision become a reality. This, too, has been clearly demonstrated to me in my short time here with our recently announced planned acquisition of Bioniche Pharma, which immediately makes Mylan a player in the North American injectables market, yet another successful accomplishment of a stated objective.
Whether it be product approvals, such as those we have recently seen, or acquisitions such as Bioniche, it is developments and actions such as these that demonstrate that Mylan executes on what says it's going to do and continues to make me confident in Mylan's long-term growth targets. 
Now moving on to my review of our second quarter financial results. As Kris mentioned, I'm going to be referring to actual and projected financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. We present these non-GAAP financial measures because they're prepared on the same basis as used by our management and Board of Directors to evaluate the performance of our business. This afternoon's earnings release includes a complete reconciliation from our GAAP to non-GAAP financial measures for our second quarter 2010 and 2009 results. Earnings release is available on our website and I encourage you to take a look at it. 
In summary, the more significant items that are excluded in arriving at our adjusted basis results for the 2010 second quarter are: purchase accounting amortization of $71 million; integration and other expenses of $18 million; incremental interest expense, which is primarily the imputed interest expense related to our convertible debt, of $14 million; charges related to the net settlement of litigation, totaling $12 million; costs associated with our recent issuance of the new senior unsecured notes, which I will discuss later, totaling $15 million, which was mainly related to the write-off of debt issuance costs and certain costs associated with the termination of interest rate swaps; and finally, the net tax benefit related to the excluded items, of approximately $53 million. 
I strongly agree with Robert and Heather's comments on the quarter and first six months, both of which were very solid operationally and financially. Let me start at the top of the income statement.
Total revenues for the quarter were $1.37 billion, an increase of 8% over last year's second quarter total adjusted revenue of $1.27 billion. The effect of foreign currency translation did not have a significant impact on our second quarter results as compared to the same prior-year period, as the effect of a weaker euro was offset by the strengthening of the currencies of our other subsidiaries, mainly the rupee, the yen and the Australian dollar.
To reiterate what Heather mentioned earlier, new product launches and favorable volume on our existing base business more than compensated for the decline in sales due to the loss of exclusivity on divalproex ER in the prior year. 
Absent the drop in sales as a result of Divalproex, our increase in sales in both the current quarter and current year-to-date period would have been significantly higher. For the full year, we continue to project total revenues in the range of $5.4 billion to $5.6 billion.
Looking at our operating profitability measures, adjusted gross margin for the quarter was approximately 45% compared to 47% in the prior year and two points below our full year guidance range of 47% to 49%. Our Q2 gross margin was dampened by close to 1% as a result of an atypical level of inventory charges. 
The year-over-year decrease in margin is primarily the result of the loss of exclusivity on divalproex in the second half of 2009. For the reasons Heather mentioned in her remarks, we continue to fully expect our operating performance and gross margin to improve during the second half of 2010, and we expect full year margin will be within our guidance range, though nearer to the low end. 
Adjusted R&D expense for the quarter was $66 million or approximately 5% of revenues. This spending is slightly above that of our first quarter 2010 spending level, but is in line with our revised full year guidance range of 5% to 6% of revenues as Heather previously discussed. Importantly, our R&D projects remain on target, and we are planning for higher levels of spending over the remainder of the year. 
Adjusted SG&A expense was $251 million for the quarter or 18% of revenues, within our full year guidance range of 18% to 20%. Our second quarter adjusted EBITDA was $335 million. If you combine this result with our expectation for generating higher levels of earnings later in the year, we see ourselves on track to meet our adjusted EBITDA guidance, which we have revised to a range of $1.45 billion to $1.55 billion for the full year. 
Now let me move to couple of non-operating financial metrics. Second quarter 2010 adjusted interest expense was $65 million. We continue to forecast adjusted interest expense for the year to be in the range of $280 million to $300 million, which continues to consider the potential for higher short-term interest rates and a higher level of interest expense as a result of our Q2 issuance of new senior unsecured notes. 
Income taxes. Our second quarter adjusted effective income tax rate was 29%. Today's narrowed guidance range incorporates a full year projected adjusted effective income tax rate range of 28% to 29%.
In summary, second quarter adjusted net income was $163 million or $0.37 per share, which was slightly negatively impacted by changes in foreign currency exchange rates versus those existing at the time when we provided earnings guidance earlier in the year. 
In calculating our adjusted diluted EPS, the impact of assuming the conversion of our preferred shares into 125 million common shares was more dilutive than the $35 million quarterly preferred dividend. Therefore, adjusted diluted EPS for the second quarter is calculated based on an average outstanding diluted share count of 440 million shares. 
Touching briefly on the year-to-date results. The more significant items that are excluded in arriving at our adjusted basis results for the 2010 year-to-date period are: purchase accounting amortization of $143 million; integration and other expenses of $31 million; incremental interest expense, which is primarily the imputed interest expense related to our convertible debt, of $24 million; charges related to the net settlement of litigation totaling $13 million; costs associated with our recent issuance of new unsecured notes totaling $15 million; and finally, the net tax benefit related to the excluded items of approximately $86 million. 
For the six months ended June 30, 2010, total revenues were $2.66 billion, an increase of 9% over adjusted revenues of $2.45 billion in the same prior-year period. Foreign currency translations did impact our year-to-date result with a favorable effect of approximately 3% due mainly to the strengthening of the Canadian dollar, the rupee, the yen and the Australian dollar versus the U.S. dollar. The euro did not have a significant effect. 
Adjusted gross margin for the six months was approximately 45%, with the impact of divalproex also having an unfavorable effect on our year-to-date margin when compared to the prior year. Adjusted R&D expense was $126 million, and adjusted SG&A was $496 million for the current six-month period. Our adjusted EBITDA for the first half of 2010 was $658 million. Adjusted income was $322 million, and adjusted diluted EPS was $0.73 per share. 
As in the quarter, adjusted diluted EPS was calculated assuming the conversion of our preferred shares into 125 million shares of common stock. The number of shares assumed in the conversion of our preferred stock is dependent upon our stock price. We expect our share price to continue to remain at a level at which 125 million shares will be the assumed conversion amount. Additionally, depending on the market value of our common stock going forward, our average outstanding diluted share count could increase further due to the additional dilution from stock options and other potentially dilutive financial instruments, such as our convertible debt obligations and the related warrant. 
We have considered the potential for a higher average diluted share count in our full year adjusted diluted EPS guidance range, which, as Robert indicated, we have narrowed to $1.55 to $1.65 per share, with adjusted EPS in the fourth quarter expected to exceed that of the third quarter. 
In our earnings release this afternoon, we provided a comparison of exchange rates that were used in preparing our initial guidance to those that were used in preparing our revised guidance. Prospectively, we will continue to update you on the FX rates we are using whenever we revise our guidance. This is intended to ease your understanding of our forecast.
As you'll see, certain currencies, in particular the euro, have weakened since our original guidance was prepared. It is important to note, however, that most of our non-U.S. operations have their revenues and their cost structures based in their local currencies. 
For our euro-based entities, their euro-denominated cash flows are offset against euro-denominated debt. As such, while changes in the euro, either positive or negative, will impact our reported U.S. dollar results, there is little impact from a truly economic standpoint. 
Turning to our cash flow metrics. Our second quarter cash flow from operations was $118 million compared to $210 million in last year's second quarter. The decrease is primarily the result of the timing of collection of receivables, for which a substantial amount was received in early July; the timing of income tax payments; and the payment of approximately $22 million related to the termination of certain interest rate swaps associated with the financing completed this quarter. We do continue to project full year operating cash flow in the range of $725 million to $825 million excluding certain one-off items. 
Second quarter capital spending of $33 million was more than 2009 but well below our expected annual spend. However, based on anticipated project timing, we do expect spending to increase significantly in the second half of 2010 and continue to project capital spending in the range of about $250 million for the full year. 
Let me now turn to our capital structure and liquidity position. In May, we completed a private placement of $550 million of senior unsecured notes due in 2017 and bearing interest at 7 5/8% and $700 million of senior unsecured notes due in 2020 and bearing interest at 7 7/8%.
$1 billion of the net proceeds were used to pay down existing indebtedness under our credit facility. This bond issuance was in accordance with our objective of extending the maturity profile of our outstanding indebtedness. We continue to have no meaningful long-term debt maturities until the $600 million due under our convertible notes in the first quarter of 2012, which we currently intend to repay with available cash at that time. 
In addition, it is important to keep in mind that the last $35 million quarterly dividend payment related to our outstanding preferred stock is scheduled to be paid on November 15, 2010.
Also, as mentioned previously, we incurred charges of approximately $15 million associated with the issuance of these senior notes. Approximately half of this charge was to write off capitalized debt issuance costs associated with the amounts that were repaid, with the other half related to the termination of interest rate swaps also associated with the debt that was repaid. The swaps terminated restored us to what we believe to be an appropriate ratio of fixed to floating rate debt. 
Concerning leverage, as Robert has stated many times, it is our commitment to achieving a long-term leverage ratio of less -- of 3:1 or less. We are firmly committed to balancing growth in our business through the continued use of prudent and responsible financing. As such, Mylan remains committed to deleveraging over time to meet this long-term capital structure goal.
From a covenant perspective, the level of our senior secured debt is approximately 1.9x our last 12-month covenant basis adjusted EBITDA. This is well below our June 30, 2010, covenant threshold of 4x times and also comfortably ahead of our December 31, 2010 threshold of 3.5x. 
At the end of the current -- of the quarter, we had approximately $833 million of unrestricted cash and marketable securities compared to just over $400 million at December 31. We expect to use some of this cash, along with available borrowings, to finance the acquisition of Bioniche.
Bioniche is an exciting opportunity for Mylan and one that we believe will be accretive to Mylan's earnings in the first year, even before considering any synergies. It is important to note, however, that we do not believe that the impact from this acquisition will be significant to our 2010 results.
In addition to a revenue growth rate that is in excess of Mylan's growth rate, the Bioniche acquisition will be especially complementary, as A, its margins are in excess of our consolidated margins, and B, their relatively lower effective tax rate as a result of being domiciled in Ireland.
While we expect the contribution from the sale of Bioniche's products to benefit our overall gross margin, we do not foresee a significant change in our overall consolidated corporate tax rate. 
One last item that I would like to briefly address is our recently announced approval, launch and settlement with respect to minocycline ER.
Our Matrix subsidiary received final approval of its ANDA on July 20, 2010, and we began shipping immediately. On July 22, 2010, we reached a settlement with Medicis, the innovator, to resolve outstanding patent litigation. Under the terms of the agreement, we agreed to cease additional distribution of the product until November 11, 2011, or earlier under certain circumstances. 
With respect to the product already shipped, we have been released by Medicis of any potential liability associated therewith. However, because of uncertainties that could affect pricing and market conditions, accounting rules require that we defer revenue recognition. As we've done in similar situations in the past, most recently related to Amlodipine, we will defer the revenue from our initial shipments of the product until such time as the product is sold by our customers.
To reiterate: as these shipments were made in July, this is a third quarter item. We expect this revenue to be recognized throughout the second half of the year and into 2011. 
In closing, let me say once again: I am pleased with our very solid first half of the year, and I'm extremely excited about our prospects for the remainder of 2010 and beyond.
That concludes my remarks, and I'll turn the call back over to Kris to start the Q&A."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Operator, you can begin the question-and-answer.",6,"Operator, you can begin the question-and-answer."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] And we'll go first to Elliot Wilbur of Needham & Company.",13,"[Operator Instructions] And we'll go first to Elliot Wilbur of Needham & Company."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","With respect to gross margin performance year-to-date and then full year guidance. Just kind of backing into what would sort of have to happen in the second half of the year. It looks like you'd have to do close to around 49% even at the low end of revenu",122,"With respect to gross margin performance year-to-date and then full year guidance. Just kind of backing into what would sort of have to happen in the second half of the year. It looks like you'd have to do close to around 49% even at the low end of revenue guidance in order to sort of achieve, I guess, just the low end of your current forecast. And I understand that's a very complex calculation, but it just seems from our vantage point that, that's going to be a very difficult number to achieve outside of some contribution from a large exclusivity type product. I'm just maybe wondering if you could walk us through what kind of the incremental levers there maybe."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","I'm not sure there's much more to walk through. I think you've done a very eloquent job of kind of outlining the -- both bookends. And certainly, it's not uncommon. Mylan in the past had gross margins much larger than the 49%. And even though we don't hav",113,"I'm not sure there's much more to walk through. I think you've done a very eloquent job of kind of outlining the -- both bookends. And certainly, it's not uncommon. Mylan in the past had gross margins much larger than the 49%. And even though we don't have Paragraph IVs in 2010, as Heather mentioned many, many times, there are a significant number of products that we see that are very high gross margin product, and we fully expect to launch those products. We already begun that, already beginning in the third quarter and expect to see a lot more as we continue to roll out for the rest of the year."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","I have a follow-up for you, Robert, as well. I want to make sure that I understand the messaging with respect to 2011, because I think previously, the company seemed quite confident that full year earnings per share would be in excess of $2. And then, the",115,"I have a follow-up for you, Robert, as well. I want to make sure that I understand the messaging with respect to 2011, because I think previously, the company seemed quite confident that full year earnings per share would be in excess of $2. And then, the commentary in the press release today seems to be suggestive that you'll be earning $2 by the end of 2011. I'm just -- I'm wondering, are we talking about an annualized EPS run rate of $2 by the end of 2011 now? Or are you still confident that, at least at this juncture without official guidance in place, that you can still earn that $2 per share?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","The answer is simply, yes. As you know, we haven't given official range of guidance for 2011. But as I stated in my prepared remarks, and especially, getting closer to 2011 with additional visibility, the answer is absolutely yes.",39,"The answer is simply, yes. As you know, we haven't given official range of guidance for 2011. But as I stated in my prepared remarks, and especially, getting closer to 2011 with additional visibility, the answer is absolutely yes."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the next question from Gregg Gilbert from Bank of America Merrill Lynch.",16,"And we'll take the next question from Gregg Gilbert from Bank of America Merrill Lynch."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Can you talk about which of the product or which types of products were delayed? Robert, you alluded to some of that, and Heather too, in the prepared remarks.",29,"Can you talk about which of the product or which types of products were delayed? Robert, you alluded to some of that, and Heather too, in the prepared remarks."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Sure. Well, as we were just discussing, the clonidine, our clonidine patch as well as minocycline were obviously two important approvals, recent approvals for us. And certainly building to the previous question on gross margin, those -- that type of produ",62,"Sure. Well, as we were just discussing, the clonidine, our clonidine patch as well as minocycline were obviously two important approvals, recent approvals for us. And certainly building to the previous question on gross margin, those -- that type of product, those limited competition launch is obviously important for us. And those are -- that's the type of approvals we're speaking of."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","You were talking about delays that were rectified.",8,"You were talking about delays that were rectified."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Heather, do you expect AMP implementation to affect your business in the U.S. in any material way? And lastly, what's your latest thinking on patent settlement legislation? Whether it will happen and whether it would address settlements you've already sig",47,"Heather, do you expect AMP implementation to affect your business in the U.S. in any material way? And lastly, what's your latest thinking on patent settlement legislation? Whether it will happen and whether it would address settlements you've already signed? I know that's seems to change weekly."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Sure. As far as the patent settlement legislation's concerned, I don't know how closely you watched the war supplemental bill and domestic spending that they were trying to push through. I [indiscernible] that since it did not get attached, I -- my bet is",105,"Sure. As far as the patent settlement legislation's concerned, I don't know how closely you watched the war supplemental bill and domestic spending that they were trying to push through. I [indiscernible] that since it did not get attached, I -- my bet is it's extremely unlikely they'll get patent settlements reattached this year. And as you know, we've been very vocal out there about even looking at patent settlements without an authorized generic fix. This is just handicapping the generic industry. And we have continued to certainly push that agenda on the Hill as well. And your first -- is it first industry [ph]..."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","AMP.",1,"AMP."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","AMP. No, not material -- remember that, I think, that there's still -- it's going to be interesting. This is supposed to, I think, be published for the first time in October as far as the weighted average AMP. And we certainly are watching that closely, a",105,"AMP. No, not material -- remember that, I think, that there's still -- it's going to be interesting. This is supposed to, I think, be published for the first time in October as far as the weighted average AMP. And we certainly are watching that closely, and I'm sure there's a lot of concern out there. Obviously, we thought that was the best of all worlds as far as how the legislation originally came out, and what ultimately we were able to end up getting it to, that weighted average being published. But at this time, we don't see any material effect to our business."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll move on to next question from Marc Goodman from UBS.",13,"And we'll move on to next question from Marc Goodman from UBS."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","There was a comment that inventory charges that were atypical hit the gross margin. Could you just elaborate on those? Second of all, can you give us a flavor of how your German business did in the quarter and year-to-date, things like that? And then thir",90,"There was a comment that inventory charges that were atypical hit the gross margin. Could you just elaborate on those? Second of all, can you give us a flavor of how your German business did in the quarter and year-to-date, things like that? And then third, on France, you mentioned there was some pricing pressure. Can you just give us a flavor? Is that something that just started happening in the quarter? Or has that been going on all year? I don't remember if you called that out last quarter."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","So I'll take the first one on the gross margin. And without going specifically into the products or the locations within our Generics segment, there were some inventory amounts that were written off. And as the gross margin in this quarter was at 45%, I f",90,"So I'll take the first one on the gross margin. And without going specifically into the products or the locations within our Generics segment, there were some inventory amounts that were written off. And as the gross margin in this quarter was at 45%, I felt it helpful to understand that those atypical charges -- without those atypical charges, we would have been nearly a full percentage point higher in the gross margin. But it helped to understand how we were getting to the second half of the year."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","But just to be clear before we move on. You're not -- you absorbed that into your numbers. So you're still going to do 47%-plus gross margin, absorbing that?",29,"But just to be clear before we move on. You're not -- you absorbed that into your numbers. So you're still going to do 47%-plus gross margin, absorbing that?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Absolutely. All I was trying to do was to help you understand how the margin will not be burdened by that in the second half of the year.",28,"Absolutely. All I was trying to do was to help you understand how the margin will not be burdened by that in the second half of the year."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","And as far as Germany goes. Our Germany business this quarter was right in line with our expectation. So we -- it's still a very good driver for us. And, frankly...",31,"And as far as Germany goes. Our Germany business this quarter was right in line with our expectation. So we -- it's still a very good driver for us. And, frankly..."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Does that mean, was there growth there? Or I mean, is that business growing this year versus last year? Is it declining? Like where are you just relative to what's happening with all the tenders and the pricing?",38,"Does that mean, was there growth there? Or I mean, is that business growing this year versus last year? Is it declining? Like where are you just relative to what's happening with all the tenders and the pricing?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, look, I mean, like I said, it was right in line with what we expected Germany to do. It certainly, year-over-year, it has seen some decline in pressure just because, to your point, the tender market. But it was right in line with what we expected Ge",164,"Well, look, I mean, like I said, it was right in line with what we expected Germany to do. It certainly, year-over-year, it has seen some decline in pressure just because, to your point, the tender market. But it was right in line with what we expected Germany to do. And we've been -- as we've stated before, things were well-positioned with our competitive product of how we're competing that tender market. France, as far as France. No, it's nothing new. It was nothing new this quarter. What we did just want to point out is, as we've been saying, that competitive pressure, we've seen that. We anticipated the majority of that. And as I've said, we will continue to adjust our business and, given our experience here in the U.S. in what I've stated to be the most highly competitive in the world, believe that, that's the kind of experience we're being able to bear over there in Europe. Nothing new about France."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. Again, Marc, there's nothing new there. We've been projecting and been living with what we've anticipated as a downward trend in pricing, only to be offset by those metrics that we've been all along telling you, our ability to rightsize and our abili",54,"Yes. Again, Marc, there's nothing new there. We've been projecting and been living with what we've anticipated as a downward trend in pricing, only to be offset by those metrics that we've been all along telling you, our ability to rightsize and our ability to yield additional efficiencies, especially in our cost of goods."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Let me just ask one other thing, which is kind of just an extension of what the prior question was from the start. It just gets back with the $2 thing in 2011. I just want to make sure I understand this. So previously, you were $2-plus, now you're $2. You",117,"Let me just ask one other thing, which is kind of just an extension of what the prior question was from the start. It just gets back with the $2 thing in 2011. I just want to make sure I understand this. So previously, you were $2-plus, now you're $2. You've got Bioniche that helps you sometime in accretive. So I guess I'm just trying to understand what changed, relative? Is this -- this is basically the new European pricing. I mean everybody's concerned, everybody's been assuming that numbers are coming down. They're not really coming down that much for you. And I'm just trying to understand what's going on behind the scenes, excluding this Bioniche acquisition?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, Marc -- well, actually, I mean, I really appreciate this last question, only because if you have -- I want to make sure everyone is clear. You're exactly right in your description. I mean, please remember, and I probably should have pointed this out",247,"Well, Marc -- well, actually, I mean, I really appreciate this last question, only because if you have -- I want to make sure everyone is clear. You're exactly right in your description. I mean, please remember, and I probably should have pointed this out, not only have we not changed, not only does the underlying business continue to be strong, not only do I feel we have not brought down the numbers. But remember in that $2, when I -- again, remember, I forecasted that. And remembering that $2, that was with a different FX. I'm totally absorbing, as I update the $2 for 2011, the negative movement in the FX. And believe me, it's much more substantial in 2011 than it is for the rest of 2010. So yes, I appreciate, yes, this last question. And I hope we made that clear. And Bioniche, let me just address Bioniche real quick in terms of that. Remember, all along I've been telegraphing exactly what we were going to do in terms of our platform, identifying voids and layering in those voids. Bioniche is just simply doing just what we said that we were going to do. So it's been fully anticipated, as we roll out, that we -- not just on the Injectable portfolio, but other particular niche areas that we are going to layer in to our platform that will only continue to allow us to continue to achieve the objectives that we set forth."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","We'll move onto the next question from Randall Stanicky from Goldman Sachs.",13,"We'll move onto the next question from Randall Stanicky from Goldman Sachs."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Just so we're all clear. 3% constant currency growth in EMEA this quarter, 9% prior. How do we think about the sort of normalized growth for the back half going forward here on a constant-currency basis?",37,"Just so we're all clear. 3% constant currency growth in EMEA this quarter, 9% prior. How do we think about the sort of normalized growth for the back half going forward here on a constant-currency basis?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","So look, I think as we've said all along, when you look at Mylan, as Robert stressed, our overall business and that contribution. Certainly, again, some seasonality as far as when you look at the Europe and just the historical trends and our earnings ther",76,"So look, I think as we've said all along, when you look at Mylan, as Robert stressed, our overall business and that contribution. Certainly, again, some seasonality as far as when you look at the Europe and just the historical trends and our earnings there. And I think as John pointed out, the fourth quarter being overweighted on the third quarter. So I think that, that's kind of how you should think about Europe as well."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","So the first half being sort of -- the second half being sort of similar to the first half in terms of constant currency growth?",25,"So the first half being sort of -- the second half being sort of similar to the first half in terms of constant currency growth?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, and I -- well, I was more stressing that the fourth quarter being heavier than the third quarter.",19,"Well, and I -- well, I was more stressing that the fourth quarter being heavier than the third quarter."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes, I mean, that should be make clear. We continue to see that trend, as we told you, the latter half of the year. And we continue to see that, I'm not going to call it a hockey stick, but certainly a slope in the upward direction where the third quarter",70,"Yes, I mean, that should be make clear. We continue to see that trend, as we told you, the latter half of the year. And we continue to see that, I'm not going to call it a hockey stick, but certainly a slope in the upward direction where the third quarter will certainly be better than the second quarter, but the fourth quarter is certainly better than the third quarter."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Well, and just -- Robert, that's a good point. I mean, quarter you gave us a little bit of directional color. Given that there it's a pretty sharp back half EPS ramp, just thinking about the overall earnings for the company, how do we think about 3Q versu",49,"Well, and just -- Robert, that's a good point. I mean, quarter you gave us a little bit of directional color. Given that there it's a pretty sharp back half EPS ramp, just thinking about the overall earnings for the company, how do we think about 3Q versus 4Q?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","I would tell you if you take our mid-point, which hasn't changed, I would tell you that absolutely weight it more, much more to the fourth quarter than you should the third quarter, but the third quarter obviously being better than the second quarter. Tha",52,"I would tell you if you take our mid-point, which hasn't changed, I would tell you that absolutely weight it more, much more to the fourth quarter than you should the third quarter, but the third quarter obviously being better than the second quarter. That's how I would think about it."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","We'll take the next question from Chris Schott from JPMorgan.",11,"We'll take the next question from Chris Schott from JPMorgan."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Can you update us with regards to your site transfers and some of the realized cost savings from those moves? Is -- how much have we pushed through as we've got this far into 2010? And what should we think about in terms of incremental dollar savings as w",54,"Can you update us with regards to your site transfers and some of the realized cost savings from those moves? Is -- how much have we pushed through as we've got this far into 2010? And what should we think about in terms of incremental dollar savings as we look towards the second half?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","So I think a couple important metrics. We are on track, if not even exceeding a bit. And I think probably the first metric around that is just our synergies. If you remember, we're originally at $300 million, and the beginning of this year, we upped that",174,"So I think a couple important metrics. We are on track, if not even exceeding a bit. And I think probably the first metric around that is just our synergies. If you remember, we're originally at $300 million, and the beginning of this year, we upped that to $350 million. And I've stated, certainly we're on track to meet if not exceed that $350 million. And the majority of that increment over '09 was all driven to the site transfers and vertical integration. As far as -- so as you think about how that's contributing. I've said that we'll be at, by the end of this year, at about 55% having those products repatriated back to -- back internally to our supply-chain, and by the end of 2013, 70%. So certainly, we see a significant financial impact positively for the second half of '10. But also, we're going to -- that's going to continue, obviously, as we continue to bring these products in until we get to, like I said, the 70% in '13."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Second question was just coming back to France. Can you just elaborate what you're anticipating in terms of further price actions as you get later this year? I know we've had moves in several other European countries. But are you expecting that we'll see",71,"Second question was just coming back to France. Can you just elaborate what you're anticipating in terms of further price actions as you get later this year? I know we've had moves in several other European countries. But are you expecting that we'll see anything from France in the terms of -- there that's out of the ordinary relative to what we've maybe seen the last year or two or so?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","No, nothing as far as we know. We don't really see anything else in France this year.",17,"No, nothing as far as we know. We don't really see anything else in France this year."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Following the acquisition in the injectable market this quarter. Can you just elaborate a little bit in terms of what your top priorities are at this point from a business development standpoint? And what's your liquidity to pursue deals that might be in",52,"Following the acquisition in the injectable market this quarter. Can you just elaborate a little bit in terms of what your top priorities are at this point from a business development standpoint? And what's your liquidity to pursue deals that might be in the size of a Bioniche given the deleveraging priorities?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. I think what you should anticipate is exactly, again, what I've been saying. This one has been done. The other portfolio voids that I see I don't believe is anywhere near the size of, say, the injectable opportunity that we've just executed on. I've",158,"Yes. I think what you should anticipate is exactly, again, what I've been saying. This one has been done. The other portfolio voids that I see I don't believe is anywhere near the size of, say, the injectable opportunity that we've just executed on. I've also guided you -- there's -- I am looking and would like to look in Japan. That was another area, I think, that if I can find a right opportunity, it doesn't need to be large, but enough to give us further impetus to execute on our stated long-term objectives over there. So that's another area. But other than that, I don't really see anything else. And as you mentioned, we are extremely committed to the 3:1 debt-to-EBITDA ratio or below. And our cash position is, is such -- we're at a very, very strong cash position to execute on the strategies that I've just outlined to you and still maintain our objective."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the next question from Rich Silver from Barclays Capital.",13,"And we'll take the next question from Rich Silver from Barclays Capital."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Just coming back to the third quarter and the fourth quarter. Maybe I missed this, but can you help us a little bit in terms of what gives us that big bump up? How much of that is seasonality versus new launches versus synergies? Just some sense of why th",56,"Just coming back to the third quarter and the fourth quarter. Maybe I missed this, but can you help us a little bit in terms of what gives us that big bump up? How much of that is seasonality versus new launches versus synergies? Just some sense of why the big jump in the fourth quarter?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, I think he really hit on all the buckets. I mean, if you think about it, we do definitely have some seasonality, we definitely -- as we continue to yield the efficiencies, that's really where the continued growth slope is, as more and more of those",109,"Well, I think he really hit on all the buckets. I mean, if you think about it, we do definitely have some seasonality, we definitely -- as we continue to yield the efficiencies, that's really where the continued growth slope is, as more and more of those efficiencies and synergies and repatriating the external reliance to internal capabilities continues to grow each and every quarter. And that's why the fourth quarter will certainly be heavier there. Plus our anticipated product launches and product approvals, we think, again, are more back-weighted than they are front-weighted in the third quarter. Heather, do you want to add anything on top of that?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","No, not -- and I would say, even just, even these recent approvals -- so, Rich, as you can appreciate, as we get longer into the life-cycle of those products, a better -- more contribution as well.",37,"No, not -- and I would say, even just, even these recent approvals -- so, Rich, as you can appreciate, as we get longer into the life-cycle of those products, a better -- more contribution as well."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","And then just to carry that into 2011. Heather, in your prepared remarks, you spoke obviously about the 500 products globally, the OCs and then first-to-files, as well as limited competition products. Just want to make sure I understand that historically,",125,"And then just to carry that into 2011. Heather, in your prepared remarks, you spoke obviously about the 500 products globally, the OCs and then first-to-files, as well as limited competition products. Just want to make sure I understand that historically, it seemed like more of the growth would be coming from x U.S. In fact, rationale for doing the Merck Generics deals was less dependence on first-to-files and such in the U.S. Is that still the case for 2011, that we shouldn't expect the U.S. to be the primary driver, but rather x U.S.? And then the last question is just on FX. The rates that you disclosed in the press release today, are those the rates that we should be looking for 2011?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","The answer is, yes. And what we're going to for you for now on, now that we set a baseline, rather than have you guess what rates we're using at anytime, anytime we change guidance on a going-forward basis, you're going to know exactly the rates that we'r",370,"The answer is, yes. And what we're going to for you for now on, now that we set a baseline, rather than have you guess what rates we're using at anytime, anytime we change guidance on a going-forward basis, you're going to know exactly the rates that we're using in our guidance. And so the answer is yes to that. In terms of x U.S., U.S. reliance, Paragraph IVs or not, let me just explain. 2011 to me is a completely different year. To me, 2011, as I've stated all along, remember I said that 2010 is simply what we call the baseline year that represents what these three conglomerates coming together really means to grow from. 2011 completely -- it really is the first year of, the first full year of recognizing what these three assets are potentially capable of doing. If you recall, the growth, the -- our CAGR up to this point was predominantly weighted on our ability to yield the efficiencies out of these three assets. Not only is that going to continue in '11 and beyond, but now you're going to see top line growth, a robust growth in top line by the sheer number products that we're going to launch. And if you also recall, we had hardly any Paragraph IV opportunities in the last three years, especially in 2010, in our numbers and our projections, where -- because we've been building our pipeline, incubating those opportunities. You've already seen some of the settlements that are going to come through. And, yes, and we cannot forget and we should not ignore that the United States is the largest pharmaceutical company in the world by dollars. And that in the United States, I've often said, you do a little bit, you get a lot. And in the rest of the world, you do a lot, and you get a little bit. So yes, I think that these are very meaningful. But we're not going to shy away from the opportunities that we have in the United States to continue to grow our overall platform, on top of the additional opportunities that we see in market expansions throughout the world. You want to add anything, Heather?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","I mean, the only thing I'd add, Rich, is I was just trying to give some color because those -- we've spoke in the past, and people keep saying what are the drivers and give as much clarity as we can. Certainly, to Rob's point, why I wanted to point out la",113,"I mean, the only thing I'd add, Rich, is I was just trying to give some color because those -- we've spoke in the past, and people keep saying what are the drivers and give as much clarity as we can. Certainly, to Rob's point, why I wanted to point out launching 500 products around the globe. Those are very important in all other regions as well. But being able -- things that -- people are much more tangible, which are the first-to-file opportunities, the settlements we've already announced, as well as showing that we see an excess of a dozen of those limited-type competition products being launched in the U.S. next year."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And taking the next question, we'll go to David Buck from Buckingham Research Group.",14,"And taking the next question, we'll go to David Buck from Buckingham Research Group."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","First on Asia-Pacific. Can you -- it looked like it had a pretty strong quarter for the second quarter. Can talk about whether you're expecting to see that grow sequentially, and maybe what accounted for that? And then on minocycline. Can you -- based on",93,"First on Asia-Pacific. Can you -- it looked like it had a pretty strong quarter for the second quarter. Can talk about whether you're expecting to see that grow sequentially, and maybe what accounted for that? And then on minocycline. Can you -- based on the comments, John, it sounded like you may have launched as much as six months or so of demand. Is that accurate? And if not, can you help me out there? And then just a quick reminder on when you'd expect venlafaxine  to come down next year."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Let me -- John, why don't you get rid of the two ones, and then let me tell them about the -- just a little bit on the comment on the region.",32,"Let me -- John, why don't you get rid of the two ones, and then let me tell them about the -- just a little bit on the comment on the region."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. So on the minocycline. My comment was is that we would be recognizing revenue expected over the remainder of 2010 and into 2011. So I think that that's more -- speaks for itself.",34,"Yes. So on the minocycline. My comment was is that we would be recognizing revenue expected over the remainder of 2010 and into 2011. So I think that that's more -- speaks for itself."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","We haven't specifically stated what type of quantities were out there. And, Heather, what's the other products he's mentioned?",20,"We haven't specifically stated what type of quantities were out there. And, Heather, what's the other products he's mentioned?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. So we don't have a -- we haven't announced any launch timing around that.",15,"Yes. So we don't have a -- we haven't announced any launch timing around that."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","In terms of the region. David, let me just let you view it like this as we continue to roll forward. And Matrix in that region just continues to hit on all cylinders plus, plus, plus, very strong. I'm extremely pleased with what's going on now in Australi",163,"In terms of the region. David, let me just let you view it like this as we continue to roll forward. And Matrix in that region just continues to hit on all cylinders plus, plus, plus, very strong. I'm extremely pleased with what's going on now in Australia. I think they've turned the corner in terms of that base. And I think their -- I'm very, very comfortable. Our new leader there, Martin Cross, I think's got a firm handle in that particular country. And so I'm very -- I feel very good about that. In Japan, I would tell you that 2010 is a restructuring year for me. There is a lot of work to do in Japan. That I can tell you. So I'm really looking for the work that we're doing from now to the end of 2010 to really look at 2011 and beyond for the kind of growth that we anticipate in the longer-term for the Japanese market."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","And just to sort of clarify. For the second half of the year, would you expect growth in Asia-Pacific?",19,"And just to sort of clarify. For the second half of the year, would you expect growth in Asia-Pacific?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes, we've continued to say that, especially as Rob pointed out, that Matrix, accelerated double-digit growth.",16,"Yes, we've continued to say that, especially as Rob pointed out, that Matrix, accelerated double-digit growth."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll move on to the next question from John Boris from Citi [Citigroup].",15,"And we'll move on to the next question from John Boris from Citi [Citigroup]."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Just on price in particular. Are you anticipating any additional price cuts in Australia? Obviously, they had a round that was pretty significant before. Are you anticipating anything in the back half of this year or into 2011? And then on your 2011 guida",71,"Just on price in particular. Are you anticipating any additional price cuts in Australia? Obviously, they had a round that was pretty significant before. Are you anticipating anything in the back half of this year or into 2011? And then on your 2011 guidance, can you just help us understand what your price assumption is? Is it for pricing to erode at comparable levels, higher levels or lower levels than currently?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes. I mean, in terms of pricing. I wish we had the crystal ball, but you can only anticipate that we're doing the responsible thing by measuring current environment, current activity along with past trends. And really looking at each country on an indivi",198,"Yes. I mean, in terms of pricing. I wish we had the crystal ball, but you can only anticipate that we're doing the responsible thing by measuring current environment, current activity along with past trends. And really looking at each country on an individual basis and trying to evaluate not just each country, but how it rolls up as a whole. As you know, we have a certain natural erosion in the U.S. business and then with each country, the models is really the same, it really doesn't change. No, I don't think that the governments are going to allow us to increase prices or give us anything back. So I think it would be wise in your models to figure that there is some natural erosion. And then in terms of Australia, in particularly, I think you're going to -- I think we just -- I think we headed off, just here recently, some legislation that would've allowed additional price cutting there. But I mean, in Australia in particularly, I think you're going to hear a lot of noise in Australia. And certainly, we don't think it's going to stop, and we're not anticipating it to stop."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Yes, and I guess just a little more to that on the Australia front. Obviously, because of the changing government now, the dynamics, I would say there's a chance that, that legislation that was stopped, it -- that was rolling into 2011, so if anything the",70,"Yes, and I guess just a little more to that on the Australia front. Obviously, because of the changing government now, the dynamics, I would say there's a chance that, that legislation that was stopped, it -- that was rolling into 2011, so if anything there, that could be pushed out further if it takes them longer. But certainly don't see anything else in '10 as far as that goes."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","So just help me understand. In 2011, is your price erosion rate comparable to the '10 level? Or is it greater than the 2010 level?",25,"So just help me understand. In 2011, is your price erosion rate comparable to the '10 level? Or is it greater than the 2010 level?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","As I said, John, each country is done differently, and then we roll it up. And we don't, we -- I would say for Australia, I would say given the heavy, heavy hit that we've taken, say over the last 18 months, there in Australia, I don't anticipate, lets ju",82,"As I said, John, each country is done differently, and then we roll it up. And we don't, we -- I would say for Australia, I would say given the heavy, heavy hit that we've taken, say over the last 18 months, there in Australia, I don't anticipate, lets just say, as aggressive of a hit that we had to take in Australia, because it was pretty hefty. I do not anticipate as aggressive of a hit, if that's helpful to you."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","And then on Catapres Transdermal. My understanding is it's a pretty difficult product to manufacture. Can you just provide some commentary on launch quantities and whether you have adequate supply to meet the demand within that marketplace?",37,"And then on Catapres Transdermal. My understanding is it's a pretty difficult product to manufacture. Can you just provide some commentary on launch quantities and whether you have adequate supply to meet the demand within that marketplace?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","All I can answer to that is, first of all, absolutely yes. And let me remind you, even on the Fentanyl, when we launched Fentanyl. One thing I can tell you is that oftentimes, the FDA does call us every now and then against drug shortage and ask us if we",77,"All I can answer to that is, first of all, absolutely yes. And let me remind you, even on the Fentanyl, when we launched Fentanyl. One thing I can tell you is that oftentimes, the FDA does call us every now and then against drug shortage and ask us if we those capabilities. And each and every time, when it comes to those patches, Mylan is a premier producer of its patches because of our patch technology."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","And the only thing I'd add to that, just to -- in further support of that. Our clonidine patch is a very eloquent patch compared to the other out on the market. And there has already been some shortages in the marketplace prior to us getting approval. So",82,"And the only thing I'd add to that, just to -- in further support of that. Our clonidine patch is a very eloquent patch compared to the other out on the market. And there has already been some shortages in the marketplace prior to us getting approval. So to your point is, we certainly see it as a limted-competition launch, and we see it is as a very important product to us over the -- over '10 and '11 as well."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the next question from Shibani Malhotra from RBC Capital.",13,"And we'll take the next question from Shibani Malhotra from RBC Capital."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","A couple of, more accounting related. Firstly, would you be able to give us a breakdown of your Matrix sales in terms of which regions the sales came from? How we should be accounting for that? And then the second question is on the Fentanyl. I mean, we'v",74,"A couple of, more accounting related. Firstly, would you be able to give us a breakdown of your Matrix sales in terms of which regions the sales came from? How we should be accounting for that? And then the second question is on the Fentanyl. I mean, we've seen new competition in the market or perhaps increased competition, and just wondering if you are seeing any impact on pricing or share related to that."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, the answer is, on Fentanyl, we're not seeing what you're seeing at all. In terms of Matrix, no, we don't breakdown.",22,"Well, the answer is, on Fentanyl, we're not seeing what you're seeing at all. In terms of Matrix, no, we don't breakdown."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Right. What I would say to you, Shibani is that we have integrated Matrix into our global platform, and that's why it's no longer a separate segment. And so you should be thinking about our Generics segment and with Matrix...",40,"Right. What I would say to you, Shibani is that we have integrated Matrix into our global platform, and that's why it's no longer a separate segment. And so you should be thinking about our Generics segment and with Matrix..."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","So we've never really broken it down in terms of certain things. So, yes.",15,"So we've never really broken it down in terms of certain things. So, yes."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Can you just talk a little bit more, Robert, you said that you are very interested in the Japanese market. We understand this is a very exciting market, especially given the recent government initiatives to increase generic penetration. Where did you feel",84,"Can you just talk a little bit more, Robert, you said that you are very interested in the Japanese market. We understand this is a very exciting market, especially given the recent government initiatives to increase generic penetration. Where did you feel you are versus where you want to be? And can you just talk a bit more about the dynamics that you're seeing and how the increased penetration has impacted your business, if at all? And when we should see that playing through?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, first, I -- I mean, I don't want to send a signal over to Japan that we're coming on a rampage from an acquisition point of view, because the culture over there, that's one of the things that they fear, is international external companies coming in",308,"Well, first, I -- I mean, I don't want to send a signal over to Japan that we're coming on a rampage from an acquisition point of view, because the culture over there, that's one of the things that they fear, is international external companies coming in and buying them up. I think that I feel very, very strongly that generating additional activity in Japan on top of what we have, I think I feel very strongly about that being a part of our -- of the business plan and how I see us executing on grabbing our disproportionate share of the real strong growth opportunities that we see in Japan in the longer term. So I'm using 2010 to basically restructure what we already have, thinking about, rolling forward, what else I would like to have to marry up and bolt-on to what I already got in order to execute, again, in gaining our -- and garner our disproportionate share of what we think the growth opportunities are over there. That could mean as much as investing partly in a Japanese company, or if it's small enough, an outright acquisition over there, or even a joint venture of some sort over there, where there's some joint development opportunities there. So I think there's a lot of options. I don't want -- I'm glad you asked the question for clarification because I don't want you to think there's only one way that I intend on doing something in Japan. But when the -- the last question that was post to us was how we think about capital and allocating capital. I just wanted to kind of put the parameters around sort of the levels that I'm looking for. And I think at those kind of levels, I can accomplish everything that we need to get done in Japan."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the next question from Ronny Gal from Sanford Bernstein.",13,"And we'll take the next question from Ronny Gal from Sanford Bernstein."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","First, just a quick clarification. That legislation in Australia that was just about to be ratified that included an implementation of an AMP in October 1. Your point is that, that essentially has been deferred indefinitely. Is that correct?",39,"First, just a quick clarification. That legislation in Australia that was just about to be ratified that included an implementation of an AMP in October 1. Your point is that, that essentially has been deferred indefinitely. Is that correct?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, yes. They just -- it did not -- it was not able to get passed through their legislature because of the change at the top. So this -- it will have to go back, and the -- like Rob said, we don't have a crystal ball. But I think conventional wisdom rig",90,"Well, yes. They just -- it did not -- it was not able to get passed through their legislature because of the change at the top. So this -- it will have to go back, and the -- like Rob said, we don't have a crystal ball. But I think conventional wisdom right now is, that was -- that would have gone in and affected early in '11. So to the extent that legislation, however long it takes or doesn't, certainly that timeframe will probably get pushed out a bit."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","But we're feeling pretty good about it, Ron.",9,"But we're feeling pretty good about it, Ron."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Robert, two questions. Now that you got a hospital-integrated force, it sounds like something that could integrate pretty well into biosimilar initiative. When do you think you'll be able to start the first clinical on a biosimilar based on where you guys",100,"Robert, two questions. Now that you got a hospital-integrated force, it sounds like something that could integrate pretty well into biosimilar initiative. When do you think you'll be able to start the first clinical on a biosimilar based on where you guys are in that group? And second, in kind of related issue. How do you -- what's your take about the Lovenox approval by the FDA? What does it tell you about the willingness to approve complex molecules? And if, to the extent that you're willing to disclose it, do you also have an enox product somewhere in development?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Okay, well there's a lot there. Let me start by saying in terms of our biosimilar strategy. Literally, we are right on track. I am extremely pleased with what I'm seeing so far in the development, the joint development between Mylan and Biocon. I'm loving",729,"Okay, well there's a lot there. Let me start by saying in terms of our biosimilar strategy. Literally, we are right on track. I am extremely pleased with what I'm seeing so far in the development, the joint development between Mylan and Biocon. I'm loving the early results of some of the work that's being done. And so I think that that's coming along just fine and yes, the Bioniche is exactly what we were looking for in terms of that entering in, being able from a commercial point of view, being able to enter into the biosimilar market, including here in the United States. So we are very pleased. And as you mentioned, it does line up quite well to our strategy. As far as the -- my commentary in terms of just the whole issue around the FDA in terms of their most recent actions. First, I have to tell you, I believe that certain people are really trying to speak too much for the FDA and on behalf of the FDA. I think we should leave it up to the FDA to continue to speak. Certainly they have. Teva continues to try to create the fact that somehow -- that the science is not there. Well, it's there. And the FDA has and continues to demonstrate that they will look and respect good science. And they have confirmed that in their answer to the citizens petition of Teva. If you read the citizens petition, I think the FDA's actions were almost exactly what they told Teva in their answer to the citizens petition. And people should have taken note of that. No, this Lovenox is not a surprise. And lastly, in terms of Teva's position about generic Copaxone, I find it extremely difficult to believe that they could actually say so aggressively and openly, especially after the FDA's actions. I do believe, Ronny, I think you were the one that might have put out a note. I agree absolutely, if it was you, I do believe it was you. You talked about there being almost a change at the FDA in terms of it stepping itself up to be more open and demonstrating its commitment to Congress and the legislatures that it'll be more open-minded into a biosimilar strategy and an ability to approve these complex compounds. And lastly, when you take a look at our application, even our application with the FDA. That should've been a red flag. Because as you all know, and quite surprisingly, the FDA has accepted our application several months in advance of how long it took to accept the application of Momenta's and Sandoz' Copaxone application. That should've told people something right there. I've tried to explain that these are very, very strong indications in terms of my confidence level about how I feel about the particular program or how I think the FDA is thinking about things. I think the FDA is doing a fantastic job in that front. And the most important point, I think, from a Mylan perspective, that you should know, is that there are several analysts that are still somehow -- I don't know where they get their information but I think were under the impression that our formulation is a Natco formulation. That is just wrong. We certainly have -- Teva certainly knows now that it's not a Natco formulation. It's a Mylan formulation. It's a formulation to bring Copaxone to a highly regulated market like the United States. And certainly, Mylan knows how to file an application and the requirements. So I want you to combine the fact that how quickly our petition was accepted by the FDA compared to Momenta's and Sandoz'. That should've been, again, a signal and a red flag. I want you to look at Mylan's track record of -- its regulatory track record and our relationship for very, very complex compounds, and the fact that when it comes to science, we know how the FDA respects science. It's exactly what they looked at when they examined our application. And no, we don't have a Natco formulation. We have a Mylan formulation. And that needs to be clearly understood and corrected for all those analysts who I think been under a wrong impression. Again, certainly Teva knows, because in our litigation we had to turn over that to them."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And moving next to Michael Tong from Wells Fargo.",9,"And moving next to Michael Tong from Wells Fargo."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Robert, just sort of one follow-up a little bit on 2011. Sorry to beat this dead horse. But I heard your commentary about FX being more of an issue in 2011, as it impacts the bottom line, than 2010. And just trying to reconcile the local cost offsetting c",117,"Robert, just sort of one follow-up a little bit on 2011. Sorry to beat this dead horse. But I heard your commentary about FX being more of an issue in 2011, as it impacts the bottom line, than 2010. And just trying to reconcile the local cost offsetting currency impact statement that you had for 2010. So what's the disconnect there? Is there something that we need to think about more for 2011 in terms of FX? And than secondly, on  Bioniche, maybe a longer-term question. What assets does Bioniche bring to you to get you ready for biosimilars? And what additional assets do you think you need in order to be competitive in that market longer-term?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Well, let me go back. I'll go backwards. If you -- it is our feeling here, it's our vision here, that in order to market biosimilar products here in the United States, having a large hospital presence, we think, is going to be critical. Okay? So they brin",283,"Well, let me go back. I'll go backwards. If you -- it is our feeling here, it's our vision here, that in order to market biosimilar products here in the United States, having a large hospital presence, we think, is going to be critical. Okay? So they bring that to us instantly. And no, I don't believe I really need any more at this time in terms of assets. Bioniche has resolved almost every metric that we outline. One, I said I will not do a transaction unless it was financially accretive. They are. Two, they fill a strategic void in a therapeutic category that we were not in before. And three, they do it in a very large way. We have instant critical mass to be meaningful as we work, over the next few years, to build upon that as we get ready to layer in our biosimilars, as legislation and the FDA continues to set forth its revelatory path. In terms of the FX. You've missed absolutely nothing except something very small, which could be very large in your thinking. And that is, there's only six months left in 2010. There's a whole year left in 2011. And, if you couple the fact that we see continued growth in 2011, you don't only have a whole year left, but you have larger numbers. So if you take a look at the fact that I'm using today's current rates compared to when I originally gave that projection, that forecast of $2 in 2011, and adjust the prior rates to today's rates and then roll it forward, I think that if you do the math, you'll see exactly what I meant by that."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And we'll take the final question from Ken Cacciatore from Cowen and Company.",14,"And we'll take the final question from Ken Cacciatore from Cowen and Company."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","Robert, just some clarification on your discussion about Natco and it being a Mylan formulation. Is this not the formulation that Natco is marketing in India? And if not, what part of the relationship do they then have with you?",40,"Robert, just some clarification on your discussion about Natco and it being a Mylan formulation. Is this not the formulation that Natco is marketing in India? And if not, what part of the relationship do they then have with you?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","Okay. The answer is no, it's not the formulation that they are marketing in India. And yes, they have a voluminous amount of integral relationships with us on a number of fronts, in terms of being able to be effective, to distribute this product around th",51,"Okay. The answer is no, it's not the formulation that they are marketing in India. And yes, they have a voluminous amount of integral relationships with us on a number of fronts, in terms of being able to be effective, to distribute this product around the world. As well as manufacturing."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Analysts","The international markets -- and I'm going to go at this probably a little bit differently, but I think folks are asking it the same way. When asking or discussing or trying to get from you what we should think about growth, you answered a couple question",201,"The international markets -- and I'm going to go at this probably a little bit differently, but I think folks are asking it the same way. When asking or discussing or trying to get from you what we should think about growth, you answered a couple questions by throwing in there efficiencies and rationalizing. So clearly kind of below the line, which is -- I understand. But you just did another 3% kind of year-over-year organic growth, constant currency, if I understand you correctly. So why would investors, or why should investors think that the international -- your European business specifically grow more than 5% a year? Is there somehow -- you talk about the product flow, and I guess you're assuming it's going to inflect. I guess we're a couple of years now past on the integration. What is it in terms of top line that gives you confidence that this is not just a 5% growth company? Or is that the right way to model it, and we should continue to understand that you're going to generate great efficiencies beyond -- I mean, below the line? Or is that just the wrong way to look at the top line?"
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","No, I actually think that you've asked and almost basically answered the question. I think that if you look at the growth from 2007 to 2010 when we acquired this, I told you that, that CAGR would predominantly become -- that growth would predominantly com",188,"No, I actually think that you've asked and almost basically answered the question. I think that if you look at the growth from 2007 to 2010 when we acquired this, I told you that, that CAGR would predominantly become -- that growth would predominantly come from the efficiencies from the bottom line. I told you that within this timeframe, by the end of 2010, we are loading up. So again, you've answer the question. It's 2011 and beyond that you're going to see an explosion of the number of a products that we intend to launch. So yes, I think that you can expect in 2011 top line growth mainly, predominately coming from the number of voluminous amount of products that we intend to launch. Everything we've been incubating at the end of '07, '08, '09, '10 is now going to -- that's how long it takes to get these products approved. Everything we put in our pipeline will begin to be launched in a voluminous way 2011 and beyond. And yes, we do intend to continue to get bottom line improvement as well, as we roll on."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","And that concludes today's question-and-answer session. I'd like to turn the conference back over to our speakers for any closing remarks.",22,"And that concludes today's question-and-answer session. I'd like to turn the conference back over to our speakers for any closing remarks."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Executives","No, just thank you all, and thank you all for your confidence and support. And again, thank you to our employees around the world. Thank you.",26,"No, just thank you all, and thank you all for your confidence and support. And again, thank you to our employees around the world. Thank you."
290203,109299417,70381,"Mylan, Inc., Q2 2010 Earnings Call, Jul-28-2010",2010-07-28,"Earnings Calls","Viatris Inc.","Operator","That concludes today's presentation. Thank you for your participation.",10,"That concludes today's presentation. Thank you for your participation."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Good day, and welcome to the Mylan, Inc. Third Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King, Vice President of Global Investor Relations. Please go ahead.",40,"Good day, and welcome to the Mylan, Inc. Third Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King, Vice President of Global Investor Relations. Please go ahead."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Lisa. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; and Executive Vice Pre",361,"Thank you, Lisa. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; and Executive Vice President and Chief Operating Officer, Rajiv Malik.
During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our annual report on Form 10-K for the year ended December 31, 2009, and in our other SEC filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov, and we strongly encourage you to do so. 
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP measures. It should be noted that non-GAAP financial measures such as adjusted revenues, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website as it contains detailed GAAP to non-GAAP reconciliations of our actual 2010 and 2009 third quarter results, including the allocation of each reconciled line item to specific income statement line items. 
Before I turn the call over to Robert, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission. 
With that, I'll now turn the call over to Robert."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris. Welcome, everyone and thank you for taking the time to join us this afternoon. I would also like to welcome all of the Mylan employees on the call today, especially those from Bioniche Pharma, who are listening as the new members of the M",530,"Thank you, Kris. Welcome, everyone and thank you for taking the time to join us this afternoon. I would also like to welcome all of the Mylan employees on the call today, especially those from Bioniche Pharma, who are listening as the new members of the Mylan family. On behalf of the Board of Directors and our leadership team, I'd like to thank each and everyone of you for your continued hard work, dedication and outstanding performance.
I am extremely pleased to report to you yet another strong quarter performance of exceptional earnings. As I mentioned on the last conference call, I did anticipate the third quarter to be better than the second quarter, and I am extremely pleased to report adjusted diluted earnings per share of $0.43, a 16% increase from our second quarter results. With that said, I still expect at this time that the fourth quarter will come in slightly better than the third quarter.
We maintain this position even with the most recent ruling related to our Paroxetine CR. While we are extremely disappointed with the lower court's ruling, we believe strongly that the lower court has erred in its decision not to grant us an injunction, and we have appealed that decision. It should also be noted that this is still just a ruling on an injunction. It is not a final decision resolving Mylan's rights on this matter. Regardless of the outcome of the appellant court decision on the injunction, we will continue our litigation to enforce our contractual rights and all of its negotiated provisions with GSK.
With that said, and irrespective of this short-term distraction, the longer-term fundamentals of our business have not changed, which is why we remain committed to our stated targets of $2 of adjusted diluted earnings per share for calendar year 2011 and our longer-term growth targets of 15% top line and 20% bottom line CAGR by the end of 2013. We very much look forward to providing you a detailed breakdown of our 2011 guidance on our next conference call.
Moving on to other activity in the quarter. You will recall that we issued $300 million in follow-on 10-year bonds to finance the acquisition of Bioniche Pharma. In addition, we are also able to use part of the strong operating cash flows that we continue to generate to prepay $300 million in term loan borrowings in the third quarter as well, further reducing our leverage and staying committed to our stated objective to achieve a 3:1 debt-to-adjusted-EBITDA leverage ratio. 
And finally, you may remember that on November 15 of this year, our mandatory convertible preferred stock will automatically convert to common stock. Given the recent growth and strength of our stock price performance, we anticipate issuing the lowest number of shares required under the terms of the preferred stock agreement, which is approximately 125 million shares. A further note, November 15 will also mark the final payment of the preferred stock dividend, thereby substantially enhancing our future free cash flows to the company by $139 million per year.
I look forward to answering your questions, and I'd now like to turn the call over to Heather Bresch."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert, and good afternoon, everyone. As Robert said, we are very pleased with our strong third quarter performance and a great start to our expected strong second half of 2010. We remain highly confident in our ability to deliver 2010 results",1328,"Thank you, Robert, and good afternoon, everyone. As Robert said, we are very pleased with our strong third quarter performance and a great start to our expected strong second half of 2010. We remain highly confident in our ability to deliver 2010 results in line with the guidance we have reaffirmed today. We also continue to be extremely confident about our growth prospects for '11 and beyond. I too would like to commend our employees around the world for making our continued exceptional performance possible.
During my remarks today, I'll review our performance by segment, provide an update on synergies and comment on why we remain so confident about our future. I'd now like to walk you through the performance of our commercial operations. During the third quarter, we generated total revenues of $1.36 billion, an increase of 7% compared to last year's third quarter total revenues of $1.26 billion. On a constant currency basis, revenues were up approximately 9% year-over-year, and on the bottom line, we generated $0.43 of adjusted EPS, a 34% increase over last year's third quarter result of $0.32.
We also delivered a strong adjusted gross margin of 48.4% during the  third quarter, up from our second quarter performance of 45% and right in line with our full year expected range of 47% to 49%. As expected, driving the strong performance were recent approvals on higher margin, limited competition products, higher sales in our Specialty segment and continued synergy realization.
Within our Generics segment, our North American operations delivered third-party net sales for the third quarter of $573 million, up 17% from last year's third quarter result of $488 million. The increase was mainly the result of new product launches in the United States. Among those launches were limited competition products, Minocycline ER, Clonidine Transdermal and Tacrolimus, bringing to ten the dozen such products we anticipate launching by year end, and we remain on track to achieve our full year target of 50 to 60 launches in the U.S.
Our third quarter also includes results from Bioniche, a Specialty Injectables business we acquired on September 7. The integration has been seamless so far, and on October 4, we announced our first approval from the FDA for our Bioniche product, Fludarabine, an injectable chemotherapy medication for leukemia. Our ANDA filings now include those of Bioniche Pharma. Currently, we have 153 ANDAs pending FDA approval, representing about $95 billion in annual brand sales. 45 of these pending ANDAs are potential first-to-file opportunities, representing more than $24 billion in annual branded sales. 
In EMEA, third-party net sales of $364 million, 12% versus last year's third quarter third-party sales of $414 million. However, on a constant currency basis, operational performance in EMEA declined only 3% year-over-year while year-to-date, sales have risen almost 2%. That result was driven by unfavorable pricing throughout Europe, which was partially offset by new product launches in several markets. 
Looking forward, we continue to see our ability to even further offset negative trends in the region, thanks to the sheer number of internal products we expect to launch in 2011 and beyond. In addition, we continue to repatriate finished dosage forms, which will continue to add to our competitive position throughout Europe. 
In France, third quarter local currency sales rose compared to the year-ago quarter. New product launches and higher volumes on existing products more than offset ongoing competitive pricing pressures. With more than 30% market share, our market position remains very strong in France, which drives our performance in Europe.
We also experienced higher year-over-year third quarter local currency sales in Italy, where we benefited from a combination of new product launches, higher generic penetration and the continued favorable effect of regulatory changes. And in Spain, our new product launches offset the impact of government-posed price reduction.
Other markets such as Portugal and Germany experienced lower sales during the third quarter due to government-imposed price reductions and the impact of tender systems, respectively.
Turning now to our Asia Pacific region. We delivered very strong third quarter results. Third-party net sales for $268 million, up 30% over last year's third quarter sales on $206 million. On a constant currency basis, sales rose about 22%. Matrix, Australia and Japan all contributed to the strong results. Matrix continued to deliver strong double-digit growth through API and ARV sales and our ARV portfolio now contains 33 products.
Finally, Dey, our Specialty segment performed well during the third quarter. Third-party net sales rose 6% to $141 million over the same period last year after adjusting last year's third-party sales to account for the fact that in 2010, our Mylan Pharmaceutical division assumes responsibility for selling Dey's generic products. The primary driver of our growth was domestic sales of EpiPen Auto-Injector, which were strong compared to the third quarter of '09. Recall that last October, we launched our next-generation needle-protected auto-injector, which has been received favorably in the U.S. and Canada. In addition, compared to our second quarter, sales benefited from the seasonal return of children to school. Further, we can continue to experience double-digit growth in many markets outside the U.S. as we continue the expansion opportunities for this very important product, mainly through focusing on an underserved population.
Moving on now to synergies. I'm pleased that we remain on track to deliver more than $350 million in cumulative annual benefit by the end of this year. We continue to seek out and capture additional opportunities to further increase our efficiency and leverage our powerful operating platform. Looking ahead to '11, as Robert stated, we will provide formal guidance for the year on our next conference call. 
Nonetheless, it's important to note and to remind you that we continue to see Mylan entering the new year with very strong momentum, especially as we launch more products around the globe than we have ever launched in our company's history. In 2011, we look forward to monetizing or continuing to monetize several opportunities resulting from prior settlements such as Minocycline ER, voriconazole, letrozole and Venlafaxine ER. We see a number of 30-month stay to expiring on other opportunities, some of which are first-to-file. We look forward to introducing oral contraceptives in the U.S., and once again, launching more than a dozen limited competition products. 
Worldwide, we continue to expect to launch approximately 500 products. As important, our pipeline is stronger than ever. We currently have about 15,000 global products initiatives pending approval. 
Before I turn the call over to John, I'd like to step back and make some observations about our company and how far we've come. Earlier this month, we've celebrated the three year anniversary of the union of legacy Mylan, Matrix and Merck. Behind that union was our vision that the world could be served far better if we created a global, vertically integrated and highly disciplined company that could consistently supply any market with high-quality, affordable generic and specialty pharmaceuticals.
Over the past three years, we have focused relentlessly on executing on our vision by integrating vertically, delivering synergies far beyond our expectations and serving customers in more than 140 countries and territories. Those accomplishments alone allowed us to meet or exceed Street [Wall Street] estimates for 13 consecutive quarters. 
But that's not all we've been doing for the last three years. We've also been selling our global network with internally supplied products by applying the same methodology and fundamentals that made our integration so successful. Among the actions we've been taking, optimizing R&D, enhancing our portfolio and management capabilities, repatriating products and filling gaps in our product line, we also have created a biologic strategy and strengthening the promising future of our Specialty business, Dey. And perhaps most important, we have filed approximately 3,000 applications globally by the end of this year. Now, we're ready to reap what we've sown. That is why we're so confident about our growth over the next three years and beyond. 
With that, I'll now turn the call over to John."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good afternoon, everyone. This afternoon, I will begin by walking you through our third quarter 2010 financial results, which, as Heather and Robert have both indicated, were exceptional. I will then provide an update on our capita",1936,"Thank you, Heather, and good afternoon, everyone. This afternoon, I will begin by walking you through our third quarter 2010 financial results, which, as Heather and Robert have both indicated, were exceptional. I will then provide an update on our capital structure and liquidity position.
As Kris mentioned earlier, I'm going to be referring to actual and projected financial metrics that has been prepared on an adjusted basis. These are non-GAAP financial measures. We present these non-GAAP financial measures because they're prepared on the same basis as used by our management and Board of Directors to evaluate the performance of our business. This afternoon's earnings release includes a complete reconciliation from our GAAP to non-GAAP financial measures for our third quarter 2010 and 2009 results. Our earnings release is available on our website, and I encourage you to take a look at it.
Starting at the top of the income statement. Total revenues for the quarter were $1.36 billion, an increase of 7% over last year's third quarter total revenues of $1.26 billion. The effect of foreign currency translation had an unfavorable impact of approximately 2% on our third quarter revenues, reflecting a weaker euro in comparison to the U.S. dollar, partially offset by the strengthening of other currencies, primarily the rupee, the yen and the Australian dollar.
During the third quarter, we launched Minocycline ER. As I discussed with you on last quarter's call, because of significant uncertainties surrounding the pricing and market conditions with respect to Minocycline, we are not able to reasonably estimate the magnitude of potential price adjustments, including product returns, and as a result, have deferred revenue recognition until such uncertainties are resolved. At this time, we considered such uncertainties to be resolved upon the sale by our customers of the product and have recognized revenue accordingly.
Looking at our operating profitability measures, adjusted gross margin for the quarter was approximately 48.4% compared to 46% in the prior year. As expected, this adjusted gross margin is an improvement from that of the first and second quarters and is within our full year guidance range of 47% to 49% and is primarily the result of new product launches in North America and favorable pricing on our Specialty segment, EpiPen Auto-Injector.
Adjusted R&D expense for the quarter was $69 million or approximately 5% of revenues. Also as expected, this level of spending represents an increase over the first half of 2010 and is in line with our revised full year guidance range of 5% to 6% of revenues. Importantly, our R&D projects remained on target, and we are planning for even higher levels of spending in the fourth quarter.
Adjusted SG&A expense was $257 million for the quarter or 19% of revenues, within our full year guidance range of 18% to 20%, and our third quarter adjusted EBITDA was $368 million.
Now let me move to a couple of non-operating financial metrics. Third quarter 2010 adjusted interest expense was $70 million. We continue to forecast adjusted interest expense for the year to be at or near the low end of our guidance range of $280 million to $300 million, which continues to consider the potential for higher short-term interest rates. Our third quarter adjusted effective income tax rate was 26%, which translates into a year-to-date and full year projected adjusted effective income tax rate of 28%, which is at the low end of our forecasted range of 28% to 29%. We do fully anticipate this full year effective tax rate to be sustainable going forward. In summary, third quarter adjusted net income was $189 million or $0.43 per share.
In calculating our adjusted diluted EPS, the impact of assuming the conversion of our preferred shares into 125 million common shares was more dilutive than the $35 million quarterly preferred dividend. Therefore, adjusted diluted EPS for the third quarter is calculated based on an average outstanding diluted share count of approximately 438 million shares.
Touching briefly on the year-to-date results, and again, please refer to our earnings release for a complete reconciliation from our GAAP to our non-GAAP financial measures. For the nine months ended September 30, 2010, total revenues were $4.02 billion, an increase of 8% over adjusted revenues of $3.71 billion in the same prior year period. For the nine months, foreign currency translation had a favorable impact on revenues of approximately 1% due mainly to the strengthening of the rupee, yen, and Australian dollar versus the U.S. dollar, partially offset by a weaker euro.
Adjusted gross margin for the nine months was approximately 46% compared to 47% in the same prior year period. The lower gross margin in the current year is the result of a loss of exclusivity on divalproex during the third quarter of 2009. However, the current year gross margin was negatively impacted by certain inventory charges, principally in Q2. Excluding the impacts of these inventory charges, year-to-date gross margin would have approached 47%. We continue to see full year gross margin at the low end of our 47% to 49% guidance range. 
Adjusted R&D expense was $195 million, and adjusted SG&A expense was $753 million for the current nine-month period. Our adjusted EBITDA for the first nine months of 2010 was $1.03 billion. Adjusted net income was $511 million and adjusted diluted EPS was $1.16 per share.
As in the previous quarter, adjusted diluted EPS was calculated assuming the conversion of our preferred shares into 125 million shares of common stock. On November 15 of this year, our mandatory convertible preferred stock will automatically convert into shares of common stock. The number of convertible shares will be based upon the closing stock price over the 20-day trading period ending on November 12. Based on the current stock price, we expect that approximately 125 million shares will be the conversion amount. 
As mentioned before, we have been including this preferred stock conversion in our forecasted results. As such, the actual conversion will not result in an additional dilution to our guidance amounts. November 15 will also mark the final payment of the preferred stock dividend. 
Depending on the market value of our common stock going forward, our average outstanding diluted share count could increase further due to additional dilution from stock options and other potentially dilutive financial instruments such as our convertible debt obligations and related warrants. We also include such potential dilution in our forecasted results. 
As I mentioned previously, the impact of foreign exchange translation on our results was not significant, and actual foreign currency exchange rates during the period ended September 30, 2010, did not differ materially from those used to calculate our 2010 guidance, which we discussed with you last quarter.
More recently, we have seen the euro strengthened steadily against the U.S. dollar. However, we do not expect currency to have a significant impact on our results for the remainder of the year. This is due to the fact that the currencies of other markets in which we operate are moving in the opposite direction of the euro, and it's also a result of various hedging strategies that we've employed.
We've taken measures in an effort to prevent our results from being impacted significantly by changes in foreign currency exchange rates. In addition to having on our balance sheet euro-denominated long-term debt against which the cash flows of our euro-denominated subsidiaries are offset, we use financial instruments such as forward contracts in order to mitigate this risk. Any favorable or unfavorable variances resulting from foreign exchange for the three- and nine-month period ended September 30, 2010, are included in the adjusted diluted per-share amount of $0.43 and $1.16 per share, respectively.
Turning to our cash flow metrics. Our third quarter GAAP cash flow from operations was nearly $380 million, the highest in our company's history or $360 million excluding certain items. While we don't anticipate fourth quarter cash flow from operations to approach this level, we do continue to project full year operating cash flow in the range of $725 million to $825 million excluding certain one-off items.
Our strong current quarter cash from operations was made possible through positive changes in our working capital, primarily accounts receivable as a result in improved cash collections, including amounts received with respect to Minocycline.
As you may recall, on last quarter's call, I indicated that Q2 cash from operations were negatively impacted by the timing of collection of receivables, for which a substantial amount was received in early July. Q3 cash from operations was also impacted by the timing of collection of receivables, for which a substantial amount was received prior to September 30, 2010. 
Third quarter capital spending was $53 million, including approximately $10 million paid toward the acquisition of a finished dose manufacturing facility in India. Based on the anticipated timing of spending on certain projects, we now project capital spending in the range of $200 million to $250 million for the full year. Our current quarter also include a cash outflow of approximately $544 million with respect to our acquisition of Bioniche Pharma, which is net of any cash acquired. As Heather mentioned, results of Bioniche are included in our current quarter results from September 7.
The Bioniche acquisition was financed through a combination of cash on hand and the proceeds from recent notes offerings. As discussed last quarter, in May, we completed a private placement of $1.25 billion of senior unsecured notes due in 2017 and 2020. In the current quarter, we completed an add-on offering of an additional $300 million of the 2020 notes. These notes were issued at initial price of 105.5% and a coupon of 7 7/8% or an effective yield to maturity of slightly over 7%.
The notes issued in the current quarter's offering, together with the 2020 notes from the May offering, are treated as a single class of notes under the indenture. In addition to funding the Bioniche acquisition, the bond issuances were done in accordance with our objective of extending the maturity profile of our outstanding indebtedness. $1 billion of the net proceeds from the May issuance were used to pay down existing indebtedness under our credit facility. In late September, we used our strong operating cash to repay an additional $300 million of existing indebtedness under our credit facility. As a result of these repayments, we continue to have no meaningful long-term debt maturities until the $600 million due under our convertible notes in the first quarter of 2012, which we currently intend to repay with available cash at that time.
At September 30, 2010, following the additional debt repayment of $300 million, we continue to have unrestricted cash and marketable securities totaling over $640 million.
Continuing on with the capital structure, concerning leverage. As Robert have stated many times, it is our commitment to achieve a long-term leverage ratio of 3:1 or less. We are firmly committed to balancing growth in our business from the continued use of prudent and responsible financing. As such, Mylan remains committed to deleveraging over time to meet this long-term capital structure goal. We continue to expect to generate approximately $4 billion of cumulative operating cash flows by the end of 2013.
From a covenant perspective, the level of our senior secured debt is approximately 1.7x our last 12 months covenant basis adjusted EBITDA, comfortably ahead of our December 31, 2010 threshold of 3.5x. In closing, I'm very pleased with our solid quarterly performance. A great start to what we've been saying will be a strong second half of 2010. 
That concludes my remarks. Lisa, I'll turn the call back over to you to start the Q&A."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from Randall Stanicky with Goldman Sachs.",12,"[Operator Instructions] Our first question comes from Randall Stanicky with Goldman Sachs."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Can you just drill down on the EMEA result and when we can expect a return to growth from that region? And then the follow-up would be maybe, Robert, with the EMEA result in conjunction with the Paxil CR news, can you just talk about some of the offsets t",64,"Can you just drill down on the EMEA result and when we can expect a return to growth from that region? And then the follow-up would be maybe, Robert, with the EMEA result in conjunction with the Paxil CR news, can you just talk about some of the offsets that allow you to remain comfortable as we think about the $2 target for 2011?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Sure, Randall. First, again, there are many, many mitigating factors, and it's difficult, I understand from your perspective, not to be able to evaluate the number of moving variables. But let's start with EMEA. I said that this would be basically almost",634,"Sure, Randall. First, again, there are many, many mitigating factors, and it's difficult, I understand from your perspective, not to be able to evaluate the number of moving variables. But let's start with EMEA. I said that this would be basically almost a two-bucket approach. I've been telling you all along that we continue to see what we've anticipated, what the governments are doing over there in terms of pricing and pushing prices down lower. But we've often said that we felt very comfortable with our position to be able to mitigate that by all the other initiatives that we have in place, including, I'll pull a knot, cost infrastructure that really doesn't fit with the new system, the new wave of direction where Europe is going. Our cost of goods, our repatriation, our bringing in a lot of the third parties back in-house, and of course, our increase in volumes. So that's kind of sort of -- and the races in Europe, Randall, the races, again, what I've always stated, the speed at which governments move and the speed at which we can, through a regulatory process, be able to yield all the benefits that we've been telling you all along. And in terms of the Paxil CR, we are in litigation. It's been a long-standing position of ours, and not to comment when we are on litigation. I tried to give you a signal, obviously, in our opening remarks about how I feel as a whole about that whole situation. We're extremely confident in our position. We think there's a lot more involved in terms of the dealings between GSK and Apotex, and it wasn't just a one-off type of situation. And that's what litigation is all about, and I'm very confident that we'll prevail once we have an opportunity to get inside. In terms of the $2, the last piece of your question, look, all these factors have -- there's nothing really new. There's just nothing new in terms of what we've thought about, what we've been trying to anticipate. And the best way I can explain to you on the $2 on why we're still confident is actually for two reasons. One, Randall, the fundamentals, the long-term fundamentals of the company have not changed at all, at all. Basically, what we're dealing with is the short-term issues that we have to just continue to manage or work our way through. And what I would bring to your attention is go back for the last 13 quarters where we have been trying the same exact question that we're faced with today about visibility in 2011 and beyond. When we were in 2007 roughly at $0.45 and an $0.80 in 2008 and $1.30 in 2009 and roughly a midpoint of $1.60 in 2010, nobody understood how we were going to get there. And what I can tell you, and what we have done already is this management team promised that it would manage. It would manage this new acquired platform for earnings growth. And I can tell you that when we were back at $0.45 and $0.80 and $1.30 and $1.60 in terms of our respective midpoints, when we started out that guidance and where we thought those earnings per share are going to come from and where they actually came from are not always exactly the same. That's just the nature of our business. So I can assure you that when we once again I think we have become at least somewhat predictable to all of you guys. If we tell you that our vision is in the balancing act, what we can see the number of variables versus what you may not be able to see, we are very comfortable that the $2 target in calendar year 2011 is achievable."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","That's irregardless if Paxil CR will come again, just to be clear.",13,"That's irregardless if Paxil CR will come again, just to be clear."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. I mean you have to look at the Paxil CR this way. Take a look at a vein in your body, forgive me. But blood flows through, right one side of the vein to the other. And every once in a while, a vein can blow up in the middle when you have an issue. An",153,"Yes. I mean you have to look at the Paxil CR this way. Take a look at a vein in your body, forgive me. But blood flows through, right one side of the vein to the other. And every once in a while, a vein can blow up in the middle when you have an issue. And what you hope for and so as the vein blows up, the blood's still going to get through the other side. You have this bubble. And I can only tell you that unless we thought, Randall, that somehow Paxil CR was never going to achieve competition ever, ever, ever, then I can say that, that would be an effect on us. In a generic company, one can never project that a generic product forever will be in your product without competition. So obviously, it's a timing issue. And that's why the long-term fundamentals simply haven't changed."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Chris Schott with JPMorgan.",9,"Our next question comes from Chris Schott with JPMorgan."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just another follow-up on EMEA and specifically France. Can you just elaborate a little bit more in the trends you're seeing in that market? I guess specifically, how does some of the recent proposals from the French government that call, for it seem to b",105,"Just another follow-up on EMEA and specifically France. Can you just elaborate a little bit more in the trends you're seeing in that market? I guess specifically, how does some of the recent proposals from the French government that call, for it seem to be a pretty modest 2011 drug cost savings compared to your expectations? And then second question on EMEA. We had obviously the Teva Russia front deal closed this quarter. Just what are your thoughts in terms of the likelihood of further consolidation in the EU market over time? And what implications does that have, that consolidation have for your business?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'll answer the first one and you can talk about France. But in terms of -- I do see more consolidation in Europe. I believe that, that is one market that will go from a seller's market to a buyer's market. That is one region, I believe, that the multiple",217,"I'll answer the first one and you can talk about France. But in terms of -- I do see more consolidation in Europe. I believe that, that is one market that will go from a seller's market to a buyer's market. That is one region, I believe, that the multiples ought to contract. And my rationale is that I think what all of Europe is experiencing is the more regional companies, the more local companies, it's very, very difficult as Europe moves in the direction of some of the other markets around the world to be able to compete if you don't have scale. And without scale, again, that cost competitiveness, they're going to feel it. And I think that some of these mom-and-pop companies, these local companies, these regional companies begin to realize that the writing is on the wall. I think it will force them indirectly towards more activity. And I think as the more activity percolates, I think the supply-demand curve will kick in, and when there's more supply than there is demand, I think that you'll see multiples come down. So I do see more consolidation. I do think it's extremely healthy over in Europe to bring more capacity out of the market, and I do think that scale will prevail. Heather?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And just I guess to elaborate a little more on EMEA. I guess, just a couple of things. One, I'd remind you that Q3 has always been historically lower throughout Europe because of the summer and the holiday, the extended holiday season throughout Europe. S",210,"And just I guess to elaborate a little more on EMEA. I guess, just a couple of things. One, I'd remind you that Q3 has always been historically lower throughout Europe because of the summer and the holiday, the extended holiday season throughout Europe. So we do expect Q4 to see growth back from a revenue perspective. And as far as France and some of the trends, we absolutely what just came out for the 2011 time period we anticipated, and as you note, fairly modest. And to the extent that, like I said, we believe that was right in line with our thinking of where 2011 would be as well as some continuing to look at the whole value chain, not just the generic manufacturers. So as we've seen with other regulations and some of the pricing throughout Europe, Spain, Italy continuing to do the same, not looking at just the generic manufacturers, but kind of the entire supply chain. So that's why I stated the trends, and as I said, the tender markets whether it's Germany and some of the pricing pressure that you see that blimp that of course was attached to this quarter. And like I said, we see that revenue growth coming back in Q4."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is from Rich Silver with Barclays Capital.",10,"Our next question is from Rich Silver with Barclays Capital."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just shifting to the North American business. Can you elaborate to explain the sequential decline in just a little bit more detail on the drivers there and what we can look for going forward?",34,"Just shifting to the North American business. Can you elaborate to explain the sequential decline in just a little bit more detail on the drivers there and what we can look for going forward?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'll start off by saying timing, timing, timing, timing and timing. Heather?",13,"I'll start off by saying timing, timing, timing, timing and timing. Heather?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think obviously, Rich, that's why we say that this business will try to gauge its snapshot quarterly is not representative of the business as a whole. Rob's viewpoint, there's certainly, we've had timing issues of some of our launches. Certainly, we did",124,"I think obviously, Rich, that's why we say that this business will try to gauge its snapshot quarterly is not representative of the business as a whole. Rob's viewpoint, there's certainly, we've had timing issues of some of our launches. Certainly, we did get some more of those limited competition market. In Q3, again we'll  have the benefit of the full value of those products within the next quarter. So really, nothing other than like I said, kind of normal variations like go back and forth through some of our products. And like I said, some of the timing of some of our regulatory launches, but nothing out of the ordinary and nothing that we don't see kind of again coming back in Q4."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Putting aside Paxil CR, kind of all else equal, as what you're saying, if you were providing full year guidance, revenue guidance for North America, it would be unchanged even with the third quarter looking a little weak? And then just one last one, which",80,"Putting aside Paxil CR, kind of all else equal, as what you're saying, if you were providing full year guidance, revenue guidance for North America, it would be unchanged even with the third quarter looking a little weak? And then just one last one, which is a whole paragraph devoted to Minocycline ER, can you give us some sense of the materiality of that product given that you made a point of putting that much base in the press release?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, a couple of things. One, I guess just quickly on North America, and I guess just to point towards, again year-over-year  17% growth out of that business. So again sequentially, timing. I don't want to lose the fact that we've seen nice growth and he",124,"Well, a couple of things. One, I guess just quickly on North America, and I guess just to point towards, again year-over-year  17% growth out of that business. So again sequentially, timing. I don't want to lose the fact that we've seen nice growth and healthy growth in that business year-over-year from Q3 '09 to Q3 this year. And as far as Minocycline, look, I think what we are trying and I'll let John elaborate, but what I'm trying to explain from a revenue recognition perspective, said it was not a blimp like a bolus of the 180 days, and so I think we wanted to go above and beyond and try to make sure people understood exactly how we were treating that product."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Just two points, Rich. I guess number one, yes, I wouldn't be focused on changing our full year revenue guidance for North America if we were providing North American revenue guidance. And I think the way Heather, both Robert and Heather have described No",145,"Just two points, Rich. I guess number one, yes, I wouldn't be focused on changing our full year revenue guidance for North America if we were providing North American revenue guidance. And I think the way Heather, both Robert and Heather have described North America as a timing matter. It's exactly what that is. Number two, with respect to Minocycline, we launched Minocycline in the latter part of July, and we indicated in the second quarter earnings call that we would recognize that revenue on the deferred method and the pull-through method. And therefore, obviously it has an impact, but not nearly as large an impact as it would if we were recognizing it all in the current quarter. The other thing is that if the impact of Minocycline will increase as the amounts of our product there are being consumed by our customers'  increases."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","And our next question comes from John Boris with Citi Investment Research.",12,"And our next question comes from John Boris with Citi Investment Research."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First one just has to do with Janet Woodcock at least indicated that she's hired some additional help to try and clear up the backlog of well in excess of 2000 ANDAs. Any thoughts on progress on cleaning this backlog up? Are you seeing any improvement in",51,"First one just has to do with Janet Woodcock at least indicated that she's hired some additional help to try and clear up the backlog of well in excess of 2000 ANDAs. Any thoughts on progress on cleaning this backlog up? Are you seeing any improvement in timelines on ANDAs?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think from my perspective I see two mitigating factors here. I'm very happy that they actually have maybe gone out to the private sector to -- let's just help them with the queue and develop the right queue for better efficiency in flow of what they nee",184,"I think from my perspective I see two mitigating factors here. I'm very happy that they actually have maybe gone out to the private sector to -- let's just help them with the queue and develop the right queue for better efficiency in flow of what they need to do. But on the other hand, let's not forget that there are comments out there, ""in the year"" of what we've always seen coming and we would support. And that's a tightening of specs. So if you're going to be tightening specs on one hand, I think that further creates a little bit of a backlog only to be offset, I hope, by this outside resource that she's going to bring in from the private sector. So I'm not sure yet how the two are going to offset and whether or not we're going to get more efficiency or whether or not the tighter specs may cause a little bit more. I think it's yet to be seen, but we're very encouraged in terms of the FDA taking the initiative to improve the entire process."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just a follow-on to the tighter specs, she's also hinted that she's somewhat concerned about some of the generic supply that's out there. Can you help maybe elaborate on what she's implying? Are anticipating that there might be some other recalls on the h",45,"Just a follow-on to the tighter specs, she's also hinted that she's somewhat concerned about some of the generic supply that's out there. Can you help maybe elaborate on what she's implying? Are anticipating that there might be some other recalls on the horizon?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, I think one area that certainly we've been pretty vocal about is on the user fee front. And as you know, we have public comments out there and have been working closely with FDA and the industry to really set up a fair level playing field as far as",219,"Well, I think one area that certainly we've been pretty vocal about is on the user fee front. And as you know, we have public comments out there and have been working closely with FDA and the industry to really set up a fair level playing field as far as foreign inspections and this truly global supply chain that the FDA has to be able to support a product that's being sold into the U.S. So she, obviously, in her remarks have been very, very supportive of leveling that playing field and making sure that FDA has the resources they need to do inspections every two years of anyone who's supplying products into the U.S. market. So I think that some of her comments certainly go to the fact that, that heightening attention, the heightening of resources and us being able to put something through that would allow the FDA to accomplish that would certainly benefit not only leveling that playing field, but back to Robert's point, it will also even go towards the backlog and where we see the applications, and I think, could see an improvement in those median times all being connected together, and that's the approach we certainly are taking of advocating and believe that FDA believes that, that would be beneficial on all fronts."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Ronny Gal with Sanford Bernstein.",10,"Our next question comes from Ronny Gal with Sanford Bernstein."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First, a quick one for John. John, if I look at the reconciliation table that you've provided us with, it looks like you are excluding about $125 million and the tax effect offsetting that is about $80 million or 64% of the excluded amount. That looks lik",104,"First, a quick one for John. John, if I look at the reconciliation table that you've provided us with, it looks like you are excluding about $125 million and the tax effect offsetting that is about $80 million or 64% of the excluded amount. That looks like a very high tax rate on the excluded amount. If you can give us a clue about that. And still on the issue of integration, was there about $32 million this quarter for acquisition and integration charges? Can you help us understand how that will trail off over the next year if there are no additional acquisitions?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","On the first item, with respect to the taxes, remember that what we're doing with the tax reconciliation is not just in the tax adjustment, it's not just simply the tax affect of the reconciling items, but it is also to adjust the tax rate to the 28% full",81,"On the first item, with respect to the taxes, remember that what we're doing with the tax reconciliation is not just in the tax adjustment, it's not just simply the tax affect of the reconciling items, but it is also to adjust the tax rate to the 28% full year effective rate, so to the extent that there are, let me say, one-time or unusual items within taxes, the tax expense or tax benefit, we also have to adjust those out."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And as far as your integration point, obviously, we've seen that come down tremendously year-over-year as we've gotten further into this integration. So yes, we continue to see that trailing off.",31,"And as far as your integration point, obviously, we've seen that come down tremendously year-over-year as we've gotten further into this integration. So yes, we continue to see that trailing off."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Follow-up on the Dey business. Some of your competitors have been talking about the opportunity in the respiratory area over the next few years, and you obviously have a respiratory platform. How do you think about this platform? If you can give us some v",70,"Follow-up on the Dey business. Some of your competitors have been talking about the opportunity in the respiratory area over the next few years, and you obviously have a respiratory platform. How do you think about this platform? If you can give us some view about what you're developing internally and what you might be interested in bringing from the outside to put on top of that sales force?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. Absolutely, we have said this is an extremely an important niche in the Specialty business, not only, obviously, how we marry up to that, but just I think in the United States overall, it's a very important niche area that we've seen a ton of growth",170,"Yes. Absolutely, we have said this is an extremely an important niche in the Specialty business, not only, obviously, how we marry up to that, but just I think in the United States overall, it's a very important niche area that we've seen a ton of growth as an industry. And I think we have a lot of opportunity. As Robert's talked about looking for complementary products to be able to put into the infrastructure that we already have and the doctors that we're already calling on as well as our own internal R&D pipeline on the COPD front with combo and of course our current performance. So that infrastructure, and I think that allergy marrying up again to EpiPen and what we've talked about being this underserved market is again that education around market expansion and how we continue to see an awareness, of building an awareness and that again continuing to expand that market for us both on the respiratory, from respiratory docs as well as the allergists."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Greg Gilbert with Bank of America Merrill Lynch.",13,"Our next question comes from Greg Gilbert with Bank of America Merrill Lynch."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","A couple for Heather and one for Robert. Heather, first, can you clarify what you meant about growth in EMEA in 4Q? Or are you saying you expect growth over the 4Q of '09 level of $482 million?",38,"A couple for Heather and one for Robert. Heather, first, can you clarify what you meant about growth in EMEA in 4Q? Or are you saying you expect growth over the 4Q of '09 level of $482 million?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, I was just saying both, that one obviously Q3 has historically been lower. So last year, Q3 was [indiscernible] than Q4. This year, we're anticipating growth both over Q3 as well as over Q4 of '09.",37,"Yes, I was just saying both, that one obviously Q3 has historically been lower. So last year, Q3 was [indiscernible] than Q4. This year, we're anticipating growth both over Q3 as well as over Q4 of '09."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And that would be mostly driven by new launches? Or is that other sort of organic drivers that would result in growth after a couple of quarters of decline?",29,"And that would be mostly driven by new launches? Or is that other sort of organic drivers that would result in growth after a couple of quarters of decline?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","A couple of things. We've got a lot of product launches this quarter as well as the benefit of a full quarter of some of the launches we've had throughout the year.",32,"A couple of things. We've got a lot of product launches this quarter as well as the benefit of a full quarter of some of the launches we've had throughout the year."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And then my other Europe question is whether or not you're seeing signs in Europe as governments understand the importance of making generic substitution happen or are they still just focused on finding short-term savings?",36,"And then my other Europe question is whether or not you're seeing signs in Europe as governments understand the importance of making generic substitution happen or are they still just focused on finding short-term savings?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","No, I've got a glimmer of hope that they are saying that the sustainability of utilization, that penetration is much more effective than a one-off price cut. I think we're starting to see that in Italy and Spain, as well as France. France, obviously, to m",167,"No, I've got a glimmer of hope that they are saying that the sustainability of utilization, that penetration is much more effective than a one-off price cut. I think we're starting to see that in Italy and Spain, as well as France. France, obviously, to me, is kind of the most mature in that Southern European region. And I see Italy and Spain kind of starting to follow a suit as far as some incentives and increasing. And we've seen an increase in penetration on both of those markets. And look, I can assure you, will not stop our efforts of being out there educating and showing the sustainability of generic penetration versus just, like I said, the price cuts. And I think the other point to note here is the responsibility that we have seen and demonstrate between looking at the entire supply chain and not just the generic manufacturer, whether it's from the pharmacy perspective, the brand arena. So it's balancing both of those fronts."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Mark Goodman with UBS.",9,"Our next question comes from Mark Goodman with UBS."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I just want to make sure I'm clear on this EMEA following on the last question. So we're going to have growth versus last year. Can you talk about what countries are going to be the key areas where you're talking about these new product launches? Is it Fr",121,"I just want to make sure I'm clear on this EMEA following on the last question. So we're going to have growth versus last year. Can you talk about what countries are going to be the key areas where you're talking about these new product launches? Is it France? Is Germany going to come back? Second question is maybe you can give us a sense of what happened in the quarter in Asia, just Australia versus Japan versus India? Just so we have a little more flavor there. Then the third question is just talk about EpiPen in the quarter. Was there growth year-over-year in EpiPen? It seemed a little weaker than what I thought it was going to be."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Okay, so I'll start backwards so I don't forget anything. Yes, we saw, we definitely saw growth in EpiPen, both in volume as well as we had pricing in the year, but we certainly have seen some market expansion seeing the -- we saw the peak start a little",196,"Okay, so I'll start backwards so I don't forget anything. Yes, we saw, we definitely saw growth in EpiPen, both in volume as well as we had pricing in the year, but we certainly have seen some market expansion seeing the -- we saw the peak start a little earlier and last a little bit longer in the seasonality of the product. So we continue, as I said, to see our efforts around awareness to continue to help in that expansion. As far as Europe's concerned, obviously, as we continue to say, France is certainly the driver for us across the European region. As I noted this quarter,our  sales were up year-over-year for France as well as Italy and Spain, and we continue to see those being contributors as well in this growth for Q4 both year-over-year and sequentially. As far as APAC is concerned, Matrix, while we don't break out the individual divisions within a segment, we have continued and will continue to at least give what the leaders are and Matrix has led that with double-digit growth from the APAC region, but we did have contribution both from Australia as well as Japan year-over-year."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is from Elliot Wilbur with Needham & Company.",10,"Our next question is from Elliot Wilbur with Needham & Company."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First question, I just want to drill down a little bit more on the strong gross margin performance thinking about it sequentially up about 300 basis points. It doesn't really look like it's a mix issue given that North America and Specialty were relativel",78,"First question, I just want to drill down a little bit more on the strong gross margin performance thinking about it sequentially up about 300 basis points. It doesn't really look like it's a mix issue given that North America and Specialty were relatively the same percentage of sales. Also, so it's not really a volume issue. So is it fair to say that the bulk, if not the entire degree of improvement sequentially, is attributable to synergies?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. Look, I'd say certainly, as we forecasted and anticipated, synergy realization was going to be stronger in the second half of the year, but I wouldn't lose total sight on mix. We had important approvals of higher margin products as limited competitio",84,"Yes. Look, I'd say certainly, as we forecasted and anticipated, synergy realization was going to be stronger in the second half of the year, but I wouldn't lose total sight on mix. We had important approvals of higher margin products as limited competition, like in clonidine, like in Minocycline and Tacrolimus so there is still -- you do have mix issues, which is why you have to look at the annual, the overall gross margin and the guidance, obviously, that we have out there."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I have a good question for John as well. With respect to the company's current capital structure and the duration of the debt obligations, sort of understand that you have quite a bit of financial flexibility through your first bolus payment in 2012 in li",159,"I have a good question for John as well. With respect to the company's current capital structure and the duration of the debt obligations, sort of understand that you have quite a bit of financial flexibility through your first bolus payment in 2012 in lieu of $700 million in total. But if you look out to 2014, there's roughly $2 billion bullet that's due, and that just happens to coincide with I guess sort of a large systemic increase in overall debt obligations coming due in the U.S. And given the likelihood that there's going to be a lot of folks looking to refinance debt and also the fact that tremendous rates probably are going to be a lot higher than where they are now, just sort of how should we be thinking about maybe potential addition what it means on your part to maybe flatten out the maturity ladder or even extend it further, which you've already done?"
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I would say this. If you go back eight months ago, seven months ago, we had over $3 billion of maturity in 2014. And over the course of this year, we've reduced that by $1.3 billion. So we have flattened out the 2014 maturity significantly. We will contin",172,"I would say this. If you go back eight months ago, seven months ago, we had over $3 billion of maturity in 2014. And over the course of this year, we've reduced that by $1.3 billion. So we have flattened out the 2014 maturity significantly. We will continue to look to extend the maturity profile at appropriate points in time. We'll use our strong positive cash flow to continue to reduce the amount of the 2014 as we did here in the third quarter by repaying $300 million. So I actually feel really good about where we stand in the capital structure. Our free cash flow is over $500 million a year with the final preferred dividend that we're making here in the fourth quarter. That will increase our free cash flow by $139 million a year. So I see us with a lot of cash. Robert has talked about the fact that we're not looking to make another strategic acquisition. We're fully committed to reducing our leverage to 3:1 or lower."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Let me just add something. First of all, you may not have caught it, but we did prepay $300 million. So we're actually at $1.7 billion now from the $3 billion or the $2 billion in which you've mentioned, Elliot. So you can see, and as a matter fact, when",179,"Let me just add something. First of all, you may not have caught it, but we did prepay $300 million. So we're actually at $1.7 billion now from the $3 billion or the $2 billion in which you've mentioned, Elliot. So you can see, and as a matter fact, when we first prepaid the $1 billion, I think we said at the time we felt fairly comfortable at that time that we would generate enough operating cash flow actually to retire the debt itself. So taking the need for this organization to have to tap the market was exactly what we intended not to put ourselves in. So I feel very comfortable that we will continue to generate very strong free cash flows with the continued commitment to delever, but I will say at  the same time I'm saying that, I wouldn't hesitate in a second to further extend those maturities if the opportunity arises and interest rates continue to be as advantageous as they are and simply give ourselves even more flexibility than what we've already provided ourselves."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","And our final question comes from John Newman with Oppenheimer.",10,"And our final question comes from John Newman with Oppenheimer."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I just wanted to ask a clarifying question on EMEA. It looks like the revenues for EMEA last fourth quarter pretty robust, and I think I recall you saying that you were expecting both a quarter-over-quarter increase from 4Q this year versus current quarte",96,"I just wanted to ask a clarifying question on EMEA. It looks like the revenues for EMEA last fourth quarter pretty robust, and I think I recall you saying that you were expecting both a quarter-over-quarter increase from 4Q this year versus current quarter and also last year. So just wondering, Tom, is there something specific that is going to give you a pretty significant push? Because it seems like an increase over third quarter this year seems totally reasonable, but fourth quarter last year seems like maybe a little kind of a challenging comp there."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","All I can say is as we continue to stress the strength of our pipeline and launches not just third-party launches, but now our internal launches starting to roll in, that's really, like I said, the driver not only of just launches we're doing in Q4 but lu",112,"All I can say is as we continue to stress the strength of our pipeline and launches not just third-party launches, but now our internal launches starting to roll in, that's really, like I said, the driver not only of just launches we're doing in Q4 but lunches we've now done throughout the year that we're getting, reaping the full benefit by the time it hits Q4. So it just continues to be the product launches and what we're able to do with those launches throughout all of the country. And again, Q4 being, if you go back the year before, Q4 has been a very robust year throughout Europe historically."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","This concludes today's question-and-answer session. At this time, I'd like to turn the conference back over to our speakers for any additional comments or closing remarks.",27,"This concludes today's question-and-answer session. At this time, I'd like to turn the conference back over to our speakers for any additional comments or closing remarks."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I just like to thank everybody for their participation today, and at this point, Lisa, you can close out the call.",21,"I just like to thank everybody for their participation today, and at this point, Lisa, you can close out the call."
290203,114621935,81947,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","This does conclude today's conference call. Thank you for your participation.",12,"This does conclude today's conference call. Thank you for your participation."
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Good day, and welcome to the Mylan, Inc. Third Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King, Vice President of Global Investor Relations. Please go ahead.",40,"Good day, and welcome to the Mylan, Inc. Third Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King, Vice President of Global Investor Relations. Please go ahead.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Lisa. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; and Executive Vice Pre",361,"Thank you, Lisa. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; and Executive Vice President and Chief Operating Officer, Rajiv Malik.
During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our annual report on Form 10-K for the year ended December 31, 2009, and in our other SEC filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov, and we strongly encourage you to do so. 
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP measures. It should be noted that non-GAAP financial measures such as adjusted revenues, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website as it contains detailed GAAP to non-GAAP reconciliations of our actual 2010 and 2009 third quarter results, including the allocation of each reconciled line item to specific income statement line items. 
Before I turn the call over to Robert, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission. 
With that, I'll now turn the call over to Robert.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris. Welcome, everyone and thank you for taking the time to join us this afternoon. I would also like to welcome all of the Mylan employees on the call today, especially those from Bioniche Pharma, who are listening as the new members of the M",530,"Thank you, Kris. Welcome, everyone and thank you for taking the time to join us this afternoon. I would also like to welcome all of the Mylan employees on the call today, especially those from Bioniche Pharma, who are listening as the new members of the Mylan family. On behalf of the Board of Directors and our leadership team, I'd like to thank each and everyone of you for your continued hard work, dedication and outstanding performance.
I am extremely pleased to report to you yet another strong quarter performance of exceptional earnings. As I mentioned on the last conference call, I did anticipate the third quarter to be better than the second quarter, and I am extremely pleased to report adjusted diluted earnings per share of $0.43, a 16% increase from our second quarter results. With that said, I still expect at this time that the fourth quarter will come in slightly better than the third quarter.
We maintain this position even with the most recent ruling related to our Paroxetine CR. While we are extremely disappointed with the lower court's ruling, we believe strongly that the lower court has erred in its decision not to grant us an injunction, and we have appealed that decision. It should also be noted that this is still just a ruling on an injunction. It is not a final decision resolving Mylan's rights on this matter. Regardless of the outcome of the appellant court decision on the injunction, we will continue our litigation to enforce our contractual rights and all of its negotiated provisions with GSK.
With that said, and irrespective of this short-term distraction, the longer-term fundamentals of our business have not changed, which is why we remain committed to our stated targets of $2 of adjusted diluted earnings per share for calendar year 2011 and our longer-term growth targets of 15% top line and 20% bottom line CAGR by the end of 2013. We very much look forward to providing you a detailed breakdown of our 2011 guidance on our next conference call.
Moving on to other activity in the quarter. You will recall that we issued $300 million in follow-on 10-year bonds to finance the acquisition of Bioniche Pharma. In addition, we are also able to use part of the strong operating cash flows that we continue to generate to prepay $300 million in term loan borrowings in the third quarter as well, further reducing our leverage and staying committed to our stated objective to achieve a 3:1 debt-to-adjusted-EBITDA leverage ratio. 
And finally, you may remember that on November 15 of this year, our mandatory convertible preferred stock will automatically convert to common stock. Given the recent growth and strength of our stock price performance, we anticipate issuing the lowest number of shares required under the terms of the preferred stock agreement, which is approximately 125 million shares. A further note, November 15 will also mark the final payment of the preferred stock dividend, thereby substantially enhancing our future free cash flows to the company by $139 million per year.
I look forward to answering your questions, and I'd now like to turn the call over to Heather Bresch.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert, and good afternoon, everyone. As Robert said, we are very pleased with our strong third quarter performance and a great start to our expected strong second half of 2010. We remain highly confident in our ability to deliver 2010 results",1328,"Thank you, Robert, and good afternoon, everyone. As Robert said, we are very pleased with our strong third quarter performance and a great start to our expected strong second half of 2010. We remain highly confident in our ability to deliver 2010 results in line with the guidance we have reaffirmed today. We also continue to be extremely confident about our growth prospects for '11 and beyond. I too would like to commend our employees around the world for making our continued exceptional performance possible.
During my remarks today, I'll review our performance by segment, provide an update on synergies and comment on why we remain so confident about our future. I'd now like to walk you through the performance of our commercial operations. During the third quarter, we generated total revenues of $1.36 billion, an increase of 7% compared to last year's third quarter total revenues of $1.26 billion. On a constant currency basis, revenues were up approximately 9% year-over-year, and on the bottom line, we generated $0.43 of adjusted EPS, a 34% increase over last year's third quarter result of $0.32.
We also delivered a strong adjusted gross margin of 48.4% during the  third quarter, up from our second quarter performance of 45% and right in line with our full year expected range of 47% to 49%. As expected, driving the strong performance were recent approvals on higher margin, limited competition products, higher sales in our Specialty segment and continued synergy realization.
Within our Generics segment, our North American operations delivered third-party net sales for the third quarter of $573 million, up 17% from last year's third quarter result of $488 million. The increase was mainly the result of new product launches in the United States. Among those launches were limited competition products, Minocycline ER, Clonidine Transdermal and Tacrolimus, bringing to ten the dozen such products we anticipate launching by year end, and we remain on track to achieve our full year target of 50 to 60 launches in the U.S.
Our third quarter also includes results from Bioniche, a Specialty Injectables business we acquired on September 7. The integration has been seamless so far, and on October 4, we announced our first approval from the FDA for our Bioniche product, Fludarabine, an injectable chemotherapy medication for leukemia. Our ANDA filings now include those of Bioniche Pharma. Currently, we have 153 ANDAs pending FDA approval, representing about $95 billion in annual brand sales. 45 of these pending ANDAs are potential first-to-file opportunities, representing more than $24 billion in annual branded sales. 
In EMEA, third-party net sales of $364 million, 12% versus last year's third quarter third-party sales of $414 million. However, on a constant currency basis, operational performance in EMEA declined only 3% year-over-year while year-to-date, sales have risen almost 2%. That result was driven by unfavorable pricing throughout Europe, which was partially offset by new product launches in several markets. 
Looking forward, we continue to see our ability to even further offset negative trends in the region, thanks to the sheer number of internal products we expect to launch in 2011 and beyond. In addition, we continue to repatriate finished dosage forms, which will continue to add to our competitive position throughout Europe. 
In France, third quarter local currency sales rose compared to the year-ago quarter. New product launches and higher volumes on existing products more than offset ongoing competitive pricing pressures. With more than 30% market share, our market position remains very strong in France, which drives our performance in Europe.
We also experienced higher year-over-year third quarter local currency sales in Italy, where we benefited from a combination of new product launches, higher generic penetration and the continued favorable effect of regulatory changes. And in Spain, our new product launches offset the impact of government-posed price reduction.
Other markets such as Portugal and Germany experienced lower sales during the third quarter due to government-imposed price reductions and the impact of tender systems, respectively.
Turning now to our Asia Pacific region. We delivered very strong third quarter results. Third-party net sales for $268 million, up 30% over last year's third quarter sales on $206 million. On a constant currency basis, sales rose about 22%. Matrix, Australia and Japan all contributed to the strong results. Matrix continued to deliver strong double-digit growth through API and ARV sales and our ARV portfolio now contains 33 products.
Finally, Dey, our Specialty segment performed well during the third quarter. Third-party net sales rose 6% to $141 million over the same period last year after adjusting last year's third-party sales to account for the fact that in 2010, our Mylan Pharmaceutical division assumes responsibility for selling Dey's generic products. The primary driver of our growth was domestic sales of EpiPen Auto-Injector, which were strong compared to the third quarter of '09. Recall that last October, we launched our next-generation needle-protected auto-injector, which has been received favorably in the U.S. and Canada. In addition, compared to our second quarter, sales benefited from the seasonal return of children to school. Further, we can continue to experience double-digit growth in many markets outside the U.S. as we continue the expansion opportunities for this very important product, mainly through focusing on an underserved population.
Moving on now to synergies. I'm pleased that we remain on track to deliver more than $350 million in cumulative annual benefit by the end of this year. We continue to seek out and capture additional opportunities to further increase our efficiency and leverage our powerful operating platform. Looking ahead to '11, as Robert stated, we will provide formal guidance for the year on our next conference call. 
Nonetheless, it's important to note and to remind you that we continue to see Mylan entering the new year with very strong momentum, especially as we launch more products around the globe than we have ever launched in our company's history. In 2011, we look forward to monetizing or continuing to monetize several opportunities resulting from prior settlements such as Minocycline ER, voriconazole, letrozole and Venlafaxine ER. We see a number of 30-month stay to expiring on other opportunities, some of which are first-to-file. We look forward to introducing oral contraceptives in the U.S., and once again, launching more than a dozen limited competition products. 
Worldwide, we continue to expect to launch approximately 500 products. As important, our pipeline is stronger than ever. We currently have about 15,000 global products initiatives pending approval. 
Before I turn the call over to John, I'd like to step back and make some observations about our company and how far we've come. Earlier this month, we've celebrated the three year anniversary of the union of legacy Mylan, Matrix and Merck. Behind that union was our vision that the world could be served far better if we created a global, vertically integrated and highly disciplined company that could consistently supply any market with high-quality, affordable generic and specialty pharmaceuticals.
Over the past three years, we have focused relentlessly on executing on our vision by integrating vertically, delivering synergies far beyond our expectations and serving customers in more than 140 countries and territories. Those accomplishments alone allowed us to meet or exceed Street [Wall Street] estimates for 13 consecutive quarters. 
But that's not all we've been doing for the last three years. We've also been selling our global network with internally supplied products by applying the same methodology and fundamentals that made our integration so successful. Among the actions we've been taking, optimizing R&D, enhancing our portfolio and management capabilities, repatriating products and filling gaps in our product line, we also have created a biologic strategy and strengthening the promising future of our Specialty business, Dey. And perhaps most important, we have filed approximately 3,000 applications globally by the end of this year. Now, we're ready to reap what we've sown. That is why we're so confident about our growth over the next three years and beyond. 
With that, I'll now turn the call over to John.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good afternoon, everyone. This afternoon, I will begin by walking you through our third quarter 2010 financial results, which, as Heather and Robert have both indicated, were exceptional. I will then provide an update on our capita",1936,"Thank you, Heather, and good afternoon, everyone. This afternoon, I will begin by walking you through our third quarter 2010 financial results, which, as Heather and Robert have both indicated, were exceptional. I will then provide an update on our capital structure and liquidity position.
As Kris mentioned earlier, I'm going to be referring to actual and projected financial metrics that has been prepared on an adjusted basis. These are non-GAAP financial measures. We present these non-GAAP financial measures because they're prepared on the same basis as used by our management and Board of Directors to evaluate the performance of our business. This afternoon's earnings release includes a complete reconciliation from our GAAP to non-GAAP financial measures for our third quarter 2010 and 2009 results. Our earnings release is available on our website, and I encourage you to take a look at it.
Starting at the top of the income statement. Total revenues for the quarter were $1.36 billion, an increase of 7% over last year's third quarter total revenues of $1.26 billion. The effect of foreign currency translation had an unfavorable impact of approximately 2% on our third quarter revenues, reflecting a weaker euro in comparison to the U.S. dollar, partially offset by the strengthening of other currencies, primarily the rupee, the yen and the Australian dollar.
During the third quarter, we launched Minocycline ER. As I discussed with you on last quarter's call, because of significant uncertainties surrounding the pricing and market conditions with respect to Minocycline, we are not able to reasonably estimate the magnitude of potential price adjustments, including product returns, and as a result, have deferred revenue recognition until such uncertainties are resolved. At this time, we considered such uncertainties to be resolved upon the sale by our customers of the product and have recognized revenue accordingly.
Looking at our operating profitability measures, adjusted gross margin for the quarter was approximately 48.4% compared to 46% in the prior year. As expected, this adjusted gross margin is an improvement from that of the first and second quarters and is within our full year guidance range of 47% to 49% and is primarily the result of new product launches in North America and favorable pricing on our Specialty segment, EpiPen Auto-Injector.
Adjusted R&D expense for the quarter was $69 million or approximately 5% of revenues. Also as expected, this level of spending represents an increase over the first half of 2010 and is in line with our revised full year guidance range of 5% to 6% of revenues. Importantly, our R&D projects remained on target, and we are planning for even higher levels of spending in the fourth quarter.
Adjusted SG&A expense was $257 million for the quarter or 19% of revenues, within our full year guidance range of 18% to 20%, and our third quarter adjusted EBITDA was $368 million.
Now let me move to a couple of non-operating financial metrics. Third quarter 2010 adjusted interest expense was $70 million. We continue to forecast adjusted interest expense for the year to be at or near the low end of our guidance range of $280 million to $300 million, which continues to consider the potential for higher short-term interest rates. Our third quarter adjusted effective income tax rate was 26%, which translates into a year-to-date and full year projected adjusted effective income tax rate of 28%, which is at the low end of our forecasted range of 28% to 29%. We do fully anticipate this full year effective tax rate to be sustainable going forward. In summary, third quarter adjusted net income was $189 million or $0.43 per share.
In calculating our adjusted diluted EPS, the impact of assuming the conversion of our preferred shares into 125 million common shares was more dilutive than the $35 million quarterly preferred dividend. Therefore, adjusted diluted EPS for the third quarter is calculated based on an average outstanding diluted share count of approximately 438 million shares.
Touching briefly on the year-to-date results, and again, please refer to our earnings release for a complete reconciliation from our GAAP to our non-GAAP financial measures. For the nine months ended September 30, 2010, total revenues were $4.02 billion, an increase of 8% over adjusted revenues of $3.71 billion in the same prior year period. For the nine months, foreign currency translation had a favorable impact on revenues of approximately 1% due mainly to the strengthening of the rupee, yen, and Australian dollar versus the U.S. dollar, partially offset by a weaker euro.
Adjusted gross margin for the nine months was approximately 46% compared to 47% in the same prior year period. The lower gross margin in the current year is the result of a loss of exclusivity on divalproex during the third quarter of 2009. However, the current year gross margin was negatively impacted by certain inventory charges, principally in Q2. Excluding the impacts of these inventory charges, year-to-date gross margin would have approached 47%. We continue to see full year gross margin at the low end of our 47% to 49% guidance range. 
Adjusted R&D expense was $195 million, and adjusted SG&A expense was $753 million for the current nine-month period. Our adjusted EBITDA for the first nine months of 2010 was $1.03 billion. Adjusted net income was $511 million and adjusted diluted EPS was $1.16 per share.
As in the previous quarter, adjusted diluted EPS was calculated assuming the conversion of our preferred shares into 125 million shares of common stock. On November 15 of this year, our mandatory convertible preferred stock will automatically convert into shares of common stock. The number of convertible shares will be based upon the closing stock price over the 20-day trading period ending on November 12. Based on the current stock price, we expect that approximately 125 million shares will be the conversion amount. 
As mentioned before, we have been including this preferred stock conversion in our forecasted results. As such, the actual conversion will not result in an additional dilution to our guidance amounts. November 15 will also mark the final payment of the preferred stock dividend. 
Depending on the market value of our common stock going forward, our average outstanding diluted share count could increase further due to additional dilution from stock options and other potentially dilutive financial instruments such as our convertible debt obligations and related warrants. We also include such potential dilution in our forecasted results. 
As I mentioned previously, the impact of foreign exchange translation on our results was not significant, and actual foreign currency exchange rates during the period ended September 30, 2010, did not differ materially from those used to calculate our 2010 guidance, which we discussed with you last quarter.
More recently, we have seen the euro strengthened steadily against the U.S. dollar. However, we do not expect currency to have a significant impact on our results for the remainder of the year. This is due to the fact that the currencies of other markets in which we operate are moving in the opposite direction of the euro, and it's also a result of various hedging strategies that we've employed.
We've taken measures in an effort to prevent our results from being impacted significantly by changes in foreign currency exchange rates. In addition to having on our balance sheet euro-denominated long-term debt against which the cash flows of our euro-denominated subsidiaries are offset, we use financial instruments such as forward contracts in order to mitigate this risk. Any favorable or unfavorable variances resulting from foreign exchange for the three- and nine-month period ended September 30, 2010, are included in the adjusted diluted per-share amount of $0.43 and $1.16 per share, respectively.
Turning to our cash flow metrics. Our third quarter GAAP cash flow from operations was nearly $380 million, the highest in our company's history or $360 million excluding certain items. While we don't anticipate fourth quarter cash flow from operations to approach this level, we do continue to project full year operating cash flow in the range of $725 million to $825 million excluding certain one-off items.
Our strong current quarter cash from operations was made possible through positive changes in our working capital, primarily accounts receivable as a result in improved cash collections, including amounts received with respect to Minocycline.
As you may recall, on last quarter's call, I indicated that Q2 cash from operations were negatively impacted by the timing of collection of receivables, for which a substantial amount was received in early July. Q3 cash from operations was also impacted by the timing of collection of receivables, for which a substantial amount was received prior to September 30, 2010. 
Third quarter capital spending was $53 million, including approximately $10 million paid toward the acquisition of a finished dose manufacturing facility in India. Based on the anticipated timing of spending on certain projects, we now project capital spending in the range of $200 million to $250 million for the full year. Our current quarter also include a cash outflow of approximately $544 million with respect to our acquisition of Bioniche Pharma, which is net of any cash acquired. As Heather mentioned, results of Bioniche are included in our current quarter results from September 7.
The Bioniche acquisition was financed through a combination of cash on hand and the proceeds from recent notes offerings. As discussed last quarter, in May, we completed a private placement of $1.25 billion of senior unsecured notes due in 2017 and 2020. In the current quarter, we completed an add-on offering of an additional $300 million of the 2020 notes. These notes were issued at initial price of 105.5% and a coupon of 7 7/8% or an effective yield to maturity of slightly over 7%.
The notes issued in the current quarter's offering, together with the 2020 notes from the May offering, are treated as a single class of notes under the indenture. In addition to funding the Bioniche acquisition, the bond issuances were done in accordance with our objective of extending the maturity profile of our outstanding indebtedness. $1 billion of the net proceeds from the May issuance were used to pay down existing indebtedness under our credit facility. In late September, we used our strong operating cash to repay an additional $300 million of existing indebtedness under our credit facility. As a result of these repayments, we continue to have no meaningful long-term debt maturities until the $600 million due under our convertible notes in the first quarter of 2012, which we currently intend to repay with available cash at that time.
At September 30, 2010, following the additional debt repayment of $300 million, we continue to have unrestricted cash and marketable securities totaling over $640 million.
Continuing on with the capital structure, concerning leverage. As Robert have stated many times, it is our commitment to achieve a long-term leverage ratio of 3:1 or less. We are firmly committed to balancing growth in our business from the continued use of prudent and responsible financing. As such, Mylan remains committed to deleveraging over time to meet this long-term capital structure goal. We continue to expect to generate approximately $4 billion of cumulative operating cash flows by the end of 2013.
From a covenant perspective, the level of our senior secured debt is approximately 1.7x our last 12 months covenant basis adjusted EBITDA, comfortably ahead of our December 31, 2010 threshold of 3.5x. In closing, I'm very pleased with our solid quarterly performance. A great start to what we've been saying will be a strong second half of 2010. 
That concludes my remarks. Lisa, I'll turn the call back over to you to start the Q&A.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from Randall Stanicky with Goldman Sachs.",12,"[Operator Instructions] Our first question comes from Randall Stanicky with Goldman Sachs.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Can you just drill down on the EMEA result and when we can expect a return to growth from that region? And then the follow-up would be maybe, Robert, with the EMEA result in conjunction with the Paxil CR news, can you just talk about some of the offsets t",64,"Can you just drill down on the EMEA result and when we can expect a return to growth from that region? And then the follow-up would be maybe, Robert, with the EMEA result in conjunction with the Paxil CR news, can you just talk about some of the offsets that allow you to remain comfortable as we think about the $2 target for 2011?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Sure, Randall. First, again, there are many, many mitigating factors, and it's difficult, I understand from your perspective, not to be able to evaluate the number of moving variables. But let's start with EMEA. I said that this would be basically almost",634,"Sure, Randall. First, again, there are many, many mitigating factors, and it's difficult, I understand from your perspective, not to be able to evaluate the number of moving variables. But let's start with EMEA. I said that this would be basically almost a two-bucket approach. I've been telling you all along that we continue to see what we've anticipated, what the governments are doing over there in terms of pricing and pushing prices down lower. But we've often said that we felt very comfortable with our position to be able to mitigate that by all the other initiatives that we have in place, including, I'll pull a knot, cost infrastructure that really doesn't fit with the new system, the new wave of direction where Europe is going. Our cost of goods, our repatriation, our bringing in a lot of the third parties back in-house, and of course, our increase in volumes. So that's kind of sort of -- and the races in Europe, Randall, the races, again, what I've always stated, the speed at which governments move and the speed at which we can, through a regulatory process, be able to yield all the benefits that we've been telling you all along. And in terms of the Paxil CR, we are in litigation. It's been a long-standing position of ours, and not to comment when we are on litigation. I tried to give you a signal, obviously, in our opening remarks about how I feel as a whole about that whole situation. We're extremely confident in our position. We think there's a lot more involved in terms of the dealings between GSK and Apotex, and it wasn't just a one-off type of situation. And that's what litigation is all about, and I'm very confident that we'll prevail once we have an opportunity to get inside. In terms of the $2, the last piece of your question, look, all these factors have -- there's nothing really new. There's just nothing new in terms of what we've thought about, what we've been trying to anticipate. And the best way I can explain to you on the $2 on why we're still confident is actually for two reasons. One, Randall, the fundamentals, the long-term fundamentals of the company have not changed at all, at all. Basically, what we're dealing with is the short-term issues that we have to just continue to manage or work our way through. And what I would bring to your attention is go back for the last 13 quarters where we have been trying the same exact question that we're faced with today about visibility in 2011 and beyond. When we were in 2007 roughly at $0.45 and an $0.80 in 2008 and $1.30 in 2009 and roughly a midpoint of $1.60 in 2010, nobody understood how we were going to get there. And what I can tell you, and what we have done already is this management team promised that it would manage. It would manage this new acquired platform for earnings growth. And I can tell you that when we were back at $0.45 and $0.80 and $1.30 and $1.60 in terms of our respective midpoints, when we started out that guidance and where we thought those earnings per share are going to come from and where they actually came from are not always exactly the same. That's just the nature of our business. So I can assure you that when we once again I think we have become at least somewhat predictable to all of you guys. If we tell you that our vision is in the balancing act, what we can see the number of variables versus what you may not be able to see, we are very comfortable that the $2 target in calendar year 2011 is achievable.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","That's irregardless if Paxil CR will come again, just to be clear.",13,"That's irregardless if Paxil CR will come again, just to be clear.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. I mean you have to look at the Paxil CR this way. Take a look at a vein in your body, forgive me. But blood flows through, right one side of the vein to the other. And every once in a while, a vein can blow up in the middle when you have an issue. An",153,"Yes. I mean you have to look at the Paxil CR this way. Take a look at a vein in your body, forgive me. But blood flows through, right one side of the vein to the other. And every once in a while, a vein can blow up in the middle when you have an issue. And what you hope for and so as the vein blows up, the blood's still going to get through the other side. You have this bubble. And I can only tell you that unless we thought, Randall, that somehow Paxil CR was never going to achieve competition ever, ever, ever, then I can say that, that would be an effect on us. In a generic company, one can never project that a generic product forever will be in your product without competition. So obviously, it's a timing issue. And that's why the long-term fundamentals simply haven't changed.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Chris Schott with JPMorgan.",9,"Our next question comes from Chris Schott with JPMorgan.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just another follow-up on EMEA and specifically France. Can you just elaborate a little bit more in the trends you're seeing in that market? I guess specifically, how does some of the recent proposals from the French government that call, for it seem to b",105,"Just another follow-up on EMEA and specifically France. Can you just elaborate a little bit more in the trends you're seeing in that market? I guess specifically, how does some of the recent proposals from the French government that call, for it seem to be a pretty modest 2011 drug cost savings compared to your expectations? And then second question on EMEA. We had obviously the Teva Russia front deal closed this quarter. Just what are your thoughts in terms of the likelihood of further consolidation in the EU market over time? And what implications does that have, that consolidation have for your business?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'll answer the first one and you can talk about France. But in terms of -- I do see more consolidation in Europe. I believe that, that is one market that will go from a seller's market to a buyer's market. That is one region, I believe, that the multiple",217,"I'll answer the first one and you can talk about France. But in terms of -- I do see more consolidation in Europe. I believe that, that is one market that will go from a seller's market to a buyer's market. That is one region, I believe, that the multiples ought to contract. And my rationale is that I think what all of Europe is experiencing is the more regional companies, the more local companies, it's very, very difficult as Europe moves in the direction of some of the other markets around the world to be able to compete if you don't have scale. And without scale, again, that cost competitiveness, they're going to feel it. And I think that some of these mom-and-pop companies, these local companies, these regional companies begin to realize that the writing is on the wall. I think it will force them indirectly towards more activity. And I think as the more activity percolates, I think the supply-demand curve will kick in, and when there's more supply than there is demand, I think that you'll see multiples come down. So I do see more consolidation. I do think it's extremely healthy over in Europe to bring more capacity out of the market, and I do think that scale will prevail. Heather?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And just I guess to elaborate a little more on EMEA. I guess, just a couple of things. One, I'd remind you that Q3 has always been historically lower throughout Europe because of the summer and the holiday, the extended holiday season throughout Europe. S",210,"And just I guess to elaborate a little more on EMEA. I guess, just a couple of things. One, I'd remind you that Q3 has always been historically lower throughout Europe because of the summer and the holiday, the extended holiday season throughout Europe. So we do expect Q4 to see growth back from a revenue perspective. And as far as France and some of the trends, we absolutely what just came out for the 2011 time period we anticipated, and as you note, fairly modest. And to the extent that, like I said, we believe that was right in line with our thinking of where 2011 would be as well as some continuing to look at the whole value chain, not just the generic manufacturers. So as we've seen with other regulations and some of the pricing throughout Europe, Spain, Italy continuing to do the same, not looking at just the generic manufacturers, but kind of the entire supply chain. So that's why I stated the trends, and as I said, the tender markets whether it's Germany and some of the pricing pressure that you see that blimp that of course was attached to this quarter. And like I said, we see that revenue growth coming back in Q4.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is from Rich Silver with Barclays Capital.",10,"Our next question is from Rich Silver with Barclays Capital.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just shifting to the North American business. Can you elaborate to explain the sequential decline in just a little bit more detail on the drivers there and what we can look for going forward?",34,"Just shifting to the North American business. Can you elaborate to explain the sequential decline in just a little bit more detail on the drivers there and what we can look for going forward?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'll start off by saying timing, timing, timing, timing and timing. Heather?",13,"I'll start off by saying timing, timing, timing, timing and timing. Heather?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think obviously, Rich, that's why we say that this business will try to gauge its snapshot quarterly is not representative of the business as a whole. Rob's viewpoint, there's certainly, we've had timing issues of some of our launches. Certainly, we did",124,"I think obviously, Rich, that's why we say that this business will try to gauge its snapshot quarterly is not representative of the business as a whole. Rob's viewpoint, there's certainly, we've had timing issues of some of our launches. Certainly, we did get some more of those limited competition market. In Q3, again we'll  have the benefit of the full value of those products within the next quarter. So really, nothing other than like I said, kind of normal variations like go back and forth through some of our products. And like I said, some of the timing of some of our regulatory launches, but nothing out of the ordinary and nothing that we don't see kind of again coming back in Q4.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Putting aside Paxil CR, kind of all else equal, as what you're saying, if you were providing full year guidance, revenue guidance for North America, it would be unchanged even with the third quarter looking a little weak? And then just one last one, which",80,"Putting aside Paxil CR, kind of all else equal, as what you're saying, if you were providing full year guidance, revenue guidance for North America, it would be unchanged even with the third quarter looking a little weak? And then just one last one, which is a whole paragraph devoted to Minocycline ER, can you give us some sense of the materiality of that product given that you made a point of putting that much base in the press release?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, a couple of things. One, I guess just quickly on North America, and I guess just to point towards, again year-over-year  17% growth out of that business. So again sequentially, timing. I don't want to lose the fact that we've seen nice growth and he",124,"Well, a couple of things. One, I guess just quickly on North America, and I guess just to point towards, again year-over-year  17% growth out of that business. So again sequentially, timing. I don't want to lose the fact that we've seen nice growth and healthy growth in that business year-over-year from Q3 '09 to Q3 this year. And as far as Minocycline, look, I think what we are trying and I'll let John elaborate, but what I'm trying to explain from a revenue recognition perspective, said it was not a blimp like a bolus of the 180 days, and so I think we wanted to go above and beyond and try to make sure people understood exactly how we were treating that product.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Just two points, Rich. I guess number one, yes, I wouldn't be focused on changing our full year revenue guidance for North America if we were providing North American revenue guidance. And I think the way Heather, both Robert and Heather have described No",145,"Just two points, Rich. I guess number one, yes, I wouldn't be focused on changing our full year revenue guidance for North America if we were providing North American revenue guidance. And I think the way Heather, both Robert and Heather have described North America as a timing matter. It's exactly what that is. Number two, with respect to Minocycline, we launched Minocycline in the latter part of July, and we indicated in the second quarter earnings call that we would recognize that revenue on the deferred method and the pull-through method. And therefore, obviously it has an impact, but not nearly as large an impact as it would if we were recognizing it all in the current quarter. The other thing is that if the impact of Minocycline will increase as the amounts of our product there are being consumed by our customers'  increases.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","And our next question comes from John Boris with Citi Investment Research.",12,"And our next question comes from John Boris with Citi Investment Research.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First one just has to do with Janet Woodcock at least indicated that she's hired some additional help to try and clear up the backlog of well in excess of 2000 ANDAs. Any thoughts on progress on cleaning this backlog up? Are you seeing any improvement in",51,"First one just has to do with Janet Woodcock at least indicated that she's hired some additional help to try and clear up the backlog of well in excess of 2000 ANDAs. Any thoughts on progress on cleaning this backlog up? Are you seeing any improvement in timelines on ANDAs?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think from my perspective I see two mitigating factors here. I'm very happy that they actually have maybe gone out to the private sector to -- let's just help them with the queue and develop the right queue for better efficiency in flow of what they nee",184,"I think from my perspective I see two mitigating factors here. I'm very happy that they actually have maybe gone out to the private sector to -- let's just help them with the queue and develop the right queue for better efficiency in flow of what they need to do. But on the other hand, let's not forget that there are comments out there, ""in the year"" of what we've always seen coming and we would support. And that's a tightening of specs. So if you're going to be tightening specs on one hand, I think that further creates a little bit of a backlog only to be offset, I hope, by this outside resource that she's going to bring in from the private sector. So I'm not sure yet how the two are going to offset and whether or not we're going to get more efficiency or whether or not the tighter specs may cause a little bit more. I think it's yet to be seen, but we're very encouraged in terms of the FDA taking the initiative to improve the entire process.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just a follow-on to the tighter specs, she's also hinted that she's somewhat concerned about some of the generic supply that's out there. Can you help maybe elaborate on what she's implying? Are anticipating that there might be some other recalls on the h",45,"Just a follow-on to the tighter specs, she's also hinted that she's somewhat concerned about some of the generic supply that's out there. Can you help maybe elaborate on what she's implying? Are anticipating that there might be some other recalls on the horizon?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, I think one area that certainly we've been pretty vocal about is on the user fee front. And as you know, we have public comments out there and have been working closely with FDA and the industry to really set up a fair level playing field as far as",219,"Well, I think one area that certainly we've been pretty vocal about is on the user fee front. And as you know, we have public comments out there and have been working closely with FDA and the industry to really set up a fair level playing field as far as foreign inspections and this truly global supply chain that the FDA has to be able to support a product that's being sold into the U.S. So she, obviously, in her remarks have been very, very supportive of leveling that playing field and making sure that FDA has the resources they need to do inspections every two years of anyone who's supplying products into the U.S. market. So I think that some of her comments certainly go to the fact that, that heightening attention, the heightening of resources and us being able to put something through that would allow the FDA to accomplish that would certainly benefit not only leveling that playing field, but back to Robert's point, it will also even go towards the backlog and where we see the applications, and I think, could see an improvement in those median times all being connected together, and that's the approach we certainly are taking of advocating and believe that FDA believes that, that would be beneficial on all fronts.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Ronny Gal with Sanford Bernstein.",10,"Our next question comes from Ronny Gal with Sanford Bernstein.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First, a quick one for John. John, if I look at the reconciliation table that you've provided us with, it looks like you are excluding about $125 million and the tax effect offsetting that is about $80 million or 64% of the excluded amount. That looks lik",104,"First, a quick one for John. John, if I look at the reconciliation table that you've provided us with, it looks like you are excluding about $125 million and the tax effect offsetting that is about $80 million or 64% of the excluded amount. That looks like a very high tax rate on the excluded amount. If you can give us a clue about that. And still on the issue of integration, was there about $32 million this quarter for acquisition and integration charges? Can you help us understand how that will trail off over the next year if there are no additional acquisitions?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","On the first item, with respect to the taxes, remember that what we're doing with the tax reconciliation is not just in the tax adjustment, it's not just simply the tax affect of the reconciling items, but it is also to adjust the tax rate to the 28% full",81,"On the first item, with respect to the taxes, remember that what we're doing with the tax reconciliation is not just in the tax adjustment, it's not just simply the tax affect of the reconciling items, but it is also to adjust the tax rate to the 28% full year effective rate, so to the extent that there are, let me say, one-time or unusual items within taxes, the tax expense or tax benefit, we also have to adjust those out.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And as far as your integration point, obviously, we've seen that come down tremendously year-over-year as we've gotten further into this integration. So yes, we continue to see that trailing off.",31,"And as far as your integration point, obviously, we've seen that come down tremendously year-over-year as we've gotten further into this integration. So yes, we continue to see that trailing off.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Follow-up on the Dey business. Some of your competitors have been talking about the opportunity in the respiratory area over the next few years, and you obviously have a respiratory platform. How do you think about this platform? If you can give us some v",70,"Follow-up on the Dey business. Some of your competitors have been talking about the opportunity in the respiratory area over the next few years, and you obviously have a respiratory platform. How do you think about this platform? If you can give us some view about what you're developing internally and what you might be interested in bringing from the outside to put on top of that sales force?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. Absolutely, we have said this is an extremely an important niche in the Specialty business, not only, obviously, how we marry up to that, but just I think in the United States overall, it's a very important niche area that we've seen a ton of growth",170,"Yes. Absolutely, we have said this is an extremely an important niche in the Specialty business, not only, obviously, how we marry up to that, but just I think in the United States overall, it's a very important niche area that we've seen a ton of growth as an industry. And I think we have a lot of opportunity. As Robert's talked about looking for complementary products to be able to put into the infrastructure that we already have and the doctors that we're already calling on as well as our own internal R&D pipeline on the COPD front with combo and of course our current performance. So that infrastructure, and I think that allergy marrying up again to EpiPen and what we've talked about being this underserved market is again that education around market expansion and how we continue to see an awareness, of building an awareness and that again continuing to expand that market for us both on the respiratory, from respiratory docs as well as the allergists.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Greg Gilbert with Bank of America Merrill Lynch.",13,"Our next question comes from Greg Gilbert with Bank of America Merrill Lynch.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","A couple for Heather and one for Robert. Heather, first, can you clarify what you meant about growth in EMEA in 4Q? Or are you saying you expect growth over the 4Q of '09 level of $482 million?",38,"A couple for Heather and one for Robert. Heather, first, can you clarify what you meant about growth in EMEA in 4Q? Or are you saying you expect growth over the 4Q of '09 level of $482 million?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, I was just saying both, that one obviously Q3 has historically been lower. So last year, Q3 was [indiscernible] than Q4. This year, we're anticipating growth both over Q3 as well as over Q4 of '09.",37,"Yes, I was just saying both, that one obviously Q3 has historically been lower. So last year, Q3 was [indiscernible] than Q4. This year, we're anticipating growth both over Q3 as well as over Q4 of '09.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And that would be mostly driven by new launches? Or is that other sort of organic drivers that would result in growth after a couple of quarters of decline?",29,"And that would be mostly driven by new launches? Or is that other sort of organic drivers that would result in growth after a couple of quarters of decline?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","A couple of things. We've got a lot of product launches this quarter as well as the benefit of a full quarter of some of the launches we've had throughout the year.",32,"A couple of things. We've got a lot of product launches this quarter as well as the benefit of a full quarter of some of the launches we've had throughout the year.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And then my other Europe question is whether or not you're seeing signs in Europe as governments understand the importance of making generic substitution happen or are they still just focused on finding short-term savings?",36,"And then my other Europe question is whether or not you're seeing signs in Europe as governments understand the importance of making generic substitution happen or are they still just focused on finding short-term savings?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","No, I've got a glimmer of hope that they are saying that the sustainability of utilization, that penetration is much more effective than a one-off price cut. I think we're starting to see that in Italy and Spain, as well as France. France, obviously, to m",167,"No, I've got a glimmer of hope that they are saying that the sustainability of utilization, that penetration is much more effective than a one-off price cut. I think we're starting to see that in Italy and Spain, as well as France. France, obviously, to me, is kind of the most mature in that Southern European region. And I see Italy and Spain kind of starting to follow a suit as far as some incentives and increasing. And we've seen an increase in penetration on both of those markets. And look, I can assure you, will not stop our efforts of being out there educating and showing the sustainability of generic penetration versus just, like I said, the price cuts. And I think the other point to note here is the responsibility that we have seen and demonstrate between looking at the entire supply chain and not just the generic manufacturer, whether it's from the pharmacy perspective, the brand arena. So it's balancing both of those fronts.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Mark Goodman with UBS.",9,"Our next question comes from Mark Goodman with UBS.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I just want to make sure I'm clear on this EMEA following on the last question. So we're going to have growth versus last year. Can you talk about what countries are going to be the key areas where you're talking about these new product launches? Is it Fr",121,"I just want to make sure I'm clear on this EMEA following on the last question. So we're going to have growth versus last year. Can you talk about what countries are going to be the key areas where you're talking about these new product launches? Is it France? Is Germany going to come back? Second question is maybe you can give us a sense of what happened in the quarter in Asia, just Australia versus Japan versus India? Just so we have a little more flavor there. Then the third question is just talk about EpiPen in the quarter. Was there growth year-over-year in EpiPen? It seemed a little weaker than what I thought it was going to be.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Okay, so I'll start backwards so I don't forget anything. Yes, we saw, we definitely saw growth in EpiPen, both in volume as well as we had pricing in the year, but we certainly have seen some market expansion seeing the -- we saw the peak start a little",196,"Okay, so I'll start backwards so I don't forget anything. Yes, we saw, we definitely saw growth in EpiPen, both in volume as well as we had pricing in the year, but we certainly have seen some market expansion seeing the -- we saw the peak start a little earlier and last a little bit longer in the seasonality of the product. So we continue, as I said, to see our efforts around awareness to continue to help in that expansion. As far as Europe's concerned, obviously, as we continue to say, France is certainly the driver for us across the European region. As I noted this quarter,our  sales were up year-over-year for France as well as Italy and Spain, and we continue to see those being contributors as well in this growth for Q4 both year-over-year and sequentially. As far as APAC is concerned, Matrix, while we don't break out the individual divisions within a segment, we have continued and will continue to at least give what the leaders are and Matrix has led that with double-digit growth from the APAC region, but we did have contribution both from Australia as well as Japan year-over-year.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is from Elliot Wilbur with Needham & Company.",10,"Our next question is from Elliot Wilbur with Needham & Company.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First question, I just want to drill down a little bit more on the strong gross margin performance thinking about it sequentially up about 300 basis points. It doesn't really look like it's a mix issue given that North America and Specialty were relativel",78,"First question, I just want to drill down a little bit more on the strong gross margin performance thinking about it sequentially up about 300 basis points. It doesn't really look like it's a mix issue given that North America and Specialty were relatively the same percentage of sales. Also, so it's not really a volume issue. So is it fair to say that the bulk, if not the entire degree of improvement sequentially, is attributable to synergies?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. Look, I'd say certainly, as we forecasted and anticipated, synergy realization was going to be stronger in the second half of the year, but I wouldn't lose total sight on mix. We had important approvals of higher margin products as limited competitio",84,"Yes. Look, I'd say certainly, as we forecasted and anticipated, synergy realization was going to be stronger in the second half of the year, but I wouldn't lose total sight on mix. We had important approvals of higher margin products as limited competition, like in clonidine, like in Minocycline and Tacrolimus so there is still -- you do have mix issues, which is why you have to look at the annual, the overall gross margin and the guidance, obviously, that we have out there.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I have a good question for John as well. With respect to the company's current capital structure and the duration of the debt obligations, sort of understand that you have quite a bit of financial flexibility through your first bolus payment in 2012 in li",159,"I have a good question for John as well. With respect to the company's current capital structure and the duration of the debt obligations, sort of understand that you have quite a bit of financial flexibility through your first bolus payment in 2012 in lieu of $700 million in total. But if you look out to 2014, there's roughly $2 billion bullet that's due, and that just happens to coincide with I guess sort of a large systemic increase in overall debt obligations coming due in the U.S. And given the likelihood that there's going to be a lot of folks looking to refinance debt and also the fact that tremendous rates probably are going to be a lot higher than where they are now, just sort of how should we be thinking about maybe potential addition what it means on your part to maybe flatten out the maturity ladder or even extend it further, which you've already done?
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I would say this. If you go back eight months ago, seven months ago, we had over $3 billion of maturity in 2014. And over the course of this year, we've reduced that by $1.3 billion. So we have flattened out the 2014 maturity significantly. We will contin",172,"I would say this. If you go back eight months ago, seven months ago, we had over $3 billion of maturity in 2014. And over the course of this year, we've reduced that by $1.3 billion. So we have flattened out the 2014 maturity significantly. We will continue to look to extend the maturity profile at appropriate points in time. We'll use our strong positive cash flow to continue to reduce the amount of the 2014 as we did here in the third quarter by repaying $300 million. So I actually feel really good about where we stand in the capital structure. Our free cash flow is over $500 million a year with the final preferred dividend that we're making here in the fourth quarter. That will increase our free cash flow by $139 million a year. So I see us with a lot of cash. Robert has talked about the fact that we're not looking to make another strategic acquisition. We're fully committed to reducing our leverage to 3:1 or lower.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Let me just add something. First of all, you may not have caught it, but we did prepay $300 million. So we're actually at $1.7 billion now from the $3 billion or the $2 billion in which you've mentioned, Elliot. So you can see, and as a matter fact, when",179,"Let me just add something. First of all, you may not have caught it, but we did prepay $300 million. So we're actually at $1.7 billion now from the $3 billion or the $2 billion in which you've mentioned, Elliot. So you can see, and as a matter fact, when we first prepaid the $1 billion, I think we said at the time we felt fairly comfortable at that time that we would generate enough operating cash flow actually to retire the debt itself. So taking the need for this organization to have to tap the market was exactly what we intended not to put ourselves in. So I feel very comfortable that we will continue to generate very strong free cash flows with the continued commitment to delever, but I will say at  the same time I'm saying that, I wouldn't hesitate in a second to further extend those maturities if the opportunity arises and interest rates continue to be as advantageous as they are and simply give ourselves even more flexibility than what we've already provided ourselves.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","And our final question comes from John Newman with Oppenheimer.",10,"And our final question comes from John Newman with Oppenheimer.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I just wanted to ask a clarifying question on EMEA. It looks like the revenues for EMEA last fourth quarter pretty robust, and I think I recall you saying that you were expecting both a quarter-over-quarter increase from 4Q this year versus current quarte",96,"I just wanted to ask a clarifying question on EMEA. It looks like the revenues for EMEA last fourth quarter pretty robust, and I think I recall you saying that you were expecting both a quarter-over-quarter increase from 4Q this year versus current quarter and also last year. So just wondering, Tom, is there something specific that is going to give you a pretty significant push? Because it seems like an increase over third quarter this year seems totally reasonable, but fourth quarter last year seems like maybe a little kind of a challenging comp there.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","All I can say is as we continue to stress the strength of our pipeline and launches not just third-party launches, but now our internal launches starting to roll in, that's really, like I said, the driver not only of just launches we're doing in Q4 but lu",112,"All I can say is as we continue to stress the strength of our pipeline and launches not just third-party launches, but now our internal launches starting to roll in, that's really, like I said, the driver not only of just launches we're doing in Q4 but lunches we've now done throughout the year that we're getting, reaping the full benefit by the time it hits Q4. So it just continues to be the product launches and what we're able to do with those launches throughout all of the country. And again, Q4 being, if you go back the year before, Q4 has been a very robust year throughout Europe historically.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","This concludes today's question-and-answer session. At this time, I'd like to turn the conference back over to our speakers for any additional comments or closing remarks.",27,"This concludes today's question-and-answer session. At this time, I'd like to turn the conference back over to our speakers for any additional comments or closing remarks.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I just like to thank everybody for their participation today, and at this point, Lisa, you can close out the call.",21,"I just like to thank everybody for their participation today, and at this point, Lisa, you can close out the call.
"
290203,114621935,81981,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","This does conclude today's conference call. Thank you for your participation.",12,"This does conclude today's conference call. Thank you for your participation.

"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Good day, and welcome to the Mylan, Inc. Third Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King, Vice President of Global Investor Relations. Please go ahead.",40,"Good day, and welcome to the Mylan, Inc. Third Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King, Vice President of Global Investor Relations. Please go ahead."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Lisa. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; and Executive Vice Pre",361,"Thank you, Lisa. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; and Executive Vice President and Chief Operating Officer, Rajiv Malik.
During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our annual report on Form 10-K for the year ended December 31, 2009, and in our other SEC filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov, and we strongly encourage you to do so. 
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylans on an adjusted basis, which are non-GAAP measures. It should be noted that non-GAAP financial measures such as adjusted revenues, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website as it contains detailed GAAP to non-GAAP reconciliations of our actual 2010 and 2009 third quarter results, including the allocation of each reconciled line item to specific income statement line items. 
Before I turn the call over to Robert, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission. 
With that, I'll now turn the call over to Robert."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris. Welcome, everyone and thank you for taking the time to join us this afternoon. I would also like to welcome all of the Mylan employees on the call today, especially those from Bioniche Pharma, who are listening as the new members of the M",531,"Thank you, Kris. Welcome, everyone and thank you for taking the time to join us this afternoon. I would also like to welcome all of the Mylan employees on the call today, especially those from Bioniche Pharma, who are listening as the new members of the Mylan family. On behalf of the Board of Directors and our leadership team, I'd like to thank each and every one of you for your continued hard work, dedication and outstanding performance.
I am extremely pleased to report to you yet another strong quarter performance of exceptional earnings. As I mentioned on the last conference call, I did anticipate the third quarter to be better than the second quarter, and I am extremely pleased to report adjusted diluted earnings per share of $0.43, a 16% increase from our second quarter results. With that said, I still expect at this time that the fourth quarter will come in slightly better than the third quarter.
We maintain this position even with the most recent ruling related to our Paroxetine CR. While we are extremely disappointed with the lower court's ruling, we believe strongly that the lower court has erred in its decision not to grant us an injunction, and we have appealed that decision. It should also be noted that this is still just a ruling on an injunction. It is not a final decision resolving Mylan's rights on this matter. Regardless of the outcome of the appellant court decision on the injunction, we will continue our litigation to enforce our contractual rights and all of its negotiated provisions with GSK.
With that said, and irrespective of this short-term distraction, the longer-term fundamentals of our business have not changed, which is why we remain committed to our stated targets of $2 of adjusted diluted earnings per share for calendar year 2011 and our longer-term growth targets of 15% top line and 20% bottom line CAGR by the end of 2013. We very much look forward to providing you a detailed breakdown of our 2011 guidance on our next conference call.
Moving on to other activity in the quarter. You will recall that we issued $300 million in follow-on 10-year bonds to finance the acquisition of Bioniche Pharma. In addition, we are also able to use part of the strong operating cash flows that we continue to generate to prepay $300 million in term loan borrowings in the third quarter as well, further reducing our leverage and staying committed to our stated objective to achieve a 3:1 debt-to-adjusted-EBITDA leverage ratio. 
And finally, you may remember that on November 15 of this year, our mandatory convertible preferred stock will automatically convert to common stock. Given the recent growth and strength of our stock price performance, we anticipate issuing the lowest number of shares required under the terms of the preferred stock agreement, which is approximately 125 million shares. Of further note, November 15 will also mark the final payment of the preferred stock dividend, thereby substantially enhancing our future free cash flows to the company by $139 million per year.
I look forward to answering your questions, and I'd now like to turn the call over to Heather Bresch."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert, and good afternoon, everyone. As Robert said, we are very pleased with our strong third quarter performance and a great start to our expected strong second half of 2010. We remain highly confident in our ability to deliver 2010 results",1329,"Thank you, Robert, and good afternoon, everyone. As Robert said, we are very pleased with our strong third quarter performance and a great start to our expected strong second half of 2010. We remain highly confident in our ability to deliver 2010 results in line with the guidance we have reaffirmed today. We also continue to be extremely confident about our growth prospects for '11 and beyond. I too would like to commend our employees around the world for making our continued exceptional performance possible.
During my remarks today, I'll review our performance by segment, provide an update on synergies and comment on why we remain so confident about our future. I'd now like to walk you through the performance of our commercial operations. During the third quarter, we generated total revenues of $1.36 billion, an increase of 7% compared to last year's third quarter total revenues of $1.26 billion. On a constant currency basis, revenues were up approximately 9% year-over-year, and on the bottom line, we generated $0.43 of adjusted EPS, a 34% increase over last year's third quarter result of $0.32.
We also delivered a strong adjusted gross margin of 48.4% during the third quarter, up from our second quarter performance of 45% and right in line with our full year expected range of 47% to 49%. As expected, driving the strong performance were recent approvals on higher margin, limited competition products, higher sales in our Specialty segment and continued synergy realization.
Within our Generics segment, our North American operations delivered third-party net sales for the third quarter of $573 million, up 17% from last year's third quarter result of $488 million. The increase was mainly the result of new product launches in the United States. Among those launches were limited competition products, Minocycline ER, Clonidine Transdermal, and Tacrolimus, bringing to ten the dozen such products we anticipate launching by year end, and we remain on track to achieve our full year target of 50 to 60 launches in the U.S.
Our third quarter also includes results from Bioniche, a Specialty Injectables business we acquired on September 7. The integration has been seamless so far, and on October 4, we announced our first approval from the FDA for our Bioniche product, Fludarabine, an injectable chemotherapy medication for leukemia. Our ANDA filings now include those of Bioniche Pharma. Currently, we have 153 ANDAs pending FDA approval, representing about $95 billion in annual brand sales. 45 of these pending ANDAs are potential first-to-file opportunities, representing more than $24 billion in annual branded sales. 
In EMEA, third-party net sales of $364 million fell 12% versus last year's third quarter third-party sales of $414 million. However, on a constant currency basis, operational performance in EMEA declined only 3% year-over-year while year-to-date, sales have risen almost 2%. That result was driven by unfavorable pricing throughout Europe, which was partially offset by new product launches in several markets. 
Looking forward, we continue to see our ability to even further offset negative trends in the region, thanks to the sheer number of internal products we expect to launch in 2011 and beyond. In addition, we continue to repatriate finished dosage forms, which will continue to add to our competitive position throughout Europe. 
In France, third quarter local currency sales rose compared to the year-ago quarter. New product launches and higher volumes on existing products more than offset ongoing competitive pricing pressures. With more than 30% market share, our market leadership position remains very strong in France, which drives our performance in Europe.
We also experienced higher year-over-year third quarter local currency sales in Italy, where we benefited from a combination of new product launches, higher generic penetration and the continued favorable effects of regulatory changes. And in Spain, our new product launches offset the impact of government-posed price reduction.
Other markets such as Portugal and Germany experienced lower sales during the third quarter due to government-imposed price reductions and the impact of tender systems, respectively.
Turning now to our Asia Pacific region. We delivered very strong third quarter results. Third-party net sales were $268 million, up 30% over last year's third quarter sales on $206 million. On a constant currency basis, sales rose about 22%. Matrix, Australia and Japan all contributed to the strong results. Matrix continued to deliver strong double-digit growth through API and ARV sales and our ARV portfolio now contains 33 products.
Finally, Dey, our Specialty segment performed well during the third quarter. Third-party net sales rose 6% to $141 million over the same period last year after adjusting last year's third-party sales to account for the fact that in 2010, our Mylan Pharmaceutical division assumed responsibility for selling Dey's generic products. The primary driver of our growth was domestic sales of EpiPen Auto-Injector, which were strong compared to the third quarter of '09. Recall that last October, we launched our next-generation needle-protected auto-injector, which has been received favorably in the U.S. and Canada. In addition, compared to our second quarter, sales benefited from the seasonal return of children to school. Further, we can continue to experience double-digit growth in many markets outside the U.S. as we continue the expansion opportunities for this very important product, mainly through focusing on an underserved population.
Moving on now to synergies. I'm pleased that we remain on track to deliver more than $350 million in cumulative annual benefit by the end of this year. We continue to seek out and capture additional opportunities to further increase our efficiency and leverage our powerful operating platform. Looking ahead to '11, as Robert stated, we will provide formal guidance for the year on our next conference call. 
Nonetheless, it's important to note and to remind you that we continue to see Mylan entering the new year with very strong momentum, especially as we launch more products around the globe than we have ever launched in our company's history. In 2011, we look forward to monetizing or continuing to monetize several opportunities resulting from prior settlements such as Minocycline ER, voriconazole, letrozole and Venlafaxine ER. We see a number of 30-month stays expiring on other opportunities, some of which are first-to-file. We look forward to introducing oral contraceptives in the U.S., and once again, launching more than a dozen limited competition products. 
Worldwide, we continue to expect to launch approximately 500 products. As important, our pipeline is stronger than ever. We currently have about 1,500 global products submissions pending approval. 
Before I turn the call over to John, I'd like to step back and make some observations about our company and how far we've come. Earlier this month, we celebrated the three year anniversary of the union of legacy Mylan, Matrix and Merck. Behind that union was our vision that the world could be served far better if we created a global, vertically integrated and highly disciplined company that could consistently supply any market with high-quality, affordable generic and specialty pharmaceuticals.
Over the past three years, we have focused relentlessly on executing on our vision by integrating vertically, delivering synergies far beyond our expectations and serving customers in more than 140 countries and territories. Those accomplishments alone allowed us to meet or exceed Street [Wall Street] estimates for 13 consecutive quarters. 
But that's not all we've been doing for the last three years. We've also been filling our global network with internally supplied products by applying the same methodology and fundamentals that made our integration so successful. Among the actions we've been taking, optimizing R&D, enhancing our portfolio and management capabilities, repatriating products and filling gaps in our product line, we also have created a biologic strategy and strengthening the promising future of our Specialty business, Dey. And perhaps most important, we have filed approximately 3,000 applications globally by the end of this year. Now, we're ready to reap what we've sown. That is why we're so confident about our growth over the next three years and beyond. 
With that, I'll now turn the call over to John."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good afternoon, everyone. This afternoon, I will begin by walking you through our third quarter 2010 financial results, which, as Heather and Robert have both indicated, were exceptional. I will then provide an update on our capita",1933,"Thank you, Heather, and good afternoon, everyone. This afternoon, I will begin by walking you through our third quarter 2010 financial results, which, as Heather and Robert have both indicated, were exceptional. I will then provide an update on our capital structure and liquidity position.
As Kris mentioned earlier, I'm going to be referring to actual and projected financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. We present these non-GAAP financial measures because they're prepared on the same basis as used by our management and Board of Directors to evaluate the performance of our business. This afternoon's earnings release includes a complete reconciliation from our GAAP to non-GAAP financial measures for our third quarter 2010 and 2009 results. Our earnings release is available on our website, and I encourage you to take a look at it.
Starting at the top of the income statement. Total revenues for the quarter were $1.36 billion, an increase of 7% over last year's third quarter total revenues of $1.26 billion. The effect of foreign currency translation had an unfavorable impact of approximately 2% on our third quarter revenues, reflecting a weaker euro in comparison to the U.S. dollar, partially offset by the strengthening of other currencies, primarily the rupee, the yen and the Australian dollar.
During the third quarter, we launched Minocycline ER. As I discussed with you on last quarter's call, because of significant uncertainties surrounding the pricing and market conditions with respect to Minocycline, we are not able to reasonably estimate the magnitude of potential price adjustments, including product returns, and as a result, have deferred revenue recognition until such uncertainties are resolved. At this time, we consider such uncertainties to be resolved upon the sale by our customers of the product and have recognized revenue accordingly.
Looking at our operating profitability measures, adjusted gross margin for the quarter was approximately 48.4% compared to 46% in the prior year. As expected, this adjusted gross margin is an improvement from that of the first and second quarters and is within our full year guidance range of 47% to 49% and is primarily the result of new product launches in North America and favorable pricing on our Specialty segment, EpiPen Auto-Injector.
Adjusted R&D expense for the quarter was $69 million or approximately 5% of revenues. Also as expected, this level of spending represents an increase over the first half of 2010 and is in line with our revised full-year guidance range of 5% to 6% of revenues. Importantly, our R&D projects remained on target, and we are planning for even higher levels of spending in the fourth quarter.
Adjusted SG&A expense was $257 million for the quarter or 19% of revenues, within our full year guidance range of 18% to 20%, and our third quarter adjusted EBITDA was $368 million.
Now let me move to a couple of non-operating financial metrics. Third quarter 2010 adjusted interest expense was $70 million. We continue to forecast adjusted interest expense for the year to be at or near the low end of our guidance range of $280 million to $300 million, which continues to consider the potential for higher short-term interest rates. Our third quarter adjusted effective income tax rate was 26%, which translates into a year-to-date and full year projected adjusted effective income tax rate of 28%, which is at the low end of our forecasted range of 28% to 29%. We do fully anticipate this full year effective tax rate to be sustainable going forward. In summary, third quarter adjusted net income was $189 million or $0.43 per share.
In calculating our adjusted diluted EPS, the impact of assuming the conversion of our preferred shares into 125 million common shares was more dilutive than the $35 million quarterly preferred dividend. Therefore, adjusted diluted EPS for the third quarter is calculated based on an average outstanding diluted share count of approximately 438 million shares.
Touching briefly on the year-to-date results, and again, please refer to our earnings release for a complete reconciliation from our GAAP to our non-GAAP financial measures. For the nine months ended September 30, 2010, total revenues were $4.02 billion, an increase of 8% over adjusted revenues of $3.71 billion in the same prior year period. For the nine months, foreign currency translation had a favorable impact on revenues of approximately 1% due mainly to the strengthening of the rupee, yen, and Australian dollar versus the U.S. dollar, partially offset by a weaker euro.
Adjusted gross margin for the nine months was approximately 46% compared to 47% in the same prior year period. The lower gross margin in the current year is the result of a loss of exclusivity on divalproex during the third quarter of 2009. However, the current year gross margin was negatively impacted by certain inventory charges, principally in Q2. Excluding the impacts of these inventory charges, year-to-date gross margin would have approached 47%. We continue to see full year gross margin at the low end of our 47% to 49% guidance range. 
Adjusted R&D expense was $195 million, and adjusted SG&A expense was $753 million for the current nine-month period. Our adjusted EBITDA for the first nine months of 2010 was $1.03 billion. Adjusted net income was $511 million and adjusted diluted EPS was $1.16 per share.
As in the previous quarter, adjusted diluted EPS was calculated assuming the conversion of our preferred shares into 125 million shares of common stock. On November 15 of this year, our mandatory convertible preferred stock will automatically convert into shares of common stock. The number of convertible shares will be based upon the closing stock price over the 20-day trading period ending on November 12. Based on the current stock price, we expect that approximately 125 million shares will be the conversion amount. 
As mentioned before, we have been including this preferred stock conversion in our forecasted results. As such, the actual conversion will not result in an additional dilution to our guidance amounts. November 15 will also mark the final payment of the preferred stock dividend. 
Depending on the market value of our common stock going forward, our average outstanding diluted share count could increase further due to additional dilution from stock options and other potentially dilutive financial instruments such as our convertible debt obligations and related warrants. We also include such potential dilution in our forecasted results. 
As I mentioned previously, the impact of foreign exchange translation on our results was not significant, and actual foreign currency exchange rates during the period ended September 30, 2010, did not differ materially from those used to calculate our 2010 guidance, which we discussed with you last quarter.
More recently, we have seen the euro strengthen steadily against the U.S. dollar. However, we do not expect currency to have a significant impact on our results for the remainder of the year. This is due to the fact that the currencies of other markets in which we operate are moving in the opposite direction of the euro, and it's also a result of various hedging strategies that we've employed.
We've taken measures in an effort to prevent our results from being impacted significantly by changes in foreign currency exchange rates. In addition to having on our balance sheet euro-denominated long-term debt against which the cash flows of our euro-denominated subsidiaries are offset, we use financial instruments such as forward contracts in order to mitigate this risk. Any favorable or unfavorable variances resulting from foreign exchange for the three- and nine-month periods ended September 30, 2010, are included in the adjusted diluted per-share amount of $0.43 and $1.16 per share, respectively.
Turning to our cash flow metrics. Our third quarter GAAP cash flow from operations was nearly $380 million, the highest in our company's history or $360 million excluding certain items. While we don't anticipate fourth quarter cash flow from operations to approach this level, we do continue to project full year operating cash flow in the range of $725 million to $825 million excluding certain one-off items.
Our strong current quarter cash from operations was made possible through positive changes in our working capital, primarily accounts receivable as a result in improved cash collections, including amounts received with respect to Minocycline. As you may recall, on last quarter's call, I indicated that Q2 cash from operations were negatively impacted by the timing of collection of receivables, for which a substantial amount was received in early July. Q3 cash from operations was also impacted by the timing of collection of receivables, for which a substantial amount was received prior to September 30, 2010. 
Third quarter capital spending was $53 million, including approximately $10 million paid toward the acquisition of a finished dose manufacturing facility in India. Based on the anticipated timing of spending on certain projects, we now project capital spending in the range of $200 million to $250 million for the full year. Our current quarter also included a cash outflow of approximately $544 million with respect to our acquisition of Bioniche Pharma, which is net of any cash acquired. As Heather mentioned, results of Bioniche are included in our current quarter results from September 7.
The Bioniche acquisition was financed through a combination of cash-on-hand and the proceeds from recent notes offerings. As discussed last quarter, in May, we completed a private placement of $1.25 billion of senior unsecured notes due in 2017 and 2020. In the current quarter, we completed an add-on offering of an additional $300 million of the 2020 notes. These notes were issued at initial price of 105.5% and a coupon of 7 7/8% or an effective yield to maturity of slightly over 7%.
The notes issued in the current quarter's offering, together with the 2020 notes from the May offering, are treated as a single class of notes under the indenture. In addition to funding the Bioniche acquisition, the bond issuances were done in accordance with our objective of extending the maturity profile of our outstanding indebtedness. $1 billion of the net proceeds from the May issuance were used to pay down existing indebtedness under our credit facility. In late September, we used our strong operating cash to repay an additional $300 million of existing indebtedness under our credit facility. As a result of these repayments, we continue to have no meaningful long-term debt maturities until the $600 million due under our convertible notes in the first quarter of 2012, which we currently intend to repay with available cash at that time.
At September 30, 2010, following the additional debt repayment of $300 million, we continue to have unrestricted cash and marketable securities totaling over $640 million.
Continuing on with the capital structure, concerning leverage. As Robert has stated many times, it is our commitment to achieve a long-term leverage ratio of 3:1 or less. We are firmly committed to balancing growth in our business through the continued use of prudent and responsible financing. As such, Mylan remains committed to de-leveraging over time to meet this long-term capital structure goal. We continue to expect to generate approximately $4 billion of cumulative operating cash flows by the end of 2013.
From a covenant perspective, the level of our senior secured debt is approximately 1.7x our last 12 month covenant basis adjusted EBITDA, comfortably ahead of our December 31, 2010 threshold of 3.5x. In closing, I'm very pleased with our solid quarterly performance. A great start to what we've been saying will be a strong second half of 2010. 
That concludes my remarks. Lisa, I'll turn the call back over to you to start the Q&A."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from Randall Stanicky with Goldman Sachs.",12,"[Operator Instructions] Our first question comes from Randall Stanicky with Goldman Sachs."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Can you just drill down on the EMEA result and when we can expect a return to growth from that region net reach? And then the follow-up would be maybe, Robert, with the EMEA result in conjunction with the Paxil CR news, can you just talk about some of the",66,"Can you just drill down on the EMEA result and when we can expect a return to growth from that region net reach? And then the follow-up would be maybe, Robert, with the EMEA result in conjunction with the Paxil CR news, can you just talk about some of the offsets that allow you to remain comfortable as we think about the $2 target for 2011?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Sure, Randall. First, again, there are many, many mitigating factors, and it's difficult, I understand from your perspective, not to be able to evaluate the number of moving variables. But let's start with EMEA. I said that this would be a basically almos",635,"Sure, Randall. First, again, there are many, many mitigating factors, and it's difficult, I understand from your perspective, not to be able to evaluate the number of moving variables. But let's start with EMEA. I said that this would be a basically almost a two-bucket approach. I've been telling you all along that we continue to see what we've anticipated, what the governments are doing over there in terms of pricing and pushing prices down lower. But we've often said that we felt very comfortable with our position to be able to mitigate that by all the other initiatives that we have in place, including, I'll pull a knot, cost infrastructure that really doesn't fit with the new system, the new wave of direction where Europe is going. Our cost of goods, our repatriation, our bringing in a lot of the third parties back in-house, and of course, our increase in volumes. So that's kind of sort of -- and the races in Europe, Randall, the races, again, what I've always stated, the speed at which governments move and the speed at which we can, through a regulatory process, be able to yield all the benefits that we've been telling you all along. And in terms of the Paxil CR, we are in litigation. It's been a long-standing position of ours, and not to comment when we are in litigation. I tried to give you a signal, obviously, in our opening remarks about how I feel as a whole about that whole situation. We're extremely confident in our position. We think there's a lot more involved in terms of the dealings between GSK and Apotex, and it wasn't just a one-off type of situation. And that's what litigation is all about, and I'm very confident that we'll prevail once we have an opportunity to get inside. In terms of the $2, the last piece of your question, look, all these factors have -- there's nothing really new. There's just nothing new in terms of what we've thought about, what we've been trying to anticipate. And the best way I can explain to you on the $2 on why we're still confident is actually for two reasons. One, Randall, the fundamentals, the long-term fundamentals of the company have not changed at all. At all. Basically, what we're dealing with is the short-term issues that we have to just continue to manage or work our way through. And what I would bring to your attention is go back for the last 13 quarters where we have been trying the same exact questions that we're faced with today about visibility in 2011 and beyond. When we were in 2007 roughly at $0.45 and then $0.80 in 2008 and $1.30 in 2009 and roughly a midpoint of $1.60 in 2010, nobody understood how we were going to get there. And what I can tell you, and what we have done already is this management team promised that it would manage. It would manage this new acquired platform for earnings growth. And I can tell you that when we were back at $0.45 and $0.80 and $1.30 and $1.60 in terms of our respective midpoints, when we started out that guidance and where we thought those earnings per share were going to come from and where they actually came from are not always exactly the same. That's just the nature of our business. So I can assure you that when we once again I think we have become at least somewhat predictable to all of you guys. If we tell you that our vision is in the balancing act, what we can see the number of variables versus what you may not be able to see, we are very comfortable that the $2 target in calendar year 2011 is achievable."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","That's irregardless of a Paxil CR will come [indiscernible] again, just to be clear.",15,"That's irregardless of a Paxil CR will come [indiscernible] again, just to be clear."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. I mean you have to look at a Paxil CR this way. Take a look at a vein in your body, forgive me. But blood flows through, right one side of the vein to the other. And every once in a while, a vein can blow up in the middle when you have an issue. And",153,"Yes. I mean you have to look at a Paxil CR this way. Take a look at a vein in your body, forgive me. But blood flows through, right one side of the vein to the other. And every once in a while, a vein can blow up in the middle when you have an issue. And what you hope for and so as the vein blows up, the blood's still going to get through the other side. You have this bubble. And I can only tell you that unless we thought, Randall, that somehow Paxil CR was never going to achieve competition ever, ever, ever, then I can say that, that would be an effect on us. In a generic company, one can never project that a generic product forever will be in your product without competition. So obviously, it's a timing issue. And that's why the longer-term fundamentals simply haven't changed."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Chris Schott with JPMorgan.",9,"Our next question comes from Chris Schott with JPMorgan."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just another follow-up on EMEA and specifically France. Can you just elaborate a little bit more on the trends you're seeing in that market? I guess specifically, how does some of the recent proposals from the French government that call, for what seem to",105,"Just another follow-up on EMEA and specifically France. Can you just elaborate a little bit more on the trends you're seeing in that market? I guess specifically, how does some of the recent proposals from the French government that call, for what seem to be a pretty modest 2011 drug cost savings compared to your expectations? And then second question on EMEA. We had obviously the Teva Russia front deal closed this quarter. Just what are your thoughts in terms of the likelihood of further consolidation in the EU market over time? And what implications does that have, that consolidation have, for your business?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'll answer the first one and you can talk about France. But in terms of the -- I do see more consolidation in Europe. I believe that, that is one market that will go from a seller's market to a buyer's market. That is one region, I believe, that the mult",217,"I'll answer the first one and you can talk about France. But in terms of the -- I do see more consolidation in Europe. I believe that, that is one market that will go from a seller's market to a buyer's market. That is one region, I believe, that the multiples ought to contract. And my rationale is that I think what all of Europe is experiencing is the more regional companies, the more local companies, it's very, very difficult as Europe moves in direction of some of the other markets around the world to be able to compete if you don't have scale. And without scale, again, that cost competitiveness, they're going to feel it. And I think that some of these mom-and-pop companies, these local companies, these regional companies begin to realize that the writing is on the wall. I think it will force them indirectly towards more activity. And I think as the more activity percolates, I think the supply-demand curve will kick in, and when there's more supply than there is demand, I think that you'll see multiples come down. So I do see more consolidation. I do think it's extremely healthy over in Europe to bring more capacity out of the market, and I do think that scale will prevail. Heather?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And just I guess to elaborate a little more on EMEA. I guess, just a couple of things. One, I'd remind you that Q3 has always been historically lower throughout Europe because of the summer and the holiday, the extended holiday season throughout Europe. S",211,"And just I guess to elaborate a little more on EMEA. I guess, just a couple of things. One, I'd remind you that Q3 has always been historically lower throughout Europe because of the summer and the holiday, the extended holiday season throughout Europe. So we do expect Q4 to see growth back from a revenues perspective. And as far as France and some of the trends, we absolutely what just came out for the 2011 time period we anticipated, and as you note, fairly modest. And to the extent that, like I said, we believe that was right in line with our thinking of where 2011 would be as well as them continuing to look at the whole value chain, not just the generic manufacturers. So as we've seen with other regulations and some of the pricing throughout Europe, Spain, Italy continuing to do the same, not looking at just the generic manufacturers, but kind of the entire supply chain. So that's why I say to the trends, and as I said, the tender markets whether it's Germany and some of the pricing pressure that you see that blimp that of course was attached to this quarter. And like I said, we see that revenue growth coming back in Q4."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is from Rich Silver with Barclays Capital.",10,"Our next question is from Rich Silver with Barclays Capital."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just shifting to the North American business. Can you elaborate to explain the sequential decline in just a little bit more detail on the drivers there and what we can look for going forward?",34,"Just shifting to the North American business. Can you elaborate to explain the sequential decline in just a little bit more detail on the drivers there and what we can look for going forward?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'll start off by saying timing, timing, timing, timing and timing. Heather?",13,"I'll start off by saying timing, timing, timing, timing and timing. Heather?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think obviously, Rich, that's why we say that this business to try to gauge a snapshot quarterly is not representative of the business as a whole. Rob's viewpoint, there's certainly, we've had timing issues of some of our launches. Certainly, we did get",124,"I think obviously, Rich, that's why we say that this business to try to gauge a snapshot quarterly is not representative of the business as a whole. Rob's viewpoint, there's certainly, we've had timing issues of some of our launches. Certainly, we did get some more of those limited competition market. In Q3, again we'll  have the benefit of the full value of those products within the next quarter. So really, nothing other than like I said, kind of normal variations that go back and forth through some of our products. And like I said, some of the timing of some of our regulatory launches, but nothing out of the ordinary and nothing that we don't see kind of again coming back in Q4."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Putting aside Paxil CR, kind of all else equal, is what you're saying, if you were providing full year guidance, revenue guidance for North America, it would be unchanged even with the third quarter looking a little weak? And then just one last one, which",80,"Putting aside Paxil CR, kind of all else equal, is what you're saying, if you were providing full year guidance, revenue guidance for North America, it would be unchanged even with the third quarter looking a little weak? And then just one last one, which is a whole paragraph devoted to Minocycline ER, can you give us some sense of the materiality of that product given that you made a point of loading that much base in the press release?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, a couple of things. One, I guess just quickly on North America, and I guess just to point towards, again year-over-year  17% growth out of that business. So again sequentially, timing. I don't want to lose the fact that we've seen nice growth and he",123,"Well, a couple of things. One, I guess just quickly on North America, and I guess just to point towards, again year-over-year  17% growth out of that business. So again sequentially, timing. I don't want to lose the fact that we've seen nice growth and healthy growth in that business year-over-year from Q3 '09 to Q3 this year. And as far as Minocycline, look, I think what we are trying and I'll let John elaborate, but was trying to explain from a revenue recognition perspective, said it was not a blimp like a bolus of the 180 days, and so I think we wanted to go above and beyond and try to make sure people understood exactly how we were treating that product."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Just two points, Rich. I guess number one, yes, I wouldn't be focused on changing our full year revenue guidance for North America if we were providing North American revenue guidance. And I think the way Heather, both Robert and Heather have described No",145,"Just two points, Rich. I guess number one, yes, I wouldn't be focused on changing our full year revenue guidance for North America if we were providing North American revenue guidance. And I think the way Heather, both Robert and Heather have described North America as a timing matter is exactly what that is. Number two, with respect to Minocycline, we launched Minocycline in the latter part of July, and we indicated in the second quarter earnings call that we would recognize that revenue on the deferred method and the pull-through method. And therefore, obviously it has an impact, but not nearly as large an impact as it would if we were recognizing it all in the current quarter. The other thing is that if the impact of Minocycline will increase as the amounts of our product there are being consumed by our customers increases."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","And our next question comes from John Boris with Citi Investment Research.",12,"And our next question comes from John Boris with Citi Investment Research."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First one just has to do with Janet Woodcock has at least indicated that she's hired some additional help to try and clear up the backlog of well in excess of 2000 ANDAs. Any thoughts on progress on cleaning this backlog up? Are you seeing any improvement",52,"First one just has to do with Janet Woodcock has at least indicated that she's hired some additional help to try and clear up the backlog of well in excess of 2000 ANDAs. Any thoughts on progress on cleaning this backlog up? Are you seeing any improvement in timelines on ANDAs?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think from my perspective I see two mitigating factors here. I'm very happy that they actually have maybe gone out to the private sector to -- let's just help them with the queue and develop the right queue for better efficiency in flow of what they nee",184,"I think from my perspective I see two mitigating factors here. I'm very happy that they actually have maybe gone out to the private sector to -- let's just help them with the queue and develop the right queue for better efficiency in flow of what they need to do. But on the other hand, let's not forget that there are comments out there, ""in the year"" of what we've always seen coming and we would support. And that's a tightening of specs. So if you're going to be tightening specs on one hand, I think that further creates a little bit of a backlog only to be offset, I hope, by this outside resource that she's going to bring in from the private sector. So I'm not sure yet how the two are going to offset and whether or not we're going to get more efficiency or whether or not the tighter specs may cause a little bit more. I think it's yet to be seen, but we're very encouraged in terms of the FDA taking the initiative to improve the entire process."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just a follow-on to the tighter specs, she's also hinted that she's somewhat concerned about some of the generic supply that's out there. Can you help maybe elaborate on what she's implying? Are anticipating that there might be some other recalls on the h",45,"Just a follow-on to the tighter specs, she's also hinted that she's somewhat concerned about some of the generic supply that's out there. Can you help maybe elaborate on what she's implying? Are anticipating that there might be some other recalls on the horizon?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, I think one area that certainly we've been pretty vocal about is on the user fee front. And as you know, we have public comments out there and have been working closely with FDA and the industry to really set up a fair level playing field as far as",218,"Well, I think one area that certainly we've been pretty vocal about is on the user fee front. And as you know, we have public comments out there and have been working closely with FDA and the industry to really set up a fair level playing field as far as foreign inspections and this truly global supply chain that the FDA has to be able to support a product that's being sold into the U.S. So she, obviously, in her remarks have been very, very supportive of leveling that playing field and making sure that FDA has the resources they need to do inspections every two years of anyone who's supplying products into the U.S. market. So I think that some of her comments certainly go to the fact that, that heightening attention, the heightening of resources and us being able to put something through that would allow the FDA to accomplish that would certainly benefit not only leveling that playing field, but back to Robert's point, it will also even go towards the backlog and where we see the applications, and I think, could see an improvement in those median times all being connected together, and that's the approach weve certainly taking of advocating and believe that FDA believes that, that would be beneficial on all fronts."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Ronny Gal with Sanford Bernstein.",10,"Our next question comes from Ronny Gal with Sanford Bernstein."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First, a quick one for John. John, if I look at the reconciliation table that you've provided us with, it looks like you are excluding about $125 million and the tax effect offsetting that is about $80 million or 64% of the excluded amount. That looks lik",104,"First, a quick one for John. John, if I look at the reconciliation table that you've provided us with, it looks like you are excluding about $125 million and the tax effect offsetting that is about $80 million or 64% of the excluded amount. That looks like a very high tax rate on the excluded amount. If you can give us a clue about that. And still on the issue of integration, was that about $32 million this quarter for acquisition and integration charges? Can you help us understand how that will trail off over the next year if there are no additional acquisitions?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","On the first item, with respect to the taxes, remember that what we're doing with the tax reconciliation is not just in the tax adjustment, it's not just simply the tax affect of the reconciling items, but it is also to adjust the tax rate to the 28% full",80,"On the first item, with respect to the taxes, remember that what we're doing with the tax reconciliation is not just in the tax adjustment, it's not just simply the tax affect of the reconciling items, but it is also to adjust the tax rate to the 28% full-year effective rate, so to the extent that there are, let me say, one-time or unusual items within taxes, the tax expense or tax benefit, we also have to adjust those out."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And as far as your integration point, obviously, we've seen that come down tremendously year-over-year as we've gotten further into this integration. So yes, we continue to see that trailing off.",31,"And as far as your integration point, obviously, we've seen that come down tremendously year-over-year as we've gotten further into this integration. So yes, we continue to see that trailing off."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Follow-up on the Dey business. Some of your competitors have been talking about the opportunity in the respiratory area over the next few years, and you obviously have a respiratory platform. How do you think about this platform? If you can give us some v",70,"Follow-up on the Dey business. Some of your competitors have been talking about the opportunity in the respiratory area over the next few years, and you obviously have a respiratory platform. How do you think about this platform? If you can give us some view about what you're developing internally and what you might be interested in bringing from the outside to put on top of that sales force?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. Absolutely, we have said this is an extremely an important niche in the Specialty business, not only, obviously, how we marry up to that, but just I think in the United States overall, it's a very important niche area that we've seen a ton of growth",170,"Yes. Absolutely, we have said this is an extremely an important niche in the Specialty business, not only, obviously, how we marry up to that, but just I think in the United States overall, it's a very important niche area that we've seen a ton of growth as an industry. And I think we have a lot of opportunity. As Robert's talked about looking for complementary products to be able to put into the infrastructure that we already have and the doctors that we're already calling on as well as our own internal R&D pipeline on the COPD front with combo and of course our current performance. So that infrastructure, and I think that allergy marrying up again to EpiPen and what we've talked about being this underserved market is again that education around market expansion and how we continue to see an awareness, of building an awareness and that again continuing to expand that market for us both on the respiratory, from respiratory docs as well as the allergists."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Greg Gilbert with Bank of America Merrill Lynch.",13,"Our next question comes from Greg Gilbert with Bank of America Merrill Lynch."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","A couple for Heather and one for Robert. Heather, first, can you clarify what you meant about growth in EMEA in 4Q? Are you saying you expect growth over the 4Q of '09 level of $482 million?",37,"A couple for Heather and one for Robert. Heather, first, can you clarify what you meant about growth in EMEA in 4Q? Are you saying you expect growth over the 4Q of '09 level of $482 million?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, I was just saying both, that one, obviously Q3 has historically been lower. So last year, Q3 was less than Q4. This year, we're anticipating growth both over Q3 as well as over Q4 of '09.",37,"Yes, I was just saying both, that one, obviously Q3 has historically been lower. So last year, Q3 was less than Q4. This year, we're anticipating growth both over Q3 as well as over Q4 of '09."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And that would be mostly driven by new launches? Or is that other sort of organic drivers that would result in growth after a couple of quarters of decline?",29,"And that would be mostly driven by new launches? Or is that other sort of organic drivers that would result in growth after a couple of quarters of decline?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","A couple of things. We've got a lot of product launches this quarter as well as the benefit of a full quarter of some of the launches we've had throughout the year.",32,"A couple of things. We've got a lot of product launches this quarter as well as the benefit of a full quarter of some of the launches we've had throughout the year."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And then my other Europe question is whether or not you're seeing signs in Europe as governments understand the importance of making generic substitution happen or are they still just focused on finding short-term savings?",36,"And then my other Europe question is whether or not you're seeing signs in Europe as governments understand the importance of making generic substitution happen or are they still just focused on finding short-term savings?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","No, I've got a glimmer of hope that they are saying that the sustainability of utilization, that penetration is much more effective than a one-off price cut. I think we're starting to see that in Italy and Spain, as well as France. France, obviously, to m",166,"No, I've got a glimmer of hope that they are saying that the sustainability of utilization, that penetration is much more effective than a one-off price cut. I think we're starting to see that in Italy and Spain, as well as France. France, obviously, to me, is kind of the most mature in that Southern European region. And I see Italy and Spain kind of starting to follow suit as far as some incentives and increasing. And we've seen an increase in penetration in both of those markets. And look, I can assure you, will not stop our efforts of being out there educating and showing the sustainability of generic penetration versus just, like I said, the price cuts. And I think the other point to note here is the responsibility that we have seen and demonstrate between looking at the entire supply chain and not just the generic manufacturer, whether it's from the pharmacy perspective, the brand arena. So it's balancing both of those fronts."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Mark Goodman with UBS.",9,"Our next question comes from Mark Goodman with UBS."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I just want to make sure I'm clear on this EMEA following on the last questions. So we're going to have growth versus last year. Can you talk about what countries are going to be the key areas where you're talking about these new product launches? Is it F",121,"I just want to make sure I'm clear on this EMEA following on the last questions. So we're going to have growth versus last year. Can you talk about what countries are going to be the key areas where you're talking about these new product launches? Is it France? Is Germany going to come back? Second question is maybe you can give us a sense of what happened in the quarter in Asia, just Australia versus Japan versus India? Just so we have a little more flavor there. Then the third question is just talk about EpiPen in the quarter. Was there growth year-over-year in EpiPen? It seemed a little weaker than what I thought it was going to be."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Okay, so I'll start backwards so I don't forget anything. Yes, we saw, we definitely saw growth in EpiPen, both in volume as well as we had pricing in the year, but we certainly have seen some market expansion seeing the -- we saw the peak start a little",197,"Okay, so I'll start backwards so I don't forget anything. Yes, we saw, we definitely saw growth in EpiPen, both in volume as well as we had pricing in the year, but we certainly have seen some market expansion seeing the -- we saw the peak start a little earlier and last a little bit longer in the seasonality of that product. So we continue, as I said, to see our efforts around awareness to continue to help in that expansion. As far as Europe's concerned, obviously, as we continue to say, France is certainly the driver for us across the European region. As I noted this quarter, our sales were up year-over-year for France as well as Italy and Spain, and we continue to see those being contributors as well in this growth for Q4 both year-over-year and sequentially. As far as APAC is concerned, Matrix, while we don't break out the individual divisions within a segment, we have continued and will continue to at least give what the leaders are and Matrix has led that with double-digit growth from the APAC region, but we did have contribution both from Australia as well as Japan year-over-year."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is from Elliot Wilbur with Needham & Company.",10,"Our next question is from Elliot Wilbur with Needham & Company."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First question, I just want to drill down a little bit more on the strong gross margin performance thinking about it sequentially up about 300 basis points. It doesn't really look like it's a mix issue given that North America and Specialty were relativel",78,"First question, I just want to drill down a little bit more on the strong gross margin performance thinking about it sequentially up about 300 basis points. It doesn't really look like it's a mix issue given that North America and Specialty were relatively the same percentage of sales. Also, so it's not really a volume issue. So is it fair to say that the bulk, if not the entire degree of improvement sequentially, is attributable to synergies?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. Look, I'd say certainly, as we forecasted and anticipated, synergy realization was going to be stronger in the second half of the year, but I wouldn't lose total sight on mix. We had important approvals of higher margin products as limited competitio",84,"Yes. Look, I'd say certainly, as we forecasted and anticipated, synergy realization was going to be stronger in the second half of the year, but I wouldn't lose total sight on mix. We had important approvals of higher margin products as limited competition, like in clonidine, like in Minocycline and Tacrolimus so there is still -- you do have mix issues, which is why you have to look at the annual, the overall gross margin and the guidance, obviously, that we have out there."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I have a question for John as well. With respect to the company's current capital structure and the duration of the debt obligations, sort of understand that you have quite a bit of financial flexibility through your first bolus payment in 2012, a little",161,"I have a question for John as well. With respect to the company's current capital structure and the duration of the debt obligations, sort of understand that you have quite a bit of financial flexibility through your first bolus payment in 2012, a little -- about $700 million in total. But if you look out to 2014, there's roughly a $2 billion bullet that's due, and that just happens to coincide with I guess sort of a large systemic increase in overall debt obligations coming due in the U.S. And given the likelihood that there's going to be a lot of folks looking to refinance debt and also the fact that short-term interest rates probably are going to be a lot higher than where they are now, just sort of how should we be thinking about maybe potential addition what it means on your part to maybe flatten out the maturity ladder or even extend it further, which you've already done?"
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I would say this. If you go back eight months ago, seven months ago, we had over $3 billion of maturity in 2014. And over the course of this year, we've reduced that by $1.3 billion. So we have flattened out the 2014 maturity significantly. We will contin",172,"I would say this. If you go back eight months ago, seven months ago, we had over $3 billion of maturity in 2014. And over the course of this year, we've reduced that by $1.3 billion. So we have flattened out the 2014 maturity significantly. We will continue to look to extend the maturity profile at appropriate points in time. We'll use our strong positive cash flow to continue to reduce the amount of the 2014 as we did here in the third quarter by repaying $300 million. So I actually feel really good about where we stand in the capital structure. Our free cash flow is over $500 million a year with the final preferred dividend that we're making here in the fourth quarter. That will increase our free cash flow by $139 million a year. So I see us with a lot of cash. Robert has talked about the fact that we're not looking to make another strategic acquisition. We're fully committed to reducing our leverage to 3:1 or lower."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Let me just add something. First of all, you may not have caught it, but we did pre-pay $300 million. So we're actually at $1.7 billion now from the $3 billion or the $2 billion in which you've mentioned, Elliot. So you can see, and as a matter fact, when",180,"Let me just add something. First of all, you may not have caught it, but we did pre-pay $300 million. So we're actually at $1.7 billion now from the $3 billion or the $2 billion in which you've mentioned, Elliot. So you can see, and as a matter fact, when we first prepaid the $1 billion, I think what we said at the time we felt fairly comfortable at that time that we would generate enough operating cash flow actually to retire the debt itself. So taking the need for this organization to have to tap the market was exactly what we intended not to put ourselves in. So I feel very comfortable that we will continue to generate very strong free cash flows with the continued commitment to de-lever, but I will say at the same time I'm saying that, I wouldn't hesitate in a second to further extend those maturities if the opportunity arises and interest rates continue to be as advantageous as they are and simply give ourselves even more flexibility than what we've already provided ourselves."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","And our final question comes from John Newman with Oppenheimer.",10,"And our final question comes from John Newman with Oppenheimer."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I just wanted to ask a clarifying question on EMEA. It looks like the revenues for EMEA last fourth quarter, pretty robust, and I think I recall you saying that you were expecting both a quarter-over-quarter increase from 4Q this year versus current quart",95,"I just wanted to ask a clarifying question on EMEA. It looks like the revenues for EMEA last fourth quarter, pretty robust, and I think I recall you saying that you were expecting both a quarter-over-quarter increase from 4Q this year versus current quarter and also last year. So just wondering, is there something specific that is going to give you a pretty significant push? Because it seems like an increase over third quarter this year seems totally reasonable, but fourth quarter last year seems like maybe a little kind of a challenging comp there."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","All I can say is as we continue to stress the strength of our pipeline and launches not just third-party launches, but now our internal launches starting to roll in, that's really, like I said, the driver not only of just launches we're doing in Q4 but la",113,"All I can say is as we continue to stress the strength of our pipeline and launches not just third-party launches, but now our internal launches starting to roll in, that's really, like I said, the driver not only of just launches we're doing in Q4 but launches we've now done throughout the year that we're getting, reaping the full benefit of by the time it hits Q4. So it just continues to be the product launches and what we're able to do with those launches throughout all of the countries. And again, Q4 being, if you go back the year before, Q4 has been a very robust year throughout Europe historically."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","This concludes today's question-and-answer session. At this time, I'd like to turn the conference back over to our speakers for any additional comments or closing remarks.",27,"This concludes today's question-and-answer session. At this time, I'd like to turn the conference back over to our speakers for any additional comments or closing remarks."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I just like to thank everybody for their participation today, and at this point, Lisa, you can close out the call.",21,"I just like to thank everybody for their participation today, and at this point, Lisa, you can close out the call."
290203,114621935,82028,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","This does conclude today's conference call. Thank you for your participation.",12,"This does conclude today's conference call. Thank you for your participation."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Third Quarter 2010 Western Union Corporation Earnings Conference Call. My name is Chris, and I will be your operator for today. [Operator Instructions] I would now like to turn the conference over to your",56,"Good day, ladies and gentlemen, and welcome to the Third Quarter 2010 Western Union Corporation Earnings Conference Call. My name is Chris, and I will be your operator for today. [Operator Instructions] I would now like to turn the conference over to your host for today, Mr. Mike Salop, Senior VP of Investor Relations. Please proceed."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you. And good afternoon, everyone. On today's call, we will have comments from Hikmet Ersek, our President and Chief Executive Officer; and Scott Scheirman, Executive Vice President and Chief Financial Officer. The slides that accompany this call an",253,"Thank you. And good afternoon, everyone. On today's call, we will have comments from Hikmet Ersek, our President and Chief Executive Officer; and Scott Scheirman, Executive Vice President and Chief Financial Officer. The slides that accompany this call and webcast can be found at westernunion.com under the Investor Relations tab and will remain available after the call. Additional operational statistics have been provided in a supplemental table with our press release. Since we previously released our expected revenue and transaction trends on September 29 and held our Investor Day on September 30, we will keep our comments today fairly brief.
As a reminder, today's call is being recorded, and our comments include forward-looking statements. Please refer to the cautionary language in the earnings release and in Western Union's filings with the Securities and Exchange Commission, including the 2009 Form 10-K, for additional information concerning factors that could cause actual results to differ materially from the forward-looking statements. During the call, we will discuss some items that do not conform to generally accepted accounting principles. We have reconciled those items to the most comparable GAAP measures on our website, westernunion.com, under the Investor Relations section. All statements made by Western Union officers on this call are the property of the Western Union Company and subject to copyright protection. Other than the replay, Western Union has not authorized and disclaims responsibility for any recording, replay or distribution of any transcription of this call. I would now like to turn the call over to Hikmet Ersek."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Mike, and welcome, everybody, on the call. As Mike mentioned, approximately a month ago at the Investors Day, we gave you a strategy and business update. Now I am pleased to report at the close of third quarter by making steady progress with ou",989,"Thank you, Mike, and welcome, everybody, on the call. As Mike mentioned, approximately a month ago at the Investors Day, we gave you a strategy and business update. Now I am pleased to report at the close of third quarter by making steady progress with our business across the globe. 
Transaction and constant-currency revenue trends in our Consumer-to-Consumer business have now improved for four quarters in a row, with overall transaction growth increasing to 10% in the third quarter. Compared to the second quarter, the Americas and Asia-Pacific regions delivered improved trends, and the EMEASA region was steady. We took further steps to expand our retail footprint in Europe through a planned relationship with DHL and to advance our banking strategy in the U.S. by signing an agreement to offer money transfer services at KeyBank.
In Global Business Payments, the billed payments revenue decline was fairly consistent with the second quarter. Custom House delivered a solid $27 million in revenue and remains on track for double-digit revenue growth for the year. We are currently re-branding customers to Western Union business solutions. I believe Western Union's global brand strength and high awareness levels, as well as the company's agents and regulatory relationships, should benefit our business-to-business category as we expand into new markets.
In Bill Pay, we are piloting an enhanced walk-in payment service in the U.S. This new service provides repeat customers a simplified, formless process for urgent payments and is being tested at select agent locations. We also received approvals for a bank license in Brazil, which will allow us to offer Bill Payment like we do it in Argentina, Panama and Peru, as well as intra-country money transfer and other services such as prepaid cards. These are, of course, in addition to our existing cross-border Consumer Money Transfer business.
Now overall, the company generated strong margin improvement in the third quarter, led by the Consumer-to-Consumer business, which delivered 30% margins. We continue to generate strong cash flow and return capital to shareholders as we repurchased almost $100 million of stock in the quarter and declared nearly $40 million in dividends. Including the latest dividend, which was paid in October, year-to-date, we have now returned over $630 million to shareholders through repurchase and dividends.
Now based on the third quarter performance, current business trends and improved tax rate, we are pleased to be able to raise our full year 2010 earnings per share outlook again. Although the environment remains challenging, with high global unemployment, our diversified portfolio is delivering results. The momentum has been positive, and our increased confidence is also allowing us to make incremental investment in the business in the fourth quarter. Scott will give you more details on the third quarter financial results and our outlook in a few minutes. But before this, following our Investors Days presentation, I would like to provide a quick update on progress with our strategic initiatives.
In Electronic Money Transfer, we continue to grow. westernunion.com transaction in the international markets once again increased over 60% in the quarter. Including the U.S., the global westernunion.com transaction growth was almost 20%. 
Account-based money transfer transaction, which includes both account to cash, cash to account with banks, grew more than 50% in the quarter. We now have 27 banks globally that have agreed to offer this service through Western Union. 
In mobile, we have enabled approximately 70,000 agent locations in 27 countries to provide cash to mobile service. Consumer can also send money transfers to mobile recipients from westernunion.com sites in six countries. We also expanded our relationship with the State Bank of India to allow account holders to receive money transfers in their bank accounts using their mobile phones beginning 2011. In Canada, we entered a strategic alliance with EnStream to allow Zoompass mobile wallet holders to send cross-border and domestic money transfers directly from their mobile phones.
Electronic channels are still a relatively small part of our portfolio today, at only 2% of revenues. But we continue to grow fast and lay the groundwork for the future. In prepaid, we had over 650,000 cards-in-force at the end of the quarter, and we increased our retail distribution in the U.S. to over to over 9,000 locations. 
As we reported at our Investors Day, year-to-date through the end of September, over $240 million of principal has been loaded on the cards to approximately 1.1 million loads. We began a direct response television campaign in the U.S. for our prepaid cards in the quarter, and also signed an agreement with CCH, a lead software for tax and accounting professionals. This agreement will allow customers to receive U.S. tax refunds on a Western Union MoneyWise Prepaid MasterCard beginning in 2011. We have also initiated plans for expanding prepaid into select international markets with several countries in the works for 2011. We believe the global opportunities for prepaid are large, and we are well positioned to offer this service in the appropriate markets.
So this is a quick progress update on some of our key initiatives. As we discussed at our recent Investors Day, this organization highly focused on four key strategic priorities: growing our Retail Money Transfer business; expanding Electronic Channels; developing our product portfolio with new services, such as prepaid cards and business-to-business solutions; and improving processes and productivity.
Since I was named CEO, I have spent a large amount of my time evaluating the company's competitive position, global market opportunities, organizational capabilities and processes. I strongly believe we now have the right strategy in place, and moving forward, our success will be highly dependent on execution. We are creating the proper alignment, processes, tools and incentives to drive results, and I believe we took some encouraging steps in this right direction in the third quarter.
Now to give you a more detailed review of the financial results and the full year outlook, I would like to turn the call over to Scott."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Hikmet. Our third quarter revenue and transaction results were consistent with what we reported in our September 29 press release. We are pleased with the continued progress in Consumer-to-Consumer and Western Union business solutions, which wa",1715,"Thank you, Hikmet. Our third quarter revenue and transaction results were consistent with what we reported in our September 29 press release. We are pleased with the continued progress in Consumer-to-Consumer and Western Union business solutions, which was formerly Custom House. While U.S. Bill Payment remains challenging, the rate of decline in Bill Payment did moderate slightly. 
Overall for the quarter, we reported consolidated revenue growth of 1% or 3% on a constant-currency basis. Total Western Union transaction fee revenue represented 78% of company revenue and was flat from the prior year. Foreign exchange revenue represented 20% of total company revenue and increased 11% in the quarter, benefiting from the acquisition of Custom House.
Our Consumer-to-Consumer segment revenue increased 1% or 3% in constant currency. As Hikmet noted, each region contributed to this progress with steady to improving trends. 
Transaction growth in our C2C segment continued to accelerate with 10% year-over-year growth. Trends in the international C2C business were comparable to the second quarter. Revenue grew 2% in the third quarter or 4% constant currency on transaction growth of 7%. The company's C2C cross-border principal increased 4% in the quarter or 6% on a constant-currency basis. C2C principal per transaction decreased 4% year-over-year or declined 3% in constant-currency terms, generally in line with recent quarterly trends.
Turning to our regions. Our C2C business in Europe, Middle East, Africa and South Asia region grew transactions consistent with the second quarter at 5%. Revenue declined 2% and was again negatively impacted by currency translation. On a constant-currency basis, EMEASA revenue increased in the quarter. 
We continue to see good performance from large markets, such as the U.K., Germany and Russia, while the Gulf states remained challenged, with transaction declines consistent with the second quarter. India transactions and revenues increased 2%, and transactions continue to be impacted by the Gulf state softness.
In the quarter, we also launched westernunion.com transaction site in Switzerland, agreed with certain banking partners in Romania, Turkey and Russia to offer account-based money transfer and introduced the Western Union loyalty card in Romania. 
Turning to the Americas region. Momentum continued with 13% transaction growth and 2% revenue increase in the quarter. U.S. domestic repositioning once again drove activity, led by the $0.00 to $50 principal band. Domestic money transfer delivering strong transaction growth of 35% in the quarter, revenue declined only 6%, and we continue to expect positive domestic revenue growth in the fourth quarter. Mexico transactions grew 2% as revenue declined 1%, and the U.S. Outbound business continued to perform well, with the Philippines and Jamaican corridors leading the revenue growth.
The Asia-Pacific region delivered strong performance in the quarter, with growth of 15% in transactions and 12% in revenue. In China, transactions and revenue each grew 6%. We continue to see network expansion in corridor marketing as key drivers to growing share in this important country, and we'll be activating thousands of new locations with our new and existing bank partners over the next few years.
The Philippines and Australia also contributed to the regions' growth in the quarter, with especially strong performance of our Intra business in the Philippines. For the overall C2C business, the spread between transaction and revenue growth in the quarter was seven percentage points, excluding the impact of currency, which had a negative two point impact. Consistent with the first half of 2010, the factors affecting the currency-adjusted spread included the domestic money transfer repositioning, international pricing and mix.
Domestic money transfer contributed four points of the transaction-to-revenue spread as a result of both pricing and mix. As we begin to anniversary the domestic repositioning in the fourth quarter, we anticipate the C2C transaction revenue spread will narrow, although we believe the $5 price point will still be an important growth driver going forward.
Moving to the Global Business Payments segment. Revenue increased 5% or declined 7%, excluding business solutions, consistent with our expectations. While the U.S. business continued to be challenged, particularly by the mortgage market, Banco Brasil in South America had another solid quarter. The integration of the Bill Payment business under the direction of Stewart Stockdale in the Americas region continues, and our objective is to gain revenue and cost efficiencies over time.
Western Union business solution revenues were strong at $27 million and remain on track for double-digit revenue growth this year. As a reminder, we acquired Custom House in September of 2009, so there was one month of revenue or $8 million in our third quarter results a year ago.
Turning to our margins. Third quarter consolidated GAAP operating margin was 26%. Excluding restructuring charges, the consolidated operating margin was 27%. We recorded $14 million of restructuring expenses in the quarter related to our May 27 announcement. Approximately $5 million of the charges is including cost of services, and $9 million is in SG&A. These amounts are not included in our segment operating results. 
For purposes of year-over-year comparisons, the third quarter of 2009 included a $71 million expense accrual related to the settlement with Arizona and several other states. To simplify operational comparisons, I will exclude both the 2010 restructuring charge and the 2009 settlement accrual from my margin commentary.
The operating margin, excluding restructuring charges, improved approximately 70 basis points from the third quarter of last year and 40 basis points compared to the second quarter of 2010. Compared to the third quarter of 2009, increased costs related to business solution investment spending and acquisition-related amortization were offset by lower marketing expenses and operating efficiencies. 
Third quarter earnings per share were $0.36 or $0.37, excluding restructuring expenses. On a constant-currency basis, EPS was $0.01 higher or $0.38 excluding restructuring. This compares to GAAP EPS of $0.26 in the third quarter of last year or $0.33 excluding the settlement accrual. 
Our C2C segment operating margin was 30%, an increase of 230 basis points over the same period last year. The margin increase was primarily due to lower marketing, operating efficiencies and currency. Segment margin increased 80 basis points compared to the second quarter of 2010.
Global Business Payments operating margin of 15% included the Custom House intangible amortization expense and investment spending for future growth. Excluding Business Solutions, segment margin of 23% was down from 26% in the third quarter last year, driven by lower U.S. Bill Payments revenue. 
Moving to our cash flow and balance sheet. Our financial position remains strong. In the quarter, we generated cash flow from operations of $384 million, while capital expenditures were $44 million. We repurchased 6 million shares in the quarter at an average price of $16.15 per share for a total of $98 million. Year-to-date, we have spent $514 million to repurchase 32 million shares or 5% of the total shares outstanding at an average price of $16.23. As of September 30, we had $486 million remaining under the current stock repurchase authorization.
In the quarter, we also declared another $0.06 per share dividend, for which $39 million was paid on October 14. At quarter end, the company had total debt of $3.3 billion, and cash of $2 billion, of which approximately $900 million of cash was outside the United States. On a year-to-date basis, cash flow from operations was $710 million and includes the impact of the $250 million refundable tax deposit that we made with the IRS in the first quarter.
Turning to our full year 2010 outlook. As Hikmet mentioned, we are increasing our earnings per share range for the year. Our C2C margins have been strong, our tax rate has improved, and we expect constant-currency revenues will be closer to the higher end of the previous range. The recent strengthening of the euro should aid GAAP revenues in the fourth quarter, although the impact on earnings will be lower due to our hedging programs.  As a result of the hedges, the strengthening of the euro will likely have a negative impact on fourth quarter operating margin. 
We plan to invest in the business in the fourth quarter to aid future growth, including incremental marketing spending and other strategic investments. The additional marketing spend will include investments in loyalty programs and general holiday advertising and promotion. We expect our marketing percentage, which was slightly below 4% of revenue, for the first nine months of 2010 to be around 5% in the fourth quarter, although for the full year, we should still be at approximately 4%.
We continue to expect our full year operating margin, excluding restructuring, to be between 26% and 26.5%. Including restructuring charges, we expect GAAP operating margins in the range of 24.5% to 25%. The full year tax rate, excluding the restructuring charge, is projected to be between 22% and 23%. Year-to-date through September, our tax rate, excluding restructuring, was approximately 23%. We expect the fourth quarter rate to benefit from onetime adjustments and certain favorable resolutions. We do not expect these benefits to affect the 2011 tax rate. Including the impact of restructuring, the outlook for the GAAP tax rate for the year would be between 21.5% and 22.5%. 
Given all these factors, our updated outlook for full year 2010 is: GAAP revenue growth in the range of plus 1% to plus 2%; constant-currency revenue growth, one point higher than GAAP or plus 2% to plus 3%; GAAP EPS of $1.29 to $1.32, including $0.07 of restructuring charges; EPS of $1.36 to $1.39, excluding restructuring; and constant-currency EPS, $0.01 higher.
We now expect GAAP cash flows from operating activities of $900 million to $1 billion, including the $250 million reduction in the first quarter refundable tax deposit. Capital expenditures are projected at 2% to 3% of revenue. We continue to expect the majority of the $80 million in restructuring charges announced in May to occur in 2010, with approximately $10 million of related savings this year.
In summary, we are pleased with the improving trends in our business. We have raised our EPS outlook, excluding restructuring, up from their previous outlook of $1.31 to $1.36 to our current outlook of $1.36 to $1.39. We will continue to balance margin enhancement with investments for future growth and believe we have the opportunities for both over the long term.
That concludes our prepared comments for the quarter. I would now like to turn the call back to Mike."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thanks, Scott. We'll now move on to the Q&A. In order to maximize the number of people we can get on the call, we do ask that each person limit themselves to one question. Chris, we're ready for the first question.",41,"Thanks, Scott. We'll now move on to the Q&A. In order to maximize the number of people we can get on the call, we do ask that each person limit themselves to one question. Chris, we're ready for the first question."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from the line of Bob Napoli of Piper Jaffray.",15,"[Operator Instructions] Our first question comes from the line of Bob Napoli of Piper Jaffray."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I'd just like to dig a little bit more into the expense improvement and the tax rate outlook for 2011. I mean, your expenses came in comfortably below what we were looking for. And you did say that marketing was a little bit lower. But where primarily did",83,"I'd just like to dig a little bit more into the expense improvement and the tax rate outlook for 2011. I mean, your expenses came in comfortably below what we were looking for. And you did say that marketing was a little bit lower. But where primarily did you come in better than I think what you had anticipated on the operating expense side? And how much of that is sustainable? And what is the tax rate for '11, the outlook long-term?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","This is Scott. For the third quarter and even year-to-date 2010, we've had marketing at close or about a little bit less than 4% of revenue. For the fourth quarter, we expect that to be closer to 5%. Although for the full year, itll be around 4% from t",158,"This is Scott. For the third quarter and even year-to-date 2010, we've had marketing at close or about a little bit less than 4% of revenue. For the fourth quarter, we expect that to be closer to 5%. Although for the full year, itll be around 4% from that standpoint. Weve had particularly good experience with operating expense efficiency, both from the restructuring we did back in May, we'll realize about $10 million of savings this year on that, and then just continuing to leverage our fixed expenses. As far as 2011, it's probably a little bit too early to get into the details of that. We'll provide more details in February. But for sure, we're going to balance investment spending with our margin objectives. And we think as the market improves, as revenue reaccelerates, we've got a business that's set up for margin expansion. But we'll balance that with investing in the business as we move forward."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","But just the tax rate, is the tax rate from this year like a number we should think about longer term? Or should it decline?",25,"But just the tax rate, is the tax rate from this year like a number we should think about longer term? Or should it decline?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, I don't want to give any 2011 outlook at this time. But one thing I would emphasize about 2010, that a number of the benefits that we've had to the 2010 tax rate probably will not repeat themselves in 2011. One example I would give you, early in the",95,"Yes, I don't want to give any 2011 outlook at this time. But one thing I would emphasize about 2010, that a number of the benefits that we've had to the 2010 tax rate probably will not repeat themselves in 2011. One example I would give you, early in the year, we resolved some tax issues dating back from 2002 and 2004, favorably resolved those. Again, I don't anticipate those on a go-forward basis, so some of the items that we're benefiting with the tax rate in '10, I don't expect to continue into 2011."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of James Friedman of Susquehanna.",12,"Our next question comes from the line of James Friedman of Susquehanna."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Ill focus on APAC. I know at the Analyst Day, Drena Uy [ph], if I'm saying her name properly, had spoken eloquently about your initiatives in APAC. The China numbers were kind of consistent with what we had thought, but the overall number was higher. Y",78,"Ill focus on APAC. I know at the Analyst Day, Drena Uy [ph], if I'm saying her name properly, had spoken eloquently about your initiatives in APAC. The China numbers were kind of consistent with what we had thought, but the overall number was higher. You alluded to Philippines and Australia. How much more do you have to go to fill the bucket in Philippines and Australia? Could those regions potentially fuel growth in APAC going forward?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","James, this is Hikmet. APAC has been, for us, always opportunity market. If you look at our portfolio, only a small part of our portfolio is currently APAC. And we have strong growth rates in APAC. Also, the market in Philippines are doing well and also m",206,"James, this is Hikmet. APAC has been, for us, always opportunity market. If you look at our portfolio, only a small part of our portfolio is currently APAC. And we have strong growth rates in APAC. Also, the market in Philippines are doing well and also market like Australia is growing. But I believe there are also markets like Indonesia, Malaysia, Vietnam, where we have opportunities. And recently, as we announced last quarter, we opened Japan also. That's also an opportunity. Also we are expanding our network there. In some markets, we have high brand awareness. In some markets, we are building the brand name, and it's a market where we are investing. The interesting thing on APAC is also not only an inbound opportunity like in Philippines or China, but we also see intra-region within APAC: outbound and corridor building, inbound and outbound activities. And the other example is the Philippines' intra-money transfer market, I think we are very well positioned there. We have strong growth there. And we also see there these opportunities to expanded in Indonesia and Malaysia, also in the intra market. So overall, I would say in APAC, given our 200 countries presence, also in APAC, we have huge opportunities here."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Bryan Keane of Credit Suisse.",13,"Our next question comes from the line of Bryan Keane of Credit Suisse."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just on the Global Business Payments operating margin, that one came in a little bit below what we were expecting. Can you talk about what the outlook is there? And I know at the Analyst Day, you guys were talking about trying to do some quick fixes there",65,"Just on the Global Business Payments operating margin, that one came in a little bit below what we were expecting. Can you talk about what the outlook is there? And I know at the Analyst Day, you guys were talking about trying to do some quick fixes there. Maybe you can give us some color on how you guys plan to fix the operating margin."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, on that business, Bryan, one of our challenges, and if you exclude Custom House, is the revenues declining from the U.S. Bill Payment business. So one thing we've done is combined that business with the Americas under Stewart Stockdale's leadership.",221,"Yes, on that business, Bryan, one of our challenges, and if you exclude Custom House, is the revenues declining from the U.S. Bill Payment business. So one thing we've done is combined that business with the Americas under Stewart Stockdale's leadership. And our thinking there, strategic thinking there, is to really to continue to try and drive new sales and new business. It takes some time to sell, it takes some time for that business to convert, but we've got to push hard on the top line to get that top line going north and not south, if you will. But also equally as important is looking at operating efficiencies or synergies and combining, if you will, those two organizations, so we create better leverage as we move forward. And then I'd just say, broadly, too, just, Pago Facil is doing well. It's a smaller piece of the business. But what's important for our business model in that area is product diversification, geographic diversification, and Custom House will play an element of that. And Custom House is only in seven countries today, but broadly, we have an opportunity to expand Custom House further not only deepen the penetration in the existing seven countries, but move to additional countries. So that will help that segment business broadly as we move forward, too."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Bryan, let me just add on that on the U.S. Bill Payment, my team is focused and were operational fix [ph], that's a part of the business. As Scott said, we do have some top line issues, but we are expanding the portfolio to get more revenue. But also o",74,"Bryan, let me just add on that on the U.S. Bill Payment, my team is focused and were operational fix [ph], that's a part of the business. As Scott said, we do have some top line issues, but we are expanding the portfolio to get more revenue. But also on the part of the business, we are really looking in the very deep dive [ph] there and we are very focused on that, Bryan."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And then my follow-up is, Scott, the raise in EPS, how much of that was the better operating margin versus lower tax rate?",24,"And then my follow-up is, Scott, the raise in EPS, how much of that was the better operating margin versus lower tax rate?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Bryan, are you referring to the third quarter or for full year?",12,"Bryan, are you referring to the third quarter or for full year?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I guess for the full year, just to take up a guidance.",12,"I guess for the full year, just to take up a guidance."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Sure, sure. I would say it's a combination of several things. Let me walk you through those, Bryan. It's clearly, we've got revenue at the upper end of our constant currency, so we've got some revenue help that's pulling through to the bottom line or EPS.",162,"Sure, sure. I would say it's a combination of several things. Let me walk you through those, Bryan. It's clearly, we've got revenue at the upper end of our constant currency, so we've got some revenue help that's pulling through to the bottom line or EPS. So that's definitely a factor. And it's also the tax rate, the simple math on the tax rate if you do it, it's about $0.02. But then I'd say that's also offset by some investment spending we're making in the fourth quarter. So we're investing some more in the fourth quarter behind marketing and some other strategic initiatives. So there's investment there that we use to fund some growth things that will help us in the fourth quarter and 2011. So to really get a combination of revenue at the top end of the constant currency outlook we've had, somewhat from the tax rate and then some offset from more investment spending in the fourth quarter."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Julio Quinteros of Goldman Sachs.",13,"Our next question comes from the line of Julio Quinteros of Goldman Sachs."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Scott, I just wanted to come back to the comment that you made about the $5 price point not likely to go away. At least, I didn't catch if that was a one or two quarter event. Can you just give us some clarity on what you mean by that? And is that necessa",81,"Scott, I just wanted to come back to the comment that you made about the $5 price point not likely to go away. At least, I didn't catch if that was a one or two quarter event. Can you just give us some clarity on what you mean by that? And is that necessary, I guess, to sustain the recent improvements in the Americas transaction volume growth? And for how long should we expect that price point to be in place?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, right now, we see the domestic business as a growth business. We think one element of that is the $5 for $50 price point, but also it's broader with the repositioning that we've done with that with simplified the pricing. We've got a good message the",184,"Yes, right now, we see the domestic business as a growth business. We think one element of that is the $5 for $50 price point, but also it's broader with the repositioning that we've done with that with simplified the pricing. We've got a good message there. And the $5 for $50 is bringing customers back to the company that we haven't seen and also some new customers in there. So we think we believe that's going to be part of our go-forward strategy, is to offer that $5 for $50. We think that's important. I think what's equally important to think about is that for the quarter, we had 35% transaction growth, 35% transaction growth. Revenue was down only 6%. And the reason I say it is that it moderated from being down 20% in the fourth quarter about a year ago, so that's really moderating. By the fourth quarter, we expect positive revenue growth. And that's a business that carries 30% margins. So we feel like we've got a very good formula in that business to drive growth as we move forward."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Adam Frisch of Morgan Stanley.",13,"Our next question comes from the line of Adam Frisch of Morgan Stanley."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Hikmet, you're getting off to a really good start on the C2C performance here. Are you seeing anything in the market today which would give you any concerns about the growth in margin expansion continuing? And then the follow-up would be how dependent are",54,"Hikmet, you're getting off to a really good start on the C2C performance here. Are you seeing anything in the market today which would give you any concerns about the growth in margin expansion continuing? And then the follow-up would be how dependent are your goals for C2C margin growth dependent on the economy?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, Adam, first of all, the beauty of our business being in 200 countries, right, we do see opportunities globally where we are present, but we do see also some challenges, unemployment rate on parts of the economy, parts of the world is still high. And",178,"Well, Adam, first of all, the beauty of our business being in 200 countries, right, we do see opportunities globally where we are present, but we do see also some challenges, unemployment rate on parts of the economy, parts of the world is still high. And Gulf states has still challenging, right? And parts of like Spain has a still 20% unemployment rate. So the beauty of our business, though, we have been in 200 countries, right? So we do like Russia, Germany, U.K., [indiscernible], right? The U.S. business is doing well. Americas region had another solid quarter. So I would say that we really, the luxury [ph] of the portfolio to respond to the market challenges and the opportunities. I would say also we are very well positioned once the economy really picks up, right? We've been here. We are very well positioned. We are here. We have our 450,000 locations. We have our brand. As I mentioned in the Investor Conference, we have our strong fundamentals to expand even to the other channels also, right, so."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Jason Kupferberg of UBS.",12,"Our next question comes from the line of Jason Kupferberg of UBS."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just wanted to follow up on some of the margin commentary. Obviously, everyones thinking about where the '11 margins might fall out. And you guys have been pretty consistent in your commitment to expanding margins over time. And I know you can't give u",126,"Just wanted to follow up on some of the margin commentary. Obviously, everyones thinking about where the '11 margins might fall out. And you guys have been pretty consistent in your commitment to expanding margins over time. And I know you can't give us any specifics yet in terms of guidance there. But can you help us understand at least the relative importance of some of the relevant factors that are going to impact margins next year? I'm thinking about all the variables like revenue growth and pricing, reinvestments in the business, maybe some initial restructuring savings. Just some qualitative commentary on kind of the relative importance of each of those factors as we start to think about conceptually where margins could shake out next year."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Sure, Jason. Let me walk you through some factors to think about. Again, it's too early to get to your point, 2011 guidance or outlook. But if you start very macro, we do believe we've got a business model that can drive margin expansion as revenue accele",215,"Sure, Jason. Let me walk you through some factors to think about. Again, it's too early to get to your point, 2011 guidance or outlook. But if you start very macro, we do believe we've got a business model that can drive margin expansion as revenue accelerates. So probably one of the key things is the top line revenue for 2011 as we think about that. Clearly, we've done some things with productivity that have been helpful. The May restructuring we announced will have about $30 million to $40 million of savings next year. We continue to move forward with our commission optimization initiatives and so forth. But again, we want to balance that with making the right investments in the business. And those investments would be strategically aligned to really drive the retail expansion, drive electronic expansion, rounding out our product portfolio with Prepaid and Business Solutions. So we'll continue to invest in the business as we move forward. But as a leadership team, we are committed to driving margin expansion. We'll balance that with investments. And probably the macro thing that will be the most helpful or could be a challenge, as Hikmet alluded to, is the global operating environment and what the top line revenue growth looks like as we move forward."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Kartik Mehta of Northcoast Research.",13,"Our next question comes from the line of Kartik Mehta of Northcoast Research."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","This is Grant Keeney in for Kartik. I realize you don't want to give guidance for 2011. But just directionally just to make sense, assuming the economy doesn't deteriorate in 2011 and you witness revenue growth, any reason to think the operating margin do",46,"This is Grant Keeney in for Kartik. I realize you don't want to give guidance for 2011. But just directionally just to make sense, assuming the economy doesn't deteriorate in 2011 and you witness revenue growth, any reason to think the operating margin does not improve?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Again, it's too early to get into 2011 in specifics. And we could play a lot of scenarios, and I don't want to go through a lot of scenarios here. But clearly, the leadership team, Id probably just emphasize, we're very focused on gaining share. We bel",95,"Again, it's too early to get into 2011 in specifics. And we could play a lot of scenarios, and I don't want to go through a lot of scenarios here. But clearly, the leadership team, Id probably just emphasize, we're very focused on gaining share. We believe the secular trends are intact. We want to drive the top line, drive productivity and again, balance that with investments for the right long-term growth of the business. But as a leadership team, one of our objectives over the long term is we want to expand the margins."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think if you look at our strategy back in Australia, they're built on that. The first three parts are driving the top line revenue, finding the new segment and the last one is the improving our process and productivity. I think our business model then s",54,"I think if you look at our strategy back in Australia, they're built on that. The first three parts are driving the top line revenue, finding the new segment and the last one is the improving our process and productivity. I think our business model then stretches the line to expand our margins, right?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Is there any increased competition in the EMEASA region just based on the transaction growth and revenue decline of the third quarter?",22,"Is there any increased competition in the EMEASA region just based on the transaction growth and revenue decline of the third quarter?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think there is nothing surprising since last quarter, right? So I think competition has been always there, but we are gaining market share. I mean, globally, if you look at our market share, again, market share [ph], we have some challenges in some coun",86,"I think there is nothing surprising since last quarter, right? So I think competition has been always there, but we are gaining market share. I mean, globally, if you look at our market share, again, market share [ph], we have some challenges in some countries, but like countries in the EMEASA region, like Germany, like the U.K., Russia are performing well. And on the EMEASA region, we have challenges on the Gulf states. And that continue, but it's more economic-related challenges than competition-related challenges, I guess."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And Grant, the revenue decline was really just due to currency translation.",12,"And Grant, the revenue decline was really just due to currency translation."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Andrew Jeffrey of SunTrust.",12,"Our next question comes from the line of Andrew Jeffrey of SunTrust."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I know one of the big issues around the stock has been concern over competition, and I think you did a great job at the Investor Day addressing your competitive position. There have been a couple of competitive announcements or maybe the flushing out of s",197,"I know one of the big issues around the stock has been concern over competition, and I think you did a great job at the Investor Day addressing your competitive position. There have been a couple of competitive announcements or maybe the flushing out of some competitive positions in the last week or so, and I wonder if I might ask you about them. One would be PayPal's efforts to market an account-to-cash solution for banks and really speeding up the settlement times, which have been more [ph], I think, Paypal's competitive disadvantage historically, among others. And I find it curious that they're trying to partner with banks, whereas there is also a competitive issue that banks have with PayPal for sure in terms of producing interchange. And I just wonder if you could give an update on your efforts to increase account-to-cash? At U.S. banks, obviously, youve had some wins of late, but maybe talk about it in a competitive context. And then, Chase has offered or introduced a B2B solution similar to Custom House, at least in certain markets. Im wondering if you could sort of address your competitive position against both of those products?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Let me address that. I believe that we are very well positioned for expanding our portfolio in the account-to-cash, cash-to-account money transfer. The reason for that is we can pay out in minutes cash, right, or collect cash and pay out in an account in",207,"Let me address that. I believe that we are very well positioned for expanding our portfolio in the account-to-cash, cash-to-account money transfer. The reason for that is we can pay out in minutes cash, right, or collect cash and pay out in an account in minutes cash, and in that in 16,000 corridors. Currently, we have 27 banks internationally. Also actually globally, we have 27 banks, which allows us to do account-based money transfer. We are growing about 50%. And so what we are doing is really connecting the accounts with the cash payout with our locations, which gives us a huge competitive advantage, I guess. The other thing also is that on the B2B money transfer, I think with the Custom House acquisition, we started seeing an opportunity here that we can serve also small business entities globally. Currently, we are with Custom House in seven countries. And given our global brand awareness, global presence, global network, global agent relationship we have, we believe that we could service SMEs globally in a bigger market. That's why we are also changing the Custom House name now to Western Union Business solutions and promoting that within the SMEs and expanding with our -- longer-term, expanding that business globally."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","This is Scott. The one thing I would add there with Custom House or Business Solutions is that our market share there is very, very small. So for us, the game is market share gain, customers that had been underserved by banks, and so we think we can compe",57,"This is Scott. The one thing I would add there with Custom House or Business Solutions is that our market share there is very, very small. So for us, the game is market share gain, customers that had been underserved by banks, and so we think we can compete well in that space as we move forward."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Tien-Tsin Huang of JPMorgan.",13,"Our next question comes from the line of Tien-Tsin Huang of JPMorgan."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","The marketing spend, the 5% spend in the fourth quarter, is that higher than what you budgeted this time last quarter? And I'm curious if this is just more of a one-off investment around the holidays or if it's more permanent kind of spend?",44,"The marketing spend, the 5% spend in the fourth quarter, is that higher than what you budgeted this time last quarter? And I'm curious if this is just more of a one-off investment around the holidays or if it's more permanent kind of spend?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","This is Hikmet. I mean, first of all, as you know, we do marketing depending on seasonality, depending on opportunities, depending on corridor opportunities. Globally, we allocate the marketing. Definitely, we see some opportunity as part of the core [ph]",113,"This is Hikmet. I mean, first of all, as you know, we do marketing depending on seasonality, depending on opportunities, depending on corridor opportunities. Globally, we allocate the marketing. Definitely, we see some opportunity as part of the core [ph] business to invest in the marketing in the fourth quarter, which we believe, is the right investment. Also some parts of the investment is also about our new initiatives, right? I think what we do is that we are really diversifying our marketing investment against opportunities, and we do see opportunities in Q4 and into some more [ph] countries. And traditionally, I believe we've been about 4%, right, Scott? I think its the..."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. I mean, and just macro-ly -- on an annual basis, the last two or three years, we've been around 4% to 6%. It'll vary quarter-by-quarter. As we spoke about earlier, we're a little bit below 4% the first three quarters. We'll be closer to 5%. But we ju",99,"Yes. I mean, and just macro-ly -- on an annual basis, the last two or three years, we've been around 4% to 6%. It'll vary quarter-by-quarter. As we spoke about earlier, we're a little bit below 4% the first three quarters. We'll be closer to 5%. But we just see an opportunity to make some investments behind the holidays, behind some of the loyalty programs that we think will not only have some benefits in the fourth quarter, but as important or more importantly, have more benefits for us in 2011. So we make sure it's the right investment."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I think, Scott, you went through some of the spread discussion. Can you give us an idea, and maybe you gave this or not, what the normalized spread between revenue and transaction growth would look like domestically now that we're going to, we've lapped t",60,"I think, Scott, you went through some of the spread discussion. Can you give us an idea, and maybe you gave this or not, what the normalized spread between revenue and transaction growth would look like domestically now that we're going to, we've lapped the October repositioning? Because I think that could drive some confusion as we see that domestically."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, and heres how I think about it, Tien-Tsin, is probably from this dimension, if you will, that theres, as I reminded everybody, there's really two price points we've got to lap in the fourth quarter. The first one is, call it October 1 a year ag",156,"Yes, and heres how I think about it, Tien-Tsin, is probably from this dimension, if you will, that theres, as I reminded everybody, there's really two price points we've got to lap in the fourth quarter. The first one is, call it October 1 a year ago, where we got all the prices uniformity throughout the U.S. And then just a little bit before Thanksgiving, call it November 15, about a year ago, we introduced the $5 for $50 program or promotion, if you will. So weve kind of got two sets of pricings to lap, if you will. I think the important thing to think about is that we expect positive revenue growth in the fourth quarter. We do expect the spread between transactions and revenue will narrow somewhat in the fourth quarter, but I think the key element is it'll be positive through revenue growth with a business that carries a 30% plus margin."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of David Togut of Evercore Partners.",13,"Our next question comes from the line of David Togut of Evercore Partners."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First, Hikmet, could you comment on recent trends you've seen in agent productivity and how they might compare to a year ago? These are for new agents.",27,"First, Hikmet, could you comment on recent trends you've seen in agent productivity and how they might compare to a year ago? These are for new agents."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, generally, we look on agent productivity constantly. It's both sides, right? Agent do look in their productivity in getting more transaction their locations and getting more traffic depending on the agent portfolio. And also from our side, from the",120,"Well, generally, we look on agent productivity constantly. It's both sides, right? Agent do look in their productivity in getting more transaction their locations and getting more traffic depending on the agent portfolio. And also from our side, from the commissions side, we also look our agent commissions constantly. Having that global presence, having so many agents, more than 1,000 agents, 900,000 agents, we do look at our agent portfolio, and when the contracts are coming and we renegotiating the country-by-country, quarter-by-quarter the agent contracts, and depending on that. So I think we are constantly looking at it as a part of our process and productivity initiative, and so I would say that, that's a constant work that we doing."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Scott, what are your capital allocation priorities for 2011?",9,"Scott, what are your capital allocation priorities for 2011?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","On a long-term basis, if it's really first, to invest in the business, David, which runs 2% to 3% of our revenues, so call it $100 million to $150 million. Second priority is acquisitions, mergers and acquisitions, reinvesting back in the business that wa",148,"On a long-term basis, if it's really first, to invest in the business, David, which runs 2% to 3% of our revenues, so call it $100 million to $150 million. Second priority is acquisitions, mergers and acquisitions, reinvesting back in the business that way. But there well be selective. It's got to be strategically fit very well, have to have the right cash- on-cash economic return. And then third, which is very important, is returning cash to shareholders both through dividends and stock buyback. And we continue to move more towards a balanced approach with -- as we talked about at the Investor Day back in December, we increased the dividend payout last December. So we very much view a balance payout as important as we move forward, too. So thosell be the priorities for our capital allocation as we think about the next couple of years."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Darrin Peller of Barclays Capital.",13,"Our next question comes from the line of Darrin Peller of Barclays Capital."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First question, and a quick follow-up, how much did you spend on investments overall in Custom House, Prepaid and Payment Services Directive so for this year or at least the ballpark amount? Really how much were margins pressured from those and other rein",79,"First question, and a quick follow-up, how much did you spend on investments overall in Custom House, Prepaid and Payment Services Directive so for this year or at least the ballpark amount? Really how much were margins pressured from those and other reinvestments? And then do you see similar amounts going forward next year? I guess, really do you expect meaningful incremental revenue generation also from Payment Services, on the PSD, Payments Services Directive in Q4 and next year?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, Darrin, this is Scott. Let me kind of give you a full year view of the investment spending. And we talked earlier in the year about roughly about $50 million that we would spend between, call it, Electronic Channels, PSD, Custom House, all those thin",229,"Yes, Darrin, this is Scott. Let me kind of give you a full year view of the investment spending. And we talked earlier in the year about roughly about $50 million that we would spend between, call it, Electronic Channels, PSD, Custom House, all those things. Thats up from about $25 million in 2009. So that was generally ratably or will be ratably spent over the year, over 2010. As we move forward into 2011, again a little early to give specific outlook. But as we think about the business, we want to continue to invest in the business to drive that growth, but also balance that with a business model that we believe can drive margin expansion. I mean, expanding the margins is important. So we'll balance all those things as we move forward. On PSD, every quarter, it's contributing more revenue. It's not hugely meaningful in 2010, but we are on track for it to be 1% of revenue in 2011. I think what's important there is we have opportunities in Europe to really expand the retail class of trade, especially in countries such as Germany in bank, where it's really been dominated by banks or post banks. And just what we've done in the U.S. with retail, we can do that in Europe. We think that's an important initiative over the next two to three years."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And just to follow up on the PSD side, on the Payment Services Directive, is that higher-margin revenue given that versus the super agent kind before, given that you're now moving more into the retail channel in Europe?",38,"And just to follow up on the PSD side, on the Payment Services Directive, is that higher-margin revenue given that versus the super agent kind before, given that you're now moving more into the retail channel in Europe?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I mean, what PSD does give us a different portfolio, also, right? We do had banks and post offices with certain commission rates in the PSD. We do have the license and also certain commission rates. Obviously, we don't disclose the commission rates from a",125,"I mean, what PSD does give us a different portfolio, also, right? We do had banks and post offices with certain commission rates in the PSD. We do have the license and also certain commission rates. Obviously, we don't disclose the commission rates from all the agents. But I think we are constantly looking at our portfolio, where we have the optimal agent relationship and the agent commission rate. But given the -- we are expecting about 1% incremental revenue through PSD next year, so I think it's too small to have a general impact on our numbers currently. But we believe it's a long-term opportunity because it gives the customers longer opening hour, reachable everywhere, so I think we have the right strategy here."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Tim Willi of Wells Fargo.",13,"Our next question comes from the line of Tim Willi of Wells Fargo."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","My question was just any comments you might have around the trends you saw during the quarter, just having a chance to review everything a bit more detail. And specifically, is there anything you would note around the Gulf region, which I think was the re",81,"My question was just any comments you might have around the trends you saw during the quarter, just having a chance to review everything a bit more detail. And specifically, is there anything you would note around the Gulf region, which I think was the region that was able to maintain its strength the longest before finally sort of softening up towards the end of last year, early this year? And just sort of lapping those comparisons, any thoughts around that?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, let me start, and Scott jump in on that. I think if you look at our business, really, we do see parts of the world improvement and parts of the world still remaining challenging. We do see Gulf states continue to be challenging in that, obviously, t",125,"Well, let me start, and Scott jump in on that. I think if you look at our business, really, we do see parts of the world improvement and parts of the world still remaining challenging. We do see Gulf states continue to be challenging in that, obviously, the same steady declines as we had in last quarter, but I think we have the right strategy there. We have the right agents there. Once the economy really picks up there, also, the investments picks up there. And different part of the industry, the construction service, hotel industry, I believe that long term, we have the right strategy. We are in the right place to respond to the challenges also in the Gulf states. You have something?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","The other thing I would add, Tim, to trends, if you will. Ill try have you think about it from a macro basis. But if you think about the third quarter, this is the fourth consecutive quarter in a row where sequentially both C2C transactions and C2C con",91,"The other thing I would add, Tim, to trends, if you will. Ill try have you think about it from a macro basis. But if you think about the third quarter, this is the fourth consecutive quarter in a row where sequentially both C2C transactions and C2C constant-currency revenue have increased. I think everybody knows that C2C is 85% of our revenues. We have 30% margins in the quarter. So clearly, the sequential improvement continues for four quarters in a row, and we're pleased with that during the past four quarters."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","But in general, if you sort of had to just sort of think about the franchise, you don't have any major countries or corridors even that were seeing declines accelerate. Maybe sort of the worst case is rates have declined began to stabilize for ""the softer",69,"But in general, if you sort of had to just sort of think about the franchise, you don't have any major countries or corridors even that were seeing declines accelerate. Maybe sort of the worst case is rates have declined began to stabilize for ""the softer spots"" in the franchise, whereas other parts of the franchise, we've seen that sort of sequential acceleration. Would that be a fair characterization?"
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'd probably go back to its the portfolio approach that we're in 200 countries, right? And if you just take a picture of International business, which is 70% of our revenue, those transactions have grown 7% the last couple of quarters. Constant-currenc",137,"I'd probably go back to its the portfolio approach that we're in 200 countries, right? And if you just take a picture of International business, which is 70% of our revenue, those transactions have grown 7% the last couple of quarters. Constant-currency revenue has grown 4%. The Gulf was soft in Q3, like it was like in Q2, so no dramatic change up or down there. But there are certain countries, such as Russia or Germany. Recall that Australia and Philippines, those growth rates were a little bit better in Q3 than they were in Q2. But it kind of comes back to the portfolio approach of doing business in 200 countries, and it's helpful that not every country has got to be perfect. But when you're in 200 countries, it's helpful as you move forward."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Just to finish on that probably, we are very focused on executing, or to finish the call, Mike, maybe, we are very focused on executing against our key strategies. I believe we have the right strategies, right initiatives. We are also pleased with the qua",69,"Just to finish on that probably, we are very focused on executing, or to finish the call, Mike, maybe, we are very focused on executing against our key strategies. I believe we have the right strategies, right initiatives. We are also pleased with the quarter and build on the fundamentals. We are proud to be [ph] very focused against our execution strategy. So thank you for joining the call."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thanks, everyone, for joining the call, and have a good afternoon.",11,"Thanks, everyone, for joining the call, and have a good afternoon."
290203,114621935,82091,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Have a great day.",21,"Thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Have a great day."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Good day, and welcome to the Mylan, Inc. Third Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King, Vice President of Global Investor Relations. Please go ahead.",40,"Good day, and welcome to the Mylan, Inc. Third Quarter Fiscal 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the conference over to Ms. Kris King, Vice President of Global Investor Relations. Please go ahead."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Lisa. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; and Executive Vice Pre",361,"Thank you, Lisa. Good afternoon, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; Executive Vice President and Chief Financial Officer, John Sheehan; and Executive Vice President and Chief Operating Officer, Rajiv Malik.
During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our annual report on Form 10-K for the year ended December 31, 2009, and in our other SEC filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov, and we strongly encourage you to do so. 
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylans on an adjusted basis, which are non-GAAP measures. It should be noted that non-GAAP financial measures such as adjusted revenues, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website as it contains detailed GAAP to non-GAAP reconciliations of our actual 2010 and 2009 third quarter results, including the allocation of each reconciled line item to specific income statement line items. 
Before I turn the call over to Robert, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission. 
With that, I'll now turn the call over to Robert."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris. Welcome, everyone and thank you for taking the time to join us this afternoon. I would also like to welcome all of the Mylan employees on the call today, especially those from Bioniche Pharma, who are listening as the new members of the M",531,"Thank you, Kris. Welcome, everyone and thank you for taking the time to join us this afternoon. I would also like to welcome all of the Mylan employees on the call today, especially those from Bioniche Pharma, who are listening as the new members of the Mylan family. On behalf of the Board of Directors and our leadership team, I'd like to thank each and every one of you for your continued hard work, dedication and outstanding performance.
I am extremely pleased to report to you yet another strong quarter performance of exceptional earnings. As I mentioned on the last conference call, I did anticipate the third quarter to be better than the second quarter, and I am extremely pleased to report adjusted diluted earnings per share of $0.43, a 16% increase from our second quarter results. With that said, I still expect at this time that the fourth quarter will come in slightly better than the third quarter.
We maintain this position even with the most recent ruling related to our Paroxetine CR. While we are extremely disappointed with the lower court's ruling, we believe strongly that the lower court has erred in its decision not to grant us an injunction, and we have appealed that decision. It should also be noted that this is still just a ruling on an injunction. It is not a final decision resolving Mylan's rights on this matter. Regardless of the outcome of the appellant court decision on the injunction, we will continue our litigation to enforce our contractual rights and all of its negotiated provisions with GSK.
With that said, and irrespective of this short-term distraction, the longer-term fundamentals of our business have not changed, which is why we remain committed to our stated targets of $2 of adjusted diluted earnings per share for calendar year 2011 and our longer-term growth targets of 15% top line and 20% bottom line CAGR by the end of 2013. We very much look forward to providing you a detailed breakdown of our 2011 guidance on our next conference call.
Moving on to other activity in the quarter. You will recall that we issued $300 million in follow-on 10-year bonds to finance the acquisition of Bioniche Pharma. In addition, we are also able to use part of the strong operating cash flows that we continue to generate to prepay $300 million in term loan borrowings in the third quarter as well, further reducing our leverage and staying committed to our stated objective to achieve a 3:1 debt-to-adjusted-EBITDA leverage ratio. 
And finally, you may remember that on November 15 of this year, our mandatory convertible preferred stock will automatically convert to common stock. Given the recent growth and strength of our stock price performance, we anticipate issuing the lowest number of shares required under the terms of the preferred stock agreement, which is approximately 125 million shares. Of further note, November 15 will also mark the final payment of the preferred stock dividend, thereby substantially enhancing our future free cash flows to the company by $139 million per year.
I look forward to answering your questions, and I'd now like to turn the call over to Heather Bresch."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Robert, and good afternoon, everyone. As Robert said, we are very pleased with our strong third quarter performance and a great start to our expected strong second half of 2010. We remain highly confident in our ability to deliver 2010 results",1329,"Thank you, Robert, and good afternoon, everyone. As Robert said, we are very pleased with our strong third quarter performance and a great start to our expected strong second half of 2010. We remain highly confident in our ability to deliver 2010 results in line with the guidance we have reaffirmed today. We also continue to be extremely confident about our growth prospects for '11 and beyond. I too would like to commend our employees around the world for making our continued exceptional performance possible.
During my remarks today, I'll review our performance by segment, provide an update on synergies and comment on why we remain so confident about our future. I'd now like to walk you through the performance of our commercial operations. During the third quarter, we generated total revenues of $1.36 billion, an increase of 7% compared to last year's third quarter total revenues of $1.26 billion. On a constant currency basis, revenues were up approximately 9% year-over-year, and on the bottom line, we generated $0.43 of adjusted EPS, a 34% increase over last year's third quarter result of $0.32.
We also delivered a strong adjusted gross margin of 48.4% during the third quarter, up from our second quarter performance of 45% and right in line with our full year expected range of 47% to 49%. As expected, driving the strong performance were recent approvals on higher margin, limited competition products, higher sales in our Specialty segment and continued synergy realization.
Within our Generics segment, our North American operations delivered third-party net sales for the third quarter of $573 million, up 17% from last year's third quarter result of $488 million. The increase was mainly the result of new product launches in the United States. Among those launches were limited competition products, Minocycline ER, Clonidine Transdermal, and Tacrolimus, bringing to ten the dozen such products we anticipate launching by year end, and we remain on track to achieve our full year target of 50 to 60 launches in the U.S.
Our third quarter also includes results from Bioniche, a Specialty Injectables business we acquired on September 7. The integration has been seamless so far, and on October 4, we announced our first approval from the FDA for our Bioniche product, Fludarabine, an injectable chemotherapy medication for leukemia. Our ANDA filings now include those of Bioniche Pharma. Currently, we have 153 ANDAs pending FDA approval, representing about $95 billion in annual brand sales. 45 of these pending ANDAs are potential first-to-file opportunities, representing more than $24 billion in annual branded sales. 
In EMEA, third-party net sales of $364 million fell 12% versus last year's third quarter third-party sales of $414 million. However, on a constant currency basis, operational performance in EMEA declined only 3% year-over-year while year-to-date, sales have risen almost 2%. That result was driven by unfavorable pricing throughout Europe, which was partially offset by new product launches in several markets. 
Looking forward, we continue to see our ability to even further offset negative trends in the region, thanks to the sheer number of internal products we expect to launch in 2011 and beyond. In addition, we continue to repatriate finished dosage forms, which will continue to add to our competitive position throughout Europe. 
In France, third quarter local currency sales rose compared to the year-ago quarter. New product launches and higher volumes on existing products more than offset ongoing competitive pricing pressures. With more than 30% market share, our market leadership position remains very strong in France, which drives our performance in Europe.
We also experienced higher year-over-year third quarter local currency sales in Italy, where we benefited from a combination of new product launches, higher generic penetration and the continued favorable effects of regulatory changes. And in Spain, our new product launches offset the impact of government-posed price reduction.
Other markets such as Portugal and Germany experienced lower sales during the third quarter due to government-imposed price reductions and the impact of tender systems, respectively.
Turning now to our Asia Pacific region. We delivered very strong third quarter results. Third-party net sales were $268 million, up 30% over last year's third quarter sales on $206 million. On a constant currency basis, sales rose about 22%. Matrix, Australia and Japan all contributed to the strong results. Matrix continued to deliver strong double-digit growth through API and ARV sales and our ARV portfolio now contains 33 products.
Finally, Dey, our Specialty segment performed well during the third quarter. Third-party net sales rose 6% to $141 million over the same period last year after adjusting last year's third-party sales to account for the fact that in 2010, our Mylan Pharmaceutical division assumed responsibility for selling Dey's generic products. The primary driver of our growth was domestic sales of EpiPen Auto-Injector, which were strong compared to the third quarter of '09. Recall that last October, we launched our next-generation needle-protected auto-injector, which has been received favorably in the U.S. and Canada. In addition, compared to our second quarter, sales benefited from the seasonal return of children to school. Further, we can continue to experience double-digit growth in many markets outside the U.S. as we continue the expansion opportunities for this very important product, mainly through focusing on an underserved population.
Moving on now to synergies. I'm pleased that we remain on track to deliver more than $350 million in cumulative annual benefit by the end of this year. We continue to seek out and capture additional opportunities to further increase our efficiency and leverage our powerful operating platform. Looking ahead to '11, as Robert stated, we will provide formal guidance for the year on our next conference call. 
Nonetheless, it's important to note and to remind you that we continue to see Mylan entering the new year with very strong momentum, especially as we launch more products around the globe than we have ever launched in our company's history. In 2011, we look forward to monetizing or continuing to monetize several opportunities resulting from prior settlements such as Minocycline ER, voriconazole, letrozole and Venlafaxine ER. We see a number of 30-month stays expiring on other opportunities, some of which are first-to-file. We look forward to introducing oral contraceptives in the U.S., and once again, launching more than a dozen limited competition products. 
Worldwide, we continue to expect to launch approximately 500 products. As important, our pipeline is stronger than ever. We currently have about 1,500 global products submissions pending approval. 
Before I turn the call over to John, I'd like to step back and make some observations about our company and how far we've come. Earlier this month, we celebrated the three year anniversary of the union of legacy Mylan, Matrix and Merck. Behind that union was our vision that the world could be served far better if we created a global, vertically integrated and highly disciplined company that could consistently supply any market with high-quality, affordable generic and specialty pharmaceuticals.
Over the past three years, we have focused relentlessly on executing on our vision by integrating vertically, delivering synergies far beyond our expectations and serving customers in more than 140 countries and territories. Those accomplishments alone allowed us to meet or exceed Street [Wall Street] estimates for 13 consecutive quarters. 
But that's not all we've been doing for the last three years. We've also been filling our global network with internally supplied products by applying the same methodology and fundamentals that made our integration so successful. Among the actions we've been taking, optimizing R&D, enhancing our portfolio and management capabilities, repatriating products and filling gaps in our product line, we also have created a biologic strategy and strengthening the promising future of our Specialty business, Dey. And perhaps most important, we have filed approximately 3,000 applications globally by the end of this year. Now, we're ready to reap what we've sown. That is why we're so confident about our growth over the next three years and beyond. 
With that, I'll now turn the call over to John."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good afternoon, everyone. This afternoon, I will begin by walking you through our third quarter 2010 financial results, which, as Heather and Robert have both indicated, were exceptional. I will then provide an update on our capita",1933,"Thank you, Heather, and good afternoon, everyone. This afternoon, I will begin by walking you through our third quarter 2010 financial results, which, as Heather and Robert have both indicated, were exceptional. I will then provide an update on our capital structure and liquidity position.
As Kris mentioned earlier, I'm going to be referring to actual and projected financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. We present these non-GAAP financial measures because they're prepared on the same basis as used by our management and Board of Directors to evaluate the performance of our business. This afternoon's earnings release includes a complete reconciliation from our GAAP to non-GAAP financial measures for our third quarter 2010 and 2009 results. Our earnings release is available on our website, and I encourage you to take a look at it.
Starting at the top of the income statement. Total revenues for the quarter were $1.36 billion, an increase of 7% over last year's third quarter total revenues of $1.26 billion. The effect of foreign currency translation had an unfavorable impact of approximately 2% on our third quarter revenues, reflecting a weaker euro in comparison to the U.S. dollar, partially offset by the strengthening of other currencies, primarily the rupee, the yen and the Australian dollar.
During the third quarter, we launched Minocycline ER. As I discussed with you on last quarter's call, because of significant uncertainties surrounding the pricing and market conditions with respect to Minocycline, we are not able to reasonably estimate the magnitude of potential price adjustments, including product returns, and as a result, have deferred revenue recognition until such uncertainties are resolved. At this time, we consider such uncertainties to be resolved upon the sale by our customers of the product and have recognized revenue accordingly.
Looking at our operating profitability measures, adjusted gross margin for the quarter was approximately 48.4% compared to 46% in the prior year. As expected, this adjusted gross margin is an improvement from that of the first and second quarters and is within our full year guidance range of 47% to 49% and is primarily the result of new product launches in North America and favorable pricing on our Specialty segment, EpiPen Auto-Injector.
Adjusted R&D expense for the quarter was $69 million or approximately 5% of revenues. Also as expected, this level of spending represents an increase over the first half of 2010 and is in line with our revised full-year guidance range of 5% to 6% of revenues. Importantly, our R&D projects remained on target, and we are planning for even higher levels of spending in the fourth quarter.
Adjusted SG&A expense was $257 million for the quarter or 19% of revenues, within our full year guidance range of 18% to 20%, and our third quarter adjusted EBITDA was $368 million.
Now let me move to a couple of non-operating financial metrics. Third quarter 2010 adjusted interest expense was $70 million. We continue to forecast adjusted interest expense for the year to be at or near the low end of our guidance range of $280 million to $300 million, which continues to consider the potential for higher short-term interest rates. Our third quarter adjusted effective income tax rate was 26%, which translates into a year-to-date and full year projected adjusted effective income tax rate of 28%, which is at the low end of our forecasted range of 28% to 29%. We do fully anticipate this full year effective tax rate to be sustainable going forward. In summary, third quarter adjusted net income was $189 million or $0.43 per share.
In calculating our adjusted diluted EPS, the impact of assuming the conversion of our preferred shares into 125 million common shares was more dilutive than the $35 million quarterly preferred dividend. Therefore, adjusted diluted EPS for the third quarter is calculated based on an average outstanding diluted share count of approximately 438 million shares.
Touching briefly on the year-to-date results, and again, please refer to our earnings release for a complete reconciliation from our GAAP to our non-GAAP financial measures. For the nine months ended September 30, 2010, total revenues were $4.02 billion, an increase of 8% over adjusted revenues of $3.71 billion in the same prior year period. For the nine months, foreign currency translation had a favorable impact on revenues of approximately 1% due mainly to the strengthening of the rupee, yen, and Australian dollar versus the U.S. dollar, partially offset by a weaker euro.
Adjusted gross margin for the nine months was approximately 46% compared to 47% in the same prior year period. The lower gross margin in the current year is the result of a loss of exclusivity on divalproex during the third quarter of 2009. However, the current year gross margin was negatively impacted by certain inventory charges, principally in Q2. Excluding the impacts of these inventory charges, year-to-date gross margin would have approached 47%. We continue to see full year gross margin at the low end of our 47% to 49% guidance range. 
Adjusted R&D expense was $195 million, and adjusted SG&A expense was $753 million for the current nine-month period. Our adjusted EBITDA for the first nine months of 2010 was $1.03 billion. Adjusted net income was $511 million and adjusted diluted EPS was $1.16 per share.
As in the previous quarter, adjusted diluted EPS was calculated assuming the conversion of our preferred shares into 125 million shares of common stock. On November 15 of this year, our mandatory convertible preferred stock will automatically convert into shares of common stock. The number of convertible shares will be based upon the closing stock price over the 20-day trading period ending on November 12. Based on the current stock price, we expect that approximately 125 million shares will be the conversion amount. 
As mentioned before, we have been including this preferred stock conversion in our forecasted results. As such, the actual conversion will not result in an additional dilution to our guidance amounts. November 15 will also mark the final payment of the preferred stock dividend. 
Depending on the market value of our common stock going forward, our average outstanding diluted share count could increase further due to additional dilution from stock options and other potentially dilutive financial instruments such as our convertible debt obligations and related warrants. We also include such potential dilution in our forecasted results. 
As I mentioned previously, the impact of foreign exchange translation on our results was not significant, and actual foreign currency exchange rates during the period ended September 30, 2010, did not differ materially from those used to calculate our 2010 guidance, which we discussed with you last quarter.
More recently, we have seen the euro strengthen steadily against the U.S. dollar. However, we do not expect currency to have a significant impact on our results for the remainder of the year. This is due to the fact that the currencies of other markets in which we operate are moving in the opposite direction of the euro, and it's also a result of various hedging strategies that we've employed.
We've taken measures in an effort to prevent our results from being impacted significantly by changes in foreign currency exchange rates. In addition to having on our balance sheet euro-denominated long-term debt against which the cash flows of our euro-denominated subsidiaries are offset, we use financial instruments such as forward contracts in order to mitigate this risk. Any favorable or unfavorable variances resulting from foreign exchange for the three- and nine-month periods ended September 30, 2010, are included in the adjusted diluted per-share amount of $0.43 and $1.16 per share, respectively.
Turning to our cash flow metrics. Our third quarter GAAP cash flow from operations was nearly $380 million, the highest in our company's history or $360 million excluding certain items. While we don't anticipate fourth quarter cash flow from operations to approach this level, we do continue to project full year operating cash flow in the range of $725 million to $825 million excluding certain one-off items.
Our strong current quarter cash from operations was made possible through positive changes in our working capital, primarily accounts receivable as a result in improved cash collections, including amounts received with respect to Minocycline. As you may recall, on last quarter's call, I indicated that Q2 cash from operations were negatively impacted by the timing of collection of receivables, for which a substantial amount was received in early July. Q3 cash from operations was also impacted by the timing of collection of receivables, for which a substantial amount was received prior to September 30, 2010. 
Third quarter capital spending was $53 million, including approximately $10 million paid toward the acquisition of a finished dose manufacturing facility in India. Based on the anticipated timing of spending on certain projects, we now project capital spending in the range of $200 million to $250 million for the full year. Our current quarter also included a cash outflow of approximately $544 million with respect to our acquisition of Bioniche Pharma, which is net of any cash acquired. As Heather mentioned, results of Bioniche are included in our current quarter results from September 7.
The Bioniche acquisition was financed through a combination of cash-on-hand and the proceeds from recent notes offerings. As discussed last quarter, in May, we completed a private placement of $1.25 billion of senior unsecured notes due in 2017 and 2020. In the current quarter, we completed an add-on offering of an additional $300 million of the 2020 notes. These notes were issued at initial price of 105.5% and a coupon of 7 7/8% or an effective yield to maturity of slightly over 7%.
The notes issued in the current quarter's offering, together with the 2020 notes from the May offering, are treated as a single class of notes under the indenture. In addition to funding the Bioniche acquisition, the bond issuances were done in accordance with our objective of extending the maturity profile of our outstanding indebtedness. $1 billion of the net proceeds from the May issuance were used to pay down existing indebtedness under our credit facility. In late September, we used our strong operating cash to repay an additional $300 million of existing indebtedness under our credit facility. As a result of these repayments, we continue to have no meaningful long-term debt maturities until the $600 million due under our convertible notes in the first quarter of 2012, which we currently intend to repay with available cash at that time.
At September 30, 2010, following the additional debt repayment of $300 million, we continue to have unrestricted cash and marketable securities totaling over $640 million.
Continuing on with the capital structure, concerning leverage. As Robert has stated many times, it is our commitment to achieve a long-term leverage ratio of 3:1 or less. We are firmly committed to balancing growth in our business through the continued use of prudent and responsible financing. As such, Mylan remains committed to de-leveraging over time to meet this long-term capital structure goal. We continue to expect to generate approximately $4 billion of cumulative operating cash flows by the end of 2013.
From a covenant perspective, the level of our senior secured debt is approximately 1.7x our last 12 month covenant basis adjusted EBITDA, comfortably ahead of our December 31, 2010 threshold of 3.5x. In closing, I'm very pleased with our solid quarterly performance. A great start to what we've been saying will be a strong second half of 2010. 
That concludes my remarks. Lisa, I'll turn the call back over to you to start the Q&A."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from Randall Stanicky with Goldman Sachs.",12,"[Operator Instructions] Our first question comes from Randall Stanicky with Goldman Sachs."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Can you just drill down on the EMEA result and when we can expect a return to growth from that region net reach? And then the follow-up would be maybe, Robert, with the EMEA result in conjunction with the Paxil CR news, can you just talk about some of the",66,"Can you just drill down on the EMEA result and when we can expect a return to growth from that region net reach? And then the follow-up would be maybe, Robert, with the EMEA result in conjunction with the Paxil CR news, can you just talk about some of the offsets that allow you to remain comfortable as we think about the $2 target for 2011?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Sure, Randall. First, again, there are many, many mitigating factors, and it's difficult, I understand from your perspective, not to be able to evaluate the number of moving variables. But let's start with EMEA. I said that this would be a basically almos",635,"Sure, Randall. First, again, there are many, many mitigating factors, and it's difficult, I understand from your perspective, not to be able to evaluate the number of moving variables. But let's start with EMEA. I said that this would be a basically almost a two-bucket approach. I've been telling you all along that we continue to see what we've anticipated, what the governments are doing over there in terms of pricing and pushing prices down lower. But we've often said that we felt very comfortable with our position to be able to mitigate that by all the other initiatives that we have in place, including, I'll pull a knot, cost infrastructure that really doesn't fit with the new system, the new wave of direction where Europe is going. Our cost of goods, our repatriation, our bringing in a lot of the third parties back in-house, and of course, our increase in volumes. So that's kind of sort of -- and the races in Europe, Randall, the races, again, what I've always stated, the speed at which governments move and the speed at which we can, through a regulatory process, be able to yield all the benefits that we've been telling you all along. And in terms of the Paxil CR, we are in litigation. It's been a long-standing position of ours, and not to comment when we are in litigation. I tried to give you a signal, obviously, in our opening remarks about how I feel as a whole about that whole situation. We're extremely confident in our position. We think there's a lot more involved in terms of the dealings between GSK and Apotex, and it wasn't just a one-off type of situation. And that's what litigation is all about, and I'm very confident that we'll prevail once we have an opportunity to get inside. In terms of the $2, the last piece of your question, look, all these factors have -- there's nothing really new. There's just nothing new in terms of what we've thought about, what we've been trying to anticipate. And the best way I can explain to you on the $2 on why we're still confident is actually for two reasons. One, Randall, the fundamentals, the long-term fundamentals of the company have not changed at all. At all. Basically, what we're dealing with is the short-term issues that we have to just continue to manage or work our way through. And what I would bring to your attention is go back for the last 13 quarters where we have been trying the same exact questions that we're faced with today about visibility in 2011 and beyond. When we were in 2007 roughly at $0.45 and then $0.80 in 2008 and $1.30 in 2009 and roughly a midpoint of $1.60 in 2010, nobody understood how we were going to get there. And what I can tell you, and what we have done already is this management team promised that it would manage. It would manage this new acquired platform for earnings growth. And I can tell you that when we were back at $0.45 and $0.80 and $1.30 and $1.60 in terms of our respective midpoints, when we started out that guidance and where we thought those earnings per share were going to come from and where they actually came from are not always exactly the same. That's just the nature of our business. So I can assure you that when we once again I think we have become at least somewhat predictable to all of you guys. If we tell you that our vision is in the balancing act, what we can see the number of variables versus what you may not be able to see, we are very comfortable that the $2 target in calendar year 2011 is achievable."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","That's irregardless of a Paxil CR will come [indiscernible] again, just to be clear.",15,"That's irregardless of a Paxil CR will come [indiscernible] again, just to be clear."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. I mean you have to look at a Paxil CR this way. Take a look at a vein in your body, forgive me. But blood flows through, right one side of the vein to the other. And every once in a while, a vein can blow up in the middle when you have an issue. And",153,"Yes. I mean you have to look at a Paxil CR this way. Take a look at a vein in your body, forgive me. But blood flows through, right one side of the vein to the other. And every once in a while, a vein can blow up in the middle when you have an issue. And what you hope for and so as the vein blows up, the blood's still going to get through the other side. You have this bubble. And I can only tell you that unless we thought, Randall, that somehow Paxil CR was never going to achieve competition ever, ever, ever, then I can say that, that would be an effect on us. In a generic company, one can never project that a generic product forever will be in your product without competition. So obviously, it's a timing issue. And that's why the longer-term fundamentals simply haven't changed."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Chris Schott with JPMorgan.",9,"Our next question comes from Chris Schott with JPMorgan."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just another follow-up on EMEA and specifically France. Can you just elaborate a little bit more on the trends you're seeing in that market? I guess specifically, how does some of the recent proposals from the French government that call, for what seem to",105,"Just another follow-up on EMEA and specifically France. Can you just elaborate a little bit more on the trends you're seeing in that market? I guess specifically, how does some of the recent proposals from the French government that call, for what seem to be a pretty modest 2011 drug cost savings compared to your expectations? And then second question on EMEA. We had obviously the Teva Russia front deal closed this quarter. Just what are your thoughts in terms of the likelihood of further consolidation in the EU market over time? And what implications does that have, that consolidation have, for your business?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'll answer the first one and you can talk about France. But in terms of the -- I do see more consolidation in Europe. I believe that, that is one market that will go from a seller's market to a buyer's market. That is one region, I believe, that the mult",217,"I'll answer the first one and you can talk about France. But in terms of the -- I do see more consolidation in Europe. I believe that, that is one market that will go from a seller's market to a buyer's market. That is one region, I believe, that the multiples ought to contract. And my rationale is that I think what all of Europe is experiencing is the more regional companies, the more local companies, it's very, very difficult as Europe moves in direction of some of the other markets around the world to be able to compete if you don't have scale. And without scale, again, that cost competitiveness, they're going to feel it. And I think that some of these mom-and-pop companies, these local companies, these regional companies begin to realize that the writing is on the wall. I think it will force them indirectly towards more activity. And I think as the more activity percolates, I think the supply-demand curve will kick in, and when there's more supply than there is demand, I think that you'll see multiples come down. So I do see more consolidation. I do think it's extremely healthy over in Europe to bring more capacity out of the market, and I do think that scale will prevail. Heather?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And just I guess to elaborate a little more on EMEA. I guess, just a couple of things. One, I'd remind you that Q3 has always been historically lower throughout Europe because of the summer and the holiday, the extended holiday season throughout Europe. S",211,"And just I guess to elaborate a little more on EMEA. I guess, just a couple of things. One, I'd remind you that Q3 has always been historically lower throughout Europe because of the summer and the holiday, the extended holiday season throughout Europe. So we do expect Q4 to see growth back from a revenues perspective. And as far as France and some of the trends, we absolutely what just came out for the 2011 time period we anticipated, and as you note, fairly modest. And to the extent that, like I said, we believe that was right in line with our thinking of where 2011 would be as well as them continuing to look at the whole value chain, not just the generic manufacturers. So as we've seen with other regulations and some of the pricing throughout Europe, Spain, Italy continuing to do the same, not looking at just the generic manufacturers, but kind of the entire supply chain. So that's why I say to the trends, and as I said, the tender markets whether it's Germany and some of the pricing pressure that you see that blimp that of course was attached to this quarter. And like I said, we see that revenue growth coming back in Q4."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is from Rich Silver with Barclays Capital.",10,"Our next question is from Rich Silver with Barclays Capital."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just shifting to the North American business. Can you elaborate to explain the sequential decline in just a little bit more detail on the drivers there and what we can look for going forward?",34,"Just shifting to the North American business. Can you elaborate to explain the sequential decline in just a little bit more detail on the drivers there and what we can look for going forward?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I'll start off by saying timing, timing, timing, timing and timing. Heather?",13,"I'll start off by saying timing, timing, timing, timing and timing. Heather?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think obviously, Rich, that's why we say that this business to try to gauge a snapshot quarterly is not representative of the business as a whole. Rob's viewpoint, there's certainly, we've had timing issues of some of our launches. Certainly, we did get",124,"I think obviously, Rich, that's why we say that this business to try to gauge a snapshot quarterly is not representative of the business as a whole. Rob's viewpoint, there's certainly, we've had timing issues of some of our launches. Certainly, we did get some more of those limited competition market. In Q3, again we'll  have the benefit of the full value of those products within the next quarter. So really, nothing other than like I said, kind of normal variations that go back and forth through some of our products. And like I said, some of the timing of some of our regulatory launches, but nothing out of the ordinary and nothing that we don't see kind of again coming back in Q4."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Putting aside Paxil CR, kind of all else equal, is what you're saying, if you were providing full year guidance, revenue guidance for North America, it would be unchanged even with the third quarter looking a little weak? And then just one last one, which",80,"Putting aside Paxil CR, kind of all else equal, is what you're saying, if you were providing full year guidance, revenue guidance for North America, it would be unchanged even with the third quarter looking a little weak? And then just one last one, which is a whole paragraph devoted to Minocycline ER, can you give us some sense of the materiality of that product given that you made a point of loading that much base in the press release?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, a couple of things. One, I guess just quickly on North America, and I guess just to point towards, again year-over-year  17% growth out of that business. So again sequentially, timing. I don't want to lose the fact that we've seen nice growth and he",123,"Well, a couple of things. One, I guess just quickly on North America, and I guess just to point towards, again year-over-year  17% growth out of that business. So again sequentially, timing. I don't want to lose the fact that we've seen nice growth and healthy growth in that business year-over-year from Q3 '09 to Q3 this year. And as far as Minocycline, look, I think what we are trying and I'll let John elaborate, but was trying to explain from a revenue recognition perspective, said it was not a blimp like a bolus of the 180 days, and so I think we wanted to go above and beyond and try to make sure people understood exactly how we were treating that product."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Just two points, Rich. I guess number one, yes, I wouldn't be focused on changing our full year revenue guidance for North America if we were providing North American revenue guidance. And I think the way Heather, both Robert and Heather have described No",145,"Just two points, Rich. I guess number one, yes, I wouldn't be focused on changing our full year revenue guidance for North America if we were providing North American revenue guidance. And I think the way Heather, both Robert and Heather have described North America as a timing matter is exactly what that is. Number two, with respect to Minocycline, we launched Minocycline in the latter part of July, and we indicated in the second quarter earnings call that we would recognize that revenue on the deferred method and the pull-through method. And therefore, obviously it has an impact, but not nearly as large an impact as it would if we were recognizing it all in the current quarter. The other thing is that if the impact of Minocycline will increase as the amounts of our product there are being consumed by our customers increases."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","And our next question comes from John Boris with Citi Investment Research.",12,"And our next question comes from John Boris with Citi Investment Research."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First one just has to do with Janet Woodcock has at least indicated that she's hired some additional help to try and clear up the backlog of well in excess of 2000 ANDAs. Any thoughts on progress on cleaning this backlog up? Are you seeing any improvement",52,"First one just has to do with Janet Woodcock has at least indicated that she's hired some additional help to try and clear up the backlog of well in excess of 2000 ANDAs. Any thoughts on progress on cleaning this backlog up? Are you seeing any improvement in timelines on ANDAs?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I think from my perspective I see two mitigating factors here. I'm very happy that they actually have maybe gone out to the private sector to -- let's just help them with the queue and develop the right queue for better efficiency in flow of what they nee",184,"I think from my perspective I see two mitigating factors here. I'm very happy that they actually have maybe gone out to the private sector to -- let's just help them with the queue and develop the right queue for better efficiency in flow of what they need to do. But on the other hand, let's not forget that there are comments out there, ""in the year"" of what we've always seen coming and we would support. And that's a tightening of specs. So if you're going to be tightening specs on one hand, I think that further creates a little bit of a backlog only to be offset, I hope, by this outside resource that she's going to bring in from the private sector. So I'm not sure yet how the two are going to offset and whether or not we're going to get more efficiency or whether or not the tighter specs may cause a little bit more. I think it's yet to be seen, but we're very encouraged in terms of the FDA taking the initiative to improve the entire process."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Just a follow-on to the tighter specs, she's also hinted that she's somewhat concerned about some of the generic supply that's out there. Can you help maybe elaborate on what she's implying? Are anticipating that there might be some other recalls on the h",45,"Just a follow-on to the tighter specs, she's also hinted that she's somewhat concerned about some of the generic supply that's out there. Can you help maybe elaborate on what she's implying? Are anticipating that there might be some other recalls on the horizon?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Well, I think one area that certainly we've been pretty vocal about is on the user fee front. And as you know, we have public comments out there and have been working closely with FDA and the industry to really set up a fair level playing field as far as",218,"Well, I think one area that certainly we've been pretty vocal about is on the user fee front. And as you know, we have public comments out there and have been working closely with FDA and the industry to really set up a fair level playing field as far as foreign inspections and this truly global supply chain that the FDA has to be able to support a product that's being sold into the U.S. So she, obviously, in her remarks have been very, very supportive of leveling that playing field and making sure that FDA has the resources they need to do inspections every two years of anyone who's supplying products into the U.S. market. So I think that some of her comments certainly go to the fact that, that heightening attention, the heightening of resources and us being able to put something through that would allow the FDA to accomplish that would certainly benefit not only leveling that playing field, but back to Robert's point, it will also even go towards the backlog and where we see the applications, and I think, could see an improvement in those median times all being connected together, and that's the approach weve certainly taking of advocating and believe that FDA believes that, that would be beneficial on all fronts."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Ronny Gal with Sanford Bernstein.",10,"Our next question comes from Ronny Gal with Sanford Bernstein."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First, a quick one for John. John, if I look at the reconciliation table that you've provided us with, it looks like you are excluding about $125 million and the tax effect offsetting that is about $80 million or 64% of the excluded amount. That looks lik",104,"First, a quick one for John. John, if I look at the reconciliation table that you've provided us with, it looks like you are excluding about $125 million and the tax effect offsetting that is about $80 million or 64% of the excluded amount. That looks like a very high tax rate on the excluded amount. If you can give us a clue about that. And still on the issue of integration, was that about $32 million this quarter for acquisition and integration charges? Can you help us understand how that will trail off over the next year if there are no additional acquisitions?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","On the first item, with respect to the taxes, remember that what we're doing with the tax reconciliation is not just in the tax adjustment, it's not just simply the tax effect of the reconciling items, but it is also to adjust the tax rate to the 28% full",80,"On the first item, with respect to the taxes, remember that what we're doing with the tax reconciliation is not just in the tax adjustment, it's not just simply the tax effect of the reconciling items, but it is also to adjust the tax rate to the 28% full-year effective rate, so to the extent that there are, let me say, one-time or unusual items within taxes, the tax expense or tax benefit, we also have to adjust those out."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","And as far as your integration point, obviously, we've seen that come down tremendously year-over-year as we've gotten further into this integration. So yes, we continue to see that trailing off.",31,"And as far as your integration point, obviously, we've seen that come down tremendously year-over-year as we've gotten further into this integration. So yes, we continue to see that trailing off."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","Follow-up on the Dey business. Some of your competitors have been talking about the opportunity in the respiratory area over the next few years, and you obviously have a respiratory platform. How do you think about this platform? If you can give us some v",70,"Follow-up on the Dey business. Some of your competitors have been talking about the opportunity in the respiratory area over the next few years, and you obviously have a respiratory platform. How do you think about this platform? If you can give us some view about what you're developing internally and what you might be interested in bringing from the outside to put on top of that sales force?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. Absolutely, we have said this is an extremely an important niche in the Specialty business, not only, obviously, how we marry up to that, but just I think in the United States overall, it's a very important niche area that we've seen a ton of growth",170,"Yes. Absolutely, we have said this is an extremely an important niche in the Specialty business, not only, obviously, how we marry up to that, but just I think in the United States overall, it's a very important niche area that we've seen a ton of growth as an industry. And I think we have a lot of opportunity. As Robert's talked about looking for complementary products to be able to put into the infrastructure that we already have and the doctors that we're already calling on as well as our own internal R&D pipeline on the COPD front with combo and of course our current performance. So that infrastructure, and I think that allergy marrying up again to EpiPen and what we've talked about being this underserved market is again that education around market expansion and how we continue to see an awareness, of building an awareness and that again continuing to expand that market for us both on the respiratory, from respiratory docs as well as the allergists."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Greg Gilbert with Bank of America Merrill Lynch.",13,"Our next question comes from Greg Gilbert with Bank of America Merrill Lynch."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","A couple for Heather and one for Robert. Heather, first, can you clarify what you meant about growth in EMEA in 4Q? Are you saying you expect growth over the 4Q of '09 level of $482 million?",37,"A couple for Heather and one for Robert. Heather, first, can you clarify what you meant about growth in EMEA in 4Q? Are you saying you expect growth over the 4Q of '09 level of $482 million?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes, I was just saying both, that one, obviously Q3 has historically been lower. So last year, Q3 was less than Q4. This year, we're anticipating growth both over Q3 as well as over Q4 of '09.",37,"Yes, I was just saying both, that one, obviously Q3 has historically been lower. So last year, Q3 was less than Q4. This year, we're anticipating growth both over Q3 as well as over Q4 of '09."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And that would be mostly driven by new launches? Or is that other sort of organic drivers that would result in growth after a couple of quarters of decline?",29,"And that would be mostly driven by new launches? Or is that other sort of organic drivers that would result in growth after a couple of quarters of decline?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","A couple of things. We've got a lot of product launches this quarter as well as the benefit of a full quarter of some of the launches we've had throughout the year.",32,"A couple of things. We've got a lot of product launches this quarter as well as the benefit of a full quarter of some of the launches we've had throughout the year."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","And then my other Europe question is whether or not you're seeing signs in Europe as governments understand the importance of making generic substitution happen or are they still just focused on finding short-term savings?",36,"And then my other Europe question is whether or not you're seeing signs in Europe as governments understand the importance of making generic substitution happen or are they still just focused on finding short-term savings?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","No, I've got a glimmer of hope that they are saying that the sustainability of utilization, that penetration is much more effective than a one-off price cut. I think we're starting to see that in Italy and Spain, as well as France. France, obviously, to m",166,"No, I've got a glimmer of hope that they are saying that the sustainability of utilization, that penetration is much more effective than a one-off price cut. I think we're starting to see that in Italy and Spain, as well as France. France, obviously, to me, is kind of the most mature in that Southern European region. And I see Italy and Spain kind of starting to follow suit as far as some incentives and increasing. And we've seen an increase in penetration in both of those markets. And look, I can assure you, will not stop our efforts of being out there educating and showing the sustainability of generic penetration versus just, like I said, the price cuts. And I think the other point to note here is the responsibility that we have seen and demonstrate between looking at the entire supply chain and not just the generic manufacturer, whether it's from the pharmacy perspective, the brand arena. So it's balancing both of those fronts."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Mark Goodman with UBS.",9,"Our next question comes from Mark Goodman with UBS."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I just want to make sure I'm clear on this EMEA following on the last questions. So we're going to have growth versus last year. Can you talk about what countries are going to be the key areas where you're talking about these new product launches? Is it F",121,"I just want to make sure I'm clear on this EMEA following on the last questions. So we're going to have growth versus last year. Can you talk about what countries are going to be the key areas where you're talking about these new product launches? Is it France? Is Germany going to come back? Second question is maybe you can give us a sense of what happened in the quarter in Asia, just Australia versus Japan versus India? Just so we have a little more flavor there. Then the third question is just talk about EpiPen in the quarter. Was there growth year-over-year in EpiPen? It seemed a little weaker than what I thought it was going to be."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Okay, so I'll start backwards so I don't forget anything. Yes, we saw, we definitely saw growth in EpiPen, both in volume as well as we had pricing in the year, but we certainly have seen some market expansion seeing the -- we saw the peak start a little",197,"Okay, so I'll start backwards so I don't forget anything. Yes, we saw, we definitely saw growth in EpiPen, both in volume as well as we had pricing in the year, but we certainly have seen some market expansion seeing the -- we saw the peak start a little earlier and last a little bit longer in the seasonality of that product. So we continue, as I said, to see our efforts around awareness to continue to help in that expansion. As far as Europe's concerned, obviously, as we continue to say, France is certainly the driver for us across the European region. As I noted this quarter, our sales were up year-over-year for France as well as Italy and Spain, and we continue to see those being contributors as well in this growth for Q4 both year-over-year and sequentially. As far as APAC is concerned, Matrix, while we don't break out the individual divisions within a segment, we have continued and will continue to at least give what the leaders are and Matrix has led that with double-digit growth from the APAC region, but we did have contribution both from Australia as well as Japan year-over-year."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is from Elliot Wilbur with Needham & Company.",10,"Our next question is from Elliot Wilbur with Needham & Company."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","First question, I just want to drill down a little bit more on the strong gross margin performance thinking about it sequentially up about 300 basis points. It doesn't really look like it's a mix issue given that North America and Specialty were relativel",78,"First question, I just want to drill down a little bit more on the strong gross margin performance thinking about it sequentially up about 300 basis points. It doesn't really look like it's a mix issue given that North America and Specialty were relatively the same percentage of sales. Also, so it's not really a volume issue. So is it fair to say that the bulk, if not the entire degree of improvement sequentially, is attributable to synergies?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Yes. Look, I'd say certainly, as we forecasted and anticipated, synergy realization was going to be stronger in the second half of the year, but I wouldn't lose total sight on mix. We had important approvals of higher margin products as limited competitio",84,"Yes. Look, I'd say certainly, as we forecasted and anticipated, synergy realization was going to be stronger in the second half of the year, but I wouldn't lose total sight on mix. We had important approvals of higher margin products as limited competition, like in clonidine, like in Minocycline and Tacrolimus so there is still -- you do have mix issues, which is why you have to look at the annual, the overall gross margin and the guidance, obviously, that we have out there."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I have a question for John as well. With respect to the company's current capital structure and the duration of the debt obligations, sort of understand that you have quite a bit of financial flexibility through your first bolus payment in 2012, a little",161,"I have a question for John as well. With respect to the company's current capital structure and the duration of the debt obligations, sort of understand that you have quite a bit of financial flexibility through your first bolus payment in 2012, a little -- about $700 million in total. But if you look out to 2014, there's roughly a $2 billion bullet that's due, and that just happens to coincide with I guess sort of a large systemic increase in overall debt obligations coming due in the U.S. And given the likelihood that there's going to be a lot of folks looking to refinance debt and also the fact that short-term interest rates probably are going to be a lot higher than where they are now, just sort of how should we be thinking about maybe potential addition what it means on your part to maybe flatten out the maturity ladder or even extend it further, which you've already done?"
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I would say this. If you go back eight months ago, seven months ago, we had over $3 billion of maturity in 2014. And over the course of this year, we've reduced that by $1.3 billion. So we have flattened out the 2014 maturity significantly. We will contin",172,"I would say this. If you go back eight months ago, seven months ago, we had over $3 billion of maturity in 2014. And over the course of this year, we've reduced that by $1.3 billion. So we have flattened out the 2014 maturity significantly. We will continue to look to extend the maturity profile at appropriate points in time. We'll use our strong positive cash flow to continue to reduce the amount of the 2014 as we did here in the third quarter by repaying $300 million. So I actually feel really good about where we stand in the capital structure. Our free cash flow is over $500 million a year with the final preferred dividend that we're making here in the fourth quarter. That will increase our free cash flow by $139 million a year. So I see us with a lot of cash. Robert has talked about the fact that we're not looking to make another strategic acquisition. We're fully committed to reducing our leverage to 3:1 or lower."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","Let me just add something. First of all, you may not have caught it, but we did pre-pay $300 million. So we're actually at $1.7 billion now from the $3 billion or the $2 billion in which you've mentioned, Elliot. So you can see, and as a matter fact, when",180,"Let me just add something. First of all, you may not have caught it, but we did pre-pay $300 million. So we're actually at $1.7 billion now from the $3 billion or the $2 billion in which you've mentioned, Elliot. So you can see, and as a matter fact, when we first prepaid the $1 billion, I think what we said at the time we felt fairly comfortable at that time that we would generate enough operating cash flow actually to retire the debt itself. So taking the need for this organization to have to tap the market was exactly what we intended not to put ourselves in. So I feel very comfortable that we will continue to generate very strong free cash flows with the continued commitment to de-lever, but I will say at the same time I'm saying that, I wouldn't hesitate in a second to further extend those maturities if the opportunity arises and interest rates continue to be as advantageous as they are and simply give ourselves even more flexibility than what we've already provided ourselves."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","And our final question comes from John Newman with Oppenheimer.",10,"And our final question comes from John Newman with Oppenheimer."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Analysts","I just wanted to ask a clarifying question on EMEA. It looks like the revenues for EMEA last fourth quarter, pretty robust, and I think I recall you saying that you were expecting both a quarter-over-quarter increase from 4Q this year versus current quart",95,"I just wanted to ask a clarifying question on EMEA. It looks like the revenues for EMEA last fourth quarter, pretty robust, and I think I recall you saying that you were expecting both a quarter-over-quarter increase from 4Q this year versus current quarter and also last year. So just wondering, is there something specific that is going to give you a pretty significant push? Because it seems like an increase over third quarter this year seems totally reasonable, but fourth quarter last year seems like maybe a little kind of a challenging comp there."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","All I can say is as we continue to stress the strength of our pipeline and launches not just third-party launches, but now our internal launches starting to roll in, that's really, like I said, the driver not only of just launches we're doing in Q4 but la",113,"All I can say is as we continue to stress the strength of our pipeline and launches not just third-party launches, but now our internal launches starting to roll in, that's really, like I said, the driver not only of just launches we're doing in Q4 but launches we've now done throughout the year that we're getting, reaping the full benefit of by the time it hits Q4. So it just continues to be the product launches and what we're able to do with those launches throughout all of the countries. And again, Q4 being, if you go back the year before, Q4 has been a very robust year throughout Europe historically."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","This concludes today's question-and-answer session. At this time, I'd like to turn the conference back over to our speakers for any additional comments or closing remarks.",27,"This concludes today's question-and-answer session. At this time, I'd like to turn the conference back over to our speakers for any additional comments or closing remarks."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Executives","I just like to thank everybody for their participation today, and at this point, Lisa, you can close out the call.",21,"I just like to thank everybody for their participation today, and at this point, Lisa, you can close out the call."
290203,114621935,83278,"Mylan, Inc., Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Viatris Inc.","Operator","This does conclude today's conference call. Thank you for your participation.",12,"This does conclude today's conference call. Thank you for your participation."
